var images_info;if (!images_info) images_info =[]; images_info["68"]={"68000":{"type":"graphic_diagnosticimage","displayName":"Cerebral cavenous malformation with hemorrhage MRI","title":"MRI of a cerebral cavernous malformation with old hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of a cerebral cavernous malformation with old hemorrhage</div><div class=\"cntnt\"><img style=\"width:283px; height:324px;\" src=\"images/NEURO/68000_Cavernous_malformation_blee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dark hemosiderin ring around the cavernous malformation is evident on this T-2 weighted MR image, suggestive of old hemorrhage.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 68000 Version 5.0</div></div></div>"},"68001":{"type":"graphic_picture","displayName":"Molluscum face 2","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:420px; height:257px;\" src=\"images/DERM/68001_Molluscum_face_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple dome-shaped papules with a central core are present on the face of this child with molluscum contagiosum.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68001 Version 2.0</div></div></div>"},"68004":{"type":"graphic_table","displayName":"Uterine cancer survival","title":"Uterine carcinoma: FIGO surgical stage and overall survival","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Uterine carcinoma: FIGO surgical stage and overall survival</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">FIGO stage</td> <td class=\"subtitle1\">Five-year overall survival, percent</td> </tr> <tr> <td>IA</td> <td>90.3</td> </tr> <tr> <td>IB</td> <td>80.8</td> </tr> <tr> <td>II</td> <td>80.5</td> </tr> <tr> <td>IIIA</td> <td>68.5</td> </tr> <tr> <td>IIIB</td> <td>53.1</td> </tr> <tr> <td>IIIC1</td> <td>58.3</td> </tr> <tr> <td>IIIC2</td> <td>51.2</td> </tr> <tr> <td>IVA</td> <td>22.0</td> </tr> <tr> <td>IVB</td> <td>21.1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data from: SEER database for patients treated in 1988 through 2006, staging in these patients includes lymphadenectomy, staged according to the 2010 FIGO staging system (from Obstet Gynecol 2010; 116:1141).</div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics; SEER: Surveillance, Epidemiology, and End Results.</div><div id=\"graphicVersion\">Graphic 68004 Version 7.0</div></div></div>"},"68005":{"type":"graphic_picture","displayName":"Megaloblastic erythropoiesis","title":"Megaloblastic erythropoiesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megaloblastic erythropoiesis</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/HEME/68005_Megaloblastic_erythropoiesi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of normal and megaloblastic erythropoiesis with respect to erythroid precursors in the bone marrow. <br />(Left panel) Normal erythropoiesis. <br />(Right panel) Megaloblastic erythropoiesis.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68005 Version 2.0</div></div></div>"},"68007":{"type":"graphic_diagnosticimage","displayName":"MRI of an intramuscular hematoma","title":"MRI of an intramuscular hematoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of an intramuscular hematoma</div><div class=\"cntnt\"><img style=\"width:504px; height:291px;\" src=\"images/RADIOL/68007_MRI_intramuscular_hematoma_SRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gluteal muscle hematoma. MR T2-weighted axial image of the pelvis shows a large hematoma (arrow) in the left gluteus muscle from a tear.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 68007 Version 3.0</div></div></div>"},"68008":{"type":"graphic_picture","displayName":"Rigid bronchoscopy equipment","title":"Rigid bronchoscopy equipment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid bronchoscopy equipment</div><div class=\"cntnt\"><img style=\"width:323px; height:501px;\" src=\"images/PULM/68008_Rigid_broncho_equip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From left to right:<br />(A) Rigid biopsy forceps.<br />(B) Rigid optical telescope for visualization.<br />(C) Rigid bronchoscope.<br />(D) Rigid tracheoscope with attachment for anesthesia port and side working channel. Note that the rigid tracheoscope is shorter for tracheal intervention compared with the longer rigid bronchoscope, which can be placed in or beyond the main stem bronchi.</div><div id=\"graphicVersion\">Graphic 68008 Version 2.0</div></div></div>"},"68009":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 3 example 1","title":"Sacroiliitis grade 3 example 1","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 3 example 1</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/68009_Sacroiliitis_grade_3_ex_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral sacroiliitis grade 3 with widening and sclerosis.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 68009 Version 4.0</div></div></div>"},"68010":{"type":"graphic_figure","displayName":"Survival cardiac amyloid","title":"Better outcome with familial amyloid cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Better outcome with familial amyloid cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:358px; height:248px;\" src=\"images/CARD/68010_Survival_cardiac_amyloid.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 36 patients with amyloid cardiomyopathy, the 24 with familial amyloidosis have a better survival free of death or the need for cardiac transplantation than those with primary (AL) amyloidosis.</div><div class=\"graphic_reference\">Data from Dubrey SW, Cha K, Skinner M, et al. Heart 1997; 78:74.</div><div id=\"graphicVersion\">Graphic 68010 Version 2.0</div></div></div>"},"68011":{"type":"graphic_table","displayName":"Differential diagnosis of primary encephalocele","title":"Differential diagnosis of primary (congenital) encephalocele","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of primary (congenital) encephalocele</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of encephalocele</td> <td class=\"subtitle1\">Differential diagnosis</td> </tr> <tr> <td rowspan=\"4\"><strong>Occipital encephalocele</strong></td> <td>Midline dermoid cysts</td> </tr> <tr> <td>Hemangiomas</td> </tr> <tr> <td>Vascular malformations of the scalp</td> </tr> <tr> <td>Cystic hygroma</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Cranial vault</strong></td> <td>Congenital parietal foramina</td> </tr> <tr> <td>Scalp defects (aplasia cutis congenita)</td> </tr> <tr> <td>Dermoid cysts</td> </tr> <tr> <td>Hemangiomas</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Frontoethmoidal and basal</strong></td> <td>Dermoid cysts</td> </tr> <tr> <td>Hemangiomas</td> </tr> <tr> <td>Sinus pericranii</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Basal</td> <td>Inflammatory nasal polyps</td> </tr> <tr> <td>Atretic cephaloceles</td> </tr> <tr> <td>Mucocele of the paranasal sinuses</td> </tr> <tr> <td>Neoplasms of the nasal cavity and pharynx</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Spheno-orbital or frontosphenoidal</td> <td>Orbital teratoma</td> </tr> <tr> <td>Unilateral agenesis of the sphenoid and orbital plate (eg, in neurofibromatosis I)</td> </tr> <tr> <td>Congenital cystic eye</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Towfighi J. Cephaloceles. MedLink Neurology 1995 (updated 12/2010). Available at: <a href=\"http://www.medlink.com/medlinkcontent.asp\" target=\"_blank\">http://www.medlink.com/medlinkcontent.asp</a> (accessed 11/15/11).</div><div id=\"graphicVersion\">Graphic 68011 Version 2.0</div></div></div>"},"68013":{"type":"graphic_table","displayName":"Chemo agents and mucositis","title":"Chemotherapy agents associated with mucositis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy agents associated with mucositis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category </td> <td class=\"subtitle1\">Specific Drugs </td> </tr> <tr> <td rowspan=\"9\">Alkylating agents </td> <td>Busulfan</td> </tr> <tr> <td>Carboplatin</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Mechlorethamine</td> </tr> <tr> <td>Melphalan</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td>Thiotepa</td> </tr> <tr> <td rowspan=\"5\">Anthracyclines </td> <td>Daunorubicin</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Epirubicin</td> </tr> <tr> <td>Idarubicin</td> </tr> <tr> <td>Mitoxantrone</td> </tr> <tr> <td rowspan=\"11\">&nbsp;<br /> Antimetabolites </td> <td>6-Mercaptopurine</td> </tr> <tr> <td>6-Thioguanine</td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Cytarabine</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Gemcitabine</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Methotexate</td> </tr> <tr> <td>Pemetrexed</td> </tr> <tr> <td>Pralatrexate</td> </tr> <tr> <td rowspan=\"3\">Antitumor antibiotics </td> <td>Dactinomycin</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Mitomycin</td> </tr> <tr> <td rowspan=\"2\">Taxanes </td> <td>Docetaxel</td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td rowspan=\"4\">Topoisomerase inhibitors </td> <td>Etoposide</td> </tr> <tr> <td>Irinotecan</td> </tr> <tr> <td>Teniposide</td> </tr> <tr> <td>Topotecan</td> </tr> <tr> <td rowspan=\"11\">&nbsp;<br /> Molecularly targeted agents</td> <td>Cabozantinib </td> </tr> <tr> <td>Cetuximab</td> </tr> <tr> <td>Erlotinib</td> </tr> <tr> <td>Everolimus</td> </tr> <tr> <td>Lenvatinib</td> </tr> <tr> <td>Palbociclib</td> </tr> <tr> <td>Panitumumab</td> </tr> <tr> <td>Regorafenib</td> </tr> <tr> <td>Sorafenib</td> </tr> <tr> <td>Sunitinib</td> </tr> <tr> <td>Temsirolimus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68013 Version 6.0</div></div></div>"},"68014":{"type":"graphic_diagnosticimage","displayName":"Brain and spine MRI of child with ADEM","title":"Brain and spine MRI of a child with acute disseminated encephalomyelitis (ADEM)","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Brain and spine MRI of a child with acute disseminated encephalomyelitis (ADEM)</div><div class=\"cntnt\"><img style=\"width:462px; height:285px;\" src=\"images/PEDS/68014_Brain_spine_MRI_ADEM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial MRI of the brain (FLAIR image) in a child with acute disseminated encephalomyelitis (ADEM) demonstrates multifocal areas of hyperintensity in both cerebral hemispheres involving cortical gray matter, centrum semiovale, and deep gray nuclei.<br />(B) Sagittal MRI of the spine (T2 image) in the same child demonstrates high signal intrinsic to the spinal cord, consistent with longitudinally extensive transverse myelitis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Tim Lotze, MD.</div><div id=\"graphicVersion\">Graphic 68014 Version 5.0</div></div></div>"},"68015":{"type":"graphic_figure","displayName":"NEC prematurity","title":"Necrotizing enterocolitis: Susceptibility of premature infants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing enterocolitis: Susceptibility of premature infants</div><div class=\"cntnt\"><img style=\"width:448px; height:272px;\" src=\"images/PEDS/68015_NEC_prematurity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immaturity of the intestinal epithelial barrier and the neonatal mucosal immune system predispose the premature infant to microbial invasion, which triggers the sequence of events leading to necrotizing enterocolitis (NEC). Stimulation of pro-inflammatory cytokines compromises intestinal defenses. An imbalance between epithelial cell injury and repair leads to a cycle of bacterial invasion, immune activation, uncontrolled inflammation, and gut barrier failure.</div><div class=\"graphic_footnotes\">NO: nitric oxide; TNF-α: tumor necrosis factor - alpha.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Pediatric Research. Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the Susceptibility of the Premature Infant to Necrotizing Enterocolitis (NEC). Pediatr Res 2008; 63:117. Copyright © 2008. <A style=\"FONT-STYLE: italic\" href=\"http://www.nature.com/pr\" target=_blank>www.nature.com/pr</A></div><div id=\"graphicVersion\">Graphic 68015 Version 10.0</div></div></div>"},"68017":{"type":"graphic_picture","displayName":"Dilation with rigid scope","title":"Severe tracheal stenosis before and after dilation","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Severe tracheal stenosis before and after dilation</div><div class=\"cntnt\"><img style=\"width:539px; height:259px;\" src=\"images/PULM/68017_Dilation_with_rigid_scope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows the bronchoscopic view of a severe tracheal stenosis in a patient with respiratory failure. The right panel depicts the same patient after dilation of the stenosis with the rigid bronchoscope.</div><div class=\"graphic_reference\">Courtesy of Heinrich Becker, MD</div><div id=\"graphicVersion\">Graphic 68017 Version 3.0</div></div></div>"},"68020":{"type":"graphic_figure","displayName":"VF HH with mac sparing","title":"Visual fields: Homonymous hemianopia with macular sparing","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Visual fields: Homonymous hemianopia with macular sparing</div><div class=\"cntnt\"><img style=\"width:516px; height:444px;\" src=\"images/NEURO/68020_VF_HH_with_mac_sparing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field showing a right homonymous hemianopia with macular sparing.</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68020 Version 12.0</div></div></div>"},"68021":{"type":"graphic_figure","displayName":"Nail trephination","title":"Nail trephination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail trephination</div><div class=\"cntnt\"><img style=\"width:320px; height:408px;\" src=\"images/PEDS/68021_Nail_trephination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A heated device is pressed against the nail in the center of the hematoma. Care should be taken to avoid the lunula and to create a hole large enough for continued drainage.</div><div class=\"graphic_reference\">Courtesy of Rebecca K Fastle, MD.</div><div id=\"graphicVersion\">Graphic 68021 Version 1.0</div></div></div>"},"68022":{"type":"graphic_picture","displayName":"DiGeorge pt infant adolesc","title":"Infant and adolescent with DiGeorge syndrome","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Infant and adolescent with DiGeorge syndrome</div><div class=\"cntnt\"><img style=\"width:456px; height:540px;\" src=\"images/ALLRG/68022_DiGeorge_pt_infant_adolesc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Infant with DiGeorge syndrome has the typical hypertelorism, antimongoloid slant of the eyes, ear malformation, and peculiar mouth. <br />(B) Older child with DiGeorge syndrome depicts characteristic facial features, which become more subtle with age. Relatively consistent features are hooded eyelids, a bulbous nose tip, a broad nasal bridge, posteriorly rotated ears, simple ear helices, and micrognathia. This child has posteriorly rotated ears with simple helices, slightly hooded eyelids, and a slightly bulbous nose tip.</div><div class=\"graphic_reference\">Reproduced with permission from: Ochs HD, Nelson DL, Stiehm ER. Other Well-Defined Immunodeficiency Syndromes. In: Immunologic Disorders in Infants &amp; Children,&nbsp;5th Edition, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. p.525. Copyright ©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 68022 Version 3.0</div></div></div>"},"68024":{"type":"graphic_picture","displayName":"Manual hematocrit","title":"Manual (spun) hematocrit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manual (spun) hematocrit</div><div class=\"cntnt\"><img style=\"width:248px; height:411px;\" src=\"images/HEME/68024_Manual_hematocrit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows two anticoagulated blood-filled Wintrobe hematocrit tubes following high speed centrifugation. The tube on the left is from a normal subject, with a hematocrit of 38 percent (blue arrow). The tube on the right is from a 19-year-old female with essential thrombocytosis, a normal white blood cell count,&nbsp;and a platelet count of 5,000,000/microL. The extreme degree of thrombocytosis can be appreciated by the presence of a marked increase in the size of the \"buffy coat\" (white arrow). When the Wintrobe tube is filled to near capacity (upper arrows), and the white blood cell count is not markedly elevated, the platelet count can be estimated by the thickness of this layer, with each mm being equivalent to one million platelets/microL. In normal subjects, the buffy coat, which is comprised of white blood cells and platelets, is only minimally visible.</div><div class=\"graphic_reference\">Courtesy of Stephen A Landaw, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68024 Version 5.0</div></div></div>"},"68025":{"type":"graphic_table","displayName":"Three-point checklist","title":"The three-point checklist of dermoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The three-point checklist of dermoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Score*</td> </tr> <tr> <td><strong>Asymmetry</strong></td> <td>Asymmetry in distribution of dermoscopic color and/or structures in one or two perpendicular axes. The contour or silhouette of the lesion does not factor into whether the lesion is symmetric or not.</td> <td>1</td> </tr> <tr> <td><strong>Atypical pigment network</strong></td> <td>Pigment network with thick lines and irregular holes.</td> <td>1</td> </tr> <tr> <td><strong>Blue-white structures</strong></td> <td>Blue-white veil and/or white scar-like depigmentation and/or blue pepper-like granules.</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Interpretation: A total score of 2 or 3 points is considered positive, and the skin lesion should be removed or submitted for further evaluation.</div><div class=\"graphic_reference\">Reproduced with permission from: Soyer HP, Argenziano G, Zalaudek I, et al. Three-point checklist of dermoscopy. A new screening method for early detection of melanoma. Dermatology 2004; 208:27. Copyright &#169; 2004 S. Karger AG, Basel. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68025 Version 3.0</div></div></div>"},"68026":{"type":"graphic_picture","displayName":"Trichuriasis scope","title":"Trichuriasis scope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichuriasis scope</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/ID/68026_Trichuriasis_scope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image showing the posterior end of an adult <em>T. trichiura</em>, taken during a colonoscopy.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Trichuriasis. Available at: <A href=\"http://www.cdc.gov/parasites/whipworm/\">http://www.cdc.gov/parasites/whipworm/</A>.</div><div id=\"graphicVersion\">Graphic 68026 Version 4.0</div></div></div>"},"68027":{"type":"graphic_figure","displayName":"Upper extremity arm pressures","title":"Upper extremity arm pressures","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Upper extremity arm pressures</div><div class=\"cntnt\"><img style=\"width:614px; height:553px;\" src=\"images/SURG/68027_Upperextremityarmpressur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm blood pressures are unequal with the left radial artery pressure 35 mmHg lower than the right. The left radial wrist-brachial index is abnormal, consistent with left upper extremity occlusive disease.<br />The arterial waveforms in the right and left subclavian, axillary, and brachial arteries are normal. The right radial artery waveform is normal, but the right ulnar artery waveform is monophasic indicating abnormal flow. The left radial artery waveform is also monophasic, and the waveform in the left ulnar artery is flat indicating no flow. Together with the unequal arm pressures, these waveforms indicate left forearm arterial occlusive disease.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Strandness's Duplex Scanning in Vascular Disorders, 4th Edition, Zierler E (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68027 Version 8.0</div></div></div>"},"68028":{"type":"graphic_picture","displayName":"Parapsoriasis large plaque","title":"Large plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68028_Parapsoriasis_large_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, thin plaques&nbsp;with minimal scale that are several centimeters in diameter.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68028 Version 5.0</div></div></div>"},"68029":{"type":"graphic_diagnosticimage","displayName":"Small bowel obstruction on plain abdominal radiograph","title":"Small bowel obstruction on plain abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction on plain abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:396px; height:482px;\" src=\"images/OBGYN/68029_KUB_small_bowel_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain upright abdominal&nbsp;film shows a distended stomach and slightly dilated loops of small bowel with air fluid levels and a paucity of colonic gas, consistent with small bowel obstruction</div><div class=\"graphic_reference\">Reproduced with permission from: Deborah Levine, MD. Copyright © Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 68029 Version 3.0</div></div></div>"},"68030":{"type":"graphic_picture","displayName":"Vaginal cuff repair","title":"Vaginal cuff repair during laparoscopic hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Vaginal cuff repair during laparoscopic hysterectomy</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/OBGYN/68030_Vaginal_cuff_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Thomas Lyons, MD.</div><div id=\"graphicVersion\">Graphic 68030 Version 3.0</div></div></div>"},"68031":{"type":"graphic_diagnosticimage","displayName":"Pulm bronchogen cyst CT I","title":"Giant intrapulmonary bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant intrapulmonary bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:254px;\" src=\"images/PULM/68031_Pulm_bronchogen_cyst_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a liquid-filled cyst in right lower lobe, compressing the adjacent lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68031 Version 3.0</div></div></div>"},"68033":{"type":"graphic_figure","displayName":"Foot ankle circles","title":"Foot ankle circles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foot ankle circles</div><div class=\"cntnt\"><img style=\"width:277px; height:284px;\" src=\"images/RHEUM/68033_Foot_ankle_circles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circle the foot at the ankle, moving the foot up and down by flexing and extending the ankle. Perform 20 rotations clockwise, then 20 rotations counterclockwise.&nbsp;The exercise is performed twice daily.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 68033 Version 4.0</div></div></div>"},"68034":{"type":"graphic_table","displayName":"Minimum intervals between doses of recommended routine vaccines","title":"Recommended and minimum ages and intervals between vaccine doses*<SUP>¶</SUP><SUP>Δ</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended and minimum ages and intervals between vaccine doses*<SUP>¶</SUP><SUP>Δ</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine and dose number</td> <td class=\"subtitle1\">Recommended age for this dose</td> <td class=\"subtitle1\">Minimum age for this dose</td> <td class=\"subtitle1\">Recommended interval through next dose</td> <td class=\"subtitle1\">Minimum interval through next dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Diphtheria and tetanus toxoids and acellular pertussis (DTaP)</td> </tr> <tr> <td class=\"indent1\">DTaP-1<sup>&#9674;</sup></td> <td>2 months</td> <td>6 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">DTaP-2</td> <td>4 months</td> <td>10 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">DTaP-3</td> <td>6 months</td> <td>14 weeks</td> <td>6 through 12 months<sup>&#167;</sup></td> <td>6 months<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">DTaP-4</td> <td>15 through 18 months</td> <td>15 months<sup>&#167;</sup></td> <td>3 years</td> <td>6 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">DTaP-5</td> <td>4 through 6 years</td> <td>4 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hepatitis A (HepA)</td> </tr> <tr> <td class=\"indent1\">HepA-1<sup>&#9674;</sup></td> <td>12 through 23 months</td> <td>12 months</td> <td>6 through 18 months</td> <td>6 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HepA-2</td> <td>&#8805;18 months</td> <td>18 months</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hepatitis B (HepB)</td> </tr> <tr> <td class=\"indent1\">HepB-1</td> <td>Birth</td> <td>Birth</td> <td>4 weeks through 4 months</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">HepB-2</td> <td>1 through 2 months</td> <td>4 weeks</td> <td>8 weeks through 17 months</td> <td>8 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HepB-3<sup>&#165;</sup></td> <td>6 through 18 months</td> <td>24 weeks</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\"><em>Haemophilus influenzae</em> type b (Hib)</td> </tr> <tr> <td class=\"indent1\">Hib-1<sup>&#9674;</sup><sup>&#135;</sup></td> <td>2 months</td> <td>6 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">Hib-2</td> <td>4 months</td> <td>10 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">Hib-3<sup>&#134;</sup></td> <td>6 months</td> <td>14 weeks</td> <td>6 through 9 months</td> <td>8 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hib-4</td> <td>12 through 15 months</td> <td>12 months</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Human papillomavirus (HPV)</td> </tr> <tr> <td class=\"indent1\">HPV-1**</td> <td>11 through 12 years</td> <td>9 years</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">HPV-2</td> <td>11 through 12 years<br /> (+2 months)</td> <td>9 years<br /> (+4 weeks)</td> <td>4 months</td> <td>12 weeks**</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HPV-3**<sup>,</sup><sup>&#182;&#182;</sup></td> <td>11 through 12 years<br /> (+6 months)</td> <td>9 years<br /> (+5 months)</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Herpes zoster vaccine (HZV)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HZV<sup>&#916;&#916;</sup></td> <td>&#8805;60 years</td> <td>60 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inactivated influenza vaccine (IIV)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IIV<sup>&#9674;&#9674;</sup></td> <td>&#8805;6 months</td> <td>6 months<sup>&#167;&#167;</sup></td> <td>4 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inactivated poliovirus (IPV)</td> </tr> <tr> <td class=\"indent1\">IPV-1<sup>&#9674;</sup></td> <td>2 months</td> <td>6 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">IPV-2</td> <td>4 months</td> <td>10 weeks</td> <td>8 weeks through 14 months</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">IPV-3</td> <td>6 through 18 months</td> <td>14 weeks</td> <td>3 through 5 years</td> <td>6 months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IPV-4<sup>&#165;&#165;</sup></td> <td>4 through 6 years</td> <td>4 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Live, attenuated influenza vaccine (LAIV)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">LAIV (intranasal)<sup>&#9674;&#9674;</sup></td> <td>2 through 49 years</td> <td>2 years</td> <td>4 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Quadrivalent meningococcal conjugate vaccine (MenACWY)</td> </tr> <tr> <td class=\"indent1\">MenACWY-1<sup>&#135;&#135;</sup></td> <td>11 through 12 years</td> <td>6 weeks<sup>&#134;&#134;</sup></td> <td>4 through 5 years</td> <td>8 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MenACWY-2</td> <td>16 years</td> <td>11 years<br /> (+8 weeks)***</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Measles, mumps, and rubella (MMR)</td> </tr> <tr> <td class=\"indent1\">MMR-1<sup>&#182;&#182;&#182;</sup></td> <td>12 through 15 months</td> <td>12 months</td> <td>3 through 5 years</td> <td>4 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MMR-2<sup>&#182;&#182;&#182;</sup></td> <td>4 through 6 years</td> <td>13 months</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Quadrivalent meningococcal polysaccharide vaccine (MPSV4)</td> </tr> <tr> <td class=\"indent1\">MPSV4-1<sup>&#135;&#135;</sup></td> <td>&ndash;</td> <td>2 years</td> <td>5 years</td> <td>5 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MPSV4-2</td> <td>&ndash;</td> <td>7 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Pneumococcal conjugate vaccine (PCV13)</td> </tr> <tr> <td class=\"indent1\">PCV13-1<sup>&#135;</sup></td> <td>2 months</td> <td>6 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">PCV13-2</td> <td>4 months</td> <td>10 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">PCV13-3</td> <td>6 months</td> <td>14 weeks</td> <td>6 months</td> <td>8 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PCV13-4</td> <td>12 through 15 months</td> <td>12 months</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Pneumococcal polysaccharide vaccine (PPSV23)</td> </tr> <tr> <td class=\"indent1\">PPSV23-1</td> <td>&ndash;</td> <td>2 years</td> <td>5 years</td> <td>3 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PPSV23-2<sup>&#916;&#916;&#916;</sup></td> <td>&ndash;</td> <td>7 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Rotavirus</td> </tr> <tr> <td class=\"indent1\">Rotavirus-1<sup>&#9674;&#9674;&#9674;</sup></td> <td>2 months</td> <td>6 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr> <td class=\"indent1\">Rotavirus-2</td> <td>4 months</td> <td>10 weeks</td> <td>8 weeks</td> <td>4 weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rotavirus-3<sup>&#9674;&#9674;&#9674;</sup></td> <td>6 months</td> <td>14 weeks</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tetanus and diphtheria toxoids (Td)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Td</td> <td>11 through 12 years</td> <td>7 years</td> <td>10 years</td> <td>5 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tdap<sup>&#167;&#167;&#167;</sup></td> <td>&#8805;11 years</td> <td>7 years</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Varicella vaccine (VAR)</td> </tr> <tr> <td class=\"indent1\">VAR-1</td> <td>12 through 15 months</td> <td>12 months</td> <td>3 through 5 years</td> <td>12 weeks<sup>&#165;&#165;&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">VAR-2</td> <td>4 through 6 years</td> <td>15 months<sup>&#135;&#135;&#135;</sup></td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PRP-OMP: polyribosylribitol phosphate-meningococcal outer membrane protein conjugate.<br />* Combination vaccines are available. Use of licensed combination vaccines is generally preferred to separate injections of their equivalent component vaccines. When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components (exception: the minimum age for the first dose of MenHibrix is 6 weeks). The minimum interval between doses is equal through the greatest interval of any of the individual components.<br />¶ Information on travel vaccines, including typhoid, Japanese encephalitis, and yellow fever can be found&nbsp;at <A href=\"https://wwwnc.cdc.gov/travel/\" target=_blank>https://wwwnc.cdc.gov/travel/</A>. Information on other vaccines that are licensed in the United States but not distributed, including anthrax and smallpox can be found&nbsp;at <A href=\"https://emergency.cdc.gov/bioterrorism/\" target=_blank>https://emergency.cdc.gov/bioterrorism/</A>.<br />Δ \"Months\" refers through calendar months.<br /><FONT class=lozenge>◊</FONT> Combination vaccines containing the hepatitis B component are available (refer to Table 3-2 available at <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-02\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-02</A>). These vaccines should not be administered to infants aged &lt;6 weeks because of the other vaccine components (ie, Hib, DTaP, HepA, and IPV).<br />§ The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3. This is a special grace period of 2 months which can be used if evaluating records retrospectively. An additional 4 days should not be added to this grace period.<br />¥ HepB-3 should be administered at least 8 weeks after HepB-2 and at least 16 weeks after HepB-1 and should not be administered before age 24 weeks.<br />‡ For Hib and PCV13, children receiving the first dose of vaccine at age ≥7 months require fewer doses to complete the series.<br />† If PRP-OMP (Pedvax-Hib) was administered at ages 2 and 4 months, a dose at age 6 months is not necessary. The final dose has a minimum age of 12 months.<br />** Quadrivalent and nine-valent HPV vaccines are approved for males and females aged 9 through 26 years. The minimum age for HPV-3 is based on the baseline minimum age for the first dose (ie, 9 years) and the minimum interval of 5 months between the first and third dose. Dose 3 need not be repeated if it is administered at least 5 months after the first dose and the intervals between dose 1 and dose 2, and dose 2 and dose 3, are maintained at 4 weeks and 12 weeks, respectively.<br />¶¶ A two-dose schedule of HPV vaccine is recommended for most persons beginning the series between 9 through 14 years of age. Refer to \"HPV vaccine-specific recommendations\" (available at <A href=\"https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf\" target=_blank>https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf</A>) for details.<br />ΔΔ Herpes zoster vaccine is recommended as a single dose for persons aged ≥60 years.<br /><FONT class=double_lozenge>◊◊</FONT> One dose of influenza vaccine per season is recommended for most persons. To determine which children younger than 9 years should receive 2 doses in a single season, please refer to influenza vaccine-specific recommendations.<SUP>[1]</SUP><br />§§ The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. Refer to the package insert for vaccine-specific minimum ages.<br />¥¥ A fourth dose is not needed if the third dose was administered at ≥4 years and at least 6 months after the previous dose.<br />‡‡ Revaccination with meningococcal vaccine is recommended for previously vaccinated persons who remain at high-risk for meningococcal disease.<SUP>[2]</SUP><br />†† MenACWY-D (Menactra) can be given as young as 9 months for high-risk persons. MenACWY-CRM (Menveo) can be given as young as 2 months for high-risk persons. Hib-MenCY can be given as young as 6 weeks for high-risk persons. Hib-MenCY is given as a 4-dose series at 2 months, 4 months, 6 months, and 12 through 18 months.<br />*** For routine non-high-risk adolescent vaccination, the minimum age for the booster dose is 16 years.<br />¶¶¶ Combination MMRV vaccine can be used for children aged 12 months through 12 years.<br />ΔΔΔ A second dose of PPSV23 5 years after the first dose is recommended for persons aged ≤65 years at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody concentration.<SUP>[3]</SUP><br /><FONT class=double_lozenge>◊◊◊</FONT> The first dose of rotavirus must be administered at age 6 weeks through 14 weeks, 6 days. The vaccine series should not be started for infants aged ≥15 weeks, 0 days. Rotavirus should not be administered to children older than 8 months, 0 days of age regardless of the number of doses received between 6 weeks and 8 months, 0 days of age. If 2 doses of Rotarix are administered as age appropriate, a third dose is not necessary.<br />§§§ Only 1 dose of Tdap is recommended. Subsequent doses should be given as Td. For management of a tetanus-prone wound in persons who have received a primary series of tetanus-toxoid-containing vaccine, the minimum interval after a previous dose of any tetanus-containing vaccine is 5 years.<br />¥¥¥ A special grace period of 2 months, based on expert opinion, can be applied to the minimum interval of 3 months, when evaluating records retrospectively, which results in an acceptable minimum interval of 4 weeks. An additional 4 days should not be added on through this grace period.<br />‡‡‡ A special grace period of 2 months, based on expert opinion, can be applied to the minimum age of 15 months when evaluating records retrospectively, which results in an acceptable minimum age of 13 months. An additional 4 days should not be added on through this grace period.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014; 63:691.</LI>&#xD;&#xA;<LI>Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.</LI></OL>Reproduced from: Centers for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP: Timing and Spacing of Immunobiologics. Available at: <A href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html</A> (Accessed July 7, 2017).</div><div id=\"graphicVersion\">Graphic 68034 Version 6.0</div></div></div>"},"68035":{"type":"graphic_table","displayName":"The inherited salt-losing renal tubulopathies","title":"The inherited salt-losing renal tubulopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The inherited salt-losing renal tubulopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"16%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Gene affected</td> <td class=\"subtitle1\">Gene product</td> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Functional studies</td> </tr> <tr> <td>Bartter syndrome type I</td> <td>SLC12A1</td> <td>NKCC2</td> <td>Antenatal Bartter syndrome (hyperprostaglandin E syndrome)</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Bartter syndrome type II</td> <td>KCNJ1</td> <td>ROMK</td> <td>Antenatal Bartter syndrome</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Bartter syndrome type III</td> <td>CLCKB</td> <td>CLC-Kb</td> <td>Classic Bartter syndrome</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Bartter syndrome type IV</td> <td>BSND</td> <td>Barttin (beta-subunit of CLC-Ka and CLC-Kb)</td> <td>Antenatal Bartter syndrome (hyperprostaglandin E syndrome) and sensorineural deafness*</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Bartter syndrome type IVb</td> <td>CLCNKA and CLCNKB</td> <td>CLC-Ka and CLC-Kb</td> <td>Antenatal Bartter syndrome (hyperprostaglandin E syndrome) and sensorineural deafness*</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Bartter syndrome type V<sup>&#182;</sup></td> <td>CaSR gene</td> <td>CaSR</td> <td>Bartter syndrome with hypocalcemia</td> <td>Concentrating capacity reduced and diluting capacity reduced</td> </tr> <tr> <td>Gitelman syndrome</td> <td>SLC12A3</td> <td>NCCT</td> <td>Gitelman syndrome</td> <td>Concentrating capacity normal/near normal and diluting capacity reduced</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Genetics and presentation of Bartter and Gitelman syndromes. There are six Bartter syndrome subtypes (I, II, III, IV, IVb, and V) corresponding to six genetic defects.</div><div class=\"graphic_footnotes\">NKCC2: furosemide-sensitive sodium-potassium-2 chloride cotransporter; ROMK: renal outer medullary potassium channel; CLC-Kb: chloride channel Kb; CLC-Ka: chloride channel Ka; CaSR: calcium-sensing receptor; NCCT: thiazide-sensitive sodium-chloride cotransporter.<br />* Sensorineural deafness occurs because ClC-Ka and CLC-Kb are highly expressed in the inner ear and interact with other transport proteins (eg, NKCC1) to maintain the high potassium concentration in the endolymph that is required for normal hearing.<br />¶ Some experts classify the mild salt-losing effect of gain-of-function mutations in the calcium-sensing receptor as Bartter syndrome type V.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: from: Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 2008; 4:560. Copyright © 2008.</div><div id=\"graphicVersion\">Graphic 68035 Version 6.0</div></div></div>"},"68041":{"type":"graphic_table","displayName":"HEEADSSS assessment","title":"The HEEADSSS acronym to screen for psychosocial problems in adolescents with chronic abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The HEEADSSS acronym to screen for psychosocial problems in adolescents with chronic abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>H &ndash; Home</strong></td> <td> <ul> <li>Family configuration and family members</li> <li>Living arrangements</li> <li>Relationships between the adolescent and family members</li> <li>Relationships among other family members</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>E &ndash; Education/employment</strong></td> <td> <ul> <li>Academic or vocational success</li> <li>Future plans</li> <li>Safety at school or in the workplace</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>E &ndash; Eating</strong></td> <td> <ul> <li>Brief nutrition history</li> <li>Risk factors for obesity</li> <li>Concerns about weight or body image</li> <li>Disordered eating behaviors</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>A &ndash; Activities</strong></td> <td> <ul> <li>Friendships with peers of the same or opposite sex </li> <li>Recreational activities </li> <li>Dating activity and relationships </li> <li>Sexual activity </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>D &ndash; Drugs</strong></td> <td> <ul> <li>Personal use of tobacco, alcohol, illicit drugs, anabolic steroids</li> <li>Peer substance use</li> <li>Family substance use</li> <li>Driving while intoxicated</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>S &ndash; Sexuality</strong></td> <td> <ul> <li>Sexual orientation</li> <li>Sexual activity</li> <li>Sexual abuse</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>S &ndash; Suicide/mental health</strong></td> <td> <ul> <li>Feelings of sadness, loneliness, depression</li> <li>Pervasive boredom</li> <li>Inappropriately high levels of anxiety (prior to onset of pain and during pain)</li> <li>Suicidal thoughts</li> </ul> </td> </tr> <tr> <td><strong>S &ndash; Safety</strong></td> <td> <ul> <li>Risk of unintentional injury</li> <li>Risk from violence</li> <li>Fighting or weapon carrying</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Jasik CB, Ozer EM. Preventive health care for adolescents and young adults. In: Neinstein's Adolescent Health Care: A Practical Guide, Neinstein LS, Katzman DK, Callahan TS, et al (Eds), 6th ed, Wolters Kluwer, Philadelphia 2016 p.50.</div><div id=\"graphicVersion\">Graphic 68041 Version 6.0</div></div></div>"},"68042":{"type":"graphic_figure","displayName":"Newborn screen trends","title":"Proportion of new diagnoses of cystic fibrosis by newborn screening, 1990 to 2013","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Proportion of new diagnoses of cystic fibrosis by newborn screening, 1990 to 2013</div><div class=\"cntnt\"><img style=\"width:560px; height:234px;\" src=\"images/PEDS/68042_Nwbrn_scrn_trnd.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry: 2013 Annual Data Report to the Center Directors, Bethesda, MD. Copyright &copy; 2014 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 68042 Version 4.0</div></div></div>"},"68046":{"type":"graphic_figure","displayName":"Outcome intracoronary radiation","title":"Intracoronary radiation therapy reduces restenosis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Intracoronary radiation therapy reduces restenosis</div><div class=\"cntnt\"><img style=\"width:471px; height:220px;\" src=\"images/CARD/68046_Outcome_intracoronary_radia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier curves show that in patients undergoing stenting, event-free survival (without myocardial infarction or repeat revascularization of the target lesion) at three years was significantly&nbsp;higher with intracoronary iridium-192 radiation therapy (77 versus 45 percent for placebo, p=0.01). The curves diverge at 3 months, and the difference increased over the next 7 months, after which clinical events were infrequent.</div><div class=\"graphic_reference\">Redrawn from Teirstein, PS, Massullo, V, Jani, S, et al, Circulation 2000; 101:360.</div><div id=\"graphicVersion\">Graphic 68046 Version 2.0</div></div></div>"},"68047":{"type":"graphic_diagnosticimage","displayName":"TEE coronary sinus","title":"Coronary sinus and mitral valve on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Coronary sinus and mitral valve on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:526px; height:234px;\" src=\"images/CARD/68047_TEE_coronary_sinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior rotation of the transesophageal echocardiogram (TEE) probe while in the vertical (90º) imaging plane allows for identification of the coronary sinus (CS) and left lower pulmonary vein (LLPV) (panel A). In panel B, slow anterior rotation of the probe delineates the posterior leaflet of the mitral valve (PML), the anterior mitral valve leaflet (AML), the CS, body of the left atrium (LA), inferior wall of the left ventricle (INF), and anterior left ventricular wall (ANT).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 68047 Version 3.0</div></div></div>"},"68048":{"type":"graphic_figure","displayName":"Baylisascariasis life cycle","title":"Baylisascariasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Baylisascariasis life cycle</div><div class=\"cntnt\"><img style=\"width:487px; height:488px;\" src=\"images/ID/68048_Baylisascariasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Baylisascaris procyonis</em> completes its life cycle in raccoons, with humans acquiring the infection as accidental hosts (dogs serve as alternate definitive hosts, as they can harbor patent and shed eggs). Unembryonated eggs are shed in the environment <strong>(1)</strong>, where they take two to four weeks to embryonate and become infective <strong>(2)</strong>. Raccoons can be infected by ingesting embryonated eggs from the environment <strong>(3)</strong>. Additionally, over 100 species of birds and mammals (especially rodents) can act as paratenic hosts for this parasite: eggs ingested by these hosts <strong>(4)</strong> hatch and larvae penetrate the gut wall and migrate into various tissues where they encyst <strong>(5)</strong>. The life cycle is completed when raccoons eat these hosts <strong>(6)</strong>. The larvae develop into egg-laying adult worms in the small intestine <strong>(7)</strong> and eggs are eliminated in raccoon feces. Humans become accidentally infected when they ingest infective eggs from the environment; typically this occurs in young children playing in the dirt <strong>(8)</strong>. Migration of the larvae through a wide variety of tissues (liver, heart, lungs, brain, eyes) results in visceral larva migrans (VLM) and ocular larva migrans (OLM) syndromes, similar to toxocariasis <strong>(9)</strong>. In contrast to <em>Toxocara</em> larvae, <em>Baylisascaris</em> larvae continue to grow during their time in the human host. Tissue damage and the signs and symptoms of baylisascariasis are often severe because of the size of <em>Baylisascaris</em> larvae, their tendency to wander widely, and the fact that they do not readily die. Diagnosis is usually made by serology, or by identifying larvae in biopsy or autopsy specimens.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Baylisascariasis. Available at: <A href=\"http://www.cdc.gov/parasites/baylisascaris/\">http://www.cdc.gov/parasites/baylisascaris/</A>.</div><div id=\"graphicVersion\">Graphic 68048 Version 3.0</div></div></div>"},"68049":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber color Doppler systole","title":"Apical four chamber view with color flow Doppler during systole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four chamber view with color flow Doppler during systole</div><div class=\"cntnt\"><img style=\"width:294px; height:229px;\" src=\"images/CARD/68049_4_chamber_color_Doppler_sys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view with color flow Doppler was obtained from a normal subject during systole. The systolic flow signal is shown in blue, ie, flow is moving away from the transducer. This signal is used to position a pulsed wave Doppler sample volume in the left ventricular outflow tract (LVOT) so that flow characteristics can be quantitated.</div><div class=\"graphic_footnotes\">LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 68049 Version 4.0</div></div></div>"},"68050":{"type":"graphic_picture","displayName":"Actinomyces israelii gram stain","title":"Gram stain of a broth culture of <EM>Actinomyces israelii</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram stain of a broth culture of <EM>Actinomyces israelii</EM></div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/ID/68050_Actinomyces_israelii_gram_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variable morphologies of these gram-positive organisms are visible, ranging from diptheroidal to coccoid filaments.</div><div class=\"graphic_reference\">Courtesy of Dr. Diane L Roscoe, Department of Pathology and Laboratory Medicine, University of British Columbia.</div><div id=\"graphicVersion\">Graphic 68050 Version 2.0</div></div></div>"},"68052":{"type":"graphic_table","displayName":"Medications for acute vertigo","title":"Medications for acute vertigo","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for acute vertigo</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antihistamines</td> </tr> <tr> <td class=\"indent1\">Dimenhydrinate</td> <td>50 mg every four to six hours</td> </tr> <tr> <td class=\"indent1\">Diphenhydramine</td> <td>25 to 50 mg every four to six hours</td> </tr> <tr> <td class=\"indent1\">Meclizine</td> <td>25 to 50 mg every six hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Alprazolam</td> <td>0.5 mg immediate release every eight hours</td> </tr> <tr> <td class=\"indent1\">Clonazepam</td> <td>0.25 to 0.5 mg every eight hours</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td>5 to 10 mg every twelve hours</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td>1 to 2 mg every eight hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antiemetics</td> </tr> <tr> <td class=\"indent1\">Domperidone</td> <td>10 to 20 mg every six to eight hours</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> <td>5 to 10 mg every six hours</td> </tr> <tr> <td class=\"indent1\">Ondansetron</td> <td>8 mg every twelve hours</td> </tr> <tr> <td class=\"indent1\">Prochlorperazine</td> <td>5 to 10 mg every six hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">For acute emergency ward use:</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Antihistamines</td> </tr> <tr> <td class=\"indent2\">Diphenhydramine</td> <td>10 to 50 mg IM or IV</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Antiemetics</td> </tr> <tr> <td class=\"indent2\">Metoclopramide</td> <td>10 to 20 mg IM</td> </tr> <tr> <td class=\"indent2\">Ondansetron</td> <td>4 mg IM or IV</td> </tr> <tr> <td class=\"indent2\">Prochlorperazine</td> <td>5 to 10 mg IM or IV</td> </tr> <tr> <td class=\"indent2\">Promethazine</td> <td>10 to 50 mg IM or IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 68052 Version 4.0</div></div></div>"},"68053":{"type":"graphic_picture","displayName":"False knot","title":"\"False\" knots - tortuosities","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">&quot;False&quot; knots - tortuosities</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/OBGYN/68053_False_knot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 68053 Version 1.0</div></div></div>"},"68054":{"type":"graphic_picture","displayName":"Pelosi cesarean technique 2","title":"Placement of the self-retaining abdominal retractor  as part of the Pelosi technique","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Placement of the self-retaining abdominal retractor  as part of the Pelosi technique</div><div class=\"cntnt\"><img style=\"width:546px; height:486px;\" src=\"images/OBGYN/68054_Self-retaining_abd_retracto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) At left, the protractor (Weck Closure Systems); at right, the Mobius (Apple Medical Corporation).<br />(B) The inner ring is squeezed cephalad into the peritoneal cavity.<br />(C) The inner ring springs open against the parietal peritoneum. A digital check is performed to assure that no tissue is trapped between the inner ring and the abdominal wall. The plastic sleeve is then placed on tension.<br />(D) The outer ring is rolled into the plastic sleeve until the ring completely inverts.<br />(E) The result is the creation of an atraumatic, circular, self-retaining area of retraction.<br />(F) A small transverse incision is made with the scalpel approximately&nbsp;1 cm above the vesicouterine peritoneal fold. The creation of the traditional bladder flap is avoided.</div><div class=\"graphic_reference\">Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.</div><div id=\"graphicVersion\">Graphic 68054 Version 3.0</div></div></div>"},"68056":{"type":"graphic_table","displayName":"Anthrax vaccine recs","title":"Recommended preexposure and postexposure vaccination schedules for anthrax vaccine absorbed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended preexposure and postexposure vaccination schedules for anthrax vaccine absorbed</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of prophylaxis</td> <td class=\"subtitle1\">Schedule</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td>Preexposure</td> <td> <p>5 doses (0 weeks, 4 weeks, 6 months, 12 months, and 18 months)</p> Annual booster to maintain immunity</td> <td>Intramuscular</td> <td>0.5 mL</td> </tr> <tr> <td>Postexposure*</td> <td>3 doses (0, 2, and 4 weeks)<sup>&#182;</sup></td> <td>Subcutaneous</td> <td>0.5 mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For previously unvaccinated persons.<br />¶ In conjunction with 60-day antimicrobial postexposure prophylaxis.</div><div class=\"graphic_reference\">Data from:<br /><br /><OL>&#xD;&#xA;<LI>Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1-36.</LI>&#xD;&#xA;<LI>US Food and Drug Administration.&nbsp;FDA&nbsp;news release:&nbsp;FDA approves vaccine for use after known or suspected anthrax exposure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474027.htm (Accessed on November 25, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 68056 Version 4.0</div></div></div>"},"68057":{"type":"graphic_picture","displayName":"Actinic cheilitis","title":"Actinic cheilitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic cheilitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68057_Actinic_cheilitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scale are present on the lower lip.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68057 Version 3.0</div></div></div>"},"68059":{"type":"graphic_picture","displayName":"Facial features of a patient with acromegaly","title":"Facial features of a patient with acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Facial features of a patient with acromegaly</div><div class=\"cntnt\"><img style=\"width:407px; height:558px;\" src=\"images/ENDO/68059_Facial_features_acromegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Facial aspect of a patient with acromegaly. The nose is widened and thickened, the cheekbones are obvious, the forehead bulges, the lips are thick, and the facial lines are marked. The forehead and overlying skin is thickened, sometimes leading to frontal bossing.<br />(C, D) Mandibular overgrowth leads to prognathism, maxillary widening, teeth separation, and jaw malocclusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008; 3:17. Copyright © 2008 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 68059 Version 3.0</div></div></div>"},"68060":{"type":"graphic_picture","displayName":"Lichen planus Koebner","title":"Koebner reaction in lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Koebner reaction in lichen planus</div><div class=\"cntnt\"><img style=\"width:396px; height:260px;\" src=\"images/DERM/68060_Lichen_planus_Koebner.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with lichen planus can exhibit the Koebner reaction, in which lesions develop in areas of trauma. In this patient, the Koebner reaction resulted from scratching.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68060 Version 1.0</div></div></div>"},"68061":{"type":"graphic_table","displayName":"Otorrhea causes","title":"Causes of otorrhea in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of otorrhea in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life-threatening conditions</td> </tr> <tr> <td class=\"indent1\">Traumatic CSF otorrhea</td> </tr> <tr> <td class=\"indent1\">Infectious complications of acute otitis media*</td> </tr> <tr> <td class=\"indent1\">Necrotizing otitis externa</td> </tr> <tr> <td class=\"indent1\">Neoplasm</td> </tr> <tr> <td class=\"subtitle1_single\">Common conditions</td> </tr> <tr> <td class=\"indent1\">Bacterial otitis externa</td> </tr> <tr> <td class=\"indent1\">Foreign body</td> </tr> <tr> <td class=\"indent1\">Acute otitis media with perforation of TM</td> </tr> <tr> <td class=\"indent1\">Chronic suppurative otitis media</td> </tr> <tr> <td class=\"indent1\">Cerumen</td> </tr> <tr> <td class=\"indent1\">Tympanostomy tube drainage</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Contact dermatitis</td> </tr> <tr> <td class=\"indent1\">Bullous myringitis with rupture of bulla</td> </tr> <tr> <td class=\"indent1\">Granulation tissue</td> </tr> <tr> <td class=\"indent1\">Polyps</td> </tr> <tr> <td class=\"indent1\">Otomycosis</td> </tr> <tr> <td class=\"indent1\">First branchial cleft cyst</td> </tr> <tr> <td class=\"indent1\">Cholesteatoma</td> </tr> <tr> <td class=\"indent1\">Spontaneous CSF otorrhea</td> </tr> <tr> <td class=\"indent1\">Histiocytosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; TM: tympanic membrane.<br />* Adjacent infections include mastoiditis and temporal bone osteomyelitis. Intracranial complications of acute otitis media include meningitis; brain abscess; epidural abscess; subdural empyema; and thrombosis of the lateral sinus, cavernous sinus, and/or carotid artery.</div><div id=\"graphicVersion\">Graphic 68061 Version 5.0</div></div></div>"},"68062":{"type":"graphic_table","displayName":"Headache triggers PI","title":"Headache triggers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Headache triggers</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diet </td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Chocolate</td> </tr> <tr> <td>Aged cheeses</td> </tr> <tr> <td>Monosodium glutamate (MSG)</td> </tr> <tr> <td>Aspartame (NutraSweet)</td> </tr> <tr> <td>Caffeine</td> </tr> <tr> <td>Nuts</td> </tr> <tr> <td>Nitrites, Nitrates</td> </tr> <tr> <td class=\"subtitle1_single\">Hormones </td> </tr> <tr> <td>Menses</td> </tr> <tr> <td>Ovulation</td> </tr> <tr> <td>Hormone replacement (progesterone)</td> </tr> <tr> <td class=\"subtitle1_single\">Sensory stimuli </td> </tr> <tr> <td>Strong light</td> </tr> <tr> <td>Flickering lights</td> </tr> <tr> <td>Odors</td> </tr> <tr> <td>Sounds, noise</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Stress </td> </tr> <tr> <td>Let-down periods</td> </tr> <tr> <td>Times of intense activity</td> </tr> <tr> <td>Loss or change (death, separation, divorce, job change)</td> </tr> <tr> <td>Moving</td> </tr> <tr> <td>Crisis</td> </tr> <tr> <td class=\"subtitle1_single\">Changes of environment or habits </td> </tr> <tr> <td>Weather</td> </tr> <tr> <td>Travel (crossing time zones)</td> </tr> <tr> <td>Seasons</td> </tr> <tr> <td>Altitude</td> </tr> <tr> <td>Schedule changes</td> </tr> <tr> <td>Sleeping patterns</td> </tr> <tr> <td>Dieting</td> </tr> <tr> <td>Skipping meals</td> </tr> <tr> <td>Irregular physical activity</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68062 Version 2.0</div></div></div>"},"68063":{"type":"graphic_table","displayName":"Rehabilitation Act Section 504","title":"Overview of Section 504 of the Rehabilitation Act","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of Section 504 of the Rehabilitation Act</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">What is Section 504?</td> </tr> <tr> <td><strong>Section 504 of the Rehabilitation Act of 1973 is a national law that protects qualified individuals from discrimination based on their disability.</strong> The nondiscrimination requirements of the law apply to employers and organizations that receive financial assistance from any federal department or agency, including the United States Department of Health and Human Services (DHHS). These organizations and employers include many hospitals, nursing homes, mental health centers, and human service programs.</td> </tr> <tr> <td>Section 504 forbids organizations and employers from excluding or denying individuals with disabilities an equal opportunity to receive program benefits and services. It defines the rights of individuals with disabilities to participate in, and have access to, program benefits and services.</td> </tr> <tr> <td class=\"subtitle1_single\">Who is protected from discrimination?</td> </tr> <tr> <td>Section 504 protects <strong>qualified individuals with disabilities</strong>. Under this law, <strong>individuals with disabilities</strong> are defined as persons with a physical or mental impairment which substantially limits one or more major life activities. People who have a history of, or who are regarded as having, a physical or mental impairment that substantially limits one or more major life activities are also covered. Major life activities include caring for oneself, walking, seeing, hearing, speaking, breathing, working, performing manual tasks, and learning. Some examples of impairments which may substantially limit major life activities, even with the help of medication or aids/devices, are: AIDS, alcoholism, blindness or visual impairment, cancer, deafness or hearing impairment, diabetes, drug addiction, heart disease, and mental illness. In addition to meeting the above definition, for purposes of receiving services, education, or training, <strong>qualified individuals with disabilities</strong> are persons who meet normal and essential eligibility requirements.</td> </tr> <tr> <td>For purposes of employment, <strong>qualified individuals with disabilities</strong> are persons who, with reasonable accommodation, can perform the essential functions of the job for which they have applied or have been hired to perform. (Complaints alleging employment discrimination on the basis of disability against a single individual will be referred to the United States Equal Employment Opportunity Commission for processing.)</td> </tr> <tr> <td><strong>Reasonable accommodation</strong> means an employer is required to take reasonable steps to accommodate your disability unless it would cause the employer undue hardship.</td> </tr> <tr> <td class=\"subtitle1_single\">Prohibited discriminatory acts in health care and human services settings</td> </tr> <tr> <td class=\"sublist1_start\">Section 504 prohibitions against discrimination apply to service availability, accessibility, delivery, employment, and the administrative activities and responsibilities of organizations receiving federal financial assistance. A recipient of federal financial assistance may not, on the basis of disability:</td> </tr> <tr> <td class=\"sublist1\">Deny qualified individuals the opportunity to participate in or benefit from federally funded programs, services, or other benefits.</td> </tr> <tr> <td class=\"sublist1\">Deny access to programs, services, benefits or opportunities to participate as a result of physical barriers.</td> </tr> <tr> <td class=\"sublist1\">Deny employment opportunities, including hiring, promotion, training, and fringe benefits, for which they are otherwise entitled or qualified.</td> </tr> <tr> <td>These and other prohibitions against discrimination based on disability can be found in the DHHS Section 504 regulation at 45 CFR Part 84.</td> </tr> <tr> <td>For information on how to file a complaint of discrimination or to obtain information of a civil rights nature, please contact us. Office of Civil Rights employees will make every effort to provide prompt service.</td> </tr> <tr> <td>Hotlines: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-368-1019<a href=\"#\" title=\"Call: 1-800-368-1019\"><img alt=\"\" title=\"Call: 1-800-368-1019\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (Voice) <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-537-7697<a href=\"#\" title=\"Call: 1-800-537-7697\"><img alt=\"\" title=\"Call: 1-800-537-7697\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (TDD)</td> </tr> <tr> <td> <p>E-mail: ocrmail&#64;hhs.gov</p> <p>Web site: http://www.hhs.gov/ocr</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68063 Version 7.0</div></div></div>"},"68064":{"type":"graphic_table","displayName":"Migraine, tension-type, and cluster headache","title":"Characteristics of migraine, tension-type, and cluster headache syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of migraine, tension-type, and cluster headache syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Migraine</td> <td class=\"subtitle1\">Tension-type</td> <td class=\"subtitle1\">Cluster</td> </tr> <tr> <td>Location</td> <td> <p>Adults: Unilateral in 60 to 70 percent, bifrontal or global in 30 percent</p> <p>Children and adolescents: Bilateral in majority</p> </td> <td>Bilateral</td> <td>Always unilateral, usually begins around the eye or temple</td> </tr> <tr> <td>Characteristics</td> <td>Gradual in onset, crescendo pattern; pulsating; moderate or severe intensity; aggravated by routine physical activity</td> <td>Pressure or tightness which waxes and wanes</td> <td>Pain begins quickly, reaches a crescendo within minutes; pain is deep, continuous, excruciating, and explosive in quality</td> </tr> <tr> <td>Patient appearance</td> <td>Patient prefers to rest in a dark, quiet room</td> <td>Patient may remain active or may need to rest</td> <td>Patient remains active</td> </tr> <tr> <td>Duration</td> <td>4 to 72 hours</td> <td>30 minutes to 7 days</td> <td>15 minutes to 3 hours</td> </tr> <tr> <td>Associated symptoms</td> <td>Nausea, vomiting, photophobia, phonophobia; may have aura (usually visual, but can involve other senses or cause speech or motor deficits)</td> <td>None</td> <td>Ipsilateral lacrimation and redness of the eye; stuffy nose; rhinorrhea; pallor; sweating; Horner syndrome; restlessness or agitation; focal neurologic symptoms rare; sensitivity to alcohol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68064 Version 6.0</div></div></div>"},"68065":{"type":"graphic_table","displayName":"Patient's Review","title":"Patient's Review","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient's Review</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Dimension of care</td> <td class=\"subtitle1\">Focus of a \"Patient's Review\"</td> <td class=\"subtitle1\">Suggestions for practice</td> </tr> <tr> <td>Respect for patients' values, preferences, and expressed needs</td> <td> <p>What are the patient's short-term and long-term goals?</p> <p>What level of involvement does the patient want in decision making?</p> <p>What does the patient need, want, or expect from the clinician and the visit?</p> </td> <td> <p>Learn about, and educate staff about, the health beliefs, practices, and mores of specific ethnic and cultural groups in your patient population.</p> <p>Use clinical interview protocols that elicit patients' perceptions about their illness and their expectations of treatment.</p> <p>Develop culturally appropriate standards for staff behavior with patients (for example, forms of address, rules of propriety).</p> <p>Ask, do not&nbsp;assume: Ask patients what they want to know; suggest questions that patients might have; ask patients if they understand.</p> <p>Ask, do not&nbsp;assume, how therapeutic decisions affect patients' lives, what patients' preferences would be among alternative treatments and outcomes.</p> <p>Negotiate therapeutic strategies with patients.</p> </td> </tr> <tr> <td>Coordination of care and integration of services within a clinical setting</td> <td> <p>Is care delivered by a range of providers effectively coordinated?</p> <p>Does the patient get consistent information from different clinicians?</p> </td> <td> <p>Give patients written and/or visual information identifying members of the clinical team, explaining the role of each, and make sure they know who is in charge of their care.</p> <p>Identify one person on the clinical team to serve as the primary conduit of information for the patient and his/her family.</p> <p>Find out about patients' experiences with clinical tests and procedures (for example, about waiting times, delays, pain or discomfort, and the information they were given).</p> <p>Give patients and their families realistic expectations about waiting times, levels of discomfort, possible side effects, and other factors relating to tests and procedures.</p> <p>Make sure that staff who come in contact with the patients have the responsibility, ability, and information to get patients what they want or need.</p> <p>Give all staff who come in regular contact with patients information about special needs, activity restrictions, and other appropriate information.</p> <p>Encourage staff at all levels to help patients solve their problems, and reward them for doing so.</p> </td> </tr> <tr> <td>Communication between patient and providers; dissemination of accurate, timely, and appropriate information; and education about the long-term implications of disease and illness</td> <td> <p>Does the patient have the information they want about clinical status, diagnostic tests, and treatment options?</p> <p>Do the patient and family know what they need to know to manage on their own to the extent they are able to do so?</p> </td> <td> <p>Establish explicit procedures that give patients ready access to knowledgeable health care professionals who can answer questions and give them help. Make sure patients understand and can follow these procedures.</p> <p>Clarify the goals of patient and provider.</p> <p>Consider giving patients access to their medical records; encourage questions; invite families and patients to write their goals for treatment in the record.</p> <p>Make communication a regular topic of staff meetings; use videotapes of real patient interactions to initiate discussion.</p> <p>Help patients learn negotiation strategies that can \"empower\" them in discussions with doctors and nurses.</p> <p>Encourage the patient and family to write down their questions and concerns.</p> <p>Learn and educate staff about the typical communication needs and patterns of the socio-demographic and cultural groups seen in your practice. Use these to heighten awareness of the differences among patients rather than to reinforce stereotypes. </p> <p>Identify staff members who have particular skill in translating \"technical\" language into \"everyday\" language, and use them to help improve communication.</p> <p>Tape record important conversations with patients and give them a copy of the tape to listen to later with their families. Encourage them to return with questions or confusion they had after listening to the tapes.</p> </td> </tr> <tr> <td>Enhancing physical comfort</td> <td> <p>Is pain alleviated as much as possible?</p> <p>Does the patient have the help they need with bathing, eating, household chores, or other activities of daily living?</p> <p>Have remediable deficits in functional status been adequately addressed?</p> </td> <td> <p>Help patients who experience pain communicate about it by asking them to rate the intensity of their pain on a scale of 1 to 10.</p> <p>Record patients' pain status along with other vital signs.</p> <p>Educate all clinical staff about appropriate pain control protocols; discuss misconceptions about narcotics and their true risks and benefits.</p> <p>Assess patients' functional status and available sources of support.</p> <p>Designate staff to get patients the help they need and reward them for doing so.</p> <p>Use natural and incandescent lighting wherever possible.</p> <p>Design traffic flow patterns and waiting areas to respect patients' privacy and need for conversational areas.</p> </td> </tr> <tr> <td>Emotional support and alleviation of fears and anxiety</td> <td> <p>Is the patient worried about their illness or its effect on the ability to care for themselves or their family?</p> <p>What are the principal stresses in the patient's life?</p> <p>Are they worried about paying medical bills or about lost income due to illness?</p> <p>Does the patient have access to appropriate support networks to help with these worries?</p> </td> <td> <p>Make videos on simple relaxation techniques available to patients to help them cope with medication side effects or stressful procedures.</p> <p>Review with patients the kind of information, assistance, and support they need and the approaches they find most helpful; make this a routine part of the history and physical.</p> <p>Identify or develop educational materials suited to patients' varied coping styles.</p> <p>Use focus groups or other methods of eliciting feedback from different types of patients to develop appropriate protocols and materials for administering the Patient Self-Determination Act.</p> <p>Using focus groups or other methods of patient involvement, plan services and programs with the same concern for patients' psychological and emotional needs that is devoted to their physical requirements.</p> <p>Identify patients with a serious illness or chronic disability and members of their families who are willing to share their experiences with others newly diagnosed.</p> <p>Give patients written information about available support and self-help groups.</p> </td> </tr> <tr> <td>Involvement of family and friends</td> <td> <p>Are family and friends included appropriately in planning and providing care?</p> <p>Do they have the support they need?</p> </td> <td> <p>Make appropriate staff available to counsel, educate, or meet with patients' family members; inform families of their availability.</p> <p>Encourage family members to write down or express their concerns; include these family notes in the patient's record.</p> <p>Offer families written or videotaped take-home materials with health information appropriate to their needs.</p> <p>Identify appropriate family support and referral services in your community. </p> <p>Train volunteers to visit the patient and family at home to help with unanticipated home care needs, such as filling prescriptions, running errands, coordinating home care services, or providing referrals to community resources.</p> <p>Develop appropriate protocols for assessing the needs of families of patients with serious or chronic ailments.</p> <p>Include patients and family members on committees or task forces to plan or evaluate clinical services.</p> </td> </tr> <tr> <td>Transition and continuity from one locus of care to another</td> <td> <p>Do the patient and family understand the medications to take, treatment regimens to follow, activities to pursue or avoid, and danger signals to look out for?</p> <p>Are there clear plans for continuing care and treatment?</p> </td> <td> <p>Identify the post-hospital needs of patients scheduled for hospitalization prior to their admission.</p> <p>Identify or design educational services that teach patients what they need to know to care for themselves away from the clinical setting.</p> <p>Encourage patients to write down their questions; make sure those questions are answered before they leave the hospital or clinic.</p> <p>Audiotape conversations at critical junctures of the patient's treatment and give patients a copy of the tape to take home.</p> <p>Make use of nursing or social work case managers to help coordinate care across sites or specialities.</p> <p>Designate staff to telephone patients after critical office visits or discharge from the hospital.</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68065 Version 6.0</div></div></div>"},"68066":{"type":"graphic_picture","displayName":"Dumon silicone stent","title":"Silicone Dumon tracheal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silicone Dumon tracheal stent</div><div class=\"cntnt\"><img style=\"width:428px; height:239px;\" src=\"images/PULM/68066_Dumon_silicone_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small studs on the external surface help prevent migration.</div><div id=\"graphicVersion\">Graphic 68066 Version 2.0</div></div></div>"},"68067":{"type":"graphic_figure","displayName":"Flow cytometry basics","title":"Fundamentals of flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Fundamentals of flow cytometry</div><div class=\"cntnt\"><img style=\"width:503px; height:432px;\" src=\"images/ALLRG/68067_Flow_cytometry_basics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorochrome (eg, fluorescein) conjugated directly to an antibody binds to a cell. Cells stained with fluorescein are stimulated by a laser-emitting light of a wavelength significant to stimulate the fluorescein molecule. Fluorescence occurs when the molecule excited by light of a particular wavelength loses its energy by emitting light of a longer wavelength. The fluorescence spectra shown above demonstrates the excitation spectra of a fluorochrome (left), the wavelength of a typical laser source, the emission spectra of a fluorochrome (right), and the wavelength range detected by a typical band pass filter.</div><div id=\"graphicVersion\">Graphic 68067 Version 2.0</div></div></div>"},"68068":{"type":"graphic_picture","displayName":"Cocci lung stain C","title":"<EM>Coccidioides</EM> spp in lung tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Coccidioides</EM> spp in lung tissue</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/ID/68068_Cocci_lung_stain_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spherules of <EM>Coccidioides</EM> spp in a transbronchial biopsy specimen stained with periodic acid-Schiff (PAS).</div><div class=\"graphic_reference\">Courtesy of Jeffrey Houck, MD.</div><div id=\"graphicVersion\">Graphic 68068 Version 3.0</div></div></div>"},"68070":{"type":"graphic_table","displayName":"Sports mouthguard PI","title":"Activities and sports that have a risk of mouth injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Activities and sports that have a risk of mouth injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acrobatics</td> <td>Racquetball</td> </tr> <tr> <td>Baseball</td> <td>Rugby</td> </tr> <tr> <td>Basketball</td> <td>Shotputting</td> </tr> <tr> <td>Bicycling</td> <td>Skateboarding</td> </tr> <tr> <td>Boxing</td> <td>Skiing</td> </tr> <tr> <td>Equestrian events</td> <td>Skydiving</td> </tr> <tr> <td>Field hockey</td> <td>Soccer</td> </tr> <tr> <td>Football</td> <td>Softball</td> </tr> <tr> <td>Gymnastics</td> <td>Squash</td> </tr> <tr> <td>Handball</td> <td>Surfing</td> </tr> <tr> <td>Ice hockey</td> <td>Volleyball</td> </tr> <tr> <td>Inline skating</td> <td>Water polo</td> </tr> <tr> <td>Lacrosse</td> <td>Weightlifting</td> </tr> <tr> <td>Martial arts</td> <td>Wrestling</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A mouthguard is recommended for children and adults who participate in any of the above activities.</div><div class=\"graphic_reference\">Adapted from: Ranalli, DN. Prevention of sports-related traumatic dental injuries. Dent Clin North Am 2000; 44:35.</div><div id=\"graphicVersion\">Graphic 68070 Version 3.0</div></div></div>"},"68071":{"type":"graphic_figure","displayName":"LVEF predicts one-year mortality after STEMI","title":"LVEF predicts one-year mortality after STEMI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LVEF predicts one-year mortality after STEMI</div><div class=\"cntnt\"><img style=\"width:422px; height:266px;\" src=\"images/CARD/68071_LVEF_post_MI_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 3197 patients with an acute ST elevation myocardial infarction (STEMI) who were treated with thrombolytic therapy in the TIMI II trial, the one-year mortality correlated with the resting left ventricular ejection fraction (LVEF) measured by radionuclide ventriculography obtained within 14 days of the event. The mortality was highest in patients with an LVEF &lt;30 percent (9.9 percent). Patients not undergoing study for any reason had an intermediate mortality of 6.6 percent.</div><div class=\"graphic_reference\">Data from Zaret BL, Wackers FJ, Terrin ML, et al. J Am Coll Cardiol 1995; 26:73.</div><div id=\"graphicVersion\">Graphic 68071 Version 3.0</div></div></div>"},"68072":{"type":"graphic_figure","displayName":"Prevalence on PPV and NPV","title":"Effect of disease prevalence on predictive values","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of disease prevalence on predictive values</div><div class=\"cntnt\"><img style=\"width:408px; height:296px;\" src=\"images/PC/68072_Prevalence_on_PPV_and_NPV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Consider a population of 2000 people and a diagnostic test that is 90 percent sensitive and specific. The positive and negative predictive values of the test vary when the prevalence of the disease is varied. <br />Left panel: If the prevalence of the disease is high at 50 percent, the positive and negative predictive values will be similar to the sensitivity and specificity (90 percent, respectively). <br />Right panel: In contrast, if the prevalence of the disease is only 10 percent, the positive predictive value decreases (50 percent), and the negative predictive value increases (99 percent).</div><div id=\"graphicVersion\">Graphic 68072 Version 2.0</div></div></div>"},"68075":{"type":"graphic_figure","displayName":"Male anatomy PI","title":"Male reproductive anatomy","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Male reproductive anatomy</div><div class=\"cntnt\"><img style=\"width:543px; height:527px;\" src=\"images/PI/68075_Male_anatomy_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows what a man's reproductive organs look like.</div><div id=\"graphicVersion\">Graphic 68075 Version 6.0</div></div></div>"},"68080":{"type":"graphic_table","displayName":"Prevalence of syncope II","title":"Causes of syncope in Framingham cohort","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of syncope in Framingham cohort</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Cause</td>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Prevalence,\npercent</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Men</td>\n\n      <td colspan=\"1\" class=\"subtitle2\">Women</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac</td>\n\n      <td>13.2</td>\n\n      <td>6.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stroke or transient ischemic attack</td>\n\n      <td>4.3</td>\n\n      <td>4.0</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Seizure disorder</td>\n\n      <td>7.2</td>\n\n      <td>3.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vasovagal </td>\n\n      <td>19.8</td>\n\n      <td>22.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Orthostatic hypotension</td>\n\n      <td>8.6</td>\n\n      <td>9.9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Medication </td>\n\n      <td>6.3</td>\n\n      <td>7.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other</td>\n\n      <td> 9.5</td>\n\n      <td>6.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Unknown</td>\n\n      <td>31.0</td>\n\n      <td>40.7</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Includes data from 727 patients.</div><div class=\"graphic_reference\">Data from Soteriades ES, Evans JC, Larson MG, et al. N Engl J Med 2002; 347:878.</div><div id=\"graphicVersion\">Graphic 68080 Version 2.0</div></div></div>"},"68081":{"type":"graphic_waveform","displayName":"ECG type I sinoatrial block","title":"Single-lead electrocardiogram (ECG) showing lead V1 in type I (Wenckebach type) sinoatrial block","html":"<div class=\"graphic normal\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing lead V1 in type I (Wenckebach type) sinoatrial block</div><div class=\"cntnt\"><img style=\"width:466px; height:87px;\" src=\"images/CARD/68081_Type_I_sinoatrial_Block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a 3:2 SA block, resulting in group beating of pairs of sinus beats. The P-P interval during the pause has a duration (1040 msec) that is less than two P-P cycles (1360 msec); this finding distinguishes this arrhythmia from type II SA block in which the pause duration is the same as that of two P-P cycles.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 68081 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"68083":{"type":"graphic_movie","displayName":"Correction of astigmatism","title":"Corrected astigmatism with cylindrical lens","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corrected astigmatism with cylindrical lens</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68083_corastgconv.mp4\" style=\"width:336px;height:226px\"></div><img style=\"width:334px; height:208px;\" src=\"images/CARD/68083_corastg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Astigmatism is corrected with cylindrical lenses to bring multiple points of focus on to the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 68083 Version 3.0</div></div></div>"},"68084":{"type":"graphic_diagnosticimage","displayName":"Angiogram clipped basilar aneurysm","title":"Clip ligation of cerebral aneurysm","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Clip ligation of cerebral aneurysm</div><div class=\"cntnt\"><img style=\"width:523px; height:308px;\" src=\"images/NEURO/68084_Clip_ligation_cerebral_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel:&nbsp;Anteroposterior cerebral angiogram demonstrating a basilar summit aneurysm.<br />Right panel: Postoperative cerebral angiogram demonstrating clip ligation of the lesion with preserved parent vessel patency.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 68084 Version 3.0</div></div></div>"},"68086":{"type":"graphic_table","displayName":"Developmental milestones 2 through 3 years","title":"Developmental milestones: 24 through 47 months","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Developmental milestones: 24 through 47 months</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"5\">Approximate chronologic age</td> </tr> <tr> <td class=\"subtitle2\">24 months</td> <td class=\"subtitle2\">2 years, 4 months</td> <td class=\"subtitle2\">2 years, 6 months</td> <td class=\"subtitle2\">2 years, 9 months</td> <td class=\"subtitle2\">3 years to 3 years, 6 months</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gross motor</strong></td> <td> <ul> <li>Walks down stairs, holding rail, both feet on each step </li> <li>Kicks ball without demo </li> <li>Throws overhand </li> </ul> </td> <td> <ul> <li>Jumps from bottom step one foot leading </li> <li>Walks on toes after demo </li> <li>Walks backward 10 steps </li> </ul> </td> <td> <ul> <li>Goes up stairs, with rail, alternating feet </li> <li>Jumps in place </li> <li>Stands with both feet on balance beam </li> <li>Walks with one foot on balance beam </li> </ul> </td> <td> <ul> <li>Walks swinging arms opposite of legs (synchronous gait) </li> </ul> </td> <td> <ul> <li>Balances on one foot: Three seconds </li> <li>Goes up stairs, no rail, alternating feet </li> <li>Pedals tricycle </li> <li>Walks heel-toe </li> <li>Catches ball, arms stiff </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fine motor/writing</strong></td> <td> <ul> <li>Makes a single-line \"train\" of cubes </li> <li>Imitates circle </li> <li>Imitates horizontal line </li> </ul> </td> <td> <ul> <li>Strings large beads (awkwardly) </li> <li>Unscrews jar lids </li> <li>Turns paper pages (often several at once) </li> </ul> </td> <td> <ul> <li>Makes an eight-cube tower </li> <li>Makes a \"train\" of cubes and includes a stack </li> </ul> </td> <td> <ul> <li>Makes a 9- to 10-cube tower </li> <li>Puts six square pegs in pegboard </li> <li>Imitates cross </li> </ul> </td> <td> <ul> <li>Copies circle </li> <li>Cuts with scissors: Side to side (awkwardly) </li> <li>Imitates bridge of cubes </li> <li>Strings small beads well </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Self-help</strong></td> <td> <ul> <li>Opens door using knob </li> <li>Sucks through straw </li> <li>Takes off clothes without buttons </li> <li>Pulls off pants </li> </ul> </td> <td> <ul> <li>Holds self and/or verbalizes toilet needs </li> <li>Pulls pants up with assistance </li> </ul> </td> <td> <ul> <li>Washes hands </li> <li>Puts things away </li> <li>Brushes teeth with assistance </li> </ul> </td> <td> <ul> <li>Toilet trained </li> <li>Puts on coat unassisted </li> </ul> </td> <td> <ul> <li>Eats independently </li> <li>Pours liquid </li> <li>Puts on shoes without laces </li> <li>Spreads with knife </li> <li>Unbuttons </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cognitive/academic</strong></td> <td> <ul> <li>Sorts objects </li> <li>Matches objects to pictures </li> <li>Shows use of familiar objects </li> </ul> </td> <td> <ul> <li>Matches shapes </li> <li>Matches colors </li> </ul> </td> <td> <ul> <li>Re-places circle in form board after it has been turned around (little or no trial and error) </li> <li>Points to small details in pictures </li> </ul> </td> <td> <ul> <li>Points to self in photos </li> <li>Points to body parts according to function (eg, \"what do you hear with...?\") </li> </ul> </td> <td> <ul> <li>Draws a two to three part person </li> <li>Understands big/small, more/less </li> <li>Knows own gender </li> <li>Knows own age </li> <li>Matches letters/numerals </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Social/emotional</strong></td> <td> <ul> <li>Parallel play </li> <li>Begins to mask emotions for social etiquette </li> </ul> </td> <td> <ul> <li>Reduction in separation anxiety </li> </ul> </td> <td> <ul> <li>Imitates adult activities (eg, sweeping, talking on the phone, pretending to hunt animals) </li> </ul> </td> <td> <ul> <li>Begins to take turns </li> <li>Tries to help with household tasks </li> </ul> </td> <td> <ul> <li>Starts to share with/without prompt </li> <li>Fears imaginary things </li> <li>Imaginative play </li> <li>Uses words to describe what someone else is thinking (eg, \"Mom thought I was asleep\") </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Receptive language</strong></td> <td> <ul> <li>Follows two-step commands </li> <li>Understands \"me\"/\"you\" </li> <li>Points to 5 to 10 pictures </li> </ul> </td> <td> <ul> <li>Understands \"just one\" </li> </ul> </td> <td> <ul> <li>Follows two prepositions (eg, \"put block in...on box\") </li> <li>Points to objects by use (eg, \"ride in...,\" \"put on feet...,\" \"write with\") </li> </ul> </td> <td> <ul> <li>Understands three prepositions </li> <li>Understands dirty/wet </li> </ul> </td> <td> <ul> <li>Points to parts of picture (eg, nose of cow, door of car) </li> <li>Understands action words (eg, playing, washing, blowing) </li> <li>Names body parts when function is described </li> <li>Understands negatives </li> <li>Groups objects (eg, food, toys) </li> <li>Understands long/short </li> </ul> </td> </tr> <tr> <td><strong>Expressive language</strong></td> <td> <ul> <li>Uses two-word sentences (noun + verb) </li> <li>Telegraphic speech </li> <li>50+ word vocabulary </li> <li>50% intelligibility </li> <li>Refers to self by name </li> <li>Names three pictures </li> </ul> </td> <td> <ul> <li>Repeats two digits </li> <li>Begins to use pronouns (eg, I, me, you) </li> <li>Names 10 to 15 pictures </li> </ul> </td> <td> <ul> <li>Echolalia and jargoning gone </li> <li>Names objects by use </li> <li>Refers to self with correct pronoun </li> <li>Recites parts of well-known story/fills in words </li> </ul> </td> <td> <ul> <li>Gives first and last name </li> <li>Rote counts to three </li> <li>Begins to use past tense </li> <li>Enjoys being read to (short books) </li> </ul> </td> <td> <ul> <li>Uses 200+ words </li> <li>Three word sentences </li> <li>Uses pronouns correctly </li> <li>75% intelligibility </li> <li>Uses plurals </li> <li>Names body parts by use </li> <li>Asks to be read to </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">© 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS: Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.</div><div id=\"graphicVersion\">Graphic 68086 Version 12.0</div></div></div>"},"68087":{"type":"graphic_diagnosticimage","displayName":"Inferior vena cava flow TR","title":"Inferior vena cava in tricuspid insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inferior vena cava in tricuspid insufficiency</div><div class=\"cntnt\"><img style=\"width:376px; height:266px;\" src=\"images/CARD/68087_Inferior_vena_cava_flow_TR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis view of the inferior vena cava (IVC) is obtained from the subcostal window (panel A); the hepatic veins (HV), and the entrance of the IVC into the right atrium (RA) are seen. Color flow Doppler (red) demonstrates retrograde systolic flow into the IVC and HV (panel B). Pulsed Doppler shows loss of normal systolic forward flow with exaggerated reversal of flow and an exaggerated V wave with inspiration (panel C). In addition to demonstrating systolic pulsations of the IVC, intavenous upper extremity saline contrast can be used detect retrograde systolic flow into the hepatic veins (panel D).</div><div id=\"graphicVersion\">Graphic 68087 Version 3.0</div></div></div>"},"68089":{"type":"graphic_figure","displayName":"Relative risk of stroke in chronic kidney disease","title":"Relative risk of stroke in chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Relative risk of stroke in chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:546px; height:272px;\" src=\"images/NEPH/68089_Stroke_risk_CKD_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The risk for stroke depending on different stages of CKD is shown: Even patients with mild to moderate reductions in the eGFR suffer from a markedly higher stroke rate. This effect was much more impressive in patients with hemodialysis, especially if atrial fibrillation occurred. However, due to differences in patient characteristics, the concrete increase in risk differed from study to study.</div><div class=\"graphic_footnotes\">eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; USRD: United States Renal Data System.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population - the Ohasama study. Nephrol Dial Transplant 2007; 22:1910.</li>&#xD;&#xA;    <li>US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases, 2006.</li>&#xD;&#xA;    <li>US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases, 2005.</li>&#xD;&#xA;    <li>Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92:868.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 68089 Version 6.0</div></div></div>"},"68090":{"type":"graphic_table","displayName":"Clinical practice guidelines criteria","title":"Criteria for trustworthy clinical practice guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for trustworthy clinical practice guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Standard</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>1. Transparency</td> <td>Guidelines should include an explicit description of process and funding.</td> </tr> <tr> <td>2. Conflict of interest</td> <td>Conflicts of interest for the guidelines development group should be managed by reporting, exclusion, and divestments.</td> </tr> <tr> <td>3. Members of the guidelines development group</td> <td>The group should be multidisciplinary and balanced.</td> </tr> <tr> <td>4. Review of the literature</td> <td>The guideline should be based on systematic reviews of the literature.</td> </tr> <tr> <td>5. Rating strength of evidence and recommendations</td> <td>Each recommendation should be accompanied by the underlying reasoning, potential benefits and harms, the evidence and its quality, the contribution of values and experience, rating of the level of confidence in the evidence and the strength of the recommendation, and differences of opinion regarding recommendations.</td> </tr> <tr> <td>6. Presentation of recommendations</td> <td>The guideline should state precisely the recommended actions, when they should be performed, and how they could be measured for evaluation of compliance.</td> </tr> <tr> <td>7. External review</td> <td>The guidelines should be reviewed by the full spectrum of relevant stakeholders. The general public should have an opportunity to review the guidelines before they are final.</td> </tr> <tr> <td>8. Updating</td> <td>Guidelines should state date of publication and evidence review and be updated when new, clinically-important evidence is available.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91713&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Clinical_practice_guidelines.htm</title></head></div><div class=\"graphic_reference\">Based on data from the consensus report: Clinical Practice Guidelines We Can Trust. Institute of Medicine of The National Academies. Report available at: <A href=\"http://nationalacademies.org/hmd/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx\">http://nationalacademies.org/hmd/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx</A>.</div><div id=\"graphicVersion\">Graphic 68090 Version 4.0</div></div></div>"},"68091":{"type":"graphic_table","displayName":"Graded prognostic assessment for brain metastases from melanoma","title":"Graded prognostic assessment for brain metastases from melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Graded prognostic assessment for brain metastases from melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle1\" colspan=\"3\">Graded prognostic assessment (GPA) scoring criteria</td> <td class=\"subtitle1\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">0.5</td> <td class=\"subtitle2\">1.0</td> </tr> <tr class=\"divider_bottom\"> <td>Age (years)</td> <td class=\"centered\">&#8805;70</td> <td class=\"centered\">&#60;0</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Karnofsky performance status (KPS)</td> <td class=\"centered\">&#8804;70</td> <td class=\"centered\">80</td> <td class=\"centered\">90 to 100</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Extracranial metastases (ECM)</td> <td class=\"centered\">Present</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Absent</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Number of brain metastases (BM)</td> <td class=\"centered\">&#62;4</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><em>BRAF</em> gene status</td> <td class=\"centered\">Negative/unknown</td> <td class=\"centered\">Positive</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td colspan=\"4\" align=\"right\"><strong>Sum:</strong></td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Median survival (months) by GPA:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>0 to 1.0 = 4.9</li>&#xD;&#xA;    <li>1.5 to 2.0 = 8.3</li>&#xD;&#xA;    <li>2.5 to 3.0 = 15.8</li>&#xD;&#xA;    <li>3.5 to 4.0 = 34.1</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reproduced from: Sperduto PW, Kased N, Roberge D, et al. Sperduto PW, Jiang W, Brown PD, et al. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 2017; 99:812. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68091 Version 6.0</div></div></div>"},"68093":{"type":"graphic_picture","displayName":"Linear ulcers Crohn Endosc","title":"Linear ulcerations in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear ulcerations in Crohn disease</div><div class=\"cntnt\"><img style=\"width:368px; height:183px;\" src=\"images/GAST/68093_Linear_ulcers_Crohns_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy shows linear ulcers that can course for several centimeters along the longitudinal axis of the colon in Crohn disease.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 68093 Version 4.0</div></div></div>"},"68095":{"type":"graphic_table","displayName":"Hypertensive herbal ingredients","title":"Hypertensive herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypertensive herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Bayberry</td>\n<td>Hypertensive, myricitrin mineralocorticoid side effect</td>\n</tr>\n<tr>\n<td>Broom</td>\n<td>Hypertensive, alkaloid effect, stated to be contraindicated in hypertensive individuals</td>\n</tr>\n<tr>\n<td>Capsicum</td>\n<td>Hypertensive, increased catecholamine secretion</td>\n</tr>\n<tr>\n<td>Cohosh, blue</td>\n<td>Hypertensive, methylcytisine has nicotinic action, alkaloid effect</td>\n</tr>\n<tr>\n<td>Cola</td>\n<td>Hypertensive, caffeine</td>\n</tr>\n<tr>\n<td>Coltsfoot</td>\n<td>Hypertensive, pressor activity</td>\n</tr>\n<tr>\n<td>Gentian</td>\n<td>Stated to be contraindicated in hypertensive individuals</td>\n</tr>\n<tr>\n<td>Ginger</td>\n<td>Hypertensive</td>\n</tr>\n<tr>\n<td>Ginseng, Panax</td>\n<td>Hypertensive, human and in vivo</td>\n</tr>\n<tr>\n<td>Liquorice</td>\n<td>Hypertensive, mineralocorticoid side effect</td>\n</tr>\n<tr>\n<td>Mat&#233;</td>\n<td>Hypertensive, caffeine</td>\n</tr>\n<tr>\n<td>Vervain</td>\n<td>Hypertensive</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p. 282.</div><div id=\"graphicVersion\">Graphic 68095 Version 2.0</div></div></div>"},"68096":{"type":"graphic_figure","displayName":"Dermatomal innervation","title":"Cutaneous dermatomal innervation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous dermatomal innervation</div><div class=\"cntnt\"><img style=\"width:319px; height:280px;\" src=\"images/PULM/68096_Dermatomal_innervation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded areas indicate the dermatomes supplied by the brachial plexus, which may be involved by superior sulcus tumors.</div><div id=\"graphicVersion\">Graphic 68096 Version 1.0</div></div></div>"},"68097":{"type":"graphic_diagnosticimage","displayName":"EUS liver metastasis FNA","title":"Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of liver metastasis","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of liver metastasis</div><div class=\"cntnt\"><img style=\"width:455px; height:364px;\" src=\"images/PULM/68097_EUS_liver_metastasis_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Endoscopic ultrasound (EUS) image of a 2 cm left liver lesion. B) EUS-guided fine-needle aspiration (FNA) of the lesion. The radio-opaque needle can be seen entering the lesion from the upper right. C) Cytology showing non-small cell carcinoma (60X).</div><div id=\"graphicVersion\">Graphic 68097 Version 5.0</div></div></div>"},"68098":{"type":"graphic_table","displayName":"Relevant info from RADS subject","title":"Relevant information to be obtained from subjects with possible reactive airways dysfunction syndrome or with asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relevant information to be obtained from subjects with possible reactive airways dysfunction syndrome or with asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Was the onset of symptoms related to one \"memorable\" event in which there was exposure to a gas, fume, or dust?</td> </tr> <tr> <td>Were there repeated gas, fume, or dust exposures of lesser intensities that still forced the subject to leave the premises?</td> </tr> <tr> <td>Is there any ongoing exposure?</td> </tr> <tr> <td>What was the nature of the substance? Has it been previously described as causing RADS (eg, acetic acid, ammonia, chlorine, isocyanates, mustard gas, fire/smoke)? Absence on a list of agents causing RADS does not exclude the diagnosis.</td> </tr> <tr> <td>Was the concentration of the offending agent likely to be above accepted levels?</td> </tr> <tr> <td>Were other workers or persons in the vicinity also affected?</td> </tr> <tr> <td>Were there ocular or nasal symptoms? How long after the exposure(s) did they develop?</td> </tr> <tr> <td>Describe the timing sequence of onset and diminution of symptoms: eg, immediate cough, shortness of breath after 30 min, wheezing after 1 hour, etc.</td> </tr> <tr> <td>Was there a visit to an emergency room or a physician's office?</td> </tr> <tr> <td>Were lung function tests, blood gases, or chest radiography performed soon after the event?</td> </tr> <tr> <td>Was treatment initiated? What medications were used? What were the dose and duration?</td> </tr> <tr> <td>Were there subsequent assessments, including records of symptoms, chest auscultation (wheezing), spirometry, bronchial responsiveness, and allergy skin tests?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68098 Version 3.0</div></div></div>"},"68100":{"type":"graphic_table","displayName":"Common causes of in-toeing","title":"Clinical features of common causes of in-toeing in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of common causes of in-toeing in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Metatarsus adductus</td> <td class=\"subtitle1\">Internal tibial torsion</td> <td class=\"subtitle1\">Increased femoral anteversion</td> </tr> <tr> <td><strong>Description</strong></td> <td>Medial deviation of the forefoot on the hindfoot</td> <td>Internal (medial) rotation of the tibia relative to the transcondylar axis of the femur</td> <td>Increased angle between the axis of the femoral neck and the transcondylar axis of the femur</td> </tr> <tr> <td><strong>Most common age group</strong></td> <td>Birth to 1 year</td> <td>1 to 3 or 4 years</td> <td>&#62;3 years</td> </tr> <tr> <td><strong>Foot progression angle</strong></td> <td>Internal</td> <td>Internal</td> <td>Internal</td> </tr> <tr> <td><strong>Patellar progression angle</strong></td> <td>Neutral/external</td> <td>Neutral/external</td> <td>Internal</td> </tr> <tr> <td><strong>Evaluation</strong></td> <td>Heel bisector line* falls lateral to second toe</td> <td>Thigh foot angle<sup>&#182;</sup> is neutral or internal (negative)</td> <td>Symmetrically increased internal (medial) hip rotation<sup>&#916;</sup></td> </tr> <tr> <td><strong>Laterality</strong></td> <td>Usually bilateral; may be unilateral with L&#62;R</td> <td>Usually bilateral; may be unilateral with L&#62;R</td> <td>Bilateral; other conditions should be considered if unilateral</td> </tr> <tr> <td><strong>Other clinical features</strong></td> <td> <p>May be associated with other \"packaging problems\"</p> Normal range of motion at ankle and subtalar joint</td> <td>Medial malleolus level with or posterior to lateral malleolus when seated with thigh directly in front of hip joint and the knee pointed straight ahead</td> <td> <p>Sits in \"W\" position</p> <p>Runs with \"egg-beater\" or \"wind-mill\" pattern</p> <p>More common in girls</p> Tends to run in families</td> </tr> <tr> <td><strong>Natural history</strong></td> <td>Resolves by age 1 year</td> <td>Resolves by age 5 years</td> <td>Resolves by age 11 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The heel bisector line is measured with the child prone, the knee flexed, and ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated parallel to the heel and extended distally to the toes. (See text for details).<br />¶ The thigh-foot angle is measured with the child prone, the knee flexed, and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle. (See text for details).<br />Δ Internal hip rotation is measured with the child prone and the knees flexed. The lower leg is rotated away from the axis of the body. (See text for details).</div><div id=\"graphicVersion\">Graphic 68100 Version 4.0</div></div></div>"},"68101":{"type":"graphic_picture","displayName":"Dome shaped papules","title":"Multiple monomorphic, dome-shaped papules and nodules that appeared on the head and neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple monomorphic, dome-shaped papules and nodules that appeared on the head and neck</div><div class=\"cntnt\"><img style=\"width:419px; height:504px;\" src=\"images/ID/68101_Dome_shaped_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &#169;2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 68101 Version 1.0</div></div></div>"},"68102":{"type":"graphic_diagnosticimage","displayName":"Traumatic subdural hematoma","title":"Traumatic subdural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic subdural hematoma</div><div class=\"cntnt\"><img style=\"width:380px; height:424px;\" src=\"images/NEURO/68102_TBI_subdural_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan showing a left acute subdural hematoma (SDH, arrow). Subdural hematomas are typically crescent-shape. In this case the SDH is causing significant mass effect and shift of midline structures to the right.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: J Claude Hemphill III, MD and Nicholas Phan, MD, FRCSC.</div><div id=\"graphicVersion\">Graphic 68102 Version 4.0</div></div></div>"},"68103":{"type":"graphic_diagnosticimage","displayName":"Effect of gestational age on UA Doppler indices","title":"Gestational age effect on umbilical arterial Doppler frequency shift waveforms","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Gestational age effect on umbilical arterial Doppler frequency shift waveforms</div><div class=\"cntnt\"><img style=\"width:549px; height:577px;\" src=\"images/OBGYN/68103_GA_effect_on_UA_Doppler_ind.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Waveform panels are organized from top to bottom according to advancing gestational age. Note the progressive increase in the end-diastolic velocity and the concomitant fall in the pulsatility as the gestation advances.</div><div class=\"graphic_footnotes\">A: 16 weeks; B: 20 weeks; C: 24 weeks; D: 28 weeks; E: 32 weeks; F:36 weeks; G: 40 weeks; m/s: meters per second.</div><div class=\"graphic_reference\">Reproduced with permission from Maulik, D. Absent end-diastolic velocity in the umbilical artery and its clinical significance. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 129, New York, Springer Verlag. Copyright &#169; 1997 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 68103 Version 2.0</div></div></div>"},"68106":{"type":"graphic_table","displayName":"Causes edema childhood","title":"Causes of edema in childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of edema in childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Generalized edema</td> </tr> <tr> <td class=\"subtitle2_single\">Increased capillary hydrostatic pressure</td> </tr> <tr> <td class=\"subtitle3_single\">Increased plasma volume from sodium and water retention</td> </tr> <tr> <td class=\"sublist3_start\">Heart failure</td> </tr> <tr> <td class=\"sublist3\">(Localization can be seen in some cardiac disease)</td> </tr> <tr> <td class=\"sublist3_start\">Primary renal disease</td> </tr> <tr> <td class=\"sublist3\">Acute glomerulonephritis</td> </tr> <tr> <td class=\"sublist3\">Renal failure (acute/chronic)</td> </tr> <tr> <td class=\"sublist3\">Nephrotic syndrome</td> </tr> <tr> <td class=\"sublist3_start\">Drug induced</td> </tr> <tr> <td class=\"sublist3\">Vasodilators (eg, minoxidil)</td> </tr> <tr> <td class=\"sublist3\">Dihydropyridine calcium channel blockers (eg, nifedepine and amlodipine)</td> </tr> <tr> <td class=\"subtitle3_single\">Venous obstruction</td> </tr> <tr> <td class=\"indent2\">Hepatic cirrhosis</td> </tr> <tr> <td class=\"subtitle2_single\">Decreased capillary oncotic pressure (Hypoalbuminemia)</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> </tr> <tr> <td class=\"indent1\">Liver failure</td> </tr> <tr> <td class=\"indent1\">Protein losing enteropathy</td> </tr> <tr> <td class=\"indent1\">Protein malnutrition (kwashiorkor)</td> </tr> <tr> <td class=\"subtitle2_single\">Increased capillary permeability</td> </tr> <tr> <td class=\"indent1\">Burn</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"subtitle1_single\">Localized edema</td> </tr> <tr> <td class=\"subtitle2_single\">Increased capillary hydrostatic pressure</td> </tr> <tr> <td class=\"subtitle3_single\">Venous obstruction</td> </tr> <tr> <td class=\"indent2\">Extrinsic compression (tumor or lymphadenopathy)</td> </tr> <tr> <td class=\"indent2\">Venous thrombosis</td> </tr> <tr> <td class=\"subtitle2_single\">Increased interstitial hydrostatic pressure</td> </tr> <tr> <td class=\"subtitle3_single\">Lymphatic obstruction</td> </tr> <tr> <td class=\"sublist3_start\">Primary</td> </tr> <tr> <td class=\"sublist3\">Turner syndrome</td> </tr> <tr> <td class=\"sublist3\">Noonan syndrome</td> </tr> <tr> <td class=\"sublist3\">Milroy's disease</td> </tr> <tr> <td class=\"sublist3\">Lymphedema praecox</td> </tr> <tr> <td class=\"sublist3_start\">Secondary</td> </tr> <tr> <td class=\"sublist3\">Lymphadenitis</td> </tr> <tr> <td class=\"sublist3\">Granulomatous lymphangitis</td> </tr> <tr> <td class=\"sublist3\">Autoimmune disease (juvenile idiopathic arthritis &#38; Crohn's disease)</td> </tr> <tr> <td class=\"subtitle2_single\">Increased capillary permeability</td> </tr> <tr> <td class=\"subtitle3_single\">Angioedema</td> </tr> <tr> <td class=\"indent2\">Allergic reaction</td> </tr> <tr> <td class=\"indent2\">Hereditary angioedema</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68106 Version 4.0</div></div></div>"},"68107":{"type":"graphic_figure","displayName":"Posterolateral view right elbow","title":"Posterolateral view of right elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterolateral view of right elbow</div><div class=\"cntnt\"><img style=\"width:445px; height:510px;\" src=\"images/EM/68107_Posterolateral_view_right_e.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68107 Version 2.0</div></div></div>"},"68108":{"type":"graphic_table","displayName":"Causes of sellar masses","title":"Causes of sellar masses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of sellar masses</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">Benign tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pituitary adenoma (most common sellar mass)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Craniopharyngioma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Meningiomas</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Pituitary hyperplasia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Lactotroph hyperplasia (during pregnancy)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Thyrotroph and gonadotroph hyperplasia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\"> Somatotroph hyperplasia due to ectopic GHRH</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Malignant tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Primary</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Germ cell tumor (ectopic pinealoma)</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Sarcoma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Chordoma</td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Pituitary carcinoma (rare)</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\">Metastatic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Lung</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Breast</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Cysts</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Rathke's cleft</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Arachnoid</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Dermoid</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pituitary abscess</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphocytic hypophysitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carotid arteriovenous fistula</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=14234&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_sellar_masses.htm</title></head></div><div class=\"graphic_footnotes\">GHRH: growth hormone-releasing hormone.</div><div id=\"graphicVersion\">Graphic 68108 Version 2.0</div></div></div>"},"68110":{"type":"graphic_picture","displayName":"Leukoerythroblastic blood smear","title":"Leukoerythroblastic peripheral blood smear","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukoerythroblastic peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/HEME/68110_Leukoerythroblastic_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leukoerythroblastic peripheral blood smear showing the presence of nucleated red cells and immature white cells. This pattern occurs with marrow replacement, usually due to fibrosis that may be idiopathic (eg, primary myelofibrosis) or reactive to conditions such as metastatic cancer.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 68110 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"68112":{"type":"graphic_picture","displayName":"Erythema gyratum repens 2","title":"Erythema gyratum repens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema gyratum repens</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68112_Erythema_gyratum_repens_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple concentric erythematous plaques are present in this patient with erythema gyratum repens.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68112 Version 4.0</div></div></div>"},"68113":{"type":"graphic_movie","displayName":"Upright BOB technique for shoulder reduction","title":"Upright best-of-both (BOB) shoulder reduction technique","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upright best-of-both (BOB) shoulder reduction technique</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/68113_BOB.mp4\" style=\"width:448px;height:352px\"></div><img style=\"width:432px; height:324px;\" src=\"images/EM/68113_BOB.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD © Scott Sherman. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68113 Version 3.0</div></div></div>"},"68114":{"type":"graphic_picture","displayName":"Nontoxic mushroom ingestion","title":"Nontoxic mushroom ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nontoxic mushroom ingestion</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/EM/68114_Nontoxic_mushroom_ingest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These mushroom pieces were brought to the emergency department after a pediatric exposure. After consultation with the regional poison control center, the mushroom was identified as the nontoxic and potentially edible Amanita rubescens (&quot;the blusher mushroom&quot;).</div><div class=\"graphic_reference\">Courtesy of Paul Dengler.</div><div id=\"graphicVersion\">Graphic 68114 Version 1.0</div></div></div>"},"68115":{"type":"graphic_picture","displayName":"Lead line in gingival tooth border","title":"Lead line in gingival tooth border","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lead line in gingival tooth border</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PC/68115_Lead_line.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This man with severe lead poisoning has a \"lead line,\" a bluish-gray thin line running along the gingival tooth border, which also has considerable plaque. It is best seen at the location of the arrow. In patients with poor oral hygiene, hydrogen sulfide released by bacteria in the gingival pockets may react with lead in the gingival circulation to produce lead sulfide, a precipitate that appears as a darkly pigmented blue-gray line.</div><div id=\"graphicVersion\">Graphic 68115 Version 3.0</div></div></div>"},"68117":{"type":"graphic_figure","displayName":"Moro reflex","title":"Moro reflex","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Moro reflex</div><div class=\"cntnt\"><img style=\"width:535px; height:645px;\" src=\"images/PEDS/68117_Moro_reflex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Moro reflex is present starting at 32 weeks gestation and disappears by three to six months of age. It is elicited by the sudden dropping of the infant's head in relation to the trunk and results in abduction and extension of the infant's arms and opening of the hands, followed by flexion.</div><div id=\"graphicVersion\">Graphic 68117 Version 2.0</div></div></div>"},"68118":{"type":"graphic_figure","displayName":"Definition standard drink","title":"Definition of a \"standard drink\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Definition of a &quot;standard drink&quot;</div><div class=\"cntnt\"><img style=\"width:446px; height:758px;\" src=\"images/PC/68118_Definition_standard_drink.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Note: Depending on factors such as the type of spirits and the recipe, one mixed drink can contain from one to three or more standard drinks.</div><div class=\"graphic_reference\">National Institute on Alcohol Abuse and Alcoholism - http://pubs.niaaa.nih.gov/publications/Practitioner/pocketguide/pocket_guide2.htm.</div><div id=\"graphicVersion\">Graphic 68118 Version 1.0</div></div></div>"},"68120":{"type":"graphic_picture","displayName":"TB breast","title":"Tuberculosis of the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis of the breast</div><div class=\"cntnt\"><img style=\"width:396px; height:255px;\" src=\"images/PC/68120_Tuberculosis_of_the_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculosis of the breast often presents with both breast and axillary sinuses.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 68120 Version 3.0</div></div></div>"},"68122":{"type":"graphic_diagnosticimage","displayName":"Tracheal diverticul CXR CT","title":"Chest radiograph and CT scan of a tracheal diverticulum","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and CT scan of a tracheal diverticulum</div><div class=\"cntnt\"><img style=\"width:578px; height:381px;\" src=\"images/PULM/68122_Tracheal_diverticul_CXR_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Chest radiograph displays a large right-sided rounded lucency at the base of the neck above the thoracic inlet. B) The CT scan confirms the nature of the lucency. It has the typical features of a tracheal diverticulum.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68122 Version 2.0</div></div></div>"},"68127":{"type":"graphic_figure","displayName":"Hindfoot forefoot mobility test","title":"Hindfoot and forefoot mobility testing","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Hindfoot and forefoot mobility testing</div><div class=\"cntnt\"><img style=\"width:455px; height:435px;\" src=\"images/SM/68127_Hindfoot_forefoot_mobility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Note the interdependence between the hindfoot and the forefoot, the heel, first metatarsal head, and fifth metatarsal head have a tripod relationship. When the first metatarsal is pronated, the forefoot supinates to get the first and fifth metatarsal heads flat on the floor and the hindfoot inverts. <br />(C, D) In the Coleman standing lateral block test, the heel and lateral border of the foot are on a 1.5-inch block, and the first and second metatarsals dangle at the edge of the block into pronation. When mobility is present between the hindfoot and the forefoot, the heel moves to its normal position of 5 degrees eversion. <br />(E, F) In the Carroll test, the patient stands with his hindfoot on a 2 or 3-inch wooden block (or a hard book) and the forefoot dangles free at the edge of the block. When flexibility between the hindfoot and forefoot is normal, the heel everts to normal position.</div><div class=\"graphic_reference\">Reproduced with permission from: Tachdjian, MO. Clinical pediatric orthopedics: the art of diagnosis and principles of management. Appleton &amp; Lange, Stamford, CT 1997. p.52. Copyright © 1997 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 68127 Version 2.0</div></div></div>"},"68129":{"type":"graphic_figure","displayName":"Gallbladder anatomy PI","title":"Anatomy of the gallbladder","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Anatomy of the gallbladder</div><div class=\"cntnt\"><img style=\"width:543px; height:396px;\" src=\"images/PI/68129_Gallbladder_anatomy_PI_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gallbladder (shown in green) is a small, pear-shaped organ that is tucked under the liver. It stores bile, a fluid that is made in the liver and helps the body break down fat. When you eat a meal that has fat in it, your gallbladder empties the bile into a tube called the &quot;bile duct.&quot; The bile duct carries the bile into the small intestine to help with digestion.</div><div id=\"graphicVersion\">Graphic 68129 Version 4.0</div></div></div>"},"68130":{"type":"graphic_algorithm","displayName":"Algorithm first-trimester bleeding","title":"Algorithm for the evaluation of first-trimester uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of first-trimester uterine bleeding</div><div class=\"cntnt\"><img style=\"width:530px; height:487px;\" src=\"images/OBGYN/68130_Algorithmvaginalbleeding.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin.<br />* This step may be omitted in women who are known to have an intrauterine pregnancy. Proceed directly to ultrasound examination.</div><div id=\"graphicVersion\">Graphic 68130 Version 5.0</div></div></div>"},"68131":{"type":"graphic_table","displayName":"ABVD chemotherapy for Hodgkin lymphoma","title":"ABVD chemotherapy for Hodgkin lymphoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ABVD chemotherapy for Hodgkin lymphoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>25 mg/m<sup>2</sup> IV</td> <td>Dilute in 50 mL normal saline (NS) and administer over three to five minutes through a central line or IV push through a peripheral line.</td> <td>Days 1 and 15</td> </tr> <tr> <td>Bleomycin*</td> <td>10 units/m<sup>2</sup> IV</td> <td> <p>Dilute in 50 mL NS and administer over 10 minutes or IV push through a peripheral line.</p> Test dose of 2 units given one hour before full dose can be considered for the first cycle.<sup>&#182;</sup></td> <td>Days 1 and 15</td> </tr> <tr> <td>Vinblastine</td> <td>6 mg/m<sup>2</sup> IV</td> <td>Administer over one minute.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_bottom\"> <td>Dacarbazine</td> <td>375 mg/m<sup>2</sup> IV</td> <td> <p>Central line: Dilute in 250 mL of 5% dextrose (D5W) and administer over 30 minutes.</p> <p>Peripheral line: Dilute in 500 mL of D5W and administer over 60 minutes.</p> Dacarbazine should be protected from light.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with acetaminophen prior to administration of the full bleomycin dose. Some clinicians administer a bleomycin test dose before the first cycle. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin and vinblastine are vesicants. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is generally not indicated, and G-CSF is avoided in some centers because of concerns that concurrent use may increase bleomycin lung toxicity. </li> <li>Refer to UpToDate topic on \"Bleomycin-induced lung injury\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A dose reduction in bleomycin of at least 25% is recommended for patients with creatinine clearance 10 to 50 mL/min, and at least 50% reduction for clearance &#60;10 mL/min. Chemotherapy dose adjustments for doxorubicin and vinblastine are needed in patients with cholestasis. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential, electrolytes, renal function, and liver function prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cumulative doxorubicin dose should be monitored. Measure left ventricular ejection fraction prior to first cycle, then as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for respiratory complaints or unexplained findings on lung exam (eg, rales). Maximum bleomycin lifetime dose not to exceed 400 mg. Measure pulmonary diffusion capacity before first cycle and then per institutional policy. </li> <li>Refer to UpToDate topic on \"Bleomycin-induced lung injury\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>No routine dose modifications; G-CSF is not routinely administered unless previous cycles were complicated by infection or fever in setting of neutropenia. </li> <li>Refer to the UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Bleomycin should be discontinued in patients with documented or strongly suspected bleomycin-induced lung injury. </li> <li>Refer to UpToDate topic on \"Bleomycin-induced lung injury\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>For severe paresthesias and/or constipation, the dose of vinblastine may be reduced by 50%; vinblastine should be discontinued permanently if an adynamic ileus occurs. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CBC: complete blood count; WBC: white blood cell.<br />* 1 mg bleomycin = 1 unit bleomycin.<br />¶ A test dose of bleomycin before the first dose is recommended by the manufacturer;<SUP>[2]</SUP> however, many institutions no longer perform this test dose. Refer to UpToDate topic on infusion reactions to systemic chemotherapy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.</LI>&#xD;&#xA;<LI>Bleomycin sulfate injection. United States Prescribing Information. US National Library of Medicine. dailymed.nlm.nih.gov (Accessed on January 3, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 68131 Version 40.0</div></div></div>"},"68132":{"type":"graphic_picture","displayName":"JXG leg","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68132_JXG_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single yellow-orange nodule on the leg of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Kate P&#252;ttgen.</div><div id=\"graphicVersion\">Graphic 68132 Version 1.0</div></div></div>"},"68133":{"type":"graphic_figure","displayName":"LV diastolic distensibility - SHF versus DHF","title":"LV diastolic distensibility - SHF versus DHF","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">LV diastolic distensibility - SHF versus DHF</div><div class=\"cntnt\"><img style=\"width:478px; height:390px;\" src=\"images/CARD/68133_SHF_vs_DHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular (LV) diastolic pressure versus volume relationship is significantly different in patients with diastolic heart failure (DHF) compared with systolic heart failure (SHF) patients. In this graph, the LV diastolic pressure versus volume relationship (from mitral valve opening to mitral valve closure) is plotted for normal individuals in green, patients with DHF in red, and patients with SHF in blue. In DHF, the LV diastolic pressure volume relationship is shifted upwards, indicating a decreased distensibility. By contrast, in patients with SHF, the LV diastolic pressure versus volume relationship is shifted to rightwards, indicating an increased distensibility. It should be clear from this graph that all patients with heart failure, whether diastolic heart failure or systolic heart failure, have a significant increase in LV diastolic pressure. However, the mechanisms responsible for these increased pressures are different between these two different patient groups.</div><div class=\"graphic_reference\">Reproduced with permission from: Aurigemma GP, Zile MR, Gaasch WH. Contractile Behavior of the Left Ventricle in Diastolic Heart Failure With Emphasis on Regional Systolic Function. Circulation 2006; 113:296. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68133 Version 7.0</div></div></div>"},"68134":{"type":"graphic_table","displayName":"Patch test units","title":"Available patch test units/devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available patch test units/devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chamber name</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Advantages/disadvantages</td> </tr> <tr> <td> <p><strong>Finn Chamber</strong></p> <p>Manufactured and distributed by SmartPractice Finland</p> </td> <td> <p>8 mm round aluminum discs</p> <p>Strips of 10</p> <p>Trays are stackable</p> </td> <td> <ol> <li>Rare reactions to aluminum </li> <li>Rare corrosion by some aqueous solutions </li> <li>Need to add filter paper for liquids </li> <li>Easy to see disc imprints </li> </ol> </td> </tr> <tr> <td> <p><strong>IQ Square Chamber/IQ Ultra Chamber</strong></p> <p>Marketed by Chemotechnique Diagnostics, distributed by Dormer Labs Inc., Toronto, Ontario</p> </td> <td> <p>9x9 mm square chambers</p> <p>Strips of 10</p> <p>Polyethylene plastic chambers</p> <p>Filter paper incorporated</p> </td> <td> <ol> <li>Thin soft chambers for comfort </li> <li>Adhesive rim to each chamber minimizes leakage </li> <li>Can reattach protective tape after filling chambers </li> </ol> </td> </tr> <tr> <td> <p><strong>Allergeaze Chamber</strong></p> <p>Marketed by SmartPractice Canada</p> </td> <td> <p>8x8 mm square chambers</p> <p>Acetal copolymer chambers</p> <p>Strips of 10 chambers mounted on nonwoven polyester</p> </td> <td>Nonwoven panel flexes and allows ease of movement</td> </tr> <tr> <td> <p><strong>van der Bend Chamber</strong></p> <p>Marketed by van der Bend B.V., The Netherlands</p> </td> <td> <p>10x10 mm square chamber</p> <p>Whatman filter paper fixed in each chamber</p> </td> <td>Chambers can be fixed on tape and joined in a row without tape</td> </tr> <tr> <td> <p><strong>Haye's Test Chamber</strong></p> <p>Marketed by HAL Allergenen Lab. B.V., The Netherlands</p> </td> <td> <p>8x8 mm square chambers</p> <p>Strips of 10 square chambers</p> <p>Hydrophilic unbleached nonwoven polyester chambers</p> </td> <td>Notches in chambers allow them to be filled without removing the cover liner</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68134 Version 2.0</div></div></div>"},"68135":{"type":"graphic_diagnosticimage","displayName":"Short Roux limb misconstruction","title":"Short Roux limb misconstruction","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Short Roux limb misconstruction</div><div class=\"cntnt\"><img style=\"width:504px; height:483px;\" src=\"images/SURG/68135_Short_Roux_limb_misconstruc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">51-year-old woman with short Roux limb misconstruction. For upper gastrointestinal examination, medium-density barium was administered through gastric tube in excluded gastric segment. Fluoroscopic image shows distal portion of stomach (asterisk) and biliary limb (arrowheads) are unremarkable. At distal anastomosis, preferential flow of contrast material into alimentary limb (white arrows) is evident with little contrast material passing distally into common limb (black arrow). Antegrade assessment of alimentary limb was limited owing to concomitant proximal anastomotic stenosis (not shown). At surgery, Roux limb measuring only 25 cm was identified. Short length allowed retrograde reflux, resulting in Roux-en-O physiologic characteristics.</div><div class=\"graphic_reference\">Reprinted with the permission of the American Journal of Roentgenology. Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in roux-en-o and other misconstructions: Rare but serious complications of roux-en-y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367. Copyright © 2008 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 68135 Version 8.0</div></div></div>"},"68136":{"type":"graphic_picture","displayName":"Elastosis 2","title":"Elastosis in photodamaged skin","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Elastosis in photodamaged skin</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68136_Elastosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coarseness and fine nodularity of skin with severe elastosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\">www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68136 Version 2.0</div></div></div>"},"68137":{"type":"graphic_picture","displayName":"Seborrheic dermatitis groin","title":"Intertriginous seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intertriginous seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:309px;\" src=\"images/DERM/68137_Seborrheic_dermatitis_groin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scaling involving the groin in a patient with flexural seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68137 Version 5.0</div></div></div>"},"68138":{"type":"graphic_table","displayName":"Technique of central venous catheterization","title":"Technique of central venous catheterization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique of central venous catheterization</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Identify vessel or pertinent landmark</td> </tr> <tr> <td>Prepare the site by scrubbing widely with antiseptic solution</td> </tr> <tr> <td>Drape the site with sterile towels and surgical drapes</td> </tr> <tr> <td>Infiltrate the skin with 1 percent lidocaine</td> </tr> <tr> <td>Cannulate the vein using the introducer needle</td> </tr> <tr> <td>Confirm position of needle by easy aspiration of venous blood; if doubt exists regarding venous versus arterial cannulation, transduction of pressures or blood gas analysis is recommended</td> </tr> <tr> <td>Remove syringe from needle hub</td> </tr> <tr> <td>Insert J-tipped guidewire through the needle into the vein and gently advance the wire; <strong>never</strong> force the wire</td> </tr> <tr> <td>Remove the needle while maintaining control of the guidewire</td> </tr> <tr> <td>Make a small skin nick contiguous with the wire using an upward-facing scalpel blade</td> </tr> <tr> <td>Advance the dilator over the wire using a twisting motion; always hold the guidewire</td> </tr> <tr> <td>Withdraw dilator while guidewire is stabilized</td> </tr> <tr> <td>Thread the catheter over the guidewire; always hold the guidewire</td> </tr> <tr> <td>Stabilize the catheter and remove the guidewire</td> </tr> <tr> <td>Evaluate ease of aspiration and flushing from each port of catheter</td> </tr> <tr> <td>Suture the catheter securely, dress site with sterile technique and topical antiseptic ointment</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68138 Version 4.0</div></div></div>"},"68139":{"type":"graphic_table","displayName":"Indications for catheterization","title":"Clinical use of the pulmonary artery catheter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical use of the pulmonary artery catheter</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td class=\"sublist1_start\">Differentiation among causes of shock</td> </tr> <tr> <td class=\"sublist1\">Cardiogenic</td> </tr> <tr> <td class=\"sublist1\">Hypovolemic</td> </tr> <tr> <td class=\"sublist1\">Distributive (sepsis) </td> </tr> <tr> <td class=\"sublist1\">Obstructive (massive pulmonary embolism)</td> </tr> <tr> <td class=\"sublist1_start\">Differentiation between mechanisms of pulmonary edema</td> </tr> <tr> <td class=\"sublist1\">Cardiogenic</td> </tr> <tr> <td class=\"sublist1\">Noncardiogenic</td> </tr> <tr> <td>Evaluation of pulmonary hypertension</td> </tr> <tr> <td>Diagnosis of pericardial tamponade</td> </tr> <tr> <td>Diagnosis of left-to-right intracardiac shunt</td> </tr> <tr> <td>Diagnosis of lymphangitic spread of tumor and fat embolism (case reports based on blood aspirated from wedge position)</td> </tr> <tr> <td>Unexplained dyspnea*</td> </tr> <tr> <td class=\"subtitle1_single\">Therapy</td> </tr> <tr> <td>Management of perioperative patient with unstable cardiac status</td> </tr> <tr> <td>Management of complicated myocardial infarction</td> </tr> <tr> <td>Management of patients following cardiac surgery</td> </tr> <tr> <td>Management of severe preeclampsia</td> </tr> <tr> <td class=\"sublist1_start\">Guide to pharmacologic therapy</td> </tr> <tr> <td class=\"sublist1\">Vasopressors</td> </tr> <tr> <td class=\"sublist1\">Inotropes</td> </tr> <tr> <td class=\"sublist1\">Vasodilators (for patients with pulmonary hypertension)</td> </tr> <tr> <td class=\"sublist1_start\">Guide to nonpharmacologic therapy</td> </tr> <tr> <td class=\"sublist1\">Fluid management</td> </tr> <tr> <td class=\"sublist2\">Gastrointestinal bleed</td> </tr> <tr> <td class=\"sublist2\">Traumatic exsanguination</td> </tr> <tr> <td class=\"sublist1\">Burns</td> </tr> <tr> <td class=\"sublist1\">Renal failure</td> </tr> <tr> <td class=\"sublist1\">Sepsis</td> </tr> <tr> <td class=\"sublist1\">Heart failure</td> </tr> <tr> <td class=\"sublist1\">Decompensated cirrhosis</td> </tr> <tr> <td>Ventilator management (assessment of best PEEP for O<sub>2</sub> delivery)</td> </tr> <tr> <td>Assess response to pulmonary hypertension specific therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Pulmonary artery catheters can be placed at rest or during exercise for the evaluation of patients with unexplained dyspnea.</div><div id=\"graphicVersion\">Graphic 68139 Version 2.0</div></div></div>"},"68140":{"type":"graphic_picture","displayName":"Normal lung autofluorescence","title":"Normal fluorescence bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal fluorescence bronchoscopy</div><div class=\"cntnt\"><img style=\"width:393px; height:368px;\" src=\"images/PULM/68140_Normal_lung_autofluorescenc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic autofluorescence image of normal airways obtained using the STORZ system.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 68140 Version 2.0</div></div></div>"},"68141":{"type":"graphic_diagnosticimage","displayName":"Right lung atelectasis","title":"Complete atelectasis of the right lung","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete atelectasis of the right lung</div><div class=\"cntnt\"><img style=\"width:392px; height:375px;\" src=\"images/PULM/68141_Right_lung_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows complete atelectasis of the right lung due to a tuberculous stricture in the right main stem bronchus. Complete opacification of the right hemithorax is shown with marked cardiomediastinal shift to the right side.&nbsp;As a result, the cardiac silhouette is obscured by the collapsed lung. The left lung is hyperexpanded and&nbsp;shifts anteriorly&nbsp;across the midline into the right hemithorax. The aortic arch imprint is clearly visible in the lower trachea (arrow) and should not be mistaken for tracheal stenosis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68141 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"68142":{"type":"graphic_waveform","displayName":"ECG pace mapping RVOT tachycardia","title":"12-lead electrocardiogram (ECG) during electrophysiologic study showing pace mapping of an idiopathic RVOT tachycardia","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) during electrophysiologic study showing pace mapping of an idiopathic RVOT tachycardia</div><div class=\"cntnt\"><img style=\"width:528px; height:408px;\" src=\"images/CARD/68142_Pace_mapping_RVOT_tachycard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: 12 lead ECG of spontaneous ventricular tachycardia (VT) in a patient with a structurally normal heart. The VT has a left bundle branch block (LBBB) and an inferior axis morphology, suggesting that the origin is in the right ventricular outflow tract (RVOT). Right panel: A mapping catheter has been positioned in the RVOT and pacing is performed from its tip during sinus rhythm. The &quot;pace map&quot; closely approximates the QRS morphology of the spontaneous VT in all 12 leads, suggesting that the mapping catheter is at or near the VT focus.</div><div class=\"graphic_footnotes\">S: pacing stimulus artifact.</div><div id=\"graphicVersion\">Graphic 68142 Version 4.0</div></div></div>"},"68143":{"type":"graphic_table","displayName":"Usual doses inhaled GC-LABA","title":"Usual doses of combination inhaled glucocorticoids and long-acting beta-agonists for the treatment of asthma in adolescents age 12 and older and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual doses of combination inhaled glucocorticoids and long-acting beta-agonists for the treatment of asthma in adolescents age 12 and older and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Low dose</td> <td class=\"subtitle1\">Medium dose</td> <td class=\"subtitle1\">High dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Budesonide-formoterol HFA (Brand name: Symbicort)</td> </tr> <tr> <td class=\"indent1\">80 mcg-4.5 mcg</td> <td>2 puffs twice a day</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">160 mcg-4.5 mcg</td> <td>&nbsp;</td> <td>2 puffs twice a day</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Flucticasone furoate-vilanterol DPI (Brand name: Breo Ellipta)*</td> </tr> <tr> <td colspan=\"4\">NOTE: Inhaled fluticasone furoate has a greater anti-inflammatory potency per microgram than fluticasone propionate inhalers. Thus, fluticasone furoate is administered at a lower daily dose and used only <strong>once</strong> daily.</td> </tr> <tr> <td class=\"indent1\">100 mcg-25 mcg</td> <td>&nbsp;</td> <td>1 inhalation once daily</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">200 mcg-25 mcg</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1 inhalation once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fluticasone propionate-salmeterol DPI (Brand name: Advair Diskus)</td> </tr> <tr> <td class=\"indent1\">100 mcg-50 mcg</td> <td>1 inhalation twice a day</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">250 mcg-50 mcg</td> <td>&nbsp;</td> <td>1 inhalation twice a day</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">500 mcg-50 mcg</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1 inhalation twice a day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fluticasone propionate-salmeterol HFA (Brand name: Advair HFA)</td> </tr> <tr> <td class=\"indent1\">45 mcg-21 mcg</td> <td>2 puffs twice a day</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">115 mcg-21 mcg</td> <td>&nbsp;</td> <td>2 puffs twice a day</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">230 mcg-21 mcg</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 puffs twice a day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mometasone-formoterol HFA (Brand name: Dulera)</td> </tr> <tr> <td class=\"indent1\">100 mcg-5 mcg</td> <td>&nbsp;</td> <td>2 puffs twice a day</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">200 mcg-5 mcg</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 puffs twice a day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Do not exceed the maximum number of inhalations/puffs per day listed in the table due to the risk of toxicity from an excess dose of long acting beta-agonist (ie, salmeterol, formoterol, or vilanterol). Brand names and dose per puff or per inhalation of commercially available fixed dose combinations are according to US licensed product information. Consult local product information before use.&nbsp;</div><div class=\"graphic_footnotes\">HFA: metered dose inhaler with hydrofluoroalkane propellant; DPI: dry powder inhaler.<br />* Not approved for use in patients &lt;18 years old.</div><div id=\"graphicVersion\">Graphic 68143 Version 12.0</div></div></div>"},"68144":{"type":"graphic_picture","displayName":"Acute fatty liver oil red O","title":"Acute fatty liver of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute fatty liver of pregnancy</div><div class=\"cntnt\"><img style=\"width:387px; height:252px;\" src=\"images/GAST/68144_Acute_fatty_liver_Oil_red_O.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of an oil red O stain of a liver biopsy from a patient with acute fatty liver of pregnancy. There are vacuolated hepatocytes containing microvesicular fat which stain red (arrows). This stain should be routinely used for the diagnosis of acute fatty liver of pregnancy and must be performed on a biopsy specimen that has not been fixed.</div><div class=\"graphic_reference\">Courtesy of Caroline A Riely, MD.</div><div id=\"graphicVersion\">Graphic 68144 Version 2.0</div></div></div>"},"68146":{"type":"graphic_table","displayName":"Degree of virulence K pneum","title":"Determination of the degree of virulence conferred by K. pneumoniae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determination of the degree of virulence conferred by K. pneumoniae</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Test</td>\n\t\t\t\t\t<td class=\"subtitle1\">Method</td>\n\t\t\t\t\t<td class=\"subtitle1\">Measurement</td>\n\t\t\t\t\t<td class=\"subtitle1\">Interpretation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">Virulence for mice</td>\n\t\t\t\t\t<td rowspan=\"4\">Intraperitoneal injection of bacterial suspension to observe the death rate of mice</td>\n\t\t\t\t\t<td rowspan=\"4\">50 percent lethal dose: LD<sub>50</sub> (CFU)</td>\n\t\t\t\t\t<td>Highly virulent: &#8804;10<sup>3</sup> CFU</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Moderate virulence: 10<sup>4</sup>-10<sup>5</sup> CFU</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Low virulence: 10<sup>6</sup>-10<sup>7</sup>CFU</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>No virulence: &#8805;10<sup>8</sup> CFU</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Phagocytosis: macrophage adherence assay</td>\n\t\t\t\t\t<td rowspan=\"2\">Human or mouse macrophage are mixed with bacteria to quantify ingesting cells</td>\n\t\t\t\t\t<td rowspan=\"2\">Percent of 100 macrophages containing attached or ingested bacteria</td>\n\t\t\t\t\t<td>Low-level binding: 2 to 3 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>High-level binding: 8 to 13 percent</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Serum resistance assay</td>\n\t\t\t\t\t<td>Nonimmune human serum are incubated with bacteria to determine colony count at serial hours</td>\n\t\t\t\t\t<td>Survival curve (the average survival ratio against time)</td>\n\t\t\t\t\t<td>Bacteria that actively proliferate in serum are resistant to serum killing</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Whole blood resistance</td>\n\t\t\t\t\t<td>Incubate fresh mouse blood with bacterial suspension</td>\n\t\t\t\t\t<td>Survival of bacteria in blood</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68146 Version 1.0</div></div></div>"},"68147":{"type":"graphic_picture","displayName":"White blood cell cast II","title":"Photomicrograph of urine sediment with white blood cell cast (II)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph of urine sediment with white blood cell cast (II)</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/NEPH/68147_White_cell_cast_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white blood cell cast, three-quarters of which is filled with leukocytes.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 68147 Version 2.0</div></div></div>"},"68148":{"type":"graphic_table","displayName":"Serious medical complications of stroke","title":"Serious medical complications of stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serious medical complications of stroke</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Complication</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>All pneumonias</td>\n\n      <td>5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aspiration pneumonia alone</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart failure</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gastrointestinal bleeding</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac arrest</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angina/MI/cardiac ischemia</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Deep venous thrombosis</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary embolism</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoxia</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary tract infection</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sepsis</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cellulitis</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Peripheral vascular disorder</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dyspnea</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary edema</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dehydration</td>\n\n      <td>1</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">In a prospective study that analyzed the placebo group of the RANTTAS database (n = 279), at least one serious medical complication (defined as prolonged, immediately life threatening, or resulting in hospitalization or death) occurred in 24 percent of patients.</div><div class=\"graphic_reference\">Data from: Johnston, KC, Li, JY, Lyden, PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998; 29:447.</div><div id=\"graphicVersion\">Graphic 68148 Version 3.0</div></div></div>"},"68149":{"type":"graphic_diagnosticimage","displayName":"Fetal pyelectasis bilateral","title":"Bilateral pyelectasis measuring 4 mm on each side","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral pyelectasis measuring 4 mm on each side</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/OBGYN/68149_Fetal_pyelectasis_bilateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 68149 Version 2.0</div></div></div>"},"68150":{"type":"graphic_figure","displayName":"Transverse incisions of the abdominal wall ","title":"Transverse incisions of the abdominal wall ","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Transverse incisions of the abdominal wall </div><div class=\"cntnt\"><img style=\"width:532px; height:346px;\" src=\"images/SURG/68150_Trans_skin_incisions_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68150 Version 6.0</div></div></div>"},"68153":{"type":"graphic_picture","displayName":"Erythema multiforme lip","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/68153_Erythema_multiforme_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucosal erosions and crusts on the lips of a patient with erythema multiforme.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68153 Version 5.0</div></div></div>"},"68154":{"type":"graphic_picture","displayName":"Dog bite with fracture","title":"Dog bite with fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dog bite with fracture</div><div class=\"cntnt\"><img style=\"width:307px; height:448px;\" src=\"images/EM/68154_Dogbitewithfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child sustained a dog bite to the foot, which was sutured at another institution. On follow-up, he had both cellulitis (Panel A) and a phalangeal fracture (Panel B), possibly complicated by osteomyelitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68154 Version 13.0</div></div></div>"},"68155":{"type":"graphic_diagnosticimage","displayName":"Pelvic lateral compression fracture type III","title":"Pelvic lateral compression fracture: Type III","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pelvic lateral compression fracture: Type III</div><div class=\"cntnt\"><img style=\"width:526px; height:407px;\" src=\"images/EM/68155_Pelviclatcompfx3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three images of Type III lateral compression fractures: (A) Schematic; (B) Anteroposterior plain radiograph; (C) CT scan.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 68155 Version 13.0</div></div></div>"},"68157":{"type":"graphic_table","displayName":"Oncogenes thyroid tumors","title":"Oncogenes and tumor suppressor genes in thyroid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oncogenes and tumor suppressor genes in thyroid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neoplasm</td> <td class=\"subtitle1\">Contributory genetic abnormalities</td> <td class=\"subtitle1\">Genetic abnormalities of uncertain importance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Benign neoplasms</td> </tr> <tr> <td class=\"indent1\">Autonomously functioning thyroid nodule</td> <td>TSH receptor-activating mutation; Gs-alpha mutation decreasing GTPase activity</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nodular goiter (colloid nodules)</td> <td>Many nodules are monoclonal, but precise gene abnormalities are unknown</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Follicular adenoma</td> <td><em>RAS </em>mutations</td> <td>c-myc and c-fos overexpressed; <em>PTEN </em>abnormalities</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Malignant neoplasms</td> </tr> <tr> <td class=\"indent1\">Papillary thyroid carcinoma</td> <td>BRAF (V600E)-activating mutation; <em>RET </em>rearrangements (RET/PTC); <em>NTRK1 </em>rearrangements (TRK); 14q13.3 and 5q34 (pre-mir-146a)</td> <td>Tumor suppressor hypermethylation; miRNA upregulation; TIMM44 mutations</td> </tr> <tr> <td class=\"indent1\">Follicular thyroid carcinoma</td> <td>PAX8-PPAR-gamma-1 fusion; RAS-activating mutations</td> <td>Tumor specific LOH throughout genome</td> </tr> <tr> <td class=\"indent1\">Anaplastic thyroid carcinoma</td> <td>p53 mutations; BRAF (V600E)-activating mutation; exon 3 CTNNB1 mutations; ALK-activating mutations</td> <td>PIK3CA</td> </tr> <tr> <td class=\"indent1\">Medullary thyroid carcinoma</td> <td>RET-activating mutations</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; Gs-alpha: the alpha subunit of the guanyl nucleotide stimulatory protein; miRNA: microRNA; LOH: loss of heterozygosity.</div><div id=\"graphicVersion\">Graphic 68157 Version 5.0</div></div></div>"},"68159":{"type":"graphic_table","displayName":"COG risk strata neuroblast","title":"Children's Oncology Group neuroblastoma risk strata","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Children's Oncology Group neuroblastoma risk strata</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">MYCN status</td> <td class=\"subtitle1\">DNA ploidy</td> <td class=\"subtitle1\">INPC</td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Low*</td> <td>1</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>2a/2b</td> <td>Any</td> <td>Not amp</td> <td>Any</td> <td>Any</td> <td>Resection &#8805;50 percent</td> </tr> <tr class=\"divider_bottom\"> <td>4s</td> <td>&#60;365 days</td> <td>Not amp</td> <td>DI &#62;1</td> <td>FH</td> <td>Asymptomatic</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"9\">Intermediate<sup>&#182;</sup></td> <td>2a/2b</td> <td>0-12 years</td> <td>Not amp</td> <td>Any</td> <td>Any</td> <td>Biopsy or resection &#60;50 percent</td> </tr> <tr> <td>3</td> <td>&#60;547 days</td> <td>Not amp</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&#8805;547 days - 12 years</td> <td>Not amp</td> <td>Any</td> <td>FH</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&#60;365 days</td> <td>Not amp</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>365 - &#60;547 days</td> <td>Not amp</td> <td>DI &#62;1</td> <td>FH</td> <td>&nbsp;</td> </tr> <tr> <td>4s</td> <td>&#60;365 days</td> <td>Not amp</td> <td>Any</td> <td>Any</td> <td>Symptomatic</td> </tr> <tr> <td>4s</td> <td>&#60;365 days</td> <td>Not amp</td> <td>DI = 1</td> <td>Any</td> <td>Asymptomatic or symptomatic</td> </tr> <tr> <td>4s</td> <td>&#60;365 days</td> <td>Not amp</td> <td>Any</td> <td>UH</td> <td>Asymptomatic or symptomatic</td> </tr> <tr class=\"divider_bottom\"> <td>4s</td> <td>&#60;365 days</td> <td>Missing</td> <td>Missing</td> <td>Missing</td> <td>Too sick for biopsy</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"9\">High<sup>&#916;</sup></td> <td>2a/2b</td> <td>Any</td> <td>Amp</td> <td>Any</td> <td>Any</td> <td>Any degree of resection</td> </tr> <tr> <td>3</td> <td>Any</td> <td>Amp</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>3</td> <td>&#8805;547 days</td> <td>Not amp</td> <td>Any</td> <td>UH</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&#60;365 days</td> <td>Amp</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>365 - &#60;547 days</td> <td>Amp</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>365 - &#60;547 days</td> <td>Any</td> <td>DI = 1</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>365 - &#60;547 days</td> <td>Any</td> <td>Any</td> <td>UH</td> <td>&nbsp;</td> </tr> <tr> <td>4</td> <td>&#8805;547 days</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>&nbsp;</td> </tr> <tr> <td>4s</td> <td>&#60;365 days</td> <td>Amp</td> <td>Any</td> <td>Any</td> <td>Asymptomatic or symptomatic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INPC: International Neuroblastoma Pathology Classification; FH: favorable histology; UH: unfavorable histology; Amp: amplified; DI: DNA Index.<br />* Low risk groups as defined in Children's Oncology Group trial ANBL00B1.<br />¶ Intermediate risk group as defined in Children's Oncology Group trial ANBL0531.<br />Δ High risk group as defined in the Children's Oncology Group trial ANBL0532.</div><div id=\"graphicVersion\">Graphic 68159 Version 3.0</div></div></div>"},"68160":{"type":"graphic_table","displayName":"Mercury poisoning versus autism","title":"Characteristic findings in patients with mercury poisoning versus autism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristic findings in patients with mercury poisoning versus autism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding </td> <td class=\"subtitle1\">Mercury poisoning </td> <td class=\"subtitle1\">Autism spectrum disorder</td> </tr> <tr> <td>Motor</td> <td>Ataxia</td> <td>Repetitive behaviors</td> </tr> <tr> <td>Vision</td> <td>Bilateral visual field constriction</td> <td>None</td> </tr> <tr> <td>Speech</td> <td>Dysarthria</td> <td>Delayed speech, echolalia</td> </tr> <tr> <td rowspan=\"2\">Sensory </td> <td rowspan=\"2\">Peripheral neuropathy, paresthesias </td> <td>Decreased responsiveness to pain</td> </tr> <tr> <td>Hyperacusis, hypersensitivity to other sensory stimuli</td> </tr> <tr> <td>Psychiatric</td> <td>Toxic psychosis; in mild cases, nonspecific depression, anxiety, irritability</td> <td>Socially aloof, insistence on sameness</td> </tr> <tr> <td>Head size</td> <td>Small</td> <td>Large</td> </tr> <tr> <td>Other</td> <td>In chronic mercury toxicity: hypertension, skin eruption, thrombocytopenia</td> <td>Seldom seen</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Nelson, KB, Bauman, ML. Thimerosal and autism? Pediatrics 2003; 111:674.</div><div id=\"graphicVersion\">Graphic 68160 Version 2.0</div></div></div>"},"68161":{"type":"graphic_diagnosticimage","displayName":"Pyriform aperture stenosis","title":"Pyriform aperture stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyriform aperture stenosis</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/PEDS/68161_Pyriform_aperture_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial&nbsp;CT image documenting the small nasal opening of pyriform aperture stenosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Ellen S Deutsch, MD.</div><div id=\"graphicVersion\">Graphic 68161 Version 3.0</div></div></div>"},"68162":{"type":"graphic_picture","displayName":"Ulcerated hemangioma axilla","title":"Ulcerated hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcerated hemangioma</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PEDS/68162_Ulcerated_hemangioma_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulceration is the most common complication of hemangiomas. Large tumors in trauma-prone locations, as the one of the axilla depicted above, have increased risk of ulceration.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 68162 Version 2.0</div></div></div>"},"68163":{"type":"graphic_diagnosticimage","displayName":"CT of acute bacterial rhinosinusitis","title":"CT of acute bacterial rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of acute bacterial rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:393px; height:316px;\" src=\"images/PC/68163_CoronalCTinptwithABRS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute bacterial rhinosinusitis. Coronal image from a CT of the paranasal sinuses showing mucosal edema (arrows) and thick secretions (asterisks).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 68163 Version 4.0</div></div></div>"},"68165":{"type":"graphic_table","displayName":"Major causes of proximal RTA","title":"Major causes of type 2 (proximal) renal tubular acidosis with or without the Fanconi syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of type 2 (proximal) renal tubular acidosis with or without the Fanconi syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary</td> </tr> <tr> <td class=\"subtitle2_single\">Idiopathic (sporadic)</td> </tr> <tr> <td class=\"subtitle2_single\">Familial</td> </tr> <tr> <td class=\"indent1\">Recessive&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&ndash;</span>&nbsp;Proximal tubule cell sodium bicarbonate co-transporter (NBCe1) defect</td> </tr> <tr> <td class=\"indent1\">Recessive <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&ndash;</span>&nbsp;Carbonic anhydrase type 2 deficiency</td> </tr> <tr> <td class=\"indent1\">Cystinosis</td> </tr> <tr> <td class=\"indent1\">Tyrosinemia</td> </tr> <tr> <td class=\"indent1\">Hereditary fructose intolerance</td> </tr> <tr> <td class=\"indent1\">Galactosemia</td> </tr> <tr> <td class=\"indent1\">Glycogen storage disease (type I)</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"indent1\">Lowe syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Ifosfamide</td> </tr> <tr> <td class=\"indent1\">Tenofovir</td> </tr> <tr> <td class=\"indent1\">Carbonic anhydrase inhibitors <span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">&ndash;</span>&nbsp;Acetazolamide, topiramate</td> </tr> <tr> <td class=\"indent1\">Aminoglycosides</td> </tr> <tr> <td class=\"subtitle2_single\">M-protein disorders</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma/light chain disease</td> </tr> <tr> <td class=\"subtitle2_single\">Heavy metals</td> </tr> <tr> <td class=\"indent1\">Lead</td> </tr> <tr> <td class=\"indent1\">Cadmium</td> </tr> <tr> <td class=\"indent1\">Mercury</td> </tr> <tr> <td class=\"indent1\">Copper</td> </tr> <tr> <td class=\"subtitle2_single\">Vitamin D deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Renal transplantation</td> </tr> <tr> <td class=\"subtitle2_single\">Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"subtitle2_single\">Sj&#246;gren's syndrome (more commonly causes distal RTA)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RTA: renal tubular acidosis.</div><div id=\"graphicVersion\">Graphic 68165 Version 11.0</div></div></div>"},"68166":{"type":"graphic_picture","displayName":"Plexiform neurofibroma 1","title":"Plexiform neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plexiform neurofibroma</div><div class=\"cntnt\"><img style=\"width:320px; height:239px;\" src=\"images/NEURO/68166_Plexiform_neurofibroma_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periphery of a plexiform neurofibroma from the sciatic nerve of a patient with neurofibromatosis type 1. The term plexiform implies that multiple nerve fascicles are involved by tumor, as illustrated by the arrows. H&amp;E, x400.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 68166 Version 2.0</div></div></div>"},"68168":{"type":"graphic_table","displayName":"Diseases with impaired taste","title":"Disease and exposures that affect the sense of taste","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease and exposures that affect the sense of taste</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease </td> <td class=\"subtitle1\">Mechanism/comments </td> </tr> <tr> <td>Bell's palsy</td> <td>72 percent of patients with unilateral disease recover taste in 12 to 14 days</td> </tr> <tr> <td>Bone marrow transplantation</td> <td>&nbsp;</td> </tr> <tr> <td>Cancer</td> <td>&nbsp;</td> </tr> <tr> <td>Crohn disease</td> <td>Zinc deficiency</td> </tr> <tr> <td>Chronic chromium exposure</td> <td>&nbsp;</td> </tr> <tr> <td>Cirrhosis of the liver</td> <td>&nbsp;</td> </tr> <tr> <td>Depression</td> <td>Zinc deficiency from poor dietary intake?</td> </tr> <tr> <td>Diabetes mellitus with peripheral neuropathy</td> <td>Hypogeusia to sweetness</td> </tr> <tr> <td>Gingivitis</td> <td>Salty dysgeusia</td> </tr> <tr> <td>Guillain-Barr&#233; syndrome</td> <td>&nbsp;</td> </tr> <tr> <td>Hemodialysis</td> <td>&nbsp;</td> </tr> <tr> <td>Herpes simplex infection</td> <td>&nbsp;</td> </tr> <tr> <td>Human immunodeficiency virus infection</td> <td>Malnutrition, a-interferon</td> </tr> <tr> <td>Hyperaldosteronism</td> <td>&nbsp;</td> </tr> <tr> <td>Influenza</td> <td>&nbsp;</td> </tr> <tr> <td>Lead or copper poisoning</td> <td>Metallic dysgeusia</td> </tr> <tr> <td>Meningitis</td> <td>&nbsp;</td> </tr> <tr> <td>Migraine headache</td> <td>Gustatory hallucinations?</td> </tr> <tr> <td>Multiple sclerosis</td> <td>&nbsp;</td> </tr> <tr> <td>Parkinson disease</td> <td>&nbsp;</td> </tr> <tr> <td>Pernicious anemia (vitamin B12)</td> <td>Taste bud degeneration</td> </tr> <tr> <td>Radiation treatment to head and neck</td> <td>&nbsp;</td> </tr> <tr> <td>Recent dental procedure</td> <td>Dysgeusia</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>Hypogeusia and xerostomia</td> </tr> <tr> <td>Tonsillectomy</td> <td>&nbsp;</td> </tr> <tr> <td>Thrush</td> <td>Dysgeusia</td> </tr> <tr> <td>Zinc deficiency (disassociated taste disorder)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from Ackerman, BH, Kasbekar, N. Pharmacotherapy 1997; 17:1.</div><div id=\"graphicVersion\">Graphic 68168 Version 2.0</div></div></div>"},"68169":{"type":"graphic_picture","displayName":"SAPHO syndrome","title":"SAPHO Syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">SAPHO Syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:301px;\" src=\"images/DERM/68169_SAPHO_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 37-year-old woman with a history of palmoplantar pustulosis presented with severe chest pain. The patient was first diagnosed with palmoplantar pustulosis at the age of 36 and soon afterwards suffered from upper chest pain. Although the pain and skin lesion had been relieved for three years after excision of the left first sternocostal articulation, she experienced subsequent relapse of sternal pain and palmoplantar pustulosis. Medication for rheumatoid arthritis, such as prednisolone, bucillamine, and methotrexate, or antibiotic therapy failed to ameliorate the symptoms. At the age of 45, she underwent palatine tonsillectomy with resolution of symptoms. At present, the patient has neither palmoplantar skin lesions nor sternal pain.</div><div class=\"graphic_reference\">Copyright © Shimizu Tominaga, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 68169 Version 11.0</div></div></div>"},"68171":{"type":"graphic_picture","displayName":"Rounded atelectasis Low","title":"Histopathology of rounded atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology of rounded atelectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/PULM/68171_Rounded_atelectasis_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows invagination of thickened visceral pleura (arrows).</div><div class=\"graphic_reference\">From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 68171 Version 2.0</div></div></div>"},"68172":{"type":"graphic_figure","displayName":"QT dispersion mortality normals","title":"QT dispersion predicts mortality","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">QT dispersion predicts mortality</div><div class=\"cntnt\"><img style=\"width:490px; height:354px;\" src=\"images/CARD/68172_QT_dispersion_mortality_nor.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 1839 normal subjects followed for mean of 3.7 years, a corrected QT dispersion (QTD) &gt;58 msec was associated with a significantly increased all-cause (p = 0.018) and cardiovascular mortality (p = 0.0016) compared to a QTD ≤58 msec. Compared to a corrected QT interval (QTc) ≤460 msec, a QTc &gt;460 msec was also predictive of all-cause (p&lt;0.0001) and cardiovascular mortality (p&lt;0.014).</div><div class=\"graphic_reference\">Data from: Okin PM, Devereux RB, Howard BV, et al. Circulation 2000; 101:61.</div><div id=\"graphicVersion\">Graphic 68172 Version 2.0</div></div></div>"},"68173":{"type":"graphic_figure","displayName":"Gastric anatomy","title":"Gastric anatomy","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Gastric anatomy</div><div class=\"cntnt\"><img style=\"width:529px; height:508px;\" src=\"images/GAST/68173_Gastric-anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regions of the stomach include the cardia, fundus, body, antrum and pylorus. During endoscopy, the endoscope usually proceeds along the greater curvature of the stomach toward the pylorus.</div><div id=\"graphicVersion\">Graphic 68173 Version 1.0</div></div></div>"},"68174":{"type":"graphic_picture","displayName":"Photo well-differentiated pancreatic NET","title":"Gross photo of a well-differentiated pancreatic neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Gross photo of a well-differentiated pancreatic neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:480px; height:313px;\" src=\"images/ONC/68174_WelldiffpancNET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photo of a well-differentiated pancreatic neuroendocrine tumor shows a well-circumscribed mass. The cut surface is pink tan with scattered yellow areas.</div><div id=\"graphicVersion\">Graphic 68174 Version 2.0</div></div></div>"},"68175":{"type":"graphic_diagnosticimage","displayName":"Renal injury delay CT","title":"Delayed CT image showing collecting system injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delayed CT image showing collecting system injury</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/EM/68175_Renal_injury_delay_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This delayed CT image shows contrast extravasating from an injury to the left collecting system (arrow). Delayed CT images are often necessary to reveal injuries to the renal pelvis and ureters.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 68175 Version 5.0</div></div></div>"},"68176":{"type":"graphic_diagnosticimage","displayName":"Ovarian stroma ultrasound","title":"Ovarian stroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian stroma</div><div class=\"cntnt\"><img style=\"width:288px; height:354px;\" src=\"images/ENDO/68176_Ovarian_stroma_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal ultrasound image from a patient with ovarian hyperthecosis: No antral follicles are visible in the ovary; there is an increase in homogeneous, hyperechogenic ovarian stroma.</div><div class=\"graphic_reference\">Courtesy of&nbsp;Manubai Nagamani, MD.</div><div id=\"graphicVersion\">Graphic 68176 Version 3.0</div></div></div>"},"68177":{"type":"graphic_table","displayName":"Sclerotherapy prevent rebleed","title":"Summary of trials of sclerotherapy for prevention of recurrent variceal hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of trials of sclerotherapy for prevention of recurrent variceal hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Follow-up duration, months</td> <td class=\"subtitle1\">Rebleeding*, percent</td> <td class=\"subtitle1\">Rebleeding*, number</td> <td class=\"subtitle1\">Deaths*, percent</td> </tr> <tr> <td>MacDougall</td> <td>No Rx vs EST<sup>&#182;</sup></td> <td>24</td> <td>75 vs 43</td> <td>100 vs 54</td> <td>38 vs 21</td> </tr> <tr> <td>Terblanche</td> <td>No Rx vs EST<sup>&#916;</sup></td> <td>60</td> <td>77 vs 58</td> <td>73 vs 43</td> <td>63 vs 62</td> </tr> <tr> <td>Westaby</td> <td>No Rx vs EST</td> <td>36</td> <td>80 vs 55</td> <td>125 vs 66</td> <td>53 vs 32<sup>&#9674;</sup></td> </tr> <tr> <td>Korula</td> <td>No Rx vs EST<sup>&#182;</sup></td> <td>38</td> <td>84 vs 49</td> <td>98 vs 48</td> <td>33 vs 33</td> </tr> <tr> <td>Soderlund and Ihre</td> <td>No Rx vs EST<sup>&#182;</sup></td> <td>28</td> <td>64 vs 58</td> <td>99 vs 50</td> <td>70 vs 62</td> </tr> <tr> <td rowspan=\"2\">Copenhagen Sclerotherapy Project</td> <td rowspan=\"2\">No Rx vs EST</td> <td>?<sup>&#167;</sup></td> <td rowspan=\"2\">54 vs 48</td> <td rowspan=\"2\">138 vs 64</td> <td rowspan=\"2\">78 vs 65</td> </tr> <tr> <td>9-52</td> </tr> <tr> <td>Burroughs</td> <td>No Rx vs EST<sup>&#916;</sup></td> <td>?<sup>&#165;</sup></td> <td>59 vs 55</td> <td>183 vs 130</td> <td>54 vs 47</td> </tr> <tr> <td>Gregory</td> <td>No Rx vs EST</td> <td>62</td> <td>60 vs 52</td> <td>180 vs 116</td> <td>56 vs 63</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Controls versus sclerotherapy.<br />¶ Rebleeding in controls treated by shunt, vasopressin, Linton tubes.<br />Δ Acute episodes of bleeding in controls were treated with EST also.<br /><FONT class=lozenge>◊</FONT> Deaths due to variceal hemorrhage markedly reduced (25 vs 5, p&lt;0.001).<br />§ Duration of follow-up not well defined (range provided). In this study survival advantage was noted only after 40 days.<br />¥ Not well defined, duration of study provided.</div><div id=\"graphicVersion\">Graphic 68177 Version 2.0</div></div></div>"},"68178":{"type":"graphic_table","displayName":"Rapid therapies for myasthenia gravis","title":"Rapid therapies for myasthenia gravis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid therapies for myasthenia gravis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Plasmapheresis</td> <td class=\"subtitle1\">Intravenous immune globulin</td> </tr> <tr> <td>Usual adult dose</td> <td>Five exchange treatments of 3 to 5 liters over 10 to 14 days</td> <td>400 mg/kg daily for five days</td> </tr> <tr> <td>Onset of effect</td> <td>One&nbsp;to&nbsp;seven days</td> <td>One&nbsp;to&nbsp;two weeks</td> </tr> <tr> <td>Maximal effect</td> <td>One&nbsp;to&nbsp;three weeks</td> <td>One&nbsp;to&nbsp;three weeks</td> </tr> <tr> <td>Adverse effects</td> <td>Line infection, hypotension, thromboembolism</td> <td>Headache, fluid overload, renal failure (rare)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68178 Version 2.0</div></div></div>"},"68180":{"type":"graphic_picture","displayName":"T2 upper lip SCC","title":"Stage T2 upper lip squamous cell carcinoma (SCC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage T2 upper lip squamous cell carcinoma (SCC)</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ONC/68180_T2_upper_lip_SCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 68180 Version 2.0</div></div></div>"},"68181":{"type":"graphic_table","displayName":"Characteristics of NOS isoforms","title":"Characteristics of the three nitric oxide synthase (NOS) isoforms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of the three nitric oxide synthase (NOS) isoforms</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Enzyme designation\n   </td>\n   <td  class=\"subtitle1\">\n   Gene designation\n   </td>\n   <td  class=\"subtitle1\">\n   Chromosomal location and gene size (kbp)\n   </td>\n   <td  class=\"subtitle1\">\n   Cell type where first identified\n   </td>\n   <td  class=\"subtitle1\">\n   Regulated by Ca++ flux\n   </td>\n   </tr>\n   <tr>\n   <td>Type I, (nNOS)</td>\n   <td>nos1</td>\n   <td>12q; &#62;100</td>\n   <td>Nerve</td>\n   <td>Yes</td>\n   </tr>\n   <tr>\n   <td>Type II, (iNOS)</td>\n   <td>nos2</td>\n   <td>17cen-q; 37</td>\n   <td>Macrophage</td>\n   <td>No</td>\n   </tr>\n   <tr>\n   <td>Type III, (eNOS)</td>\n   <td>nos3</td>\n   <td>7q; 21</td>\n   <td>Vascular endothelium</td>\n   <td>Yes</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">NOS: nitric oxide synthetase; eNOS: endothelial cell NOS; iNOS: inducible NOS; nNOS: neuronal cell NOS.</div><div id=\"graphicVersion\">Graphic 68181 Version 1.0</div></div></div>"},"68182":{"type":"graphic_picture","displayName":"Diffuse cutaneous mastocytosis","title":"Diffuse cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:346px; height:286px;\" src=\"images/RHEUM/68182_Diffuse_cutaneous_mastocyto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Affected skin in a patient with diffuse cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Soter AN. J Invest Derm 1991; 96(3):S32. Copyright © 1991 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 68182 Version 3.0</div></div></div>"},"68183":{"type":"graphic_table","displayName":"NHLBI pediatric definition of lipid levels","title":"Definition of lipid levels in children from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk reduction in Children and Adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of lipid levels in children from the 2011 Expert Panel Integrated Guidelines for Cardiovascular Health and Risk reduction in Children and Adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Acceptable<br /> mg/dL (mmol/L)</td> <td class=\"subtitle1\">Borderline<br /> mg/dL (mmol/L)</td> <td class=\"subtitle1\">High<sup>&#916;</sup></td> </tr> <tr> <td>TC</td> <td>&#60;170 (4.4)</td> <td>170 to 199 (4.4 to 5.2)</td> <td>&#8805;200 (5.2)</td> </tr> <tr> <td>LDL-C</td> <td>&#60;110 (2.8)</td> <td>110 to 129 (2.8 to 3.3)</td> <td>&#8805;130 (3.4)</td> </tr> <tr> <td>Non-HDL-C</td> <td>&#60;120 (3.1)</td> <td>120 to 144 (3.1 to 3.7)</td> <td>&#8805;145 (3.8)</td> </tr> <tr> <td>ApoB</td> <td>&#60;90 (2.3)</td> <td>90 to 109 (2.3 to 2.8)</td> <td>&#8805;110 (2.8)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">TG</td> </tr> <tr> <td class=\"sublist1\">&#8226; 0 to 9 years</td> <td class=\"sublist_other\">&#60;75 (0.8)</td> <td class=\"sublist_other\">75 to 99 (0.8 to 1.1)</td> <td class=\"sublist_other\">&#8805;100 (1.1)</td> </tr> <tr> <td class=\"sublist1\">&#8226; 10 to 19 years</td> <td class=\"sublist_other\">&#60;90 (1 mmol/L)</td> <td class=\"sublist_other\">90 to 129 (1 to 1.5)</td> <td class=\"sublist_other\">&#8805;130 (1.5)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Acceptable</td> <td class=\"subtitle1\">Borderline</td> <td class=\"subtitle1\">Low<sup>&#916;</sup></td> </tr> <tr> <td>HDL-C</td> <td>&#62;45 (1.2)</td> <td>40 to 45 (1 to 1.2)</td> <td>&#60;40 (1)</td> </tr> <tr> <td>ApoA-1</td> <td>&#62;120 (3.1)</td> <td>115 to 120 (3 to 3.1)</td> <td>&#60;115 (3)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein; ApoB: apolipoprotein B; ApoA-1: apolipoprotein A-1; TG: triglycerides.<br />* Values for plasma lipid and lipoprotein levels are from the National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children. Non-HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cut points for LDL-C. Values for plasma apoB and apoA-1 are from the National Health and Nutrition Examination Survey III (NHANES&nbsp;III).<br />Δ The threshold points for high and borderline-high values&nbsp;represent approximately the 95th and 75th percentiles, respectively. Low&nbsp;threshold points for HDL-C and apoA-1 represent approximately&nbsp;the 10th percentile.<br /></div><div class=\"graphic_reference\">Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf.</div><div id=\"graphicVersion\">Graphic 68183 Version 3.0</div></div></div>"},"68185":{"type":"graphic_diagnosticimage","displayName":"Esophageal Schatzki ring seen on barium swallow","title":"Esophageal (Schatzki) ring seen on barium swallow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal (Schatzki) ring seen on barium swallow</div><div class=\"cntnt\"><img style=\"width:289px; height:282px;\" src=\"images/GAST/68185_Schatzki_ring_Ba_swallow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophageal (Schatzki) ring&nbsp;at the gastroesophageal junction visualized on a barium swallow.</div><div class=\"graphic_reference\">Courtesy of Peter J Kahrilas, MD.</div><div id=\"graphicVersion\">Graphic 68185 Version 4.0</div></div></div>"},"68187":{"type":"graphic_figure","displayName":"Heme synthesis and porphyria","title":"Heme synthesis and the porphyrias","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Heme synthesis and the porphyrias</div><div class=\"cntnt\"><img style=\"width:533px; height:442px;\" src=\"images/HEME/68187_Heme_synthesis_porphyr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of heme synthesis and the enzymatic alterations in the porphyrias and X-linked sideroblastic anemia (XLSA), beginning with the formation of ALA from succinyl CoA and glycine. The enzymatic defect in each disease is shown by a broken red&nbsp;line.</div><div class=\"graphic_footnotes\">ALA: delta-aminolevulinic acid; PBG: porphobilinogen; HMB: hydroxymethylbilane; Uro'gen: uroporphyrinogen; copro'gen: coproporphyrinogen; Proto'gen: protoporphyrinogen; XLP: X-linked protoporphyria; XLSA: X-linked sideroblastic anemia; ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; CEP: congenital erythropoietic porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; EPP: erythropoietic protoporphyria.</div><div class=\"graphic_reference\">Courtesy of Ashwani Singal, MD and Karl Anderson, MD</div><div id=\"graphicVersion\">Graphic 68187 Version 4.0</div></div></div>"},"68189":{"type":"graphic_figure","displayName":"Hypo pit testic axis","title":"The hypothalamic-pituitary-testicular axis","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">The hypothalamic-pituitary-testicular axis</div><div class=\"cntnt\"><img style=\"width:536px; height:458px;\" src=\"images/ENDO/68189_Hypo_pit_testic_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the hypothalamic-pituitary-testicular axis shows the site of action of FSH and LH in the testes. Testosterone and inhibin are produced by the testes. Testosterone has a negative feedback on the hypothalamus and LH production, while inhibin has a negative feedback on FSH production.</div><div class=\"graphic_footnotes\">CRH: corticotrophin-releasing hormone; GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; T: testosterone.</div><div class=\"graphic_reference\">Adapted from: Griffin JE, Wilson JD. In: Metabolic Control and Disease, 8th ed, Bondy PK, Rosenberg LE (Eds) Saunders, Philadelphia, 1980, p. 1535.</div><div id=\"graphicVersion\">Graphic 68189 Version 4.0</div></div></div>"},"68191":{"type":"graphic_table","displayName":"CT grading acute pancreatitis","title":"CT findings and grading of acute pancreatitis (CT severity index [CTSI])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CT findings and grading of acute pancreatitis (CT severity index [CTSI])</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Grading based upon findings on unenhanced CT</td> </tr> <tr> <td class=\"subtitle2\">Grade</td> <td class=\"subtitle2\">Findings</td> <td class=\"subtitle2\">Score</td> </tr> <tr> <td>A</td> <td>Normal pancreas - normal size, sharply defined, smooth contour, homogeneous enhancement, retroperitoneal peripancreatic fat without enhancement</td> <td>0</td> </tr> <tr> <td>B</td> <td>Focal or diffuse enlargement of the pancreas, contour may show irregularity, enhancement may be inhomogeneous but there is no peripancreatic inflammation</td> <td>1</td> </tr> <tr> <td>C</td> <td>Peripancreatic inflammation with intrinsic pancreatic abnormalities </td> <td>2</td> </tr> <tr> <td>D</td> <td>Intrapancreatic or extrapancreatic fluid collections</td> <td>3</td> </tr> <tr> <td>E</td> <td>Two or more large collections of gas in the pancreas or retroperitoneum</td> <td>4</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Necrosis score based upon contrast enhanced CT</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Necrosis, percent</td> <td class=\"subtitle2\">Score</td> </tr> <tr> <td colspan=\"2\">0</td> <td>0</td> </tr> <tr> <td colspan=\"2\">&#60;33</td> <td>2</td> </tr> <tr> <td colspan=\"2\">33-50</td> <td>4</td> </tr> <tr> <td colspan=\"2\">&#8805;50</td> <td>6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT severity index equals unenhanced CT score plus necrosis score: maximum = 10, ≥6 = severe disease.</div><div class=\"graphic_reference\">Adapted from Balthazar, EJ, Robinson, DL, Megibow, AJ, Ranson, JH, Radiology 1990; 174:331.</div><div id=\"graphicVersion\">Graphic 68191 Version 2.0</div></div></div>"},"68192":{"type":"graphic_picture","displayName":"Mollusca contagiosa in HIV","title":"Mollusca contagiosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mollusca contagiosa</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/ID/68192_Mollusca_contagiosa_in_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A giant molluscum with typical central umbilication is visible in this close-up view of the eyelid of an HIV-infected patient.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 68192 Version 5.0</div></div></div>"},"68194":{"type":"graphic_figure","displayName":"Ca channel sympathetic activity","title":"Interaction between sympathetic activation and the calcium channel","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Interaction between sympathetic activation and the calcium channel</div><div class=\"cntnt\"><img style=\"width:516px; height:466px;\" src=\"images/CARD/68194_Ca_channel_sympathetic_acti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acceleration of sinus node automaticity by sympathetic stimulation results from an increase in the influx of sodium (If) during diastolic depolarization and an increase in calcium (Ca++) influx during phase 0; both are due to a direct stimulatory effect of the alpha subunit of the guanosine nucleotide binding protein (G protein) on the respective channels. In the resting nonstimulated state (panel A) guanosine diphosphate is bound to the alpha subunit of the G protein. With beta receptor activation (panel B), guanosine triphosphate (GTP) displaces GDP, stimulating adenyl cyclase; this generates cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) (panel C). Generation of cAMP activates protein kinase A and phosphorylation of the regulatory component of the CA++ channel; the opening of the Ca++ channel in response to membrane depolarization is increased. Activation of the alpha subunit of the G protein may also activate the Ca++ channel. With deactivation of the beta receptor, an intrinsinc GTPase hydrolyzes GTP to GDP (panel D).</div><div id=\"graphicVersion\">Graphic 68194 Version 1.0</div></div></div>"},"68197":{"type":"graphic_picture","displayName":"Annular lichen planus","title":"Annular lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Annular lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68197_Annular_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A violaceous annular plaque is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68197 Version 3.0</div></div></div>"},"68198":{"type":"graphic_picture","displayName":"Actinic keratosis hand","title":"Scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scale</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68198_ActinickeratosishandPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Actinic keratosis. Scale overlies erythematous macules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68198 Version 6.0</div></div></div>"},"68199":{"type":"graphic_table","displayName":"Ultrasound features associated with thyroid cancer risk","title":"Ultrasound features associated with thyroid cancer risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ultrasound features associated with thyroid cancer risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ultrasonographic features that are associated with an increased risk of thyroid cancer </td> </tr> <tr> <td>Hypoechoic</td> </tr> <tr> <td>Microcalcifications</td> </tr> <tr> <td>\"Twinkling\" on B-flow imaging</td> </tr> <tr> <td>Central vascularity</td> </tr> <tr> <td>Irregular margins</td> </tr> <tr> <td>Incomplete halo</td> </tr> <tr> <td>Nodule is taller than wide</td> </tr> <tr> <td>Documented enlargement of a nodule</td> </tr> <tr> <td class=\"subtitle1_single\">Ultrasonographic features that are associated with a low risk of thyroid cancer </td> </tr> <tr> <td>Hyperechoic</td> </tr> <tr> <td>Large, coarse calcifications (except medullary cancer)</td> </tr> <tr> <td>Peripheral vascularity</td> </tr> <tr> <td>Resembles puff or Napoleon pastry</td> </tr> <tr> <td>Spongiform appearance&nbsp;</td> </tr> <tr> <td>Comet-tail shadowing</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68199 Version 2.0</div></div></div>"},"68200":{"type":"graphic_picture","displayName":"Cook TriClip endosc","title":"Treatment of a bleeding gastric ulcer with an endoclip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of a bleeding gastric ulcer with an endoclip</div><div class=\"cntnt\"><img style=\"width:360px; height:365px;\" src=\"images/GAST/68200_Wilson-Cook_TriClip_endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemostasis of an actively bleeding gastric ulcer using a Cook TriClip.</div><div class=\"graphic_reference\">Courtesy of Dennis M. Jensen, MD.</div><div id=\"graphicVersion\">Graphic 68200 Version 2.0</div></div></div>"},"68201":{"type":"graphic_table","displayName":"Diagnosis of vulvovaginal mass","title":"Differential diagnosis for vulvovaginal masses and abscesses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for vulvovaginal masses and abscesses</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Inclusion cysts</td>\n   </tr>\n   <tr>\n   <td>Gartner duct cysts</td>\n   </tr>\n   <tr>\n   <td>Leiomyomas</td>\n   </tr>\n   <tr>\n   <td>Fibroma or fibroadenoma</td>\n   </tr>\n   <tr>\n   <td>Skene's duct cyst</td>\n   </tr>\n   <tr>\n   <td>Hernia</td>\n   </tr>\n   <tr>\n   <td>Hidradenoma</td>\n   </tr>\n   <tr>\n   <td>Sebaceous cysts</td>\n   </tr>\n   <tr>\n   <td>Hematomas</td>\n   </tr>\n   <tr>\n   <td>Lipomas</td>\n   </tr>\n   <tr>\n   <td>Vestibular mucous cysts</td>\n   </tr>\n   <tr>\n   <td>Endometriosis</td>\n   </tr>\n   <tr>\n   <td>Cysts of the canal of Nuck</td>\n   </tr>\n   <tr>\n   <td>Bartholin cyst or abscess or cancer</td>\n   </tr>\n   <tr>\n   <td>Syringoma</td>\n   </tr>\n   <tr>\n   <td>Accessory breast tissue</td>\n   </tr>\n   <tr>\n   <td>Folliculitis</td>\n   </tr>\n   <tr>\n   <td>Urethral diverticulae</td>\n   </tr>\n   <tr>\n   <td>Hidradenitis suppurativa</td>\n   </tr>\n   <tr>\n   <td>Extension from perianal infection (eg, anorectal abscess)</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 68201 Version 1.0</div></div></div>"},"68204":{"type":"graphic_picture","displayName":"Dentin","title":"Scanning electron micrograph of human dentin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scanning electron micrograph of human dentin</div><div class=\"cntnt\"><img style=\"width:378px; height:270px;\" src=\"images/PEDS/68204_Odontoblastic_processes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This scanning electron micrograph shows the odontoblastic processes entering the dentinal tubules in normal human dentin.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &#169; WB Saunders, 2000.</div><div id=\"graphicVersion\">Graphic 68204 Version 4.0</div></div></div>"},"68205":{"type":"graphic_diagnosticimage","displayName":"OCT AMD","title":"Wet age-related macular degeneration (AMD: Fluorescein angiogram and color fundus photograph of eye with classic choroidal veovascular membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wet age-related macular degeneration (AMD: Fluorescein angiogram and color fundus photograph of eye with classic choroidal veovascular membrane</div><div class=\"cntnt\"><img style=\"width:364px; height:358px;\" src=\"images/PC/68205_OCT_AMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal OCT (A) reveals a normal foveal thickness and contour with a small dip at the area of the foveola (arrow). Study (B) demonstrates loss of the normal anatomy, retinal edema, and a subretinal lesion consistent with a choroidal neovascular membrane (arrow). Correlation with the clinical examination and fluorescein angiogram is critical to making the correct diagnosis.</div><div class=\"graphic_footnotes\">OCT: optical coherence tomography.</div><div id=\"graphicVersion\">Graphic 68205 Version 4.0</div></div></div>"},"68206":{"type":"graphic_table","displayName":"Neurologic complications of cardiac surgery","title":"Neurologic complications of cardiac operations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic complications of cardiac operations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Preventive measures</td> </tr> <tr> <td rowspan=\"3\">Brachial plexus injury</td> <td rowspan=\"3\">2-15 percent</td> <td>Minimize sternal retraction</td> </tr> <tr> <td class=\"sublist1_start\">Attention to patient position</td> </tr> <tr> <td class=\"sublist1\">Padding arms</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"17\">Stroke</td> <td rowspan=\"17\">0.4-6 percent</td> <td class=\"sublist1_start\">Conduct of cardiopulmonary bypass</td> </tr> <tr> <td class=\"sublist1\">Minimize duration</td> </tr> <tr> <td class=\"sublist1\">Hypothermia</td> </tr> <tr> <td class=\"sublist1\">Alpha-stat pH management (?)</td> </tr> <tr> <td class=\"sublist1\">Minimally invasive procedures (?)</td> </tr> <tr> <td>Avoid perioperative hypotension</td> </tr> <tr> <td class=\"sublist1_start\">Preoperative screening</td> </tr> <tr> <td class=\"sublist1\">If significant carotid stenosis consider:</td> </tr> <tr> <td class=\"sublist2\">Preoperative stent</td> </tr> <tr> <td class=\"sublist2\">Combined CEA/CABG</td> </tr> <tr> <td class=\"sublist1_start\">Avoidance of emboli</td> </tr> <tr> <td class=\"sublist1\">De-airing maneuvers</td> </tr> <tr> <td class=\"sublist1\">Minimize aortic trauma in patients with severely calcified aortas</td> </tr> <tr> <td class=\"sublist1_start\">Monitoring</td> </tr> <tr> <td class=\"sublist1\">TEE</td> </tr> <tr> <td class=\"sublist1\">EEG/EP (?)</td> </tr> <tr> <td class=\"sublist1\">TCD (?)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Ophthalmologic</td> <td>Clinical 0.1-25 percent</td> <td rowspan=\"2\">Same as stroke</td> </tr> <tr> <td>Angiography 100 percent</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Delirium</td> <td rowspan=\"9\">3-32 percent</td> <td class=\"sublist1_start\">Minimize:</td> </tr> <tr> <td class=\"sublist1\">Sensory deprivation</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepine/narcotic use postoperatively</td> </tr> <tr> <td class=\"sublist1\">Disruption of sleep-wake cycles</td> </tr> <tr> <td class=\"sublist1_start\">Watch for metabolic encephalopathies</td> </tr> <tr> <td class=\"sublist1\">Electrolytes</td> </tr> <tr> <td class=\"sublist1\">Renal dysfunction</td> </tr> <tr> <td class=\"sublist1\">Hepatic dysfunction</td> </tr> <tr> <td>Watch for withdrawal syndromes</td> </tr> <tr class=\"divider_top\"> <td>Subtle neuropsychological</td> <td>10-79 percent</td> <td>Same as stroke</td> </tr> <tr class=\"divider_top\"> <td>Intracranial hemorrhage</td> <td>&#60;0.1 percent</td> <td>Wait 2-4 weeks after new stroke before surgery if possible</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"9\">Seizures</td> <td rowspan=\"9\">0.6 percent</td> <td class=\"sublist1_start\">Avoid:</td> </tr> <tr> <td class=\"sublist1\">Hyponatremia</td> </tr> <tr> <td class=\"sublist1\">Hypocalcemia</td> </tr> <tr> <td class=\"sublist1\">Hypomagnesemia</td> </tr> <tr> <td class=\"sublist1_start\">Avoid withdrawal of:</td> </tr> <tr> <td class=\"sublist1\">Benzodiazepines</td> </tr> <tr> <td class=\"sublist1\">Barbiturates</td> </tr> <tr> <td class=\"sublist1_start\">Avoid toxic doses of:</td> </tr> <tr> <td class=\"sublist1\">Lidocaine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CEA: carotid endarterectomy; EEG: electroencephalography; CABG: coronary artery bypass grafting; EP: evoked potentials; TEE: transesophageal echocardiography; TCD: transcranial Doppler.</div><div id=\"graphicVersion\">Graphic 68206 Version 3.0</div></div></div>"},"68208":{"type":"graphic_figure","displayName":"Endoscopic component separation technique balloon insertion","title":"Endoscopic component separation technique balloon insertion","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Endoscopic component separation technique balloon insertion</div><div class=\"cntnt\"><img style=\"width:470px; height:367px;\" src=\"images/SURG/68208_ECST-balloon-placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A balloon dissector is inserted in the midaxillary line and inflated with saline. The inflated balloon hydrodissects a vertical pocket in the subcutaneous tissue. The space is gently insufflated for exposure and two trochars are inserted under direct vision to continue the dissection.</div><div class=\"graphic_reference\">Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted &quot;components separation&quot; for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.</div><div id=\"graphicVersion\">Graphic 68208 Version 4.0</div></div></div>"},"68209":{"type":"graphic_diagnosticimage","displayName":"Primary CNS lymphoma MRI","title":"MRI scan of a patient with primary central nervous system lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI scan of a patient with primary central nervous system lymphoma</div><div class=\"cntnt\"><img style=\"width:301px; height:339px;\" src=\"images/ID/68209_Primary_CNS_lymphoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nodular enhancing lesion produces moderate mass effect on the frontal horn of the right lateral ventricle in this T1-weighted image.</div><div class=\"graphic_footnotes\">MRI:&nbsp;Magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 68209 Version 4.0</div></div></div>"},"68210":{"type":"graphic_picture","displayName":"Uveitis syphilis","title":"Uveitis and vitritis secondary to syphilis","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Uveitis and vitritis secondary to syphilis</div><div class=\"cntnt\"><img style=\"width:518px; height:261px;\" src=\"images/ID/68210_Uveitis_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photo of retina (color and after intravenous fluorescien dye) in a patient with uveitis and vitritis secondary to syphilis. The optic nerve is swollen (blurring of the optic disc margens), there is retinal edema and necrosis (retina appears white and elevated) as well as retinal vasculitis and tortuous vessels coming from the optic nerve. In addition, the presence of significant vitritis gives the picture a general haze (due to inflammatory cells floating in the vitreous).</div><div class=\"graphic_reference\">Photos courtesy of Drs. Mehri McKellar and Michael Cusick.</div><div id=\"graphicVersion\">Graphic 68210 Version 1.0</div></div></div>"},"68212":{"type":"graphic_figure","displayName":"Urea equilibration in HD","title":"Schematic figure demonstrating the relationship between urea clearance and equilibration when the access is parallel to the circulation in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic figure demonstrating the relationship between urea clearance and equilibration when the access is parallel to the circulation in hemodialysis</div><div class=\"cntnt\"><img style=\"width:439px; height:271px;\" src=\"images/NEPH/68212_Urea_equilibration_in_HD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of standard hemodialysis in which flow through the access is in parallel with the systemic circulation. The degree to which urea is removed is dependent upon the rate of urea equilibration between intracellular stores (IC) and the extracellular fluid (EC). Slow equilibrators will have a lower BUN during dialysis but a slower rate of total urea removal.</div><div id=\"graphicVersion\">Graphic 68212 Version 2.0</div></div></div>"},"68213":{"type":"graphic_figure","displayName":"Acetaminophen metabolism","title":"Acetaminophen metabolism","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Acetaminophen metabolism</div><div class=\"cntnt\"><img style=\"width:454px; height:448px;\" src=\"images/PEDS/68213_Acetaminophen_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At therapeutic doses, 90 percent of acetaminophen is metabolized in the liver to sulfate and glucuronide conjugates that are then excreted in the urine. One-half of the remaining acetaminophen is excreted unchanged in the urine and one-half is metabolized via the hepatic cytochrome P450 (CYP2E1, CYP1A2, CYP3A4 subfamilies) mixed function oxidase pathway to N-acetyl-p-benzoquinoneimine (NAPQI), which is hepatotoxic. With normal doses (blue arrows), NAPQI is rapidly conjugated to hepatic glutathione, forming nontoxic cysteine and mercaptate compounds that are excreted in the urine. With toxic doses (red arrow), the sulfate and glucuronide pathways become saturated, resulting in an increased fraction of acetaminophen being metabolized by cytochrome P450 enzymes. Once glutathione stores are depleted, NAPQI begins to accumulate and hepatic injury ensues.</div><div id=\"graphicVersion\">Graphic 68213 Version 2.0</div></div></div>"},"68214":{"type":"graphic_table","displayName":"Preventing lead exposure from paint","title":"Educational interventions to prevent exposure to lead in paint","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Educational interventions to prevent exposure to lead in paint</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Clean up loose paint chips immediately</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wipe off loose paint using damp disposable cloths or rags</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Block access to chipping paint with furniture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Put contact paper over chipping paint</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hose off porch or place down a blanket or rug where children play</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Seal or enclose areas with small amounts of chipping paint</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Do not use hazardous methods of removing paint:</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Sanding without a HEPA attachment</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Open-flame burning</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Chemical removal</td>\n    </tr>\n    <tr>\n\n      <td>Use only certified abatement contractors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Make sure family and belongings (eg, upholstered furniture) are protected during abatement</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Environmental Protection Agency. (http://www.epa.gov/lead/educationexesum.htm)</div><div id=\"graphicVersion\">Graphic 68214 Version 2.0</div></div></div>"},"68215":{"type":"graphic_picture","displayName":"Atopic dermatitis popliteal","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68215_Atopicdermatitispopliteal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, slightly scaly patches and lichenified plaques are present in the popliteal fossae of this patient with atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68215 Version 5.0</div></div></div>"},"68216":{"type":"graphic_algorithm","displayName":"Decision to intubate","title":"The decision to intubate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The decision to intubate</div><div class=\"cntnt\"><img style=\"width:341px; height:416px;\" src=\"images/EM/68216_Decision_to_intubate.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68216 Version 2.0</div></div></div>"},"68218":{"type":"graphic_diagnosticimage","displayName":"Vert collapse sickle cell","title":"Vertebral body collapse in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Vertebral body collapse in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:517px; height:248px;\" src=\"images/HEME/68218_Vert_collapse_sickle_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior-anterior (left photo) and lateral chest radiographs (right photo) of a patient with sickle cell disease (Hb SS) demonstrate collapse of several vertebral bodies, with a typical biconcave shape to each collapsed vertebral body (arrows).</div><div id=\"graphicVersion\">Graphic 68218 Version 2.0</div></div></div>"},"68219":{"type":"graphic_figure","displayName":"TB guide exchange transfusion","title":"Guidelines for exchange transfusion in infants 35 or more weeks gestation","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Guidelines for exchange transfusion in infants 35 or more weeks gestation</div><div class=\"cntnt\"><img style=\"width:554px; height:404px;\" src=\"images/PEDS/68219_TSBguideexchangetransfus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dashed lines for the first 24 hours indicate uncertainty due to a wide range of clinical circumstances and a range of responses to phototherapy. Immediate exchange transfusion is recommended if the infant shows signs of acute bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry) or if TB is ≥5 mg/dL (85 micromol/L) above these lines. Risk factors include isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, and acidosis. Measure serum albumin and calculate B/A ratio. Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin. If infant is well and 35 to 37 6/7 weeks (medium risk) can individualize TB levels for exchange based on actual gestational age. Note that these suggested levels represent a consensus of most of the committee but are based on limited evidence, and the levels shown are approximations. During birth hospitalization, exchange transfusion is recommended if the TB rises to these levels despite intensive phototherapy. For readmitted infants, if the TB level is above the exchange level, repeat TB measurement every two to three hours and consider exchange if the TB remains above the levels indicated after intensive phototherapy for six hours.</div><div class=\"graphic_footnotes\">TB: total serum or plasma bilirubin; G6PD: glucose-6-phosphate dehydrogenase; B/A: bilirubin/albumin.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 114, Pages 297-316, Copyright &copy; 2004 by the AAP.</div><div id=\"graphicVersion\">Graphic 68219 Version 20.0</div></div></div>"},"68222":{"type":"graphic_movie","displayName":"Thoracic ultrasound - Lung point","title":"Thoracic ultrasound: Lung point","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound: Lung point</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/68222_ThoracUSlungpointconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:250px;\" src=\"images/PULM/68222_ThoracicUSlungpoint.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68222 Version 2.0</div></div></div>"},"68224":{"type":"graphic_picture","displayName":"Langerhans cell histiocytosis scalp lesions","title":"Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68224_Langerhans_cell_hist_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous macules, crusts, erosions, and petechiae are present on the scalp of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68224 Version 3.0</div></div></div>"},"68225":{"type":"graphic_figure","displayName":"Annual incidence RMSF map","title":"Rocky Mountain spotted fever. Number of reported cases, by county - United States, 2010","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Rocky Mountain spotted fever. Number of reported cases, by county - United States, 2010</div><div class=\"cntnt\"><img style=\"width:607px; height:376px;\" src=\"images/ID/68225_Annual_incidence_RMSF_map.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although RMSF cases have been reported throughout most of the contiguous United States, five states (North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri) account for over 60 percent&nbsp;of RMSF cases. The primary tick that transmits R. rickettsii in these states is the American dog tick (Dermacentor variabilis Dermacentor andersoni).</div><div class=\"graphic_reference\">Reproduced from: Rocky Mountain Spotted Fever (RMSF): Statistics and Epidemiology. Centers for Disease Control and Prevention.<A href=\"http://www.cdc.gov/rmsf/stats/\" target=_blank>http://www.cdc.gov/rmsf/stats/</A> (Access on September 13, 2013).</div><div id=\"graphicVersion\">Graphic 68225 Version 2.0</div></div></div>"},"68228":{"type":"graphic_movie","displayName":"Calcific aortic stenosis color Doppler echocardiogram","title":"Calcific aortic stenosis color Doppler echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcific aortic stenosis color Doppler echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68228_aoscldopconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:318px; height:240px;\" src=\"images/CARD/68228_aoscldop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view of color flow Doppler showing echo dense calcified aortic valve and trace aortic regurgitation.</div><div id=\"graphicVersion\">Graphic 68228 Version 4.0</div></div></div>"},"68230":{"type":"graphic_picture","displayName":"Oil redO stain kid LPG","title":"Oil red-O stain for lipids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oil red-O stain for lipids</div><div class=\"cntnt\"><img style=\"width:396px; height:308px;\" src=\"images/NEPH/68230_Oil_redO_stain_kid_LPG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous red droplets are seen in the lumen of glomerular capillary. Frozen section.</div><div class=\"graphic_reference\">Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright ©2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 68230 Version 2.0</div></div></div>"},"68233":{"type":"graphic_table","displayName":"Grading of acute GVHD","title":"Grading of acute graft-versus-host disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of acute graft-versus-host disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td rowspan=\"4\">Skin</td> <td class=\"centered\">1</td> <td>Maculopapular rash over &#60;25 percent of body area</td> </tr> <tr> <td class=\"centered\">2</td> <td>Maculopapular rash over 25 to 50 percent of body area</td> </tr> <tr> <td class=\"centered\">3</td> <td>Generalized erythroderma</td> </tr> <tr> <td class=\"centered\">4</td> <td>Generalized erythroderma with bullous formation and often with desquamation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Liver</td> <td class=\"centered\">1</td> <td>Bilirubin 2.0 to 3.0 mg/dL; SGOT 150 to 750 international units</td> </tr> <tr> <td class=\"centered\">2</td> <td>Bilirubin 3.1 to 6.0 mg/dL</td> </tr> <tr> <td class=\"centered\">3</td> <td>Bilirubin 6.1 to 15.0 mg/dL</td> </tr> <tr> <td class=\"centered\">4</td> <td>Bilirubin &#62;15.0 mg/dL</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Gut</td> <td class=\"centered\">1</td> <td>Diarrhea &#62;30 mL/kg or &#62;500 mL/day</td> </tr> <tr> <td class=\"centered\">2</td> <td>Diarrhea &#62;60 mL/kg or &#62;1000 mL/day</td> </tr> <tr> <td class=\"centered\">3</td> <td>Diarrhea &#62;90 mL/kg or &#62;1500 mL/day</td> </tr> <tr> <td class=\"centered\">4</td> <td>Diarrhea &#62;90 mL/kg or &#62;2000 mL/day; or severe abdominal pain with or without ileus</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Glucksberg grade</td> </tr> <tr> <td colspan=\"3\">I &ndash; Stage 1 or 2 skin involvement; no liver or gut involvement; ECOG PS 0</td> </tr> <tr> <td colspan=\"3\">II &ndash; Stage 1 to 3 skin involvement; Grade 1 liver or gut involvement; ECOG PS 1</td> </tr> <tr> <td colspan=\"3\">III &ndash; Stage 2 or 3 skin, liver, or gut involvement; ECOG PS 2</td> </tr> <tr> <td colspan=\"3\">IV &ndash; Stage 1 to 4 skin involvement; Stage 2 to 4 liver or gut involvement; ECOG PS 3</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">International Bone Marrow Transplant Registry Severity Index</td> </tr> <tr> <td colspan=\"3\">A &ndash; Stage 1 skin involvement; no liver or gut involvement</td> </tr> <tr> <td colspan=\"3\">B &ndash; Stage 2 skin involvement; Stage 1 to 2 gut or liver involvement</td> </tr> <tr> <td colspan=\"3\">C &ndash; Stage 3 skin, liver, or gut involvement</td> </tr> <tr> <td colspan=\"3\">D &ndash; Stage 4 skin, liver, or gut involvement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SGOT: serum glutamic oxaloacetic transaminase; ECOG: Eastern Cooperative Oncology Group; PS: performance status.</div><div id=\"graphicVersion\">Graphic 68233 Version 6.0</div></div></div>"},"68234":{"type":"graphic_diagnosticimage","displayName":"Aortouniliac endovascular graft","title":"Aortouniliac endovascular graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortouniliac endovascular graft</div><div class=\"cntnt\"><img style=\"width:439px; height:540px;\" src=\"images/SURG/68234_Aortouniliac_endovasc_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aorto-uniliac Zenith Renu graft (A)&nbsp;used to repair an AAA with bilateral common iliac aneurysms extending to the iliac bifurcation. The right internal iliac artery&nbsp;has been embolized (B) with coils. A right-to-left femoral-femoral bypass (C) perfuses the left lower extremity and an Excluder limb is&nbsp;used to create a left&nbsp;external-to-internal iliac artery&nbsp;bypass (D) providing&nbsp;retrograde perfusion into the left internal iliac artery.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 68234 Version 3.0</div></div></div>"},"68235":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step five","title":"Standard cricothyrotomy step five","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step five</div><div class=\"cntnt\"><img style=\"width:372px; height:322px;\" src=\"images/EM/68235_Cric_standard_step_five.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red><FONT color=black>Insert the Trousseau dilator and open to expand the incision vertically.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 68235 Version 2.0</div></div></div>"},"68236":{"type":"graphic_picture","displayName":"Figure 8 bandage","title":"Figure of eight bandage","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Figure of eight bandage</div><div class=\"cntnt\"><img style=\"width:551px; height:166px;\" src=\"images/EM/68236_Figure_8_bandage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure of eight bandage with shoulders in position of attention.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Illustration used with permission of Elsevier Inc. All right reserved. Copyright ©2002 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 68236 Version 2.0</div></div></div>"},"68237":{"type":"graphic_figure","displayName":"Calcitonin and osteoporotic bone pain","title":"Nasal calcitonin improves bone pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal calcitonin improves bone pain</div><div class=\"cntnt\"><img style=\"width:401px; height:272px;\" src=\"images/ENDO/68237_CT_and_osteoporotic_bone_pa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of intranasal salmon calcitonin or placebo on the intensity of spontaneous bone pain (score from 0 to 20) in women with recent osteoporotic spinal fractures. Salmon calcitonin led to a more rapid reduction in pain.</div><div class=\"graphic_footnotes\">sCT: salmon calcitonin.</div><div class=\"graphic_reference\">Data from: Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 Suppl 2:S9.</div><div id=\"graphicVersion\">Graphic 68237 Version 3.0</div></div></div>"},"68238":{"type":"graphic_figure","displayName":"Anal fissure anatomy","title":"Anal fissure anatomy","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Anal fissure anatomy</div><div class=\"cntnt\"><img style=\"width:477px; height:610px;\" src=\"images/GAST/68238_Anal_fissure_anat_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68238 Version 5.0</div></div></div>"},"68239":{"type":"graphic_picture","displayName":"Mallory Weiss clot Endosc","title":"Mallory-Weiss tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallory-Weiss tear</div><div class=\"cntnt\"><img style=\"width:216px; height:278px;\" src=\"images/GAST/68239_Mallory_Weiss_clot_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy shows a Mallory-Weiss tear with an adherent clot at the apex of the tear.</div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 68239 Version 2.0</div></div></div>"},"68243":{"type":"graphic_table","displayName":"Causes of UGI bleeding in children","title":"Etiologies of upper gastrointestinal bleeding in children by age group, in approximate order of frequency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of upper gastrointestinal bleeding in children by age group, in approximate order of frequency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neonate</td> <td class=\"subtitle1\">Infant</td> <td class=\"subtitle1\">Child or adolescent</td> </tr> <tr> <td>Swallowed maternal blood*</td> <td>Stress gastritis or ulcer<sup>&#182;</sup></td> <td>Mallory-Weiss tear (associated with vomiting)</td> </tr> <tr> <td>Vitamin K deficient bleeding<sup>&#916;</sup></td> <td>Acid-peptic disease<sup>&#9674;</sup></td> <td>Acid-peptic disease<sup>&#9674;</sup></td> </tr> <tr> <td>Stress gastritis or ulcer<sup>&#182;</sup></td> <td>Mallory-Weiss tear (associated with vomiting)</td> <td>Gastric or esophageal varices</td> </tr> <tr> <td>Esophagitis</td> <td>Esophagitis</td> <td>Esophagitis</td> </tr> <tr> <td>Trauma (eg, nasogastric tube)</td> <td>Vascular anomalies<sup>&#167;</sup></td> <td>Foreign body</td> </tr> <tr> <td>Vascular anomalies<sup>&#167;</sup></td> <td>Gastrointestinal duplications</td> <td>Caustic ingestion</td> </tr> <tr> <td>Gastrointestinal duplications</td> <td>Gastric or esophageal varices</td> <td>Vasculitis (eg, Henoch-Schoenlein purpura)</td> </tr> <tr> <td>Coagulopathy (eg, associated with infection)</td> <td>Duodenal or gastric webs</td> <td>Crohn's disease</td> </tr> <tr> <td>Milk protein intolerance</td> <td>Bowel obstruction</td> <td>Bowel obstruction</td> </tr> <tr> <td>Congenital coagulation factor deficiency</td> <td>&nbsp;</td> <td>Dieulafoy lesion</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hemobilia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UGI: upper gastrointestinal; NSAID: non-steroidal anti-inflammatory drugs.<br />* This is a common cause of hematemesis in a newborn, and is easily confused with UGI bleeding.<br />¶ Typically seen in critically ill infants; gastritis also may be caused by cytomegalovirus infection.<br />Δ Effectively prevented by vitamin K prophylaxis which is usually given during routine neonatal care.<br /><FONT class=lozenge>◊</FONT> Especially if NSAIDs have been given.<br />§ Vascular anomalies include hemagiomas, telangiectasias, and other vascular malformations.</div><div class=\"graphic_reference\">Modified with permission from: Gilger MA. Upper Gastrointestinal Bleeding. In: Walker, Goulet, Kleinman, et al, Eds. Pediatric Gastrointestinal Disease, 4 Ed. B.C. Decker, Ontario, 2004. Copyright &copy; 2004 PMPH-USA, Ltd. Additional data from: Chawla S, et al, Clinical Pediatrics 2007; 46:16.</div><div id=\"graphicVersion\">Graphic 68243 Version 4.0</div></div></div>"},"68244":{"type":"graphic_table","displayName":"Renal changes with aging","title":"Renal changes with aging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal changes with aging</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anatomic</td> </tr> <tr> <td>Decrease in renal mass, mostly from cortex</td> </tr> <tr> <td>Increased renal fat and fibrosis</td> </tr> <tr> <td>Sclerosis of cortical nephrons with longest loops of Henle</td> </tr> <tr> <td class=\"subtitle1_single\">Functional</td> </tr> <tr> <td>Decreased renal blood flow</td> </tr> <tr> <td>Impaired vasodilation in response to dopamine</td> </tr> <tr> <td>Decreased creatinine clearance</td> </tr> <tr> <td>Impaired sodium excretion and conservation</td> </tr> <tr> <td>Decreased potassium excretion and conservation</td> </tr> <tr> <td>Decreased concentrating and diluting capacity</td> </tr> <tr> <td>Impaired excretion of acid loads</td> </tr> <tr> <td>Decreased serum renin and aldosterone</td> </tr> <tr> <td>Altered intrarenal nitric oxide actions</td> </tr> <tr> <td>Increased dependence on renal prostaglandins to maintain intrarenal perfusion</td> </tr> <tr> <td>Decreased vitamin D activation</td> </tr> <tr> <td>Increased vulnerability to dye, ischemia, or other insults</td> </tr> <tr> <td>Impaired recovery after insults</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Taffet GE. Physiology of aging. In: Geriatric Medicine: An Evidence-Based Approach, Cassel CK, Leipzig RM, Cohen HJ, et al (Eds), 4th ed, Springer, New York 2003.</div><div id=\"graphicVersion\">Graphic 68244 Version 1.0</div></div></div>"},"68245":{"type":"graphic_picture","displayName":"Contact dermatitis berloque 2","title":"Berloque dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Berloque dermatitis</div><div class=\"cntnt\"><img style=\"width:387px; height:576px;\" src=\"images/DERM/68245_Contact_derm_berloque_2_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmention stage of berloque dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: The Dermatology Online Atlas, <A href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</A>. Copyright &#169; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68245 Version 2.0</div></div></div>"},"68246":{"type":"graphic_picture","displayName":"Hypotonia","title":"Hypotonia-severe head lag","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypotonia-severe head lag</div><div class=\"cntnt\"><img style=\"width:280px; height:360px;\" src=\"images/PEDS/68246_Hypotonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright ©2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 68246 Version 2.0</div></div></div>"},"68247":{"type":"graphic_figure","displayName":"ICD vs no ICD MUSTT","title":"ICD reduces sudden death in MUSTT","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">ICD reduces sudden death in MUSTT</div><div class=\"cntnt\"><img style=\"width:522px; height:302px;\" src=\"images/CARD/68247_ICDvsnoICDMUSTT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MUSTT trial enrolled 704 patients with coronary artery disease, nonsustained ventricular tachycardia (VT), and a left ventricular ejection fraction ≤40 percent who had sustained VT induced during electrophysiologic (EP) study. Kaplan-Meier estimates show that the incidence of cardiac arrest or death from arrhythmia is significantly lower in those receiving an implantable cardioverter-defibrillator (ICD) compared with those receiving no therapy or those with EP-guided (EPG) antiarrhythmic drug (AAD) therapy.</div><div class=\"graphic_reference\">Data from: Buxton AE, Lee KL, Fisher JD, et al. N Engl J Med 1999; 341:1882.</div><div id=\"graphicVersion\">Graphic 68247 Version 4.0</div></div></div>"},"68248":{"type":"graphic_table","displayName":"Whole milk diets","title":"Whole milk diets for use during the rehabilitation phase of treatment for malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Whole milk diets for use during the rehabilitation phase of treatment for malnutrition</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t\n<tr>\n\t<td class=\"container\">\n\t<table cellspacing=\"0\">\n\n<tr>\n<td class=\"subtitle1_single\">To make the starter diet from milk:</td>\n</tr>\n\n<tr>\n<td>Mix 50 g sugar and 10 mL vegetable oil together thoroughly.</td>\n</tr>\n\t\n<tr>\n<td>Add 150 mL boiled whole (full cream) milk and 10 mL of the electrolyte solution (see paragraph 3) if used.</td>\n</tr>\n\n<tr>\n<td>Make up to 500 mL with boiled water. Whisk to stop oil separating out or mix vigorously before serving. This feed keeps up to 12 hours. Make more when necessary.</td>\n</tr>\n\n<tr>\n<td>In the evening make sure there is enough for the night feeds.</td>\n</tr>\n\n<tr>\n<td>Feed at a rate of 130 mL/kg body weight/24 hours. Divide into eight feeds and feed every three hours.</td>\n</tr>\n\n<tr>\n<td>A child who is breastfed should be encouraged to suckle after drinking the milk feed.</td>\n</tr>\n\n<tr>\n<td><strong>Never add salt,</strong> explain to the parent that the child needs sweet not salty food.</td>\n</tr>\n\n</table>\n</td>\n\n<td class=\"container\">\n<table cellspacing=\"0\">\n\n<tr>\n<td class=\"subtitle1_single\">To make a high energy high nutrient rehabilitation diet from milk:</td>\n</tr>\n\n<tr>\n<td>Mix 40 g sugar and 10 mL vegetable oil.</td>\n</tr>\n\n<tr>\n<td>Add 440 mL boiled whole milk and 10 mL of the electrolyte solution.</td>\n</tr>\n\n<tr>\n<td>Make up to 500 mL with boiled water and whisk vigorously.</td>\n</tr>\n\n<tr>\n<td>For two days, feed at same frequency and amount as the initial diet, then increase the amount by 10 mL/feed and reduce frequency of feeds to every four hours. Feed at a rate of approximately 200 mL/kg body weight/day (or more if child wants it). When given four hourly, each feed should be 166 mL.</td>\n</tr>\n\n<tr>\n<td>If milk is difficult to get, make a thick cereal porridge and add oil or margarine or sugar and bean, pea or peanut flour, peanut butter or eggs. Start giving fruits and vegetables, particularly those rich in vitamin A.</td>\n</tr>\n\n</table>\n</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Improving child nutrition: Treating severe malnutrition. Child Health Dialogue 200; 19. Copyright ©2000 Healthlink.</div><div id=\"graphicVersion\">Graphic 68248 Version 2.0</div></div></div>"},"68249":{"type":"graphic_table","displayName":"Meds associated with FTT","title":"Medications associated with weight loss and failure to thrive","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with weight loss and failure to thrive</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\t\n\t<tr>\n\t\t<td class=\"container\">\n\t\t<table cellspacing=\"0\">\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs that may cause anorexia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anticonvulsants</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Digoxin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Estrogens</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>H2 Blockers</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hypnotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Narcotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>NSAIDS</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Proton-pump inhibitors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psychotropics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>SSRI's</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Thyroid replacements</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs with adverse behavioral reactions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anticonvulsants</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anti-cholinergics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hypnotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Narcotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psychotropics</td>\n\t\t\t\t</tr>\n\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs that may alter taste</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>ACE inhibitors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Allopurinol</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antihistamines</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Beta 2 Agonists</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Clarithromycin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Coumadin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Digoxin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Eszopiclone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Famotidine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Furosemide</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Lithium</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Metronidazole</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nizatidine</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Omeprazole</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Phenytoin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Sertraline</td>\n\t\t\t\t</tr>\n\t\t\t\t\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t\n\t\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs associated with dysphagia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>ACE inhibitors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antibiotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antihistamines</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antivirals</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ascorbic acid</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bisphosphonates</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diuretics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>KCl</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Narcotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Nitrates</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>NSAIDS</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psychotropics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Theophyllines</td>\n\t\t\t\t</tr>\n\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Drugs with adverse GI reactions (excluding dysphagia)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acetylcholinesterase inhibitors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Amiodarone</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Antibiotics</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Chemotherapy </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Digoxin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Ferrous Sulfate</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Laxatives</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>NSAIDS</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Quinidine</td>\n\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t\t</td>\n\t\t\t\t</tr>\n</tbody>\n\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Goldberg, R, Physicians attentiveness to medication use as etiology of weight loss. Long-term Care interface 2005; 20. Copyright &#169;2005 Medicomint.</div><div id=\"graphicVersion\">Graphic 68249 Version 1.0</div></div></div>"},"68250":{"type":"graphic_figure","displayName":"The cell cycle","title":"The cell cycle","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">The cell cycle</div><div class=\"cntnt\"><img style=\"width:528px; height:532px;\" src=\"images/PC/68250_The_cell_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cell cycle is comprised of the following stages: G0, nondividing cell; G1, cell growth; S, DNA replication; G2, protein synthesis; mitosis, which lasts for 1 to 3 hours and is followed by cytokinesis or cell division. The stages of mitosis are P, prophase; M, metaphase; A, anaphase; T, telophase.</div><div class=\"graphic_reference\">Reproduced with permission from Wolters Kluwer</div><div id=\"graphicVersion\">Graphic 68250 Version 1.0</div></div></div>"},"68251":{"type":"graphic_table","displayName":"Histologic clinical class idiopathic interstitial pneumonias","title":"Classification of idiopathic interstitial pneumonias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of idiopathic interstitial pneumonias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical diagnosis</td> <td class=\"subtitle1\">Pathologic pattern</td> </tr> <tr> <td>Idiopathic pulmonary fibrosis (IPF)</td> <td>Usual interstitial pneumonia (UIP)</td> </tr> <tr> <td>Desquamative interstitial pneumonia (DIP)</td> <td>Desquamative interstitial pneumonia (DIP)</td> </tr> <tr> <td>Respiratory bronchiolitis interstitial lung disease (RBILD)</td> <td>Respiratory bronchiolitis (RB)</td> </tr> <tr> <td>Acute interstitial pneumonia (AIP)</td> <td>Diffuse alveolar damage (DAD)</td> </tr> <tr> <td>Nonspecific interstitial pneumonia (NSIP)</td> <td>Nonspecific interstitial pneumonia (NSIP)</td> </tr> <tr> <td>Cryptogenic organizing pneumonia (COP)</td> <td>Organizing pneumonia (OP)</td> </tr> <tr> <td>Lymphoid interstitial pneumonia (LIP)</td> <td>Lymphoid interstitial pneumonia (LIP)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Resp Crit Care Med 2002; 165:277.</div><div id=\"graphicVersion\">Graphic 68251 Version 4.0</div></div></div>"},"68252":{"type":"graphic_algorithm","displayName":"Thyroid tests in patients with renal failure","title":"Thyroid testing in patients with suspected hypothyroidism and renal failure","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Thyroid testing in patients with suspected hypothyroidism and renal failure</div><div class=\"cntnt\"><img style=\"width:573px; height:261px;\" src=\"images/NEPH/68252_Thyroid_tests_in_renal_fail.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for the evaluation of thyroid status in patients with renal failure suspected of possible hypothyroidism because of a decreased serum free T4 concentration.</div><div id=\"graphicVersion\">Graphic 68252 Version 4.0</div></div></div>"},"68253":{"type":"graphic_figure","displayName":"2nd trimester unconjugated estriol (uE3) levels","title":"Second trimester unconjugated estriol (uE3) levels","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Second trimester unconjugated estriol (uE3) levels</div><div class=\"cntnt\"><img style=\"width:512px; height:493px;\" src=\"images/OBGYN/68253_2triuE3lvlsgestatnlage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 68253 Version 2.0</div></div></div>"},"68254":{"type":"graphic_figure","displayName":"Incomplete breech presentation","title":"Incomplete breech presentation","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Incomplete breech presentation</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/OBGYN/68254_Incomplete_breech_presentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the incomplete breech position, one or both hips are not completely flexed. This is an incomplete, double footling breech presentation.</div><div id=\"graphicVersion\">Graphic 68254 Version 3.0</div></div></div>"},"68255":{"type":"graphic_figure","displayName":"Ureteric bud","title":"Ureteric bud","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteric bud</div><div class=\"cntnt\"><img style=\"width:392px; height:340px;\" src=\"images/OBGYN/68255_Ureteric_bud.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation of the hindgut and cloaca at the end of the fifth week. The ureteric bud penetrates the metanephric mesoderm (blastema).</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68255 Version 1.0</div></div></div>"},"68256":{"type":"graphic_table","displayName":"Prog fac CTLS AML","title":"Prognostic factors for CTLS in AML in the training sample: multivariate analysis and risk scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic factors for CTLS in AML in the training sample: multivariate analysis and risk scores</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Co-variate\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Unfavorable categories\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Regression coefficient\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   \t<p>CTLS</p>\n\t<p> \tOdds ratio (95% CI)</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   p value\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Score\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   WBC\r\n  \r\n   </td>\r\n  \r\n   <td>&#8804;25 x 10<sup>9</sup>/L</td>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   1.1\r\n  \r\n   </td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   &#60;0.001\r\n  \r\n   </td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>25-75 x 10<sup>9</sup>/L</td>\r\n  \r\n   <td>2.7 (1.4-5.4)</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;75 x 10<sup>9</sup>/L</td>\r\n  \r\n   <td>7.3 (2.0-29.1)</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Uric acid\r\n  \r\n   </td>\r\n  \r\n   <td>&#8804;7.5 mg/dL</td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   2.2\r\n  \r\n   </td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   &#60;0.001\r\n  \r\n   </td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;7.5 mg/dL</td>\r\n  \r\n   <td>9.1 (3.3-26.6)</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   LDH\r\n  \r\n   </td>\r\n  \r\n   <td>&#8804;1 x ULN</td>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   1.2\r\n  \r\n   </td>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   0.005\r\n  \r\n   </td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>1-4 x ULN</td>\r\n  \r\n   <td>3.9 (1.5-10.8)</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&#62;4 x ULN</td>\r\n  \r\n   <td>15.2 (2.2-96.8)</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">LTLS: laboratory tumor lysis syndrome; CTLS: clinical tumor lysis syndrome; WBC: white blood cell count; ULN: upper limit of normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93:9. Copyright &#169;2008 Ferrata-Storti Foundation.</div><div id=\"graphicVersion\">Graphic 68256 Version 2.0</div></div></div>"},"68257":{"type":"graphic_table","displayName":"DDx vertical gaze palsy","title":"Localization of lesions causing vertical gaze palsies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Localization of lesions causing vertical gaze palsies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bilateral vertical gaze center or rostral interstitial nuclei of the MLF</td> </tr> <tr> <td>Down-sized saccadic palsy</td> </tr> <tr> <td>Paralysis of upward and downward saccades</td> </tr> <tr> <td class=\"subtitle1_single\">Bilateral pretectal lesions or midline lesions of the posterior commissure</td> </tr> <tr> <td>Paresis of upward gaze</td> </tr> <tr> <td class=\"subtitle1_single\">Unilateral lesions of the riMLF (the vertical gaze center)</td> </tr> <tr> <td>Mild defects in vertical saccades</td> </tr> <tr> <td>Combined up- and downgaze palsies</td> </tr> <tr> <td class=\"subtitle1_single\">Unilateral mesencephalic lesions</td> </tr> <tr> <td>Bilateral upgaze palsy</td> </tr> <tr> <td>Palsy of upward and downward saccades</td> </tr> <tr> <td>Palsy of upward and downward pursuit and vestibular movements</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Lee AG, Brazis PW. Clinical Pathways in Neuro-ophthalmology: An Evidence-based Approach, Thieme, New York 1998.</div><div id=\"graphicVersion\">Graphic 68257 Version 3.0</div></div></div>"},"68258":{"type":"graphic_table","displayName":"Comparison approved Rx HBV","title":"Comparison of approved treatments of chronic hepatitis B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of approved treatments of chronic hepatitis B</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pegylated IFN&#945;</td> <td class=\"subtitle1\">Lamivudine</td> <td class=\"subtitle1\">Adefovir</td> <td class=\"subtitle1\">Entecavir</td> <td class=\"subtitle1\">Telbivudine</td> <td class=\"subtitle1\">Tenofovir</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Indications</td> </tr> <tr> <td class=\"indent1\">HBeAg+, normal ALT</td> <td>Not indicated</td> <td>Not indicated</td> <td>Not indicated</td> <td>Not indicated</td> <td>Not indicated</td> <td>Not indicated</td> </tr> <tr> <td class=\"indent1\">HBeAg+ chronic hepatitis</td> <td>Indicated</td> <td>Indicated*</td> <td>Indicated<sup>&#182;</sup></td> <td>Indicated<sup>&#916;</sup></td> <td>Indicated*</td> <td>Indicated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HBeAg- chronic hepatitis</td> <td>Indicated</td> <td>Indicated*</td> <td>Indicated<sup>&#182;</sup></td> <td>Indicated<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td>Indicated*</td> <td>Indicated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Duration of treatment</td> </tr> <tr> <td class=\"indent1\">HBeAg+ chronic hepatitis<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> <td>1 year</td> <td>&#62;1 year<sup>&#167;</sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#167;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HBeAg- chronic hepatitis<sup><span style=\"font-size: 13px;\">&#9674;</span></sup></td> <td>1 year</td> <td>&#62;1 year<sup>&#165;</sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> <td>&#62;1 year<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Route</td> <td>Subcutaneous</td> <td>Oral</td> <td>Oral</td> <td>Oral</td> <td>Oral</td> <td>Oral</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Side effects</td> <td>Many</td> <td>Negligible</td> <td>Potential nephrotoxicity</td> <td>Negligible</td> <td>Negligible</td> <td>Potential nephrotoxicity</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Drug resistance</td> <td class=\"divider_bottom\" rowspan=\"2\">-</td> <td>&sim;20 percent, year 1</td> <td>None, year 1</td> <td class=\"divider_bottom\" rowspan=\"2\">&sim;1 percent up to year 6</td> <td class=\"divider_bottom\" rowspan=\"2\">&sim;25 percent up to year 2</td> <td class=\"divider_bottom\" rowspan=\"2\">None, up to year 8</td> </tr> <tr class=\"divider_bottom\"> <td>&sim;70 percent, year 5</td> <td>29 percent, year 5</td> </tr> <tr> <td class=\"subtitle2_left\">Cost**</td> <td>High</td> <td>Low</td> <td>Intermediate</td> <td>High</td> <td>Intermediate</td> <td>High</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; anti-HBe: antibody to hepatitis B e antigen; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen.<br />* Not preferred drug due to high rate of resistance.<br />¶ Not preferred drug due to weak antiviral activity.<br />Δ Preferred for treatment-naïve patients, but not those with lamivudine resistance <br />◊ Patients <STRONG>with </STRONG>cirrhosis on nucleos(t)ide analogues should be treated indefinitely unless they clear HBsAg. <br />§ Treatment for at least 12 months after seroconversion from HBeAg to anti-HBe.<br />¥ For most patients, antiviral therapy should be continued indefinitely. However, treatment discontinuation may be considered in persons who have demonstrated loss of HBsAg. Persons who stop antiviral therapy should be monitored every month for at least 6 months.</div><div class=\"graphic_reference\">References:</P>&#xD;&#xA;<OL>&#xD;&#xA;<LI>Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at http://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright © 2009 American Association for the Study of Liver Diseases.</LI>&#xD;&#xA;<LI>Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan; 63:261.</LI></OL></div><div id=\"graphicVersion\">Graphic 68258 Version 12.0</div></div></div>"},"68260":{"type":"graphic_table","displayName":"Differential diagnosis myositis and fasciitis","title":"Differential diagnosis of necrotizing myositis and fasciitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of necrotizing myositis and fasciitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical finding</td> <td class=\"subtitle1\">Type I*</td> <td class=\"subtitle1\">Type II*</td> <td class=\"subtitle1\">Gas gangrene</td> <td class=\"subtitle1\">Pyomyositis</td> <td class=\"subtitle1\">Myositis viral/parasitic</td> </tr> <tr> <td>Fever</td> <td>++</td> <td>++++</td> <td>+++</td> <td>++</td> <td>++</td> </tr> <tr> <td>Diffuse pain</td> <td>+</td> <td>+</td> <td>+</td> <td>+</td> <td>++++<sup>&#182;</sup></td> </tr> <tr> <td>Local pain</td> <td>++</td> <td>++++<sup>&#916;</sup></td> <td>++++</td> <td>++</td> <td>++</td> </tr> <tr> <td>Systemic toxicity</td> <td>++</td> <td>++++</td> <td>++++</td> <td>+</td> <td>+</td> </tr> <tr> <td>Gas in tissue</td> <td>++</td> <td>&ndash;</td> <td>++++</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Obvious portal of entry</td> <td>++++</td> <td>&#177;<sup>&#9674;</sup></td> <td>++++<sup>&#167;</sup></td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>Diabetes mellitus</td> <td>++++</td> <td>&#177;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Type I and type II refer to the forms of necrotizing fasciitis; spontaneous gangrenous myositis is type II.<br />¶ Pain with influenza consists of diffuse myalgia; pleurodynia may be associated with severe, localized pain (eg, devil's grip); pain with trichinosis may be severe and localized.<br />Δ Severe pain is associated with necrotizing fasciitis due to group A streptococcal infection; the pain may not be severe in type I necrotizing fasciitis because it is commonly associated with diabetes with neuropathy.<br /><FONT class=lozenge>◊</FONT> 50 percent of patients with necrotizing fasciitis due to group A streptococcal infection do not have an obvious portal of entry.<br />§ Gas gangrene associated with trauma may be caused by <EM>Clostridium perfringens</EM>, <EM>C. septicum</EM>, or <EM>C. histolyticum</EM>,<EM> </EM>which always have an obvious portal of entry; in comparison, spontaneous gas gangrene caused by <EM>C. septicum</EM> usually does not have an obvious portal of entry (organisms lodge in tissue as a result of bacteremia originating from a bowel portal of entry).</div><div id=\"graphicVersion\">Graphic 68260 Version 4.0</div></div></div>"},"68261":{"type":"graphic_movie","displayName":"Echocardiogram apical 4-chamber TV carcinoid heart disease","title":"Echocardiogram apical 4-chamber showing tricuspid valve pathology in carcinoid heart disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical 4-chamber showing tricuspid valve pathology in carcinoid heart disease</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68261_4chtrcarconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:278px; height:445px;\" src=\"images/CARD/68261_4chtrcar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram in a patient with carcinoid syndrome shows thickening and immobility of the tricuspid leaflets which remain open in systole as a result of severe fibrosis. The right atrium and ventricle are dilated due to the tricuspid regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 68261 Version 3.0</div></div></div>"},"68266":{"type":"graphic_table","displayName":"Carboplatin and paclitaxel with RT for EGJ cancer","title":"Weekly carboplatin and paclitaxel chemotherapy with concurrent radiotherapy for esophageal and esophagogastric junction (EGJ) cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weekly carboplatin and paclitaxel chemotherapy with concurrent radiotherapy for esophageal and esophagogastric junction (EGJ) cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Carboplatin and paclitaxel are each given weekly for five weeks with concurrent radiotherapy (RT) followed by surgery. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>50 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS)* and administer over one hour; special tubing needed.</td> <td>Days 1, 8, 15, 22, and 29</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 2 mg/mL &times; min IV</td> <td>Dilute in 250 mL NS<sup>&#916;</sup> and administer over 30 minutes after paclitaxel.</td> <td>Days 1, 8, 15, 22, and 29</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). We recommend prophylaxis with a combination of a 5-HT3 receptor antagonist plus dexamethasone on days 1, 8, 15, 22, and 29, and with a 5-HT3 antagonist on days when radiation alone is given.</li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\" and \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin is an irritant. Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not justified (incidence of neutropenic fever &#60;1%<sup>[1]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of paclitaxel may be needed for liver impairment.<sup>[2]</sup> Carboplatin dose is calculated based upon renal function by use of the Calvert formula.<sup>&#182;</sup><sup>[3]</sup></li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes, renal, and liver function weekly during treatment.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function weekly during treatment.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity/neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Weekly doses of paclitaxel and carboplatin should not be repeated unless the ANC is at least 1500 cells/microL and the platelet count is at least 100,000/microL. Reduce paclitaxel dose by 20% for ANC &#60;500 cells/microL for a week or longer, or severe peripheral neuropathy.<sup>[2]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy require a recalculation of the carboplatin dose.</li> <li>Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor: CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.<br />* For paclitaxel administration, use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through a polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula: Total dose (mg) = (target AUC) × (GFR + 25). If using measured creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gaast AV, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric cancer: Results from a multinational randomized phase III study (abstract 4004). J Clin Oncol 2010; 28:302s.</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 5, 2011).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 5, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 68266 Version 14.0</div></div></div>"},"68267":{"type":"graphic_figure","displayName":"Eye structures lacerations","title":"Important anatomic structures that can be injured during eye trauma","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Important anatomic structures that can be injured during eye trauma</div><div class=\"cntnt\"><img style=\"width:612px; height:417px;\" src=\"images/EM/68267_Eyestructureslaceratedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lacerations to the eyelid may involve important underlying structures such as the tear duct apparatus, palpebral ligaments, and muscles. Failure to recognize these injuries can result in significant functional and cosmetic impairment.</div><div id=\"graphicVersion\">Graphic 68267 Version 5.0</div></div></div>"},"68268":{"type":"graphic_picture","displayName":"Raccoon eyes 2","title":"Raccoon eyes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Raccoon eyes</div><div class=\"cntnt\"><img style=\"width:345px; height:396px;\" src=\"images/EM/68268_Raccooneyes2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Garcia M. Basilar Skull Fracture. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI, Hendrickson RG, Silverberg M, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68268 Version 11.0</div></div></div>"},"68269":{"type":"graphic_table","displayName":"Complications of transsphenoidal surgery","title":"Complications of transsphenoidal surgery in relationship to the experience of the surgeon","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of transsphenoidal surgery in relationship to the experience of the surgeon</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Complication</td> <td class=\"subtitle1\" colspan=\"3\">Percent of operations resulting in complication</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\"># of previous operations:</td> </tr> <tr> <td class=\"subtitle3\">&#60;200</td> <td class=\"subtitle3\">200-500</td> <td class=\"subtitle3\">&#62;500</td> </tr> <tr> <td>Carotid artery injury</td> <td>1.4</td> <td>0.6</td> <td>0.4</td> </tr> <tr> <td>Central nervous system injury</td> <td>1.6</td> <td>0.9</td> <td>0.6</td> </tr> <tr> <td>Hemorrhage into tumor bed</td> <td>2.8</td> <td>4.0</td> <td>0.8</td> </tr> <tr> <td>Loss of vision </td> <td>2.4</td> <td>0.8</td> <td>0.5</td> </tr> <tr> <td>Ophthalmoplegia</td> <td>1.9</td> <td>0.8</td> <td>0.4</td> </tr> <tr> <td>Cerebrospinal fluid leak</td> <td>4.2</td> <td>2.8</td> <td>0.5</td> </tr> <tr> <td>Meningitis</td> <td>1.9</td> <td>0.8</td> <td>0.5</td> </tr> <tr> <td>Nasal septum perforation</td> <td>7.6</td> <td>4.6</td> <td>3.3 </td> </tr> <tr> <td>Anterior pituitary insufficiency </td> <td>20.6</td> <td>14.9</td> <td>7.2</td> </tr> <tr> <td>Diabetes insipidus</td> <td>19.0</td> <td>NA</td> <td>7.6</td> </tr> <tr> <td>Death</td> <td>1.2</td> <td>0.6</td> <td>0.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Data were collected from participating surgeons by questionnaire.</div><div class=\"graphic_reference\">Modified from: Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.</div><div id=\"graphicVersion\">Graphic 68269 Version 4.0</div></div></div>"},"68271":{"type":"graphic_table","displayName":"Guidelines for assessment of dehydration","title":"WHO guidelines for assessment of dehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO guidelines for assessment of dehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical feature</td> <td class=\"subtitle1\" colspan=\"3\">Predicted degree of dehydration</td> </tr> <tr> <td class=\"subtitle2\">None<br /> (&#60;5 percent)</td> <td class=\"subtitle2\">Some dehydration<br /> (5-10 percent)</td> <td class=\"subtitle2\">Severe dehydration<br /> (&#62;10 percent)</td> </tr> <tr> <td>General appearance</td> <td>Well, alert</td> <td>Restless, irritable</td> <td>Lethargic or unconscious</td> </tr> <tr> <td>Eyes</td> <td>Normal</td> <td>Sunken</td> <td>Sunken</td> </tr> <tr> <td>Thirst</td> <td>Drinks normally, not thirsty</td> <td>Thirsty, drinks eagerly</td> <td>Drinks poorly or unable to drink</td> </tr> <tr> <td>Skin pinch</td> <td>Goes back quickly</td> <td>Goes back slowly</td> <td>Goes back very slowly</td> </tr> <tr> <td>Estimated fluid deficit</td> <td>&#60;50 mL/kg</td> <td>50-100 mL/kg</td> <td>&#62;100 mL/kg</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: World Health Organization. The treatment of diarrhea: A manual for physicians and other senior health workers, 4th revision. WHO/FCH/CAH/05.1. World Health Organization, Geneva 2005. (Available at <a href=\"http://whqlibdoc.who.int/publications/2005/9241593180.pdf\" target=\"_blank\">http://whqlibdoc.who.int/publications/2005/9241593180.pdf</a>).</div><div id=\"graphicVersion\">Graphic 68271 Version 4.0</div></div></div>"},"68272":{"type":"graphic_table","displayName":"Components of complement","title":"Components of complement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of complement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Component</td> <td class=\"subtitle1\">(mcg/mL)</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Classical pathway (CP)</td> </tr> <tr> <td class=\"sublist2_start\">C1</td> <td class=\"sublist1_start\">50</td> <td class=\"sublist1_start\">Binds&nbsp;immune complexes&nbsp;to trigger classical pathway</td> </tr> <tr> <td class=\"sublist2\">C1q subcomponent</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Binds Fc portion of IgG/IgM</td> </tr> <tr> <td class=\"sublist2\">C1r subcomponent</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Protease: Cleaves C1s</td> </tr> <tr> <td class=\"sublist2\">C1s subcomponent</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Protease: Cleaves C4 and C2</td> </tr> <tr> <td class=\"indent1\">C4</td> <td>200 to 500</td> <td>Opsonin* (C4b), C4a<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">C2</td> <td>20</td> <td>Protease: Cleaves C3 and C5 as part of the convertases; zymogen cleaves C2a (active enzyme) and C2b by C1s</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lectin pathway (LP)</td> </tr> <tr> <td class=\"indent1\">MBL</td> <td>150 (wide range)</td> <td>Binds sugars to trigger LP</td> </tr> <tr> <td class=\"indent1\">MASP-1</td> <td>5</td> <td>Protease: Cleaves MASP-2</td> </tr> <tr> <td class=\"indent1\">MASP-2</td> <td>5</td> <td>Protease: Cleaves C4 and C2 </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternative pathway (AP)</td> </tr> <tr> <td class=\"indent1\">Factor D</td> <td>1 to 2</td> <td>Protease: Cleaves factor B to Ba and Bb</td> </tr> <tr> <td class=\"indent1\">Factor B</td> <td>150 to 250</td> <td>Protease: Cleaves C3 and C5 as part of the convertases</td> </tr> <tr> <td class=\"indent1\">Properdin</td> <td>25</td> <td>Stabilizes AP convertases</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Central protein</td> </tr> <tr> <td class=\"indent1\">C3</td> <td>550 to 1200</td> <td>Opsonin* (C3b), C3a<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Terminal pathway (TP)</td> </tr> <tr> <td class=\"indent1\">C5</td> <td>70</td> <td>MAC component is&nbsp;C5b; C5a<sup>&#182; </sup>(anaphylatoxin) is released</td> </tr> <tr> <td class=\"indent1\">C6</td> <td>60</td> <td>MAC component</td> </tr> <tr> <td class=\"indent1\">C7</td> <td>60</td> <td>MAC component</td> </tr> <tr> <td class=\"indent1\">C8</td> <td>60</td> <td>MAC component (pore formation)</td> </tr> <tr> <td class=\"indent1\">C9</td> <td>60</td> <td>MAC component (pore formation)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M; MBL: mannose-binding lectin;&nbsp;MASP: MBL-associated serine protease; <FONT color=black>MAC: membrane attack complex.</FONT><br />* C4b forms part of the&nbsp;classical pathway&nbsp;C3 and C5 convertases. It anchors the enzyme complex to the target. Likewise, for the&nbsp;alternative pathway&nbsp;C3 and C5 convertase, C3b anchors these enzyme complexes to the target. C3b is also part of the&nbsp;classical pathway&nbsp;and&nbsp;lectin pathway&nbsp;C5 convertase.<br />¶&nbsp;C4a, C3a, and C5a anaphylatoxins are liberated upon cleavage of C4, C3, and C5.</div><div id=\"graphicVersion\">Graphic 68272 Version 7.0</div></div></div>"},"68273":{"type":"graphic_picture","displayName":"Pulse volume recordings","title":"Pulse volume recordings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulse volume recordings</div><div class=\"cntnt\"><img style=\"width:433px; height:261px;\" src=\"images/SURG/68273_Pulse_volume_recordings.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulse volume recordings are most useful in detecting obstruction in calcified arteries in which falsely elevated pressure measurements are frequent.<br> - A normal PVR waveform is composed of a systolic upstroke with a sharp systolic peak followed by a downstroke that contains a prominent dicrotic notch.<br> - Mild to moderate disease is characterized by loss of the dicrotic notch and an outward &quot;bowing&quot; of the downstroke of the waveform.<br> - With severe disease, the amplitude of the waveform is blunted.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 68273 Version 4.0</div></div></div>"},"68274":{"type":"graphic_picture","displayName":"Large basal cell carcinoma on nose","title":"Destructive basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Destructive basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68274_Larg_basal_cell_carcin_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large basal cell carcinoma causing destruction of the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68274 Version 4.0</div></div></div>"},"68275":{"type":"graphic_figure","displayName":"Common sites and types of breast infection","title":"Common sites and types of breast infection","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Common sites and types of breast infection</div><div class=\"cntnt\"><img style=\"width:471px; height:428px;\" src=\"images/SURG/68275_Breast-infections.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mastitis refers to inflammation of the breast tissue that may or may not be accompanied by infection.&nbsp;This drawing depicts the most common types and locations of breast infections.</div><div id=\"graphicVersion\">Graphic 68275 Version 2.0</div></div></div>"},"68276":{"type":"graphic_table","displayName":"Timing of endoscopy for ingested foreign bodies","title":"Timing of endoscopy for ingested foreign bodies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of endoscopy for ingested foreign bodies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Emergent endoscopy</td> </tr> <tr> <td>Patients with esophageal obstruction (ie, unable to manage secretions)</td> </tr> <tr> <td>Disk batteries in the esophagus</td> </tr> <tr> <td>Sharp-pointed objects in the esophagus</td> </tr> <tr> <td class=\"subtitle1_single\">Urgent endoscopy</td> </tr> <tr> <td>Esophageal foreign objects that are not sharp-pointed</td> </tr> <tr> <td>Esophageal food impaction in patients without complete obstruction</td> </tr> <tr> <td>Sharp-pointed objects in the stomach or duodenum</td> </tr> <tr> <td>Objects &#62;6 cm in length at or above the proximal duodenum</td> </tr> <tr> <td>Magnets within endoscopic reach</td> </tr> <tr> <td class=\"subtitle1_single\">Non-urgent endoscopy</td> </tr> <tr> <td>Coins in the esophagus may be observed for 12-24 hours before endoscopic removal in an asymptomatic patient</td> </tr> <tr> <td>Objects in the stomach with diameter &#62;2.5 cm</td> </tr> <tr> <td>Disk batteries and cylindrical batteries that are in the stomach of patients without signs of GI injury may be observed for as long as 48 hours; batteries remaining in the stomach longer than 48 hours should be removed</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: ASGE Standards of Practice Committee. Management of ingested foreign bodies and food impactions. Gastrointest Endosc 2011; 73:1085. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68276 Version 1.0</div></div></div>"},"68277":{"type":"graphic_waveform","displayName":"Old posterior MI tutorial","title":"Chronic posterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Chronic posterior wall myocardial infarction</div><div class=\"cntnt\"><img style=\"width:525px; height:256px;\" src=\"images/CARD/68277_Old_posterior_MI_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chronic posterior wall infarct is characterized by a tall R wave in V1 (R/S &gt;1.0). There is also a rightward axis.</div><div id=\"graphicVersion\">Graphic 68277 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"68278":{"type":"graphic_diagnosticimage","displayName":"Saber sheath CT","title":"Saber sheath trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saber sheath trachea</div><div class=\"cntnt\"><img style=\"width:448px; height:304px;\" src=\"images/PULM/68278_Saber_sheath_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan demonstrates the characteristic narrow coronal and wide sagittal diameter of the trachea.</div><div id=\"graphicVersion\">Graphic 68278 Version 2.0</div></div></div>"},"68279":{"type":"graphic_diagnosticimage","displayName":"Adult humerus shaft fracture","title":"Humerus shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Humerus shaft fracture</div><div class=\"cntnt\"><img style=\"width:337px; height:468px;\" src=\"images/RHEUM/68279_Adult_humerus_shaft_fx_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a simple, slightly oblique fracture of the mid humerus.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 68279 Version 2.0</div></div></div>"},"68280":{"type":"graphic_picture","displayName":"Terminal bone tuft resorption","title":"Terminal bone tuft resorption in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Terminal bone tuft resorption in scleroderma</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/RHEUM/68280_Terminal_bone_tuft_resorpti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked terminal bone tuft resorption in a patient with limited cutaneous systemic sclerosis.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 68280 Version 1.0</div></div></div>"},"68282":{"type":"graphic_figure","displayName":"Sleeve gastrectomy PI","title":"Sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:476px; height:430px;\" src=\"images/PI/68282_Sleeve-gastrectomy-NEW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a sleeve gastrectomy, the stomach is cut down in size and made into a banana shape. The new stomach is smaller and doesn't stretch, which helps with controlling appetite and losing weight.</div><div id=\"graphicVersion\">Graphic 68282 Version 6.0</div></div></div>"},"68284":{"type":"graphic_picture","displayName":"Vulvar ulcers","title":"Vulvar ulcers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar ulcers</div><div class=\"cntnt\"><img style=\"width:360px; height:388px;\" src=\"images/PEDS/68284_Vulvarulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6<SUP>th</SUP> ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68284 Version 16.0</div></div></div>"},"68285":{"type":"graphic_figure","displayName":"Differential splicing","title":"Differential splicing of DNA","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Differential splicing of DNA</div><div class=\"cntnt\"><img style=\"width:535px; height:324px;\" src=\"images/PC/68285_Differential_splicing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Through mechanisms poorly understood, the same transcript can be spliced in multiple ways, resulting in different isoforms. Therefore, although there are &quot;only&quot; ~28,000 genes, there are actually many more types of protein.</div><div id=\"graphicVersion\">Graphic 68285 Version 1.0</div></div></div>"},"68287":{"type":"graphic_diagnosticimage","displayName":"Hematogenous nodules CT","title":"Hematogenous nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hematogenous nodules</div><div class=\"cntnt\"><img style=\"width:331px; height:308px;\" src=\"images/PULM/68287_Hematogenous_nodules_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrating innumerable small, hematogenously disseminated metastases of non-small cell lung cancer.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68287 Version 3.0</div></div></div>"},"68288":{"type":"graphic_algorithm","displayName":"Natural hx FBA","title":"Natural course of foreign body aspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural course of foreign body aspiration</div><div class=\"cntnt\"><img style=\"width:441px; height:398px;\" src=\"images/PULM/68288_Natural_hx_FBA.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68288 Version 2.0</div></div></div>"},"68291":{"type":"graphic_picture","displayName":"Squamous metaplasia","title":"Amniotic squamous metaplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniotic squamous metaplasia</div><div class=\"cntnt\"><img style=\"width:432px; height:253px;\" src=\"images/OBGYN/68291_Squamous_metaplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 68291 Version 1.0</div></div></div>"},"68293":{"type":"graphic_table","displayName":"Causes of elbow pain in children and young adolescents","title":"Differential diagnosis for elbow pain by location in children and skeletally immature adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for elbow pain by location in children and skeletally immature adolescents</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Anterior</td> </tr> <tr> <td>Occult fracture&nbsp;</td> </tr> <tr> <td>Anterior capsule strain</td> </tr> <tr> <td>Median nerve compression syndrome</td> </tr> <tr> <td>Referred nerve pain</td> </tr> <tr> <td class=\"subtitle1\">Medial</td> </tr> <tr> <td>Little League elbow*</td> </tr> <tr> <td>Medial epicondylitis</td> </tr> <tr> <td>Ulnar neuritis</td> </tr> <tr> <td>Sublime tubercle avulsion</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Posterior</td> </tr> <tr> <td>Olecranon apophysitis/stress fracture</td> </tr> <tr> <td>Olecranon bursitis</td> </tr> <tr> <td>Triceps tendon injury&nbsp;</td> </tr> <tr> <td>Valgus extension overload/posterior medial olecranon impingement syndrome</td> </tr> <tr> <td>Referred nerve pain</td> </tr> <tr> <td class=\"subtitle1\">Lateral</td> </tr> <tr> <td>Osteochondritis dessicans of the capitellum&nbsp;</td> </tr> <tr> <td>Panner disease</td> </tr> <tr> <td>Lateral epicondylitis</td> </tr> <tr> <td>Radial nerve syndromes</td> </tr> <tr> <td>Musculocutaneous nerve entrapment</td> </tr> <tr> <td>Referred nerve pain</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Little League elbow is the name used to describe a group of elbow problems related to the stress of throwing in children and young adolescents including medial epicondyle apophysitis, medial epicondyle avulsion fractures, and ulnar collateral ligament sprain. </div><div id=\"graphicVersion\">Graphic 68293 Version 4.0</div></div></div>"},"68294":{"type":"graphic_algorithm","displayName":"Gross hematuria algorithm","title":"Algorithm for gross or symptomatic microscopic hematuria in children","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Algorithm for gross or symptomatic microscopic hematuria in children</div><div class=\"cntnt\"><img style=\"width:620px; height:640px;\" src=\"images/PEDS/68294_Gross_hematuria_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on the evaluation of microscopic hematuria in children and the evaluation of gross hematuria in children for further details.</div><div class=\"graphic_footnotes\">U/A: urinalysis; RBC: red blood cell; BUN: blood urea nitrogen; Cr: creatinine; CBC: complete blood count; C3: complement component 3; C4: complement component 4.<br />* Manifestations such as proteinuria, red blood cell casts, edema, and hypertension suggest a glomerular source for the hematuria. The evaluation includes serum creatinine, complete blood count, C3, C4, and serum albumin. Other tests to consider based upon the history and the physical examination include antistreptolysin (ASO) titer and/or streptozyme testing to detect poststreptococcal glomerulonephritis, and antinuclear antibody testing to detect lupus nephritis. Such patients should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease).</div><div class=\"graphic_reference\">Modified with permission from: Patel HP, Bissler JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519. Copyright &copy; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 68294 Version 5.0</div></div></div>"},"68297":{"type":"graphic_picture","displayName":"Robotic surg robot arms","title":"Robot-assisted laparoscopy surgical device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Robot-assisted laparoscopy surgical device</div><div class=\"cntnt\"><img style=\"width:360px; height:516px;\" src=\"images/OBGYN/68297_Robotic_surg_robot_arms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">da Vinci&#174; S Surgical System patient side cart</div><div class=\"graphic_reference\">Photo courtesy of Intuitive Surgical, Inc, 2008.</div><div id=\"graphicVersion\">Graphic 68297 Version 2.0</div></div></div>"},"68300":{"type":"graphic_table","displayName":"Prevention of fatal reactions with self-injectable epinephrine","title":"Prevention of fatal reactions/important issues in the use of self-injectable epinephrine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of fatal reactions/important issues in the use of self-injectable epinephrine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Train</strong> (Teach patients in the emergency department/clinician's office to properly use the devices)</td> </tr> <tr> <td><strong>Practice</strong> (Work monthly with the training devices)</td> </tr> <tr> <td><strong>Carry</strong> (Take the self-injectable epinephrine everywhere and at all times)</td> </tr> <tr> <td><strong>Educate/notify</strong> (Inform family members, caregivers, food providers)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68300 Version 3.0</div></div></div>"},"68301":{"type":"graphic_figure","displayName":"Starting laser cone procedure","title":"Marking surgical boundaries for laser cervical (uterine cervix) conization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marking surgical boundaries for laser cervical (uterine cervix) conization</div><div class=\"cntnt\"><img style=\"width:362px; height:386px;\" src=\"images/OBGYN/68301_Starting_laser_cone_procedu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exocervical margin of planned laser cone is marked with a circle of dots placed with the laser.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68301 Version 2.0</div></div></div>"},"68302":{"type":"graphic_diagnosticimage","displayName":"Miliary nodules PA","title":"Miliary nodular pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary nodular pattern</div><div class=\"cntnt\"><img style=\"width:381px; height:345px;\" src=\"images/PULM/68302_Miliary_nodules_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard International Labor Office film for small rounded opacities, 1.5 to 3 mm in diameter (miliary nodules).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68302 Version 3.0</div></div></div>"},"68303":{"type":"graphic_picture","displayName":"Resisted thumb flexion","title":"Resisted thumb flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisted thumb flexion</div><div class=\"cntnt\"><img style=\"width:337px; height:360px;\" src=\"images/EM/68303_Resisted_thumb_flex_final.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68303 Version 1.0</div></div></div>"},"68304":{"type":"graphic_picture","displayName":"Poison oak PI","title":"Poison oak","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Poison oak</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/68304_Poison_oak_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68304 Version 5.0</div></div></div>"},"68305":{"type":"graphic_picture","displayName":"Hydroa vacciniforme 2","title":"Hydroa vacciniforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydroa vacciniforme</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/DERM/68305_Hydroa_vacciniforme_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and crusts are seen on the forearm of a 10-year-old boy with hydroa vacciniforme.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 68305 Version 5.0</div></div></div>"},"68306":{"type":"graphic_table","displayName":"Opioid withdrawal - Rapid overview","title":"Opioid withdrawal: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid withdrawal: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical and laboratory features</td> </tr> <tr> <td class=\"indent1\">Opioid-dependent individuals typically experience withdrawal after administration of an antagonist or within 6-48 hours of cessation of opioid use.</td> </tr> <tr> <td class=\"indent1\">Iatrogenic withdrawal (eg, administration of antagonist) is potentially life-threatening, while naturally-occurring withdrawal is usually not.</td> </tr> <tr> <td class=\"indent1\">Common signs of opioid withdrawal include: mydriasis, yawning, increased bowel sounds, and piloerection. Mental status is usually normal.</td> </tr> <tr> <td class=\"indent1\">Other signs and symptoms can include dysphoria, restlessness, rhinorrhea, lacrimation, myalgias, arthralgias, nausea, vomiting, abdominal cramping, diarrhea, tachycardia, and hypertension. Addicts may describe themselves as sick from not using opioids.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td class=\"indent1\">The diagnosis of opioid withdrawal is made by history alone.</td> </tr> <tr> <td class=\"indent1\">Laboratory evaluation is helpful only to assess associated conditions (eg, serum electrolyte concentrations in the setting of significant vomiting or diarrhea).</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"indent1\">If withdrawal is naturally-occurring, the physician may opt to manage the patient with either opioid or non-opioid adjunctive medication.</td> </tr> <tr> <td class=\"indent1\">Fluid resuscitation is given if needed due to losses.</td> </tr> <tr> <td class=\"indent1\">Methadone 10 mg IM or 20 mg oral is usually sufficient to relieve symptoms of withdrawal without producing intoxication.</td> </tr> <tr> <td class=\"indent1\">Adjunctive medications may include alpha 2 adrenergic agonists, benzodiazepines, antiemetics, and antidiarrheals.</td> </tr> <tr> <td class=\"indent1\">For iatrogenic withdrawal (due to an opioid antagonist) only adjunctive medications should be used, <strong>not</strong> opioids. Refer to text and separate table on Medications used in management of opioid withdrawal.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68306 Version 9.0</div></div></div>"},"68307":{"type":"graphic_figure","displayName":"Total pancreatectomy","title":"Total pancreatectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Total pancreatectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:389px;\" src=\"images/GAST/68307_Total_pancreatectomy_AGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &#169; 2003 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 68307 Version 4.0</div></div></div>"},"68308":{"type":"graphic_figure","displayName":"Cardiac events LQTS","title":"Cardiac events in LQTS by age and gender","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac events in LQTS by age and gender</div><div class=\"cntnt\"><img style=\"width:448px; height:275px;\" src=\"images/CARD/68308_Cardiac_events_LQTS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 479 probands with the long QT syndrome (LQTS), the probability of a first cardiac event by the age of 15 years was higher in males than females (74 versus 51 percent) although the incidence was similar by age 40. The same pattern of more early events in males was seen in 1020 family members with a long QT interval (QTc &gt;440).</div><div class=\"graphic_reference\">Data from: Locati EH, Zareba W, Moss AJ, et al. Circulation 1998; 97:2237.</div><div id=\"graphicVersion\">Graphic 68308 Version 2.0</div></div></div>"},"68309":{"type":"graphic_figure","displayName":"Tick sizes and appearances","title":"Tick sizes and appearances","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Tick sizes and appearances</div><div class=\"cntnt\"><img style=\"width:463px; height:456px;\" src=\"images/ID/68309_Tick_sizes_and_appearances.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. <A href=\"http://www.cdc.gov/lyme/transmission/blacklegged.html\" target=_blank>http://www.cdc.gov/lyme/transmission/blacklegged.html</A>.</div><div id=\"graphicVersion\">Graphic 68309 Version 5.0</div></div></div>"},"68311":{"type":"graphic_figure","displayName":"LH pulses and progesterone","title":"LH pulses stimulate progesterone release in mid-luteal phase","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LH pulses stimulate progesterone release in mid-luteal phase</div><div class=\"cntnt\"><img style=\"width:305px; height:291px;\" src=\"images/ENDO/68311_LH_pulses_and_progesterone.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum concentrations of luteinizing hormone and progesterone during 24 hours of blood sampling at 10-minute intervals in a normal woman studied during the mid-luteal phase. There is a significant correlation between LH pulses and increased serum progesterone concentrations. To convert serum progesterone values to nmol/L, multiply by 3.18.</div><div class=\"graphic_footnotes\">LH: luteinizing hormone.</div><div class=\"graphic_reference\">Data from: Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion.&nbsp;J Clin Invest 1984; 73:1638.</div><div id=\"graphicVersion\">Graphic 68311 Version 3.0</div></div></div>"},"68313":{"type":"graphic_picture","displayName":"Stomatocyte EM","title":"Scanning electron micrograph of a stomatocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scanning electron micrograph of a stomatocyte</div><div class=\"cntnt\"><img style=\"width:343px; height:252px;\" src=\"images/HEME/68313_Stomatocyte_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron micrograph of a stomatocyte.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68313 Version 2.0</div></div></div>"},"68314":{"type":"graphic_table","displayName":"Diarrhea causes PI","title":"Possible causes of sudden onset (acute) diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible causes of sudden onset (acute) diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infectious diarrhea</td> </tr> <tr> <td class=\"indent1\">Viral infection</td> <td>Loose stool, low-grade fever, feel ill</td> <td>None, usually resolves within 48 hours</td> </tr> <tr> <td class=\"indent1\">Bacterial infection</td> <td>Fever (temperature &#62;101&#176;F or 38.4&#176;C), bloody stools</td> <td>Usually none, antibiotics in selected situations</td> </tr> <tr> <td class=\"indent1\">Parasite</td> <td>Not common in developed countries, may be seen in returning traveler or camper</td> <td>Antibiotics in most cases</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Non-infectious diarrhea</td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> <td>Loose stool begins after antibiotic started, usually resolves with a few days after stopped</td> <td>Usually none</td> </tr> <tr> <td class=\"indent1\">Food intolerance (eg, lactose intolerance)</td> <td>Diarrhea, abdominal pain, and/or gas after consuming food</td> <td>Determine if food intolerance is the cause</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)</td> <td>Mouth sores, diarrhea, abdominal pain, weight loss, and fever</td> <td>See a healthcare provider for full evaluation and treatment</td> </tr> <tr> <td class=\"indent1\">Irritable bowel syndrome</td> <td>Chronic lower abdominal pain, diarrhea and/or constipation</td> <td>Symptomatic treatment</td> </tr> <tr> <td class=\"indent1\">Celiac disease (gluten sensitivity)</td> <td>None to diarrhea, weight loss, abdominal pain, gas</td> <td>Complete avoidance of wheat, rye, barley</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68314 Version 3.0</div></div></div>"},"68317":{"type":"graphic_diagnosticimage","displayName":"MRI recurrent chondrosarcoma","title":"Recurrent chondrosarcoma of the thoracic spine in a 70-year-old man","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Recurrent chondrosarcoma of the thoracic spine in a 70-year-old man</div><div class=\"cntnt\"><img style=\"width:475px; height:227px;\" src=\"images/ONC/68317_MRI_rcrrnt_chndrsrcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial MRI sections through the thoracic spine, demonstrating the recurrent chondrosarcoma (arrows) compressing the spinal cord (arrowheads) and the soft tissue extension adjacent to the allograft. The tumor extended to the dural margin, and intraoperative radiation was administered.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Francis J Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68317 Version 3.0</div></div></div>"},"68318":{"type":"graphic_table","displayName":"FTT examination","title":"Important aspects of the physical examination in the evaluation of failure to thrive (undernutrition)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination in the evaluation of failure to thrive (undernutrition)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination clues</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vital signs</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> <td>Adrenal or thyroid insufficiency</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>Renal disease</td> </tr> <tr> <td class=\"indent1\">Tachypnea/tachycardia</td> <td>Increased metabolic demands</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General appearance</td> </tr> <tr> <td class=\"indent1\">Pallor</td> <td>Anemia</td> </tr> <tr> <td class=\"indent1\">Drooling</td> <td>Oral motor dysfunction</td> </tr> <tr> <td class=\"indent1\">Cachexia, temporal wasting, sparse hair or alopecia</td> <td>Significant malnutrition</td> </tr> <tr> <td class=\"indent1\">Inadequate adiposity</td> <td>Indicator of nutritional inadequacy</td> </tr> <tr> <td class=\"indent1\">Dysmorphic features</td> <td>Clinical or genetic syndrome associated with failure to thrive</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Head and neck</td> </tr> <tr> <td class=\"indent1\">Microcephaly</td> <td>Neurologic disorder, fetal alcohol syndrome</td> </tr> <tr> <td class=\"indent1\">Delayed closure of fontanelle</td> <td>Vitamin D deficiency, hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Short palpebral fissures&nbsp;</td> <td>Fetal alcohol syndrome</td> </tr> <tr> <td class=\"indent1\">Cataracts</td> <td>Congenital infection, galactosemia</td> </tr> <tr> <td class=\"indent1\">Papilledema</td> <td>Increased intracranial pressure</td> </tr> <tr> <td class=\"indent1\">Smooth philtrum&nbsp;</td> <td>Fetal alcohol syndrome&nbsp;</td> </tr> <tr> <td class=\"indent1\">Aphthous stomatitis</td> <td>Crohn disease</td> </tr> <tr> <td class=\"indent1\">Thin vermillion border</td> <td>Fetal alcohol syndrome</td> </tr> <tr> <td class=\"indent1\">Oropharyngeal lesions (eg, caries, tongue enlargement, mandibular hypoplasia, tonsillar hypertrophy, defects in soft or hard palate)</td> <td>May interfere with eating</td> </tr> <tr> <td class=\"indent1\">Delayed tooth eruption</td> <td>Delayed bone age</td> </tr> <tr> <td class=\"indent1\">Thyroid enlargement</td> <td>Thyroid disease</td> </tr> <tr> <td class=\"indent1\">Low hairline</td> <td>Genetic syndrome (eg, Klippel-Feil)&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr> <td class=\"indent1\">Wheezing, crackles, prolonged expiratory phase, hyperexpansion</td> <td>Cystic fibrosis, asthma</td> </tr> <tr> <td class=\"indent1\">Cardiac murmur</td> <td>Congenital or acquired heart disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Abdominal distension, hyperactive bowel sounds</td> <td>Malabsorption</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly</td> <td>Liver disease, glycogen storage disease, malignancy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitourinary</td> </tr> <tr> <td class=\"indent1\">Genitourinary abnormalities</td> <td>Endocrinopathy</td> </tr> <tr> <td class=\"indent1\">Rectal fistulae, large perianal skin tags</td> <td>Crohn disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Clubbing</td> <td>Chronic hypoxia due to cardiac or pulmonary disorders</td> </tr> <tr> <td class=\"indent1\">Bony deformities (craniotabes, beading of the ribs, scoliosis, bowing of the legs or distal radius and ulna, enlargement of the wrist)</td> <td>Rickets</td> </tr> <tr> <td class=\"indent1\">Edema</td> <td>Protein deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Abnormal deep tendon reflexes</td> <td>Cerebral palsy</td> </tr> <tr> <td class=\"indent1\">Hypotonia, weakness, spasticity</td> <td>May be associated with oral motor dysfunction</td> </tr> <tr> <td class=\"indent1\">Neuropathy</td> <td>Vitamin deficiencies: B12, B3 (niacin), B6 (pyridoxine), E (tocopherol)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin and mucous membranes</td> </tr> <tr> <td class=\"indent1\">Scaling skin</td> <td>Zinc deficiency</td> </tr> <tr> <td class=\"indent1\">Candidiasis</td> <td>Immune deficiency</td> </tr> <tr> <td class=\"indent1\">Spoon-shaped nails</td> <td>Iron deficiency</td> </tr> <tr> <td class=\"indent1\">Cheilosis</td> <td>Vitamin deficiency: B2 (riboflavin), B3 (niacin), or B6 (pyridoxine)</td> </tr> <tr> <td class=\"indent1\">Chronic diaper rash</td> <td>Possible neglect</td> </tr> <tr> <td class=\"indent1\">Bruises in characteristic patterns</td> <td>Possible abuse</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Nutrition. Failure to thrive. In: Pediatric Nutrition, 7<SUP>th</SUP> ed, Kleinman RE, Greer FR (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2014. p.663.</LI></OL></div><div id=\"graphicVersion\">Graphic 68318 Version 10.0</div></div></div>"},"68321":{"type":"graphic_picture","displayName":"Strawberry tongue","title":"Strawberry tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strawberry tongue</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/ID/68321_strawberry_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68321 Version 3.0</div></div></div>"},"68322":{"type":"graphic_figure","displayName":"Genetic counseling retinoblastoma","title":"Genetic counseling for retinoblastoma","html":"<div class=\"graphic\"><div style=\"width: 941px\" class=\"figure\"><div class=\"ttl\">Genetic counseling for retinoblastoma</div><div class=\"cntnt\"><img style=\"width:921px; height:327px;\" src=\"images/PEDS/68322_Geneticcnslretinoblastoma.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If parent is a carrier, then 45%.</div><div class=\"graphic_reference\">Reproduced with permission from: Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004; 24:828. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 68322 Version 5.0</div></div></div>"},"68323":{"type":"graphic_picture","displayName":"Patellofemoral dynamic alignment test","title":"Patellofemoral dynamic malalignment testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patellofemoral dynamic malalignment testing</div><div class=\"cntnt\"><img style=\"width:173px; height:333px;\" src=\"images/EM/68323_PFPS_dynamic_align_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clinician can assess for dynamic malignment by having the patient perform a single leg squat or step down several stairs. Look for excessive contralateral pelvic drop, hip adduction and internal rotation, knee abduction, and excessive or insufficient foot pronation</div><div id=\"graphicVersion\">Graphic 68323 Version 4.0</div></div></div>"},"68324":{"type":"graphic_picture","displayName":"Esoph CA squamous Light","title":"Squamous cell esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell esophageal cancer</div><div class=\"cntnt\"><img style=\"width:450px; height:310px;\" src=\"images/GAST/68324_Esoph_CA_squamous_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph shows a well-differentiated invasive squamous esophageal cancer on the left adjacent to normal squamous epithelium on the right. The tumor contains keratin &quot;pearls&quot; (arrows) that are characteristic features of well-differentiated squamous cell carcinomas. In addition, the invading nests of malignant squamous cells exhibit a characteristic irregular configuration.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner- Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 68324 Version 1.0</div></div></div>"},"68325":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 14b","title":"Angiogram","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Angiogram</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/OBGYN/68325_Tumor_bleeding_14b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiogram showing one of the left intercostal arteries supplying a metastatic tumor with neovascularization (arrows).</div><div id=\"graphicVersion\">Graphic 68325 Version 2.0</div></div></div>"},"68326":{"type":"graphic_table","displayName":"Clinical findings in RBILD","title":"Clinical findings in 34 patients with RBILD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in 34 patients with RBILD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Epidemiology</td> </tr> <tr> <td>Mean age at diagnosis (range)</td> <td>39.3 yrs (22 to 65 yrs)</td> </tr> <tr> <td>Male: female ratio</td> <td>20:14</td> </tr> <tr> <td>Mean pack-years cigarette smoking (range)</td> <td>34.0 pk-yrs (0* to 80 pk-yrs)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Symptoms</td> </tr> <tr> <td>Dyspnea</td> <td>70.6 percent</td> </tr> <tr> <td>Cough</td> <td>50.0 percent</td> </tr> <tr> <td>Chest pain</td> <td>14.7 percent</td> </tr> <tr> <td>Asymptomatic</td> <td>11.8 percent</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Signs</td> </tr> <tr> <td>Clubbing</td> <td>5.9 percent</td> </tr> <tr> <td>Crackles</td> <td>41.1 percent</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Chest radiographs</td> </tr> <tr> <td>Reticular and nodular opacities</td> <td>67.6 percent</td> </tr> <tr> <td>Normal</td> <td>20.6 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* One non-smoker with occupational exposure to solder flux fumes was reported by Moon et al.</div><div class=\"graphic_reference\">Data summarized from Myers, et al. Am Rev Respir Dis 1987; Yousem, et al. Mayo Clin Proc 1989; and Moon, et al. Thorax 1999.</div><div id=\"graphicVersion\">Graphic 68326 Version 2.0</div></div></div>"},"68327":{"type":"graphic_table","displayName":"NBG code pacing nomenclature","title":"Revised NBG code for pacing nomenclature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised NBG code for pacing nomenclature</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Position</td> <td>I</td> <td>II</td> <td>III</td> <td>IV</td> <td>V</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"2\">Category</td> <td>Chamber(s) paced</td> <td>Chamber(s) sensed</td> <td>Response to sensing</td> <td>Rate modulation</td> <td>Multisite pacing</td> </tr> <tr> <td> <p>O&nbsp;= None</p> <p>A = Atrium</p> <p>V = Ventricle</p> <p>D = Dual (A+V)</p> </td> <td> <p>O&nbsp;= None</p> <p>A = Atrium</p> <p>V = Ventricle</p> <p>D = Dual (A+V)</p> </td> <td> <p>O&nbsp;= None</p> <p>T = Triggered</p> <p>I = Inhibited</p> <p>D = Dual (T+I)</p> </td> <td> <p>O&nbsp;= None</p> <p>R = Rate modulation</p> </td> <td> <p>O&nbsp;= None</p> <p>A = Atrium</p> <p>V = Ventricle</p> <p>D = Dual (A+V)</p> </td> </tr> <tr> <td class=\"subtitle1_left\">Manufacturer's designation only:</td> <td>S = Single (A or V)</td> <td>S = Single (A or V)</td> <td colspan=\"3\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: Positions I through III are used exclusively for antibradyarrythmia function.</div><div class=\"graphic_reference\">Adapted from Bernstein AD, Daubert JC, Fletcher RD, et al. Pacing Clin Electrophysiol 2002; 25:260.</div><div id=\"graphicVersion\">Graphic 68327 Version 3.0</div></div></div>"},"68329":{"type":"graphic_figure","displayName":"Interstitial brachytherapy","title":"Interstitial brachytherapy","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Interstitial brachytherapy</div><div class=\"cntnt\"><img style=\"width:542px; height:471px;\" src=\"images/SURG/68329_Interstitial-brachytherapy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For interstitial brachytherapy several small hollow catheters are placed into the breast surrounding the partial mastectomy site. The number of catheters used is dependent on the size and shape of the target. Radioactive seeds are inserted into the catheters for a short time period of time each day and then removed. The catheters are removed after five days, when treatment is completed.</div><div id=\"graphicVersion\">Graphic 68329 Version 1.0</div></div></div>"},"68332":{"type":"graphic_table","displayName":"Clin manif HIV P marneffei","title":"Clinical manifestations of HIV-infected patients with <em>Penicillium marneffei</em> infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of HIV-infected patients with <em>Penicillium marneffei</em> infection</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" rowspan=\"2\">&nbsp;</td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"2\">Number of cases (percent)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\"><p>Thailand<sup>[1]</sup></p>\r\n\t<p>(N = 80)</p></td>\r\n  \r\n   <td  class=\"subtitle2\"><p>India<sup>[2]</sup></p>\r\n\t<p>(N = 36)</p></td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fever</td>\r\n  \r\n   <td>79 (95)</td>\r\n  \r\n   <td>35 (97)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Weight loss</td>\r\n  \r\n   <td>61 (76)</td>\r\n  \r\n   <td>36 (100)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cough</td>\r\n  \r\n   <td>39 (49)</td>\r\n  \r\n   <td>N/A</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diarrhea</td>\r\n  \r\n   <td>25 (31)</td>\r\n  \r\n   <td>8 (22)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Skin lesions</td>\r\n  \r\n   <td>57 (71)</td>\r\n  \r\n   <td>29 (81)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anemia</td>\r\n  \r\n   <td>62 (77)</td>\r\n  \r\n   <td>31 (86)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lymphadenopathy</td>\r\n  \r\n   <td>46 (57)</td>\r\n  \r\n   <td>12 (33)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hepatomegaly</td>\r\n  \r\n   <td>41 (51)</td>\r\n  \r\n   <td>14 (39)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Splenomegaly</td>\r\n  \r\n   <td>13 (16)</td>\r\n  \r\n   <td>14 (39)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Genital ulcer</td>\r\n  \r\n   <td>5 (6.2)</td>\r\n  \r\n   <td>N/A</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Data from:<br> 1. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.<br> 2. Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect Dis 2002; 45:268.</div><div id=\"graphicVersion\">Graphic 68332 Version 1.0</div></div></div>"},"68336":{"type":"graphic_figure","displayName":"Cytotoxicity assays II","title":"Flow cytometry based cytotoxicity assay","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Flow cytometry based cytotoxicity assay</div><div class=\"cntnt\"><img style=\"width:482px; height:225px;\" src=\"images/ALLRG/68336_Cytotoxicity_assays_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Detection of perforin in natural killer (NK) cells.</div><div class=\"graphic_footnotes\">HLH: hemophagocytic lymphohistiocytosis.</div><div id=\"graphicVersion\">Graphic 68336 Version 2.0</div></div></div>"},"68339":{"type":"graphic_picture","displayName":"Erythrodontia in CEP","title":"Erythrodontia in CEP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrodontia in CEP</div><div class=\"cntnt\"><img style=\"width:406px; height:251px;\" src=\"images/HEME/68339_Erythrodontia_in_CEP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph taken with the aid of long wavelength ultraviolet light in a patient with congenital erythropoietic porphyria (CEP). Bright fluorescence of the teeth is demonstrated, due to the presence of high concentrations of uroporphyrin deposited in the teeth in this disorder.</div><div class=\"graphic_reference\">Photograph provided by Shigeru Sassa, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68339 Version 1.0</div></div></div>"},"68341":{"type":"graphic_figure","displayName":"Mouth retraction","title":"Retraction of the corner of the mouth by an assistant","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Retraction of the corner of the mouth by an assistant</div><div class=\"cntnt\"><img style=\"width:454px; height:248px;\" src=\"images/EM/68341_Mouth_retraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retraction of the corner of the mouth by an assistant's index finger will provide ample room for unobstructed passage of the endotracheal tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy MP, Barker TD, Schneider RE. Endotracheal intubation. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68341 Version 8.0</div></div></div>"},"68343":{"type":"graphic_table","displayName":"Questions to ask patients with dysphagia","title":"Questions to ask patients with dysphagia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to ask patients with dysphagia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Do you have problems initiating a swallow or do you feel food getting stuck a few seconds after swallowing? (Helps distinguish oropharyngeal from esophageal dysphagia.)</td> </tr> <tr> <td>Do you cough or choke or is food coming back through your nose after swallowing? (Coughing, choking, or nasal regurgitation suggests aspiration and oropharyngeal dysphagia.)</td> </tr> <tr> <td>Do you have problem swallowing solids, liquids, or both? (Liquids, not solids, suggests a motility disorder; solids progressing to liquids suggests a benign or malignant obstruction.)</td> </tr> <tr> <td>How long have you had problems swallowing and have your symptoms progressed, remained stable, or are they intermittent? (Rapidly progressive dysphagia is concerning for malignancy.)</td> </tr> <tr> <td>Could you point to where you feel food is getting stuck? (Ability to localize source of dysphagia is unreliable; best with oropharyngeal dysphagia.)</td> </tr> <tr> <td>Do you have other symptoms such as loss of appetite, weight loss, nausea, vomiting, regurgitation of food particles, heartburn, vomiting fresh or old blood, pain during swallowing, or chest pain?</td> </tr> <tr> <td>Do you have medical problems such as diabetes mellitus, scleroderma, Sj&#246;gren's syndrome, overlap syndrome, AIDS, neuromuscular disorders (stroke, Parkinson's, myasthenia gravis, muscular dystrophy, multiple sclerosis), cancer, Chagas' disease or others?</td> </tr> <tr> <td>Have you had surgery on your larynx, esophagus, stomach, or spine?</td> </tr> <tr> <td>Have you received radiation therapy in the past?</td> </tr> <tr> <td>What medications are you using now (ask specifically about potassium chloride, alendronate, ferrous sulfate, quinidine, ascorbic acid, tetracycline, aspirin and NSAIDs)? (Pill esophagitis can cause dysphagia.)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIDs: acquired immune deficiency syndrome; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 68343 Version 7.0</div></div></div>"},"68348":{"type":"graphic_algorithm","displayName":"Evaluation of acute diarrhea","title":"Evaluation of acute diarrhea","html":"<div class=\"graphic\"><div style=\"width: 1134px\" class=\"figure\"><div class=\"ttl\">Evaluation of acute diarrhea</div><div class=\"cntnt\"><img style=\"width:1114px; height:935px;\" src=\"images/ID/68348_Workupofacutediarrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines an approach to the work-up and initial management of acute diarrhea acquired in resource-rich settings, with a focus on infectious etiologies, which are the most common causes. Refer to UpToDate content on acute diarrhea in resource-rich settings for more detail.</div><div class=\"graphic_footnotes\">EHEC: enterohemorrhagic <EM>E. coli</EM>; HIV: human immunodeficiency virus.<br />* Routine stool culture will identify <EM>Salmonella</EM>, <EM>Campylobacter</EM>, and <EM>Shigella</EM>. If other bacterial organisms (eg, <EM>Vibrio</EM>, <EM>Listeria</EM>, <EM>Yersinia</EM>, <EM>Aeromonas</EM>) are suspected based on exposures, the laboratory should be notified for specific plating of the specimen. Some laboratories perform multiplex molecular testing of stool to test for multiple organisms simultaneously; the indications for such testing are similar to those for stool cultures.<br />¶ Individuals who have had antibiotic use or hospitalization within the prior three months should be tested for <EM>C. difficile</EM>. Testing for <EM>C. difficile</EM> is also often performed in patients with inflammatory bowel disease. Testing for parasites (microscopy, antigen testing, molecular testing) is generally not warranted for acute diarrhea but is appropriate in patients with persistent diarrhea (&gt;7 days), in patients with advanced HIV infection (CD4 cell count &lt;200 cells/microL), in men who have sex with men, in the setting of a community waterborne outbreak, and if stool leukocytes/lactoferrin is negative in patients with bloody diarrhea.<br />Δ Empiric antibiotic therapy can reduce the duration of diarrhea and other symptoms by several days, but the benefits of antibiotics do not outweigh potential drawbacks in most patients with acute diarrhea. For these select patients (with or at high risk for severe disease, with dysentery, or with persistent disease) empiric antibiotic treatment is reasonable, as symptom reduction may have a greater relative benefit in such patients. Fluoroquinolones are generally the drug class of choice for empiric therapy of acute diarrhea unless there is suspicion for drug resistance (eg, diarrhea after returning from Southeast Asia). In such cases or when fluoroquinolones cannot be used (eg, intolerance or pregnancy), azithromycin is an effective alternative. Empiric antibiotic therapy should be tailored to results of stool testing, if appropriate.<br /><FONT class=lozenge>◊</FONT> For most adults with highly symptomatic or severe bloody diarrhea, the benefits of antibiotic therapy likely outweigh the low risk of potential complications from treating EHEC. It is reasonable to withhold empiric antibiotic therapy until stool testing has ruled out EHEC or Shiga toxin production in stable patients when the likelihood of EHEC is higher (eg, bloody diarrhea in the setting of an outbreak or in an afebrile patient).<br />§ Loperamide and bismuth salicylates are both effective in reducing the duration and frequency of diarrhea, but loperamide is somewhat more effective. However, we avoid loperamide in patients with evidence of dysentery (fever, bloody or mucous stools) unless antibiotics are also given because of concern for exacerbation of disease. Loperamide is also often avoided when <EM>C. difficile</EM> is suspected. Patients taking loperamide should be cautioned not to exceed the maximum daily dose.</div><div id=\"graphicVersion\">Graphic 68348 Version 9.0</div></div></div>"},"68350":{"type":"graphic_table","displayName":"Additional features possible MSA","title":"Additional features of possible multiple system atrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Additional features of possible multiple system atrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Possible MSA-P or MSA-C</td> </tr> <tr> <td class=\"indent1\">Babinski sign with hyperreflexia</td> </tr> <tr> <td class=\"indent1\">Stridor</td> </tr> <tr> <td class=\"subtitle2_left\">Possible MSA-P</td> </tr> <tr> <td class=\"indent1\">Rapidly progressive parkinsonism</td> </tr> <tr> <td class=\"indent1\">Poor response to levodopa</td> </tr> <tr> <td class=\"indent1\">Postural instability within 3 years of motor onset</td> </tr> <tr> <td class=\"indent1\">Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction</td> </tr> <tr> <td class=\"indent1\">Dysphagia within 5 years of motor onset</td> </tr> <tr> <td class=\"indent1\">Atrophy on MRI scan of putamen, middle cerebellar peduncle, pons, or cerebellum</td> </tr> <tr> <td class=\"indent1\">Hypometabolism on FDG-PET scan in putamen, brainstem, or cerebellum</td> </tr> <tr> <td class=\"subtitle2_left\">Possible MSA-C</td> </tr> <tr> <td class=\"indent1\">Parkinsonism (bradykinesia and rigidity)</td> </tr> <tr> <td class=\"indent1\">Atrophy on MRI of putamen, middle cerebellar peduncle, or pons</td> </tr> <tr> <td class=\"indent1\">Hypometabolism on FDG-PET scan in putamen</td> </tr> <tr> <td class=\"indent1\">Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET scan</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDG: [18F]fluorodeoxyglucose; MSA-C: multiple system atrophy with predominant cerebellar ataxia; MSA-P: multiple system atrophy with predominant parkinsonism; PET: positron emission tomography; SPECT: single photon emission computed tomography.</div><div class=\"graphic_reference\">Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.</div><div id=\"graphicVersion\">Graphic 68350 Version 3.0</div></div></div>"},"68351":{"type":"graphic_picture","displayName":"Folliculitis vulva","title":"Folliculitis vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Folliculitis vulva</div><div class=\"cntnt\"><img style=\"width:308px; height:331px;\" src=\"images/OBGYN/68351_Folliculitis_vulva.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 68351 Version 2.0</div></div></div>"},"68353":{"type":"graphic_table","displayName":"Phlebotomy versus chelation after HCT","title":"Advantages and disadvantages of phlebotomy and iron chelation following hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of phlebotomy and iron chelation following hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Phlebotomy</td> <td> <ul> <li>Efficient </li> <li>Safe </li> <li>Inexpensive </li> <li>Permits complete iron removal and normalizes body iron content </li> <li>Iron removal is quantifiable </li> </ul> </td> <td> <ul> <li>Requires sustained engraftment (not usable in the early post-transplant period) </li> <li>Immediate effect on plasma iron/non-transferrin-bound iron </li> <li>Requires access to a phlebotomy facility </li> <li>Not appropriate for individuals with mixed chimerism</li> </ul> </td> </tr> <tr> <td>Iron chelation therapy</td> <td> <ul> <li>Efficient </li> <li>Safe </li> <li>Immediate effect on plasma iron/non-transferrin-bound iron unknown </li> <li>Access to a phlebotomy facility not required </li> <li>Can be used in individuals with hemoglobin &#60;10 g/dL</li> <li>Can be used in individuals with mixed chimerism</li> </ul> </td> <td> <ul> <li>Expensive </li> <li>Renal toxicity in patients receiving cyclosporine </li> <li>Greater toxicity at lower levels of iron burden </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hepatic iron concentration is assessed at 18 months following hematopoietic HCT, after the patient is no longer receiving transplant-related medications. Refer to UpToDate for additional information regarding the management of the&nbsp;patient with thalassemia following&nbsp;HCT and additional details regarding iron chelating agents.</div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation.</div><div class=\"graphic_reference\"><EM>Courtesy of Emanuele Angelucci, MD</EM></div><div id=\"graphicVersion\">Graphic 68353 Version 4.0</div></div></div>"},"68354":{"type":"graphic_diagnosticimage","displayName":"Radiopaque marker study slow transit","title":"Radiopaque marker study","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiopaque marker study</div><div class=\"cntnt\"><img style=\"width:448px; height:540px;\" src=\"images/GAST/68354_Radiopaq_mark_slow_transit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiopaque marker transit study showing &gt;5 radiopaque markers on x-ray taken on day 6, indicating slow transit.</div><div class=\"graphic_reference\">Courtesy of Satish S Rao, MD, PhD, FRCP, and Narasimha M Palagummi, MD.</div><div id=\"graphicVersion\">Graphic 68354 Version 1.0</div></div></div>"},"68355":{"type":"graphic_figure","displayName":"Elbow fat pads","title":"The elbow fat pads","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">The elbow fat pads</div><div class=\"cntnt\"><img style=\"width:480px; height:390px;\" src=\"images/EM/68355_Elbowfatpads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some of the coronoid fat pad lies anterior to the shallow coronoid fossa. The olecranon fat pad lies totally within the deeper olecranon fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. Evaluation of Pediatric Distal Humeral Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68355 Version 12.0</div></div></div>"},"68356":{"type":"graphic_table","displayName":"Causes of congenital hypothyroidism","title":"Congenital hypothyroidism or other causes of low total T4 at birth, with thyroid function test results","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital hypothyroidism or other causes of low total T4 at birth, with thyroid function test results</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Serum free T4</td> <td class=\"subtitle1\">Serum T4</td> <td class=\"subtitle1\">Serum TSH</td> </tr> <tr> <td class=\"sublist1_start\">Primary hypothyroidism</td> <td class=\"sublist_other_start\">1:2000 to 1:4000</td> <td class=\"sublist_other_start_centered\">&#8595;</td> <td class=\"sublist_other_start_centered\">&#8595;</td> <td class=\"sublist_other_start_centered\">&#8593;</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Thyroid dysgenesis: ectopia, aplasia, or hypoplasia </li> </ul> </td> <td class=\"sublist_other\">85 percent of cases</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8593;</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Resistance to TSH*</li> </ul> </td> <td class=\"sublist_other\">Unknown</td> <td class=\"sublist_other_centered\">Normal or &#8595;&nbsp;</td> <td class=\"sublist_other_centered\">&nbsp;Normal or &#8595;&nbsp;</td> <td class=\"sublist_other_centered\">&#8593;</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Inborn errors of thyroxine synthesis (dyshormonogenesis) </li> </ul> </td> <td class=\"sublist_other\">15 percent of cases</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8593;</td> </tr> <tr> <td class=\"sublist1_start\">Defects in thyroid hormone transport (THCMTD)<sup>&#182;</sup>&nbsp;</td> <td>Rare&nbsp;</td> <td class=\"centered\">&#8595;&nbsp;</td> <td class=\"centered\">&#8595;&nbsp;</td> <td class=\"centered\">Normal or slightly &#8593;&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Defects in thyroid hormone action: Resistance to thyroid hormone&nbsp;</td> <td>1:40,000&nbsp;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;&nbsp;</td> <td class=\"centered\">Normal or slightly &#8593;&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Central hypothyroidism</td> <td>1:16,404 to 1:29,000</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">Normal or &#8595;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Transient hypothyroidism</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Iodine deficiency (worldwide, in areas of endemic iodine deficiency) </li> </ul> </td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other_centered\">&#8595; then normalizes</td> <td class=\"sublist_other_centered\">&#8595; then normalizes</td> <td class=\"sublist_other_centered\">&#8593; then normalizes</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Iodide excess (from topical iodine antiseptics, natural supplements, drugs, or contrast agents) </li> </ul> </td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other_centered\">&#8595; then normalizes</td> <td class=\"sublist_other_centered\">&#8595; then normalizes</td> <td class=\"sublist_other_centered\">&#8593; then normalizes</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Maternal antibody-mediated hypothyroidism </li> </ul> </td> <td class=\"sublist_other\">1:180,000</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8595;</td> <td class=\"sublist_other_centered\">&#8593;</td> </tr> <tr> <td>Thyroxine-binding globulin (TBG) deficiency (causes low serum total T4 concentrations<sup>&#916;</sup> but not hypothyroidism)</td> <td>1:4000 to 1:8000</td> <td class=\"centered\">Normal</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine; TSH: thyroid stimulating hormone (thyrotropin); THCMTD: thyroid hormone cell membrane transport defect.<br />* Resistance to TSH is usually due to a mutation in the TSH receptor<br />¶THCMTD is characterized by high serum T3 and low rT3 concentrations.<br />Δ<FONT color=black>&nbsp;TBG deficiency is characterized by low serum total T4 but normal serum free T4 concentrations. </FONT>&nbsp;</div><div id=\"graphicVersion\">Graphic 68356 Version 12.0</div></div></div>"},"68357":{"type":"graphic_picture","displayName":"Barretts esoph Alcian blue","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:408px; height:252px;\" src=\"images/GAST/68357_Barretts_esoph_Alcian_blue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a biopsy specimen from a patient with Barrett's esophagus has been stained with Alcian blue, which demonstrates the abundant goblet cells.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 68357 Version 3.0</div></div></div>"},"68358":{"type":"graphic_picture","displayName":"Multiple duodenal ulcers Endosc","title":"Multiple duodenal ulcers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple duodenal ulcers</div><div class=\"cntnt\"><img style=\"width:247px; height:258px;\" src=\"images/GAST/68358_Multiple_duodenal_ulcers_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal endoscopy shows multiple duodenal ulcers (arrows) in an elderly patient who was chronically treated with a nonsteroidal antiinflammatory drug. The patient was asymptomatic, and presented only with anemia.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 68358 Version 1.0</div></div></div>"},"68359":{"type":"graphic_figure","displayName":"Incision inguinal node dissection","title":"Incisions for inguinal node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incisions for inguinal node dissection</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/OBGYN/68359_Incision_groin_node_dissect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Line of incision and pertinent landmarks.</div><div id=\"graphicVersion\">Graphic 68359 Version 3.0</div></div></div>"},"68360":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of the tibialis anterior","title":"Ultrasound of the tibialis anterior muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of the tibialis anterior muscle</div><div class=\"cntnt\"><img style=\"width:442px; height:329px;\" src=\"images/NEURO/68360_US_tibialis_ant_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are axial (left) and sagittal (right) images of the tibialis anterior muscle. Note the distinction of the muscle from the thin layer of subcutaneous tissue marked by arrows. The aponeurosis (A) stands out from the rest of the muscle in both images. The sagittal image (right) shows the bipennate attachments of the muscle fibrous tissue, which joins the aponeurosis at a distinct angle of pennation. The bone edge above the tibia (T) is bright and crisply defined.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 68360 Version 2.0</div></div></div>"},"68361":{"type":"graphic_picture","displayName":"Orofacial mask","title":"Orofacial mask","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orofacial mask</div><div class=\"cntnt\"><img style=\"width:331px; height:310px;\" src=\"images/PULM/68361_Orofacial_masks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mirage Quattro&trade; orofacial mask for use with noninvasive positive pressure ventilation.</div><div class=\"graphic_reference\">Copyright &copy; ResMed 2012. Used with permission.</div><div id=\"graphicVersion\">Graphic 68361 Version 1.0</div></div></div>"},"68362":{"type":"graphic_figure","displayName":"Sites LV measurements","title":"Sites for left ventricular measurements","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sites for left ventricular measurements</div><div class=\"cntnt\"><img style=\"width:282px; height:360px;\" src=\"images/CARD/68362_SitesLVmeasurements.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurements of left ventricular (LV) dimensions can be obtained from various views obtained from the&nbsp;two-dimensional echocardiogram. Panel A is the apical four-chamber view; M-mode tracings cannot be made from an apical view and thus measurements must be made directly from the two-dimensional image. The dimensions of the right ventricle (RV) can also be obtained from this view. Panel B is the short axis precordial view; measurements from the short axis can be made interchangeably from either M-mode or two-dimensional image. Panel C is the long axis precordial view; measurements of LV dimension can be made from either the two-dimensional image or the M-mode tracing.</div><div class=\"graphic_footnotes\">Ao: aorta; LA: left atrium; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 68362 Version 2.0</div></div></div>"},"68364":{"type":"graphic_picture","displayName":"Full-thickness wound epithelialization","title":"Full-thickness wound epithelialization","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Full-thickness wound epithelialization</div><div class=\"cntnt\"><img style=\"width:540px; height:324px;\" src=\"images/SURG/68364_Full_thickness_wound_epit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epithelialization of a full-thickness wound occurs from the wound edge.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68364 Version 1.0</div></div></div>"},"68365":{"type":"graphic_table","displayName":"Clinical features of psoriatic juvenile idiopathic arthritis","title":"Clinical features of psoriatic juvenile idiopathic arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of psoriatic juvenile idiopathic arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Series,<br /> year</td> <td class=\"subtitle1\">Sills,<br /> 1980</td> <td class=\"subtitle1\">Shore,<br /> 1982</td> <td class=\"subtitle1\">Southwood,<br /> 1989</td> <td class=\"subtitle1\">Truckenbrodt,<br /> 1990</td> <td class=\"subtitle1\">Roberton,<br /> 1996</td> <td class=\"subtitle1\">Stoll,<br /> 2006</td> <td class=\"subtitle1\">Flato,<br /> 2009</td> </tr> <tr> <td><strong>Number of patients</strong></td> <td>24</td> <td>60</td> <td>35</td> <td>48</td> <td>63</td> <td>139</td> <td>31</td> </tr> <tr> <td><strong>Percent female</strong></td> <td>71</td> <td>58</td> <td>69</td> <td>44</td> <td>70</td> <td>59</td> <td>77</td> </tr> <tr> <td><strong>Arthritis appears before psoriasis</strong></td> <td>58</td> <td>43</td> <td>48</td> <td>42</td> <td>56</td> <td>29</td> <td>50</td> </tr> <tr> <td><strong>Oligoarticular onset (&#60;5 joints)</strong></td> <td>&nbsp;</td> <td>73</td> <td>94</td> <td>85</td> <td>73</td> <td>84</td> <td>68</td> </tr> <tr> <td><strong>Cervical spine</strong></td> <td>&nbsp;</td> <td>32</td> <td>17</td> <td>&nbsp;</td> <td>25</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>TMJ</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>34</td> <td>&nbsp;</td> <td>40</td> <td>7</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Shoulder</strong></td> <td>&nbsp;</td> <td>23</td> <td>9</td> <td>8</td> <td>&nbsp;</td> <td>3</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Elbow</strong></td> <td>&nbsp;</td> <td>43</td> <td>20</td> <td>15</td> <td>30</td> <td>13</td> <td>33</td> </tr> <tr> <td><strong>Wrist</strong></td> <td>33</td> <td>62</td> <td>43</td> <td>31</td> <td>43</td> <td>25</td> <td>42</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Small joints of the hand</strong></td> <td class=\"sublist_other_start\">88</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">60</td> <td class=\"sublist_other_start\">31</td> <td class=\"sublist_other_start\">62</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">61</td> </tr> <tr> <td class=\"sublist1\">MCP</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">53</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">43</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">PIP</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">40</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">51</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">DIP</td> <td class=\"sublist_other\">63</td> <td class=\"sublist_other\">42</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">27</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td><strong>Sacroiliac joint</strong></td> <td>29</td> <td>&nbsp;</td> <td>11</td> <td>17</td> <td>5</td> <td>1</td> <td>0</td> </tr> <tr> <td><strong>Hip</strong></td> <td>33</td> <td>38</td> <td>23</td> <td>21</td> <td>32</td> <td>11</td> <td>23</td> </tr> <tr> <td><strong>Knee</strong></td> <td>67</td> <td>77</td> <td>89</td> <td>67</td> <td>84</td> <td>60</td> <td>87</td> </tr> <tr> <td><strong>Ankle</strong></td> <td>&nbsp;</td> <td>63</td> <td>63</td> <td>50</td> <td>60</td> <td>51</td> <td>71</td> </tr> <tr> <td><strong>Small joints of the foot</strong></td> <td>67</td> <td>&nbsp;</td> <td>46</td> <td>25</td> <td>56</td> <td>&nbsp;</td> <td>42</td> </tr> <tr> <td><strong>Any peripheral small joint</strong></td> <td>&#62;88</td> <td>&#62;53</td> <td>69</td> <td>&#62;31</td> <td>&#62;62</td> <td>57</td> <td>65</td> </tr> <tr> <td><strong>Dactylitis</strong></td> <td>&nbsp;</td> <td>23</td> <td>49</td> <td>67</td> <td>&nbsp;</td> <td>47<sup>[1]</sup></td> <td>30</td> </tr> <tr> <td><strong>Uveitis</strong></td> <td>8</td> <td>8</td> <td>17</td> <td>10</td> <td>14</td> <td>8</td> <td>19</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All numbers indicate percentage of patients. Blank = not reported.</div><div class=\"graphic_footnotes\">TMJ: temporomandibular joint; MCP: metacarpophalangeal; PIP: proximal interphalangeal; DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Stoll M, Nigrovic PA, unpublished data. </li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Data from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011.</div><div id=\"graphicVersion\">Graphic 68365 Version 4.0</div></div></div>"},"68366":{"type":"graphic_figure","displayName":"Length time bias a","title":"Relationship between length-time bias and speed of tumor growth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between length-time bias and speed of tumor growth</div><div class=\"cntnt\"><img style=\"width:444px; height:267px;\" src=\"images/PC/68366_Lengthtimebiasa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rapidly growing tumors come to medical attention before screening is performed, whereas more slowly growing tumors allow time for detection.</div><div class=\"graphic_footnotes\">D: diagnosis after symptoms; S: detection after screening.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68366 Version 11.0</div></div></div>"},"68369":{"type":"graphic_picture","displayName":"Nodular lymphoid hyperplasia High I","title":"Nodular lymphoid hyperplasia in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphoid hyperplasia in Sj&#246;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:352px; height:234px;\" src=\"images/PULM/68369_Pseudolymphoma_High_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows heterogenous foci of lymphocytes and plasma cells.</div><div class=\"graphic_reference\">From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 68369 Version 3.0</div></div></div>"},"68370":{"type":"graphic_picture","displayName":"Eosinophilic fasciitis biopsy 1","title":"Eosinophilic fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic fasciitis</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/RHEUM/68370_Eosinophilic_fasciitis_biop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this low-power, trichrome-stained skin and fascial biopsy, the epidermis (far left) and dermis appear to be normal in width, and the dermis shows a loose arrangement of collagen.&nbsp;By contrast, the subcutaneous fascia (right side) is markedly thickened and shows dense blue staining with trichrome, indicative of extensive collagen accumulation.</div><div class=\"graphic_reference\">Courtesy of John Varga, MD.</div><div id=\"graphicVersion\">Graphic 68370 Version 2.0</div></div></div>"},"68371":{"type":"graphic_table","displayName":"HCC surveillance recommendations","title":"Groups for whom HCC surveillance is recommended or in whom the risk of HCC is increased, but in whom efficacy of surveillance has not been demonstrated","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Groups for whom HCC surveillance is recommended or in whom the risk of HCC is increased, but in whom efficacy of surveillance has not been demonstrated</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Population group</td> <td class=\"subtitle1\">Annual incidence (percent per year) for which surveillance is considered to be cost-effective</td> <td class=\"subtitle1\">Incidence of HCC</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Surveillance recommended</td> </tr> <tr> <td class=\"indent1\">Asian male hepatitis B carriers over age 40</td> <td>0.2</td> <td>0.4-0.6% per year</td> </tr> <tr> <td class=\"indent1\">Asian female hepatitis B carriers over age 50</td> <td>0.2</td> <td>0.3-0.6% per year</td> </tr> <tr> <td class=\"indent1\">Hepatitis B carrier with family history of HCC</td> <td>0.2</td> <td>Incidence higher than without family history</td> </tr> <tr> <td class=\"indent1\">African/North American blacks with hepatitis B</td> <td>0.2</td> <td>HCC occurs at a younger age</td> </tr> <tr> <td class=\"indent1\">Cirrhotic hepatitis B carriers</td> <td>0.2-1.5</td> <td>3-8% per year</td> </tr> <tr> <td class=\"indent1\">Hepatitis C cirrhosis</td> <td>1.5</td> <td>3-5% per year</td> </tr> <tr> <td class=\"indent1\">Stage 4 primary biliary cholangitis</td> <td>1.5</td> <td>3-5% per year</td> </tr> <tr> <td class=\"indent1\">Genetic hemachromatosis and cirrhosis</td> <td>1.5</td> <td>Unknown, but probably &#62;1.5% per year</td> </tr> <tr> <td class=\"indent1\">Alpha-1 antitrypsin deficiency and cirrhosis</td> <td>1.5</td> <td>Unknown, but probably &#62;1.5% per year</td> </tr> <tr> <td class=\"indent1\">Other cirrhosis</td> <td>1.5</td> <td>Unknown</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Surveillance benefit uncertain</td> </tr> <tr> <td class=\"indent1\">Hepatitis B carriers younger than 40 (males) or 50 (females)</td> <td>0.2</td> <td>&#60;0.2% per year</td> </tr> <tr> <td class=\"indent1\">Hepatitis C and stage 3 fibrosis</td> <td>1.5</td> <td>&#60;1.5% per year</td> </tr> <tr> <td class=\"indent1\">Non-cirrhotic NAFLD</td> <td>1.5</td> <td>&#60;1.5% per year</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; NAFLD: nonalcoholic fatty liver disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010. Copyright © 2010 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 68371 Version 8.0</div></div></div>"},"68372":{"type":"graphic_table","displayName":"Compare immunohistochemical markers melanoma","title":"Comparison of five immunohistochemical markers in melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of five immunohistochemical markers in melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">S-100</td> <td class=\"subtitle1\">MART-1/Melan-A</td> <td class=\"subtitle1\">HMB-45</td> <td class=\"subtitle1\">MITF-1</td> <td class=\"subtitle1\">Tyrosinase</td> </tr> <tr> <td><strong>Antigen makeup</strong></td> <td>Calcium-binding protein</td> <td>Melanocyte differentiation antigen expressed as a transmembrane protein</td> <td>Part of gp 100 complex (premelanosome complex)</td> <td>Transcription regulator of tyrosinase gene</td> <td>Key enzyme in melanin biosynthesis</td> </tr> <tr class=\"divider_top\"> <td><strong>Staining targets</strong></td> <td>Melanoma, benign nevic cells (activated junctional nevi, dermal nevic cells in patients with HIV, blue nevi, and deep penetrating nevi), schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors, among others</td> <td>Cells of melanocytic lineage, modified perivascular smooth muscle cells of lymphangiomyomatosis, clear cell sugar tumor of the lung, renal angiomyolipoma, adrenocortical tumors, and tumors of the ovary</td> <td>Most melanomas, fetal and neonatal melanocytes, intraepidermal and superficial dermal components of benign nevi, blue nevi, and deep-penetrating nevi</td> <td>Melanoma, benign melanocytes, some perivascular epithelioid cell carcinoma, and clear cell carcinoma</td> <td>Melanoma, normal melanocytes, and nevi</td> </tr> <tr class=\"divider_top\"> <td><strong>Staining location</strong></td> <td>Nucleus</td> <td>Cytoplasm</td> <td>Cytoplasm</td> <td>Nucleus</td> <td>Cytoplasm</td> </tr> <tr class=\"divider_top\"> <td><strong>Comments</strong></td> <td>Very high sensitivity but low specificity</td> <td>Sensitive and specific for melanocytes but is not a marker of malignant transformation</td> <td>Does not react with spindle-cell melanomas</td> <td> <p>A promising marker that may be more sensitive and specific than other commercially available markers. </p> </td> <td>May have higher sensitivity for metastatic tumors than HMB-45 or MART-1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MITF: microphthalmia transcription factor.</div><div id=\"graphicVersion\">Graphic 68372 Version 8.0</div></div></div>"},"68374":{"type":"graphic_figure","displayName":"Cover uncover test","title":"Cover/uncover test","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Cover/uncover test</div><div class=\"cntnt\"><img style=\"width:480px; height:369px;\" src=\"images/PEDS/68374_Cover_uncover_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration demonstrating technique for cover/uncover test to test for strabismus. Child's eyes appear to be in good alignment. Left eye is then covered for 5 seconds. When card is removed, left eye moves back to alignment. This &quot;drifting&quot; indicates phoria.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68374 Version 1.0</div></div></div>"},"68376":{"type":"graphic_picture","displayName":"Miliaria rubra","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/PEDS/68376_Miliariarubra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Miliaria rubra, also known as heat rash, consists of small, erythematous papules and vesicles on covered portions of the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer, MD.</div><div id=\"graphicVersion\">Graphic 68376 Version 2.0</div></div></div>"},"68377":{"type":"graphic_diagnosticimage","displayName":"UPJ obstruction ultrasound","title":"Ultrasound of a unilateral left ureteropelvic junction obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of a unilateral left ureteropelvic junction obstruction</div><div class=\"cntnt\"><img style=\"width:310px; height:577px;\" src=\"images/PEDS/68377_UPJ_obstruction_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography demonstrates calyceal and renal pelvic dilatition of the left kidney and a normal appearing right kidney.</div><div class=\"graphic_reference\">Courtesy of Dr. Laurence S Baskin.</div><div id=\"graphicVersion\">Graphic 68377 Version 3.0</div></div></div>"},"68382":{"type":"graphic_table","displayName":"Antibiotic treatment of Shigella infection in adults","title":"Antibiotic treatment of <em>Shigella</em> infection in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic treatment of <em>Shigella</em> infection in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration*</td> </tr> <tr> <td>Levofloxacin<sup>&#182;</sup></td> <td>500 mg orally once daily</td> <td class=\"centered\">3 days</td> </tr> <tr> <td>Ciprofloxacin<sup>&#182;</sup></td> <td>500 mg orally twice daily or 750 mg orally once daily</td> <td class=\"centered\">3 days</td> </tr> <tr> <td>Azithromycin</td> <td>500 mg orally once daily</td> <td class=\"centered\">3 days</td> </tr> <tr> <td>Cefixime</td> <td>200 mg orally twice daily</td> <td class=\"centered\">5 days</td> </tr> <tr> <td>Ceftriaxone</td> <td>1 to 2 g intravenously once daily</td> <td class=\"centered\">5 days</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole <span style=\"white-space: nowrap;\">(co-trimoxazole)<sup>&#916;</sup></span></td> <td>160/800 mg (one double strength tablet) orally twice daily</td> <td class=\"centered\">5 days</td> </tr> <tr> <td>Ampicillin<sup>&#916;</sup></td> <td>500 mg orally every 6 hours</td> <td class=\"centered\">5 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Selection of antibiotic therapy for <em>Shigella</em> infection in adults should be based on the results of antimicrobial susceptibility testing, if possible. If an agent needs to be chosen empirically, the risk of resistance based on patient demographics and local rates of resistance should be taken into account. Refer to the topic on treatment of <em>Shigella</em> infection in adults for additional details.</div><div class=\"graphic_footnotes\">* Five to seven days of therapy should be administered to patients with infection due to <em>Shigella dysenteriae</em> type 1 or patients with HIV coinfection. Longer durations (eg, 14 days) are reasonable in the rare event of bacteremia.<br />&para; Fluoroquinolones should be avoided if the ciprofloxacin minimum inhibitory concentration (MIC) &ge;0.12 mcg/mL because of the possibility of reduced clinical response to fluoroquinolones.<br />&Delta; Because of high rates of resistance to these agents, trimethoprim-sulfamethoxazole and ampicillin should only be used for infections that have documented susceptibility.</div><div id=\"graphicVersion\">Graphic 68382 Version 6.0</div></div></div>"},"68383":{"type":"graphic_movie","displayName":"Pericardial effusion with tamponade long axis","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68383_laxpref2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/68383_laxpref2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from a two-dimensional echocardiogram shows a massive pericardial effusion (PE) surrrounding the right ventricle (RV), left ventricle (LV), and extending behind the left atrium (LA). The patient had severe hemodynamic compromise and tamponade physiology.</div><div class=\"graphic_footnotes\">Ao: aorta.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 68383 Version 2.0</div></div></div>"},"68384":{"type":"graphic_picture","displayName":"Normal bone marrow Low","title":"Normal bone marrow biopsy at low power","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow biopsy at low power</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/68384_Normal_bone_marrow_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68384 Version 2.0</div></div></div>"},"68386":{"type":"graphic_picture","displayName":"Gastric marginal zone lymphoma Low","title":"Extranodal marginal zone lymphoma of the stomach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extranodal marginal zone lymphoma of the stomach</div><div class=\"cntnt\"><img style=\"width:445px; height:288px;\" src=\"images/GAST/68386_Gastric_MALToma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a gastric marginal zone lymphoma shows dense, monotonous, lymphoid infiltrate in the lamina propria, and pale- staining cells consistent with marginal zone B-cells surrounding and infiltrating the epithelium (lymphoepithelial lesion).</div><div class=\"graphic_reference\">Courtesy of Nancy Lee Harris, MD.</div><div id=\"graphicVersion\">Graphic 68386 Version 3.0</div></div></div>"},"68387":{"type":"graphic_picture","displayName":"Pedunculated polyp endoloop II","title":"Colonic polypectomy using an endloop","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic polypectomy using an endloop</div><div class=\"cntnt\"><img style=\"width:346px; height:307px;\" src=\"images/GAST/68387_Pedunculated_polyp_endoloop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Large smooth polyp on a long pedicle; (B) Endoloop placed deep on to the pedicle, the head of the polyp is at 12 o'clock; (C) Snare placed on the pedicle above the endoloop; (D) Polyp pedicle with endoloop for hemostasis.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 68387 Version 2.0</div></div></div>"},"68389":{"type":"graphic_table","displayName":"Minimal semen parameters recommended for sperm donors","title":"Minimal semen parameters recommended for sperm donors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Minimal semen parameters recommended for sperm donors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Volume</td>\n\n      <td>&#62;2ml</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Sperm motility</td>\n\n      <td>&#62;50% moving actively in a purposeful direction</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"subtitle1_left\">Sperm concentration</td>\n      <td>&#62;50 x 10(6) motile sperm/mL</td>\n    </tr>\n    <tr>\n      <td class=\"subtitle1_left\">Sperm morphology</td>\n      <td>Normal range</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_left\">Cryosurvival</td>\n\n      <td>&#62;50 percent of initial motility</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Modified from: American Society of Reproductive Medicine. Fertil Steril 2002; 77:S15.</div><div id=\"graphicVersion\">Graphic 68389 Version 2.0</div></div></div>"},"68390":{"type":"graphic_picture","displayName":"AML FAB M2","title":"Acute myeloid leukemia (M2)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia (M2)</div><div class=\"cntnt\"><img style=\"width:416px; height:288px;\" src=\"images/HEME/68390_AML_FAB_M2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with AML (FAB classification M2). (Wright-Giemsa stain). The WBC count was 70,000/microL and was comprised almost entirely of myeloblasts with numerous azurophilic granules.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 68390 Version 2.0</div></div></div>"},"68391":{"type":"graphic_figure","displayName":"Age-adjusted death rates for diabetic hyperglycemic crises","title":"Crude and age-adjusted death rates for hyperglycemic crises as underlying cause per 100,000 diabetic population, United States, 1980 to 2009","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Crude and age-adjusted death rates for hyperglycemic crises as underlying cause per 100,000 diabetic population, United States, 1980 to 2009</div><div class=\"cntnt\"><img style=\"width:589px; height:441px;\" src=\"images/ENDO/68391_Ageadjdeathratesdiabcr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the crude and age-adjusted death rates for hyperglycemic crises as underlying cause decreased from 1980 to 2009. Declines in the crude and age-adjusted rates were similar. The age-adjusted rate decreased 64 percent from 48.4 per 100,000 diabetic population in 1980 to 17.3 per 100,000 diabetic population in 2009.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Diabetes Public Health Resource: Diabetes Data &amp; Trends (Accessed on March 26, 2014).</div><div id=\"graphicVersion\">Graphic 68391 Version 7.0</div></div></div>"},"68392":{"type":"graphic_picture","displayName":"Spitz nevus pigmented","title":"Pigmented Spitz nevus (Reed nevus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigmented Spitz nevus (Reed nevus)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68392_Spitznevuspigmented.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented spindle melanocytic tumor (Reed nevus) in an 11-year-old boy. A skin biopsy showed the typical changes of a pigmented spindle cell tumor, also known as a Reed nevus. It presents as a well-circumscribed, deeply pigmented nodule on the extremities of young adults. Histologically, it is composed of spindled melanocytes with heavy melanin pigmentation. As in a Spitz tumor, this tumor is symmetrical with maturation and lack of deep dermal mitotic figures.</div><div class=\"graphic_reference\">Copyright © David Elpern, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 68392 Version 8.0</div></div></div>"},"68393":{"type":"graphic_table","displayName":"Imaging guidelines from COG for Ewing family of tumors","title":"Guidelines for imaging for Ewing sarcoma family of tumors from the Children's Oncology Group ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for imaging for Ewing sarcoma family of tumors from the Children's Oncology Group </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">At presentation and prior to local control</td> </tr> <tr> <td class=\"subtitle2_single\">Site</td> <td class=\"subtitle2_single\">Testing</td> </tr> <tr> <td class=\"indent1\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs</td> </tr> <tr> <td class=\"indent1\">Primary tumor</td> <td class=\"indent1\">MRI with gadolinium (presurgery exam should be performed within four weeks of local control procedure)</td> </tr> <tr> <td class=\"indent1\">Bone metastases</td> <td class=\"indent1\">MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Chest</td> <td class=\"indent1\">CT</td> </tr> <tr> <td class=\"indent1\">AP and lateral radiographs (recommended at presentation only)</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy and/or FDG-PET (recommended at presentation, particularly if primary bone tumor negative on bone scintigraphy)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Baseline after local treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Site</td> <td class=\"subtitle2_single\">Testing and timing</td> </tr> <tr> <td class=\"indent1\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs within two weeks of surgery</td> </tr> <tr> <td class=\"indent1\">Primary tumor</td> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast (in patients without significant metallic artifact at primary tumor site) three to four months after local control</td> </tr> <tr> <td class=\"indent1\">Bone metastases</td> <td class=\"indent1\">MRI with gadolinium or CT scan with contrast (recommended for possible bone metastases if diagnosis uncertain)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Surveillance on chemotherapy</td> </tr> <tr> <td class=\"subtitle2_single\">Site</td> <td class=\"subtitle2_single\">Testing and timing</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs after 10 cycles (approximately halfway through postoperative chemotherapy)</td> </tr> <tr> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical intervention or radiation therapy contemplated)</td> </tr> <tr> <td class=\"indent1\">Chest</td> <td class=\"indent1\">CT after 10 cycles (approximately halfway through postoperative chemotherapy)</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy (if disease positive on prior bone scintigraphy) or FDG-PET (if disease positive on prior FDG-PET and bone scan-negative) recommended<br /> <ul> <li>At end of cytotoxic chemotherapy </li> <li>Sooner if symptoms or abnormal imaging (and surgical or other intervention contemplated) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Surveillance postchemotherapy</td> </tr> <tr> <td class=\"subtitle2_single\">Site</td> <td class=\"subtitle2_single\">Testing and timing</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Primary and bone metastases</td> <td class=\"indent1\">AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5</td> </tr> <tr> <td class=\"indent1\">MRI with gadolinium or CT scan with IV contrast recommended if symptoms or abnormal imaging (and surgical or other intervention contemplated)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Chest</td> <td class=\"indent1\">AP and lateral radiographs every three months x 8, then every six months x 6, then every 12 months x 5</td> </tr> <tr> <td class=\"indent1\">CT recommended if abnormal radiographs</td> </tr> <tr> <td class=\"indent1\">Whole body</td> <td class=\"indent1\">Technetium bone scintigraphy (if positive on prior scans) or FDG-PET (if positive on prior scans and bone scan-negative) if symptoms or abnormal imaging AND surgical or other intervention contemplated</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=93198&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">AP: anterior-posterior; MRI: magnetic resonance imaging; CT: computed tomography; FDG-PET: fluorodeoxyglucose positron emission tomography; IV: intravenous.</div><div class=\"graphic_reference\">Data from: Meter JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.</div><div id=\"graphicVersion\">Graphic 68393 Version 8.0</div></div></div>"},"68394":{"type":"graphic_table","displayName":"Motor weakness with nerve root lesions","title":"Motor weakness with nerve root lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor weakness with nerve root lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nerve root level</td> <td class=\"subtitle1\">Muscles involved</td> <td class=\"subtitle1\">Weakness</td> </tr> <tr> <td rowspan=\"2\">C5-C6</td> <td>Deltoid</td> <td>Shoulder abduction</td> </tr> <tr> <td>Biceps</td> <td>Elbow flexion</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">C6-C7</td> <td>Flexor carpi radialis</td> <td>Wrist flexion</td> </tr> <tr> <td>Triceps</td> <td>Elbow extension</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">C8-T1</td> <td>Abductor pollicis brevis</td> <td>Thumb abduction</td> </tr> <tr> <td>Abductor digiti minimi</td> <td>Finger abduction</td> </tr> <tr> <td>Extensor indicis proprius</td> <td>Index finger extension</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">L2-L3-L4</td> <td>Iliopsoas (L1-L3)</td> <td>Hip flexion</td> </tr> <tr> <td>Quadriceps</td> <td>Knee extension</td> </tr> <tr> <td>Adductor longus</td> <td>Hip adduction</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">L5</td> <td>Tibialis anterior</td> <td>Foot dorsiflexion</td> </tr> <tr> <td>Tibialis posterior</td> <td>Foot inversion</td> </tr> <tr> <td>Peroneus longus</td> <td>Foot eversion</td> </tr> <tr> <td>Extensor digitorum brevis</td> <td>Toe extension</td> </tr> <tr> <td>Gluteus medius</td> <td>Hip abduction</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">S1</td> <td>Gastrocnemius</td> <td>Foot plantar flexion</td> </tr> <tr> <td>Hamstrings</td> <td>Knee flexion</td> </tr> <tr> <td>Gluteus maximus</td> <td>Hip extension</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Seward Rutkove and Andrew Tarulli.</div><div id=\"graphicVersion\">Graphic 68394 Version 1.0</div></div></div>"},"68395":{"type":"graphic_picture","displayName":"Capillaria hepatica histopathology","title":"<em>Capillaria hepatica</em> histopathology","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\"><em>Capillaria hepatica</em> histopathology</div><div class=\"cntnt\"><img style=\"width:547px; height:547px;\" src=\"images/ID/68395_Capillaria_hepatica_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) <em>Capillaria hepatica</em> eggs in liver, stained with hematoxylin and eosin (H&amp;E). Eggs of <em>C. hepatica</em> are 50 to 70 micrometers long by 30 to 35 micrometers wide and are unembryonated when seen in human stool (an indication of a spurious infection).<br />(C) Cross section of a male <em>C. hepatica</em> in liver tissue, stained with H&amp;E. Note the presence of the intestine (blue arrow) and the coiled sections of the testes (black arrows).<br />(D) Cross section of <em>C. hepatica</em> in liver tissue, stained with H&amp;E. Note the presence of the intestine (blue arrow) and bacillary bands (black arrows).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hepatic capillariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/hepaticCapillariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/hepaticCapillariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 68395 Version 7.0</div></div></div>"},"68396":{"type":"graphic_picture","displayName":"Pilar cyst 3","title":"Pilar cyst","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pilar cyst</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68396_Pilar_cyst_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68396 Version 3.0</div></div></div>"},"68398":{"type":"graphic_figure","displayName":"Immunoglobulin variable region","title":"Immunoglobulin variable region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin variable region</div><div class=\"cntnt\"><img style=\"width:422px; height:198px;\" src=\"images/RHEUM/68398_Immunoglobulin_variable_reg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are four framework regions flanking three complementarity-determining regions. After folding into the proper conformation (immunoglobulin domain), the CDRs will be near one another forming the combining site. The variable regions for the heavy chain and light chain are shown.</div><div class=\"graphic_footnotes\">V<SUB>H</SUB>: heavy chain variable region; V<SUB>L</SUB>: light chain variable region; FR: framework region; CDR: complementarity-determining region; D: diversity segment; JH: heavy chain joining region; JL: light chain joining region.</div><div id=\"graphicVersion\">Graphic 68398 Version 4.0</div></div></div>"},"68399":{"type":"graphic_picture","displayName":"Winging of scapula","title":"Winging of the scapula","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Winging of the scapula</div><div class=\"cntnt\"><img style=\"width:528px; height:155px;\" src=\"images/EM/68399_Winging_scapula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above are two examples of winging of the scapula. Winging of the left scapula is seen from an oblique perspective in the first photograph in a patient who had long thoracic nerve entrapment. The second patient, seen from the back, developed winging in the right scapula.</div><div class=\"graphic_reference\">Courtesy of Robert P Sheon, MD and Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 68399 Version 4.0</div></div></div>"},"68400":{"type":"graphic_picture","displayName":"Fistula plug","title":"Insertion of a fistula plug in an anorectal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of a fistula plug in an anorectal fistula</div><div class=\"cntnt\"><img style=\"width:374px; height:352px;\" src=\"images/SURG/68400_AUfistulaplug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the insertion of a fistula plug into the primary internal opening of the anorectal fistula.</div><div class=\"graphic_reference\">Courtesy of Bradley J Champagne, MD.</div><div id=\"graphicVersion\">Graphic 68400 Version 6.0</div></div></div>"},"68401":{"type":"graphic_table","displayName":"Sensitivity of human organs or tissues to ionizing radiation","title":"Sensitivity of human organs or tissues to ionizing radiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity of human organs or tissues to ionizing radiation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Relative radiosensitivity</td> <td class=\"subtitle1\">Organ or tissue</td> </tr> <tr> <td>Very high</td> <td>Embryonic tissue, lymphoid organs, bone marrow, blood, testes and ovaries, small intestines</td> </tr> <tr> <td>High</td> <td>Skin, lens and cornea of eye, most gastrointestinal organs (oral cavity, esophagus, stomach, rectum), bladder, uterus</td> </tr> <tr> <td>Medium</td> <td>Growing cartilage, growing bones, blood vessels</td> </tr> <tr> <td>Low</td> <td>Mature cartilage or bone, pituitary gland, lungs, thyroid, pancreas, kidneys, adrenal glands</td> </tr> <tr> <td>Very low</td> <td>Brain, spinal cord, muscles</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Rubin P, Casarett GW. Clinical Radiation Pathology. Philadelphia; W.B. Saunders; 1968.</div><div id=\"graphicVersion\">Graphic 68401 Version 2.0</div></div></div>"},"68403":{"type":"graphic_figure","displayName":"Structure of tooth","title":"Structure of the tooth","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Structure of the tooth</div><div class=\"cntnt\"><img style=\"width:514px; height:582px;\" src=\"images/PC/68403_Structure_of_tooth.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68403 Version 2.0</div></div></div>"},"68404":{"type":"graphic_form","displayName":"Asthma monitoring form PI","title":"Asthma Record - Please bring to each visit","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Asthma Record - Please bring to each visit</div><div class=\"cntnt\"><img style=\"width:574px; height:714px;\" src=\"images/PI/68404_Asthma_monitoring_form_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68404 Version 3.0</div></div></div>"},"68405":{"type":"graphic_picture","displayName":"Cysts in LAM","title":"Lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:441px; height:324px;\" src=\"images/PULM/68405_Cysts_in_LAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph showing multiple cysts (arrow) in the lung of a patient with lymphangioleiomyomatosis.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 68405 Version 1.0</div></div></div>"},"68407":{"type":"graphic_diagnosticimage","displayName":"NSCLC pleural met PETCT","title":"Pleural metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural metastasis</div><div class=\"cntnt\"><img style=\"width:396px; height:295px;\" src=\"images/PULM/68407_NSCLC_pleural_met_PETCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET-CT showing a left lung mass and adjacent pleural thickening that is metabolically active. CT guided pleural biopsy showed non-small cell lung cancer.</div><div class=\"graphic_footnotes\">PET-CT: positron emission tomography-computed tomography; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 68407 Version 3.0</div></div></div>"},"68408":{"type":"graphic_picture","displayName":"Results of photodynamic therapy","title":"Results of photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Results of photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:320px; height:337px;\" src=\"images/PULM/68408_Results_of_photodynamic_the.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image obtained during bronchoscopy from the same patient, four months after the application of 200J of photodynamic therapy. Scar tissue is visible, and biopsies and brushings were negative for malignancy.</div><div class=\"graphic_reference\">Courtesy of Armin Ernst, MD.</div><div id=\"graphicVersion\">Graphic 68408 Version 2.0</div></div></div>"},"68410":{"type":"graphic_diagnosticimage","displayName":"Nonossifying fibroma distal tibia","title":"Nonossifying fibroma of the distal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonossifying fibroma of the distal tibia</div><div class=\"cntnt\"><img style=\"width:406px; height:540px;\" src=\"images/PEDS/68410_Nonoss_fibroma_distal_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the eccentric, solitary, radiolucent lesion on the posterior surface of the distal tibia. This lesion demonstrates a bubbly appearance and an encapsulated sclerotic margin.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68410 Version 2.0</div></div></div>"},"68411":{"type":"graphic_table","displayName":"SCFE outcome by severity","title":"Outcome of slipped capital femoral epiphysis (SCFE) according to the severity of slip*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcome of slipped capital femoral epiphysis (SCFE) according to the severity of slip*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Severity<sup>&#182;</sup></td> <td class=\"subtitle1\">Patients with this degree of severity<br /> (percent)</td> <td class=\"subtitle1\">Iowa hip score<sup>&#916;</sup> of hips at latest follow-up</td> <td class=\"subtitle1\">Osteonecrosis<br /> (percent)</td> <td class=\"subtitle1\">Chondrolysis<br /> (percent)</td> </tr> <tr> <td>Mild</td> <td class=\"centered\">43</td> <td class=\"centered\">89</td> <td class=\"centered\">2</td> <td class=\"centered\">7</td> </tr> <tr> <td>Moderate</td> <td class=\"centered\">32</td> <td class=\"centered\">81</td> <td class=\"centered\">18</td> <td class=\"centered\">16</td> </tr> <tr> <td>Severe</td> <td class=\"centered\">25</td> <td class=\"centered\">73</td> <td class=\"centered\">19</td> <td class=\"centered\">31</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Data from 155 hips in 124 patients with SCFE followed for a mean of 41 years.<br />¶ Mild slips are &lt;30 degrees of femoral head-shaft angle deviation from the contralateral side; moderate slips are between 30 and 50 degrees; severe slips are &gt;50 degrees.<br />Δ The Iowa hip score is a standardized instrument that gives points for function, freedom from pain, gait, absence of deformity and range of motion; normal score = 100.</div><div class=\"graphic_reference\">Adapted from: Carney BT, Weinstein SL, Noble J. J Bone Joint Surg Am 1991; 73:667.</div><div id=\"graphicVersion\">Graphic 68411 Version 6.0</div></div></div>"},"68412":{"type":"graphic_picture","displayName":"Acne mixed type","title":"Inflammatory and noninflammatory acne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory and noninflammatory acne</div><div class=\"cntnt\"><img style=\"width:396px; height:266px;\" src=\"images/PC/68412_Acne_mixed_type.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The face of this teenager shows open and closed comedones, papules, and pustules.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68412 Version 2.0</div></div></div>"},"68413":{"type":"graphic_table","displayName":"Dx criteria hypochondriasis","title":"DSM-IV-TR diagnostic criteria for hypochondriasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for hypochondriasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Preoccupation with fears of having, or the idea that one has, a serious disease based on the person's misinterpretation of bodily symptoms.</td> </tr> <tr> <td><strong>B.</strong> The preoccupation persists despite appropriate medical evaluation and reassurance.</td> </tr> <tr> <td><strong>C.</strong> The belief in Criterion A is not of delusional intensity (as in delusional disorder, somatic type) and is not restricted to a circumscribed concern about appearance (as in body dysmorphic disorder).</td> </tr> <tr> <td><strong>D.</strong> The preoccupation causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td> </tr> <tr> <td><strong>E.</strong> The duration of the disturbance is at least six months.</td> </tr> <tr> <td><strong>F.</strong> The preoccupation is not better accounted for by generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, a major depressive episode, separation anxiety, or another somatoform disorder.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">5/31/2010--Requested permission (JD). 6/2/2010--Permission granted; figures to Terrence, invoice to Jo (JD). The total fee of $&amp;quot;230.00&amp;quot;was originally charged to Dx_criteria_somatization Dx_criteria_undiff_somat Dx_criteria_conversion_dis Dx_criteria_pain_disorder Dx_criteria_hypochondria</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58528&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright © 2000 American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 68413 Version 14.0</div></div></div>"},"68418":{"type":"graphic_table","displayName":"Antidepressants PI","title":"2007 Revised Medication Guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2007 Revised Medication Guide</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   Medication Guide\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <strong>Talk to your, or your family member's, healthcare provider about:</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; All risks and benefits of treatment with antidepressant medicines\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; All treatment choices for depression or other serious mental illness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults when the medicine is first started.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is first started or when the dose is changed.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   4. Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Thoughts about suicide or dying\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Trouble sleeping (insomnia)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Attempts to commit suicide\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; New or worse irritability</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; New or worse depression\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Acting aggressive, being angry, or violent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; New or worse anxiety\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Acting on dangerous impulses</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Feeling very agitated or restless\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; An extreme increase in activity and talking (mania)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Panic attacks\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Other unusual changes in behavior or mood</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   5. What else do I need to know about antidepressant medicines?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Never stop an antidepressant medicine without first talking to a healthcare provider.</strong> Stopping an antidepressant medicine suddenly can cause other symptoms.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressants are medicines used to treat depression and other illnesses.</strong> It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressant medicines have other side effects.</strong> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressant medicines can interact with other medicines.</strong> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Not all antidepressant medicines prescribed for children are FDA approved for use in children.</strong> Talk to your child's healthcare provider for more information.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">This Medication Guide has been approved by the US Food and Drug Administration for all antidepressants.<br>Revised 2007.</div><div class=\"graphic_reference\">Data from: US Food and Drug Administration, Center for Drug Evaluation and Research. Medication Guide for Antidepressant Drugs. Available at: www.fda.gov/Cder/drug/antidepressants (Accessed on August 1, 2008).</div><div id=\"graphicVersion\">Graphic 68418 Version 1.0</div></div></div>"},"68419":{"type":"graphic_picture","displayName":"Belt mark","title":"Belt mark","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Belt mark</div><div class=\"cntnt\"><img style=\"width:216px; height:146px;\" src=\"images/EM/68419_Belt_mark.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the broad bands of ecchymosis that end in a buckle-shaped bruise.</div><div class=\"graphic_reference\">Courtesy of Joan E Shook, MD.</div><div id=\"graphicVersion\">Graphic 68419 Version 2.0</div></div></div>"},"68420":{"type":"graphic_table","displayName":"Dietary composition children","title":"Recommended daily amount from each food group, by calorie level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended daily amount from each food group, by calorie level</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"7\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Food group</td> <td class=\"subtitle1\" colspan=\"7\">Calorie level</td> </tr> <tr> <td class=\"subtitle2\">1200</td> <td class=\"subtitle2\">1400</td> <td class=\"subtitle2\">1600</td> <td class=\"subtitle2\">1800</td> <td class=\"subtitle2\">2000</td> <td class=\"subtitle2\">2200</td> <td class=\"subtitle2\">3000</td> </tr> <tr> <td>Grains*</td> <td>4 ounces</td> <td>5 ounces</td> <td>5 ounces</td> <td>6 ounces</td> <td>6 ounces</td> <td>7 ounces</td> <td>10 ounces</td> </tr> <tr> <td>Vegetables<sup>&#182;</sup></td> <td>1.5 cups</td> <td>1.5 cups</td> <td>2 cups</td> <td>2.5 cups</td> <td>2.5 cups</td> <td>3 cups</td> <td>4 cups</td> </tr> <tr> <td>Fruits<sup>&#916;</sup></td> <td>1 cup</td> <td>1.5 cups</td> <td>1.5 cups</td> <td>1.5 cups</td> <td>2 cups</td> <td>2 cups</td> <td>2.5 cups</td> </tr> <tr> <td>Dairy<sup>&#9674;</sup></td> <td>2.5 cups</td> <td>2.5 cups</td> <td>3 cups</td> <td>3 cups</td> <td>3 cups</td> <td>3 cups</td> <td>3 cups</td> </tr> <tr> <td>Protein foods</td> <td>3 ounces</td> <td>4 ounces</td> <td>5 ounces</td> <td>5 ounces</td> <td>5.5 ounces</td> <td>6 ounces</td> <td>7 ounces</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In general, 1 slice of bread, 1 cup of ready-to-eat cereal, or &frac12; cup of cooked rice, cooked pasta, or cooked cereal can be considered as 1 ounce equivalent from the Grains Group. At least half of these servings should be whole grains.<br />&para; 1 cup vegetables is approximately equal to 12 baby carrots, or one large tomato. Because of high water content, a serving of lettuce must be twice as large (1 cup of lettuce = 1/2 cup of other vegetables).<br />&Delta; 1 cup of fruit is approximately equal to one apple or banana, 2 plums, 1/8th melon, or eight strawberries.<br /><span class=\"lozenge\">&loz;</span> Milk should be fat-free or low-fat after two years of age.</div><div class=\"graphic_reference\">Data from: the United States Department of Agriculture \"Choose My Plate\" website, available at: <a href=\"http://www.choosemyplate.gov/\" target=\"_blank\">www.choosemyplate.gov</a>.</div><div id=\"graphicVersion\">Graphic 68420 Version 11.0</div></div></div>"},"68422":{"type":"graphic_picture","displayName":"Immunofluorescence C4d staining in RT biopsy","title":"Immunofluorescence C4d staining in a renal transplant biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence C4d staining in a renal transplant biopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/NEPH/68422_Immunofluorescence_C4d_stai.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence with C4d monoclonal antibody demonstrating diffuse and strong peritubular capillary deposition in a renal transplant biopsy. The yellow staining indicates C4d deposition. This is consistent with antibody-mediated rejection.</div><div class=\"graphic_reference\">Courtesy of Dr. Helen Liapis, Washington University School of Medicine.</div><div id=\"graphicVersion\">Graphic 68422 Version 6.0</div></div></div>"},"68424":{"type":"graphic_diagnosticimage","displayName":"CT Bilateral traumatic SDH","title":"Non contrast head CT demonstrates a traumatic acute subdural hematoma over the left hemisphere and a smaller subacute subdural hematoma over the right hemisphere","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non contrast head CT demonstrates a traumatic acute subdural hematoma over the left hemisphere and a smaller subacute subdural hematoma over the right hemisphere</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/NEURO/68424_CT_bilateral_SDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 68424 Version 3.0</div></div></div>"},"68426":{"type":"graphic_picture","displayName":"Lichen simplex chronicus1","title":"Vulvar lichen simplex chronicus","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Vulvar lichen simplex chronicus</div><div class=\"cntnt\"><img style=\"width:468px; height:353px;\" src=\"images/OBGYN/68426_Lichen_simplex_chronicus1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 68426 Version 3.0</div></div></div>"},"68430":{"type":"graphic_diagnosticimage","displayName":"Migration of abdominal aortic endograft","title":"Migration of abdominal aortic endograft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Migration of abdominal aortic endograft</div><div class=\"cntnt\"><img style=\"width:222px; height:370px;\" src=\"images/CARD/68430_Endograft_migration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast angiogram demonstrates downward migration of endograft into the aneurysm sac (arrow).</div><div id=\"graphicVersion\">Graphic 68430 Version 3.0</div></div></div>"},"68431":{"type":"graphic_table","displayName":"Hormone therapy plus NSAIDs for desmoids ","title":"Combinations of hormonal therapy plus NSAIDs in the treatment of desmoid tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Combinations of hormonal therapy plus NSAIDs in the treatment of desmoid tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agents used</td> <td class=\"subtitle1\">No of patients</td> <td class=\"subtitle1\">Duration of therapy (in months)</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Duration of response</td> <td class=\"subtitle1\">Author, year</td> </tr> <tr> <td>Sulindac plus tamoxifen</td> <td>25*</td> <td>5-84 (median 24)</td> <td> <p>3 CR</p> <p>3 PR</p> <p>11 SD</p> <p>7 PD</p> </td> <td>NR</td> <td>Hansmann, A; 2003</td> </tr> <tr class=\"divider_top\"> <td>Hormonal agent (testolactone/tamoxifen) combined with an NSAID (indomethacin, sulindac, or piroxicam)</td> <td>7</td> <td>1-92 (median 52)</td> <td> <p>1 CR</p> <p>4 PR</p> <p>1 SD</p> <p>1 PD</p> </td> <td>NR</td> <td>Waddell, W; 1991</td> </tr> <tr class=\"divider_top\"> <td>Sulindac or indomethacin plus tamoxifen</td> <td>4</td> <td>9-36 (median 20)</td> <td> <p>2 SD</p> <p>2 PD</p> </td> <td>NR</td> <td>Klein, W; 1987</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: overall response; CR: complete response; PR: partial response; NSAIDs: non-steroidal anti-inflammatory drugs; SD: stable disease; PD: progressive disease; NR: not reported.<br> * 1 out of 25 patients had a complete (R0) resection and was on combination therapy adjuvantly. This patient is not counted for responses.</div><div id=\"graphicVersion\">Graphic 68431 Version 3.0</div></div></div>"},"68432":{"type":"graphic_table","displayName":"Altered dental care delivery","title":"Conditions that can impede the delivery of dental treatment in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that can impede the delivery of dental treatment in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Effect on dental care delivery </td> <td class=\"subtitle1\">Dental management </td> </tr> <tr> <td><span style=\"color: black;\"></span>Cerebral palsy</td> <td>Wheelchair access; immobility; uncontrolled movements; reflex problems</td> <td><span style=\"color: black;\">Treatment in wheelchair; use of restraints; use of pharmacologic agents to manage movement</span></td> </tr> <tr> <td>Muscular dystrophy</td> <td>Wheelchair access; immobility; risk of aspiration; lack of muscle control</td> <td>Treatment in wheelchair; use of restraints and supports</td> </tr> <tr> <td>Mental retardation</td> <td>Inability to cooperate</td> <td>Behavior <span style=\"color: black;\">guidance</span>; use of pharmacologic agents to manage behavior</td> </tr> <tr> <td>Autism</td> <td>Inability to cooperate</td> <td>Behavior <span style=\"color: black;\">guidance</span>; use of pharmacologic agents to manage behavior</td> </tr> <tr> <td>Attention deficit hyperactivity disorder</td> <td>Short attention span</td> <td>Behavior <span style=\"color: black;\">guidance</span>; treatment when medicated</td> </tr> <tr> <td>Sensory disorders</td> <td>Communication difficulties</td> <td>Use of adjunctive communication means/interpreters; use of pharmacologic agents to manage behavior</td> </tr> <tr> <td>Spinal cord injury</td> <td>Wheelchair bound; pressure sores; autonomic dysreflexia</td> <td>Treatment in wheelchair; positioning/stabilizing techniques</td> </tr> <tr> <td>Spina bifida</td> <td>Intellectual impairment; wheelchair bound; positioning difficulties</td> <td>Behavior <span style=\"color: black;\">guidance</span>; treatment in wheelchair; positioning and stabilizing techniques</td> </tr> <tr> <td><span style=\"color: black;\">&nbsp;Obesity</span></td> <td><span style=\"color: black;\">Failed procedures, other adverse outcomes with pharmacologic management</span></td> <td><span style=\"color: black;\">Behavior guidance; alternatives to operative procedures such as silver diamine fluoride</span></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright ©2000 W.B. Saunders Co.</div><div id=\"graphicVersion\">Graphic 68432 Version 4.0</div></div></div>"},"68434":{"type":"graphic_picture","displayName":"Phalanx fracture traction and reduction","title":"Phalanx fracture reduction: Traction","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Phalanx fracture reduction: Traction</div><div class=\"cntnt\"><img style=\"width:468px; height:312px;\" src=\"images/EM/68434_Phalanx_fx_reductn_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction of a middle phalanx fracture is performed by applying longitudinal traction (shown above), and then using three-point pressure to bring the distal fragment into alignment with the proximal fragment.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 68434 Version 2.0</div></div></div>"},"68436":{"type":"graphic_picture","displayName":"Straddle injury4","title":"Straddle injury on picket fence, note puncture wound from picket fence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Straddle injury on picket fence, note puncture wound from picket fence</div><div class=\"cntnt\"><img style=\"width:504px; height:344px;\" src=\"images/EM/68436_Straddle_injury4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury does not involve hymen.</div><div class=\"graphic_reference\">Courtesy of Marc R. Laufer, MD.</div><div id=\"graphicVersion\">Graphic 68436 Version 4.0</div></div></div>"},"68437":{"type":"graphic_table","displayName":"Androgen production","title":"Androgen production in the sebaceous gland","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Androgen production in the sebaceous gland</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Dehydroepiandrosterone sulfate (DHEA-S)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8595; Steroid sulfatase\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Dehydroepiandrosterone (DHEA)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8595; 3<sub>&#946;</sub> -hydroxysteroid dehydrogenase\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Androstenedione\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8595; 17<sub>&#946;</sub> -hydroxysteroid dehydrogenase\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Testosterone\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8595; 5&#945; -reductase type I\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Dihydrotestosterone (DHT)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 68437 Version 1.0</div></div></div>"},"68440":{"type":"graphic_picture","displayName":"Phalen test carpal tunnel","title":"The Phalen maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Phalen maneuver</div><div class=\"cntnt\"><img style=\"width:394px; height:284px;\" src=\"images/RHEUM/68440_Phalen_test_carpal_tunnel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with nerve compression in the carpal tunnel, acute wrist flexion maintained for 30 to 60 seconds reproduces symptoms.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 68440 Version 2.0</div></div></div>"},"68441":{"type":"graphic_figure","displayName":"Manual intraosseous needle placement","title":"Manual intraosseous needle placement","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Manual intraosseous needle placement</div><div class=\"cntnt\"><img style=\"width:502px; height:654px;\" src=\"images/EM/68441_ManualIOneedleplacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The needle is angled slightly away from the joint space or, as some more recent sources have recommended, perpendicular to the bone.<br> (B) A back-and-forth &quot;screwing&quot; motion is used to insert the needle. &quot;Rocking&quot; the needle from side to side results in enlargement of the puncture site and extravasation of infused fluid.<br> (C) Intramedullary placement is confirmed by aspirating marrow.</div><div class=\"graphic_reference\">Reproduced with permission from: Hodge D III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM, Eds. Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68441 Version 8.0</div></div></div>"},"68443":{"type":"graphic_figure","displayName":"HBV genotype distribution","title":"Map HBV genotype distribution","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Map HBV genotype distribution</div><div class=\"cntnt\"><img style=\"width:527px; height:329px;\" src=\"images/GAST/68443_HBV_genotype_distribution.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68443 Version 1.0</div></div></div>"},"68444":{"type":"graphic_picture","displayName":"Histoplasma from culture","title":"Histoplasma from culture","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Histoplasma from culture</div><div class=\"cntnt\"><img style=\"width:498px; height:366px;\" src=\"images/ID/68444_Histo_from_culture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure showing hyaline, septate hyphae, with spherical, thick-walled conidia and smaller microconidia.</div><div class=\"graphic_reference\">Courtesy of the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 68444 Version 3.0</div></div></div>"},"68445":{"type":"graphic_picture","displayName":"Renal atheroembolus toluidine blue","title":"Renal atheroembolus toluidine blue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal atheroembolus toluidine blue</div><div class=\"cntnt\"><img style=\"width:296px; height:252px;\" src=\"images/NEPH/68445_Atheroemboli_toluidine_blue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin section, toluidine blue stain shows the characteristic cholesterol clefts of an atheroembolus in the small renal artery.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 68445 Version 2.0</div></div></div>"},"68448":{"type":"graphic_diagnosticimage","displayName":"Aneurysmal bone cyst ulna","title":"Aneurysmal bone cyst periosteal reaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aneurysmal bone cyst periosteal reaction</div><div class=\"cntnt\"><img style=\"width:227px; height:386px;\" src=\"images/PEDS/68448_Aneurysmal_bone_cyst_ulna.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal ulna. Note the large, expansile aneurysmal bone cyst affecting the distal portion of the ulna. Periosteal new bone formation near the peripheral margins of the lesion creates a buttressing effect, which is characteristic of aneurysmal bone cyst (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68448 Version 2.0</div></div></div>"},"68450":{"type":"graphic_diagnosticimage","displayName":"M-mode subcostal view IVC","title":"M-mode echocardiogram from the subcostal position showing variation in IVC size with respiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram from the subcostal position showing variation in IVC size with respiration</div><div class=\"cntnt\"><img style=\"width:253px; height:342px;\" src=\"images/CARD/68450_Subcostal_IVC_RA_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inferior vena cave (IVC) can be imaged by aligning the ultrasound beam plane parallel to the long axis of the body and placing the transducer subcostally just to the right of the midline (panel A); the white line running through the image is the beam plane used to generate the M-modes of the inferior vena cave (panels B and C). In panel B, the IVC is dilated and its collapse or narrowing in response to respiration blunted; the hepatic veins (HV) are also dilated. In panel C, the IVC is of normal size and responds normally to respiration. When the IV (RA) pressure is usually around 20 mmHg or greater; the RA pressure is usually 0 to 5 mmHg when the IVC diameter is small and good respiratory response is seen.</div><div id=\"graphicVersion\">Graphic 68450 Version 4.0</div></div></div>"},"68451":{"type":"graphic_figure","displayName":"Outlet view for radiograph of pelvis","title":"Outlet view for radiograph of pelvis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Outlet view for radiograph of pelvis</div><div class=\"cntnt\"><img style=\"width:526px; height:340px;\" src=\"images/EM/68451_Pelvic_outlet_view_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The outlet view of the pelvis is performed with the x-ray beam oriented 40 degrees cephalad.</div><div class=\"graphic_reference\">Reproduced with permission from: Gibbs, MA, Bosse, MJ. Pelvic Ring Fractures. In: Trauma Management: An Emergency Medicine Approach, Ferrara, PC, Colucciello, SA, Marx, JA, Verdile, VP, Gibbs, MA (Eds), Mosby, St. Louis 2001. p. 331. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright ©2001 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 68451 Version 4.0</div></div></div>"},"68454":{"type":"graphic_algorithm","displayName":"Algorithm for the evaluation of flushing","title":"Evaluation of flushing","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Evaluation of flushing</div><div class=\"cntnt\"><img style=\"width:622px; height:821px;\" src=\"images/PC/68454_Algoevalflushinged2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">5-HIAA: 5-hydroxyindoleoacetic acid; CBC: complete blood count; LFT: liver function test; VIP: vasoactive intestinal polypeptide.</div><div id=\"graphicVersion\">Graphic 68454 Version 8.0</div></div></div>"},"68456":{"type":"graphic_figure","displayName":"Precipitin curve: Influence of antigen to antibody ratio","title":"Precipitin curve: Influence of antigen to antibody ratio","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Precipitin curve: Influence of antigen to antibody ratio</div><div class=\"cntnt\"><img style=\"width:496px; height:360px;\" src=\"images/RHEUM/68456_Precipitin_curve_immune_com.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Heidelberger precipitin curve demonstrates the influence of antigen:antibody ratios on the size of immune complexes and amount of precipitated immune complexes. The antigens and antibodies circled with dashed lines are in precipitates. Other antigens and antibodies remain in solution.</div><div id=\"graphicVersion\">Graphic 68456 Version 3.0</div></div></div>"},"68457":{"type":"graphic_figure","displayName":"Reported cases of tularemia in United States from 2001-2010","title":"Reported cases of tularemia, United States, 2001-2010","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Reported cases of tularemia, United States, 2001-2010</div><div class=\"cntnt\"><img style=\"width:614px; height:446px;\" src=\"images/ID/68457_Tularemia_in_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One dot placed randomly within county of residence for each confirmed case. Tularemia has been reported from all states except Hawaii, but is most common in the south central United States, the Pacific Northwest, and parts of Massachusetts, including Martha's Vineyard.</div><div class=\"graphic_reference\">Reproduced from: Reported cases of tularemia, United States, 2001-2010. Centers for Disease Control and Prevention. <A href=\"http://www.cdc.gov/tularemia/statistics/map.html\" target=_blank>http://www.cdc.gov/tularemia/statistics/map.html</A>. (Access on September 10, 2013).</div><div id=\"graphicVersion\">Graphic 68457 Version 4.0</div></div></div>"},"68458":{"type":"graphic_picture","displayName":"Toxic epidermal necrolysis - back","title":"Toxic epidermal necrolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68458_Toxicepidnecrolysisback.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and large areas of denuded epidermis are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68458 Version 6.0</div></div></div>"},"68461":{"type":"graphic_figure","displayName":"DHR test","title":"DHR test","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">DHR test</div><div class=\"cntnt\"><img style=\"width:606px; height:771px;\" src=\"images/ALLRG/68461_DHR_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dihydrorhodamine (DHR)&nbsp;assay for chronic granulomatous disease (CGD) diagnosis. Unstimulated (left) and phorbol myristate acetate (PMA)&nbsp;stimulated (right) neutrophils are shown. Y axis is number of events, X axis is fluorescence intensity shown on a log scale. In the normal (top panels) there is a rightward shift seen with stimulation. In the X-linked CGD carrier state (second row), there are&nbsp;two populations seen: one is normally fluorescent, while the other is essentially the same as the unstimulated population. In the patient with X-linked CGD (third row) there is no shift in fluorescence with stimulation. In the patient with the autosomal recessive p47phox deficiency (fourth row), the rightward shift seen with stimulation is abnormally broad and not very bright.</div><div class=\"graphic_footnotes\">DHR: dihydrorhodamine; PMA: phorbol myristate acetate; X-CGD: X-linked chronic granulomatous disease; gp91: 91 kiloDalton glycoprotein (an enzyme that is part of the phagocyte oxidase system); p47phox: 47 kiloDalton phagocyte oxidase protein; CGD: chronic granulomatous disease.</div><div class=\"graphic_reference\">Tracings courtesy of Dr. Douglas B Kuhns, SAIC Frederick.</div><div id=\"graphicVersion\">Graphic 68461 Version 2.0</div></div></div>"},"68462":{"type":"graphic_table","displayName":"Antiseizure drugs in children part I","title":"Oral drug maintenance therapy for seizures in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral drug maintenance therapy for seizures in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"16%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"3\">Dose*</td> <td class=\"subtitle1\" rowspan=\"2\">Blood level</td> <td class=\"subtitle1\" rowspan=\"2\">Laboratory<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Starting</td> <td class=\"subtitle2\">Maintenance</td> <td class=\"subtitle2\">Frequency</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine (CBZ)</td> <td>10 to 20 mg/kg/day</td> <td>10 to 35 mg/kg/day (maximum in children &#8804;15 years: Lower of 35 mg/kg or 1000 mg/day; maximum in &#62;15 years: 1200 mg/day)</td> <td>Dosed three or four times daily (for IR or oral suspension); once or twice daily (for ER)</td> <td>4 to 12 mcg/mL (17 to 51 micromol/L)</td> <td> <p>HLA-B*1502 screening before starting if of Asian descent; CBC after four to six weeks, then as needed. If initial WBC low (particularly ANC), repeat as needed. CBZ level at three, six, and nine weeks; then at least every two months until stable.</p> Serum sodium prior to initiation, at maintenance dose, and as needed in patients at risk for, or with symptoms of, hyponatremia.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Clobazam</td> <td>Children &#60;2 years: 0.5 to 1 mg/kg/day (maximum: 5 mg/day)</td> <td>Children &#60;2 years: 0.5 to 1 mg/kg/day (maximum: 10 mg/day)</td> <td class=\"divider_bottom\" rowspan=\"2\">Dosed once or twice daily</td> <td class=\"divider_bottom\" rowspan=\"2\">Not useful</td> <td class=\"divider_bottom\" rowspan=\"2\">Routine lab tests not recommended.</td> </tr> <tr class=\"divider_bottom\"> <td>Children 2 to 16 years: 5 mg/day</td> <td>Children 2 to 16 years: 10 to 20 mg/day (maximum: 40 mg/day)</td> </tr> <tr class=\"divider_bottom\"> <td>Clonazepam</td> <td>0.01 to 0.03 mg/kg/day (maximum: Lower of 0.05 mg/kg/day or 1 mg/day)</td> <td>0.05 to 0.2 mg/kg/day (maximum: Lower of 0.2 mg/kg/day or 20 mg/day)</td> <td>Dosed two or three times daily</td> <td>Not useful</td> <td>Routine lab tests not recommended.</td> </tr> <tr class=\"divider_bottom\"> <td>Clorazepate</td> <td>0.3 mg/kg/day</td> <td>0.5 to 3 mg/kg/day (maximum in children 9 to 12 years: 60 mg/day; maximum in &#62;12 years: 90 mg/day)</td> <td>Dosed two or three times daily</td> <td>Not useful</td> <td>Routine lab tests not recommended.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Eslicarbazepine<sup>&#916;</sup></td> <td>Children 11 to 21 kg: 200 mg/day</td> <td>Children 11 to 21 kg: Range 400 to 600 mg/day (titrate in 200 mg increments at intervals of seven days or more)</td> <td class=\"divider_bottom\" rowspan=\"4\">Dosed once daily</td> <td class=\"divider_bottom\" rowspan=\"4\">Not well established</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Serum sodium prior to initiation, at maintenance dose, and as needed in patients at risk for, or with symptoms of, hyponatremia.</p> Eslicarbazepine is structurally similar to carbamazepine and oxcarbazepine. However, role of HLA-B*1502 screening if of Asian descent is not yet established.</td> </tr> <tr> <td>Children 22 to 31 kg: 300 mg/day</td> <td>Children 22 to 31 kg: Range 500 to 800 mg/day (titrate in 300 mg increments at intervals of seven days or more)</td> </tr> <tr> <td>Children 32 to 38 kg: 300 mg/day</td> <td>Children 32 to 38 kg: Range 600 to 900 mg/day (titrate in 300 mg increments at intervals of seven days or more)</td> </tr> <tr class=\"divider_bottom\"> <td>Children &#62;38 kg: 400 mg/day</td> <td>Children &#62;38 kg: Range 800 to 1200 mg/day (titrate in 400 mg increments at intervals of seven days or more)</td> </tr> <tr class=\"divider_bottom\"> <td>Ethosuximide</td> <td>15 mg/kg/day (maximum: 500 mg/day)</td> <td>15 to 40 mg/kg/day (maximum: 1500 mg/day)</td> <td>Dosed once or twice daily</td> <td>40 to 100 mcg/mL (280 to 700 micromol/L)</td> <td>CBC/platelets after first one to two months, as needed thereafter; ethosuximide level at one to three weeks.</td> </tr> <tr class=\"divider_bottom\"> <td>Felbamate</td> <td>15 mg/kg/day (maximum: 1200 mg/day)</td> <td>15 to 45 mg/kg/day (maximum: Lower of 45 mg/kg/day or 3600 mg/day)</td> <td>Dosed three or four times daily</td> <td>Not well established; 50 to 100 mcg/mL (210 to 420 micromol/L) has been proposed</td> <td>CBC/platelets every two to four weeks; hepatic function tests every month.</td> </tr> <tr class=\"divider_bottom\"> <td>Gabapentin</td> <td>10 to 15 mg/kg/day; may titrate to initial dose over three days (maximum: 900 mg/day)</td> <td>40 to 50 mg/kg/day (maximum: Lower of 70 mg/kg/day or 4800 mg/day)</td> <td>Dosed three times daily (for IR)</td> <td>Not useful</td> <td>CBC/platelets every three months for first six months; chemical panel as needed (routine monitoring may not be necessary).</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Lacosamide</td> <td>Children 11 to 29 kg: 2 mg/kg/day</td> <td>Children 11 to 29 kg: Range 6 to 12 mg/kg/day (titrate in 2 mg/kg/day increments at intervals of seven days or more)</td> <td class=\"divider_bottom\" rowspan=\"3\">Dosed twice daily</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Not useful</p> <p>OR</p> Not well established; 1.8 to 7.2 mcg/mL (10 to 40 micromol/L) has been proposed</td> <td class=\"divider_bottom\" rowspan=\"3\">Routine lab tests not recommended.<sup>&#9674;</sup></td> </tr> <tr> <td>Children 30 to 49 kg: 2 mg/kg/day</td> <td>Children 30 to 49 kg: Range 4 to 8 mg/kg/day (titrate in 2 mg/kg/day increments at intervals of seven days or more)</td> </tr> <tr class=\"divider_bottom\"> <td>Children &#8805;50 kg: 50 mg twice daily</td> <td> <p>Children &#8805;50 kg:</p> <p class=\"indent1\">Monotherapy: Range 300 to 400 mg/day (titrate in 100 mg/day increments at intervals of seven days or more)</p> <p class=\"indent1\">Adjunctive therapy: Range 200 to 400 mg/day (titrate in 100 mg/day increments at intervals of seven days or more)</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Lamotrigine<sup>&#167;</sup></td> <td>Monotherapy: 0.3 mg/kg/day</td> <td>4.5 to 7.5 mg/kg/day (maximum: 300 mg/day)</td> <td class=\"divider_bottom\" rowspan=\"3\">Dosed twice daily (for IR) or once daily (for ER)</td> <td class=\"divider_bottom\" rowspan=\"3\">Not well established; 1.5 to 10 mcg/mL (5.85 to 39 micromol/L) has been proposed</td> <td class=\"divider_bottom\" rowspan=\"3\">CBC/platelets every three months for first six months; chemical panel as needed (routine monitoring may not be necessary).</td> </tr> <tr> <td>Added to VPA: 0.15 mg/kg/day</td> <td>1 to 5 mg/kg/day (maximum: 200 mg/day)</td> </tr> <tr class=\"divider_bottom\"> <td>Added to inducer (PB, CBZ, PHT): 0.6 mg/kg/day</td> <td>5 to 15 mg/kg/day (maximum: 400 mg/day)</td> </tr> <tr> <td>Levetiracetam</td> <td>20 mg/kg/day (maximum: 1000 mg/day)</td> <td>40 to 60 mg/kg/day (maximum: 3000 mg/day)</td> <td>Dosed twice daily (for IR) or once daily (for ER)</td> <td>Not useful</td> <td>Routine lab tests not recommended.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Usual range of initial and maintenance doses of antiepileptic drugs (AEDs) in children with seizures. Dose adjustment and additional monitoring may be needed when therapy is altered, particularly in combination regimens including enzyme-inducing AEDs or valproate, and in children with organ dysfunction. Refer to accompanying text and Lexicomp pediatric drug-specific monographs included within UpToDate.</div><div class=\"graphic_footnotes\">IR: immediate release; ER: extended release; CBC: complete blood count; WBC: white blood cell; ANC: absolute neutrophil count; VPA: valproate; PB: phenobarbital; PHT: phenytoin.<br />* In general, the pediatric dose should not exceed the higher end of the adult dose range (shown in parentheses as the maximum dose). On a milligram per kilogram basis, doses of some of the antiepileptic drugs needed to obtain a similar blood concentration in children are greater than those for adolescents and adults.<br />¶ Additional laboratory monitoring recommendations may be contained in the approved product information in some countries; consult local product information.<br />Δ Dosing for children &gt;4 years of age. Eslicarbazepine has not been approved by the US FDA for use in children ≤4 years.<br /><FONT class=lozenge>◊</FONT> In patients with cardiac conduction abnormalities or other significant heart disease, an electrocardiogram is recommended prior to starting lacosamide and after maintenance dose is reached.<br />§ Dosing for children 2 to 12 years of age. The extended-release preparation of lamotrigine has not been approved by US FDA for use in children ≤12 years.</div><div id=\"graphicVersion\">Graphic 68462 Version 10.0</div></div></div>"},"68463":{"type":"graphic_table","displayName":"Integration GAPS routine care","title":"Steps for successful integration of comprehensive adolescent preventive services into routine medical care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steps for successful integration of comprehensive adolescent preventive services into routine medical care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">1. Conduct a needs assessment</td> </tr> <tr> <td class=\"sublist2_start\">How many adolescent patients are seen in the practice?</td> </tr> <tr> <td class=\"sublist2\">- What are their ages?</td> </tr> <tr> <td class=\"sublist2\">- What are their problems?</td> </tr> <tr> <td class=\"indent1\">What are the current preventive service practice patterns of the practitioners?</td> </tr> <tr> <td class=\"subtitle2_left\">2. Determine clinic readiness to make a systems change</td> </tr> <tr> <td class=\"indent1\">Are adolescent preventive services an important aspect of care for the staff and the clinic?</td> </tr> <tr> <td class=\"indent1\">Are adequate resources available, such as health education materials and questionnaires?</td> </tr> <tr> <td class=\"indent1\">Are the administrators supportive of change?</td> </tr> <tr> <td class=\"subtitle2_left\">3. Identify a staff prevention coordinator and specify roles and responsibilities:</td> </tr> <tr> <td class=\"indent1\">Setting goals for the implementation process</td> </tr> <tr> <td class=\"indent1\">Coordinating implementation activities</td> </tr> <tr> <td class=\"indent1\">Establishing a tracking system</td> </tr> <tr> <td class=\"indent1\">Ensuring new staff are trained</td> </tr> <tr> <td class=\"indent1\">Conducting quality assurance</td> </tr> <tr> <td class=\"subtitle2_left\">4. Identify a set of preventive services guidelines to be used by the clinic</td> </tr> <tr> <td class=\"subtitle2_left\">5. Develop clinic procedures and protocols to address the following issues:</td> </tr> <tr> <td class=\"indent1\">How will privacy and confidentiality be handled?</td> </tr> <tr> <td class=\"indent1\">How will screening questionnaires be used?</td> </tr> <tr> <td class=\"indent1\">Who will provide health guidance? Health risk reduction counseling?</td> </tr> <tr> <td class=\"subtitle2_left\">6. Provide staff training and preparation</td> </tr> <tr> <td class=\"subtitle2_left\">7. Identify and promote mechanisms to maximize reimbursement for preventive services</td> </tr> <tr> <td class=\"indent1\">Appropriate use of Current Procedural Terminology (CPT) codes</td> </tr> <tr> <td class=\"subtitle2_left\">8. Establish school and community referral sources</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=53300&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">GAPS: Guidelines for Adolescent Preventive Services.</div><div id=\"graphicVersion\">Graphic 68463 Version 4.0</div></div></div>"},"68465":{"type":"graphic_figure","displayName":"Mandible fracture epidemiology","title":"Mandible fracture epidemiology","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Mandible fracture epidemiology</div><div class=\"cntnt\"><img style=\"width:503px; height:355px;\" src=\"images/EM/68465_Mandible_fx_epidemiology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mandible fractures: sites and incidence.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68465 Version 2.0</div></div></div>"},"68466":{"type":"graphic_figure","displayName":"Passing endotracheal tube","title":"Technique for passing the endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Technique for passing the endotracheal tube</div><div class=\"cntnt\"><img style=\"width:526px; height:219px;\" src=\"images/EM/68466_Passing_ETT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endotracheal tube is rotated 90 degrees counterclockwise (B) as it is passed through the cords, changing the initial horizontal (widest) axis of the bevel (A) to the vertical (narrowest) axis (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Brown CA, Carleton SC, Reardon RF. Supplemental Oxygen. In: Manual of Emergency Airway Management, 4th ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.&nbsp;</div><div id=\"graphicVersion\">Graphic 68466 Version 13.0</div></div></div>"},"68468":{"type":"graphic_picture","displayName":"Sharp curettes","title":"Sharp uterine curettes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sharp uterine curettes</div><div class=\"cntnt\"><img style=\"width:264px; height:456px;\" src=\"images/OBGYN/68468_Sharp_curettes.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68468 Version 3.0</div></div></div>"},"68469":{"type":"graphic_diagnosticimage","displayName":"AC osteoarthritis plain xray","title":"Acromioclavicular osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular osteoarthritis</div><div class=\"cntnt\"><img style=\"width:371px; height:375px;\" src=\"images/PC/68469_AC_osteoarthritis_plain_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain x-ray demonstrates inferiorly directed osteophytes consistent with acromioclavicular (AC) osteoarthritis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 68469 Version 2.0</div></div></div>"},"68470":{"type":"graphic_figure","displayName":"Endotrach tube neck movement","title":"Endotracheal tube with movement of the neck","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube with movement of the neck</div><div class=\"cntnt\"><img style=\"width:521px; height:218px;\" src=\"images/PULM/68470_Endotrach_tube_neck_movemen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows the position of the tip of the endotracheal tube with the neck in neutral position. The tip of the tube follows the movement of the chin. The tube moves away from the carina with extension of the neck (B) and toward the carina with flexion (C) of the neck.</div><div id=\"graphicVersion\">Graphic 68470 Version 1.0</div></div></div>"},"68475":{"type":"graphic_table","displayName":"Eval isolated transaminitis","title":"Evaluation of isolated mild chronic elevation of serum aminotransferases*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of isolated mild chronic elevation of serum aminotransferases*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Step 1: Initial evaluation</td> </tr> <tr> <td class=\"indent1\">Review possible links to medications, herbal therapies, or recreational drugs</td> </tr> <tr> <td class=\"indent1\">Screen for alcohol abuse (history, screening instruments, AST/ALT ratio &#62;2:1)</td> </tr> <tr> <td class=\"indent1\">Obtain serology for hepatitis B and C (HBsAg, anti-HBs, anti-HBc, anti-HCV)</td> </tr> <tr> <td class=\"indent1\">Screen for hemochromatosis (Fe/TIBC &#62;45 percent)</td> </tr> <tr> <td class=\"indent1\">Evaluate for fatty liver (AST/ALT usually &#60;1, obtain RUQ ultrasonography)</td> </tr> <tr> <td class=\"subtitle1_single\">Step 2: Second-line evaluation (if initial evaluation is unrevealing)</td> </tr> <tr> <td class=\"indent1\">Consider autoimmune hepatitis, particularly in women and in those with a history of other autoimmune disorders (check serum protein electrophoresis; obtain ANA and ASMA if positive)</td> </tr> <tr> <td class=\"indent1\">Obtain thyroid function tests (TSH if hypothyroidism is suspected; otherwise, obtain serum TSH, free T4, and T3 concentrations)</td> </tr> <tr> <td class=\"indent1\">Consider celiac disease (especially in patients with a history of diarrhea or unexplained iron deficiency: serum IgA anti-tissue transglutaminase antibodies)</td> </tr> <tr> <td class=\"subtitle1_single\">Step 3: Evaluation for uncommon causes (if second-line evaluation is unrevealing)</td> </tr> <tr> <td class=\"indent1\">Consider Wilson disease, especially in those &#60;40 years of age (check serum ceruloplasmin, evaluate for Kayser-Fleischer rings)</td> </tr> <tr> <td class=\"indent1\">Consider alpha-1 antitrypsin deficiency, especially in patients with a history of emphysema out of proportion to their age or smoking history (obtain alpha-1 antitrypsin level)</td> </tr> <tr> <td class=\"indent1\">Consider adrenal insufficiency (8 am serum cortisol and plasma ACTH, high-dose ACTH stimulation test)</td> </tr> <tr> <td class=\"indent1\">Exclude muscle disorders (obtain creatine kinase or aldolase)</td> </tr> <tr> <td class=\"subtitle1_single\">Step 4: Obtain a liver biopsy or observe (if no source identified after steps 1 to 3)</td> </tr> <tr> <td class=\"indent1\">Observe if ALT and AST are less than twofold elevated</td> </tr> <tr> <td class=\"indent1\">Otherwise, consider a liver biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AST: aspartate aminotransferase; ALT: alanine aminotransferase; HBsAg: hepatitis B surface antigen; anti-HBs: antibody to hepatitis B surface antigen; anti-HBc: antibody to hepatitis B core antigen; anti-HCV: antibody to hepatitis C virus; Fe: iron; TIBC: total iron binding capacity; RUQ: right upper quadrant; ANA: antinuclear antibodies; ASMA: anti-smooth muscle antibodies; TSH: thyroid-stimulating hormone; IgA: immunoglobulin A; ACTH: corticotropin.&nbsp;<br />* Mild is defined as between 2 and 10 times the upper limit of normal; chronic is defined as more than six months.</div><div id=\"graphicVersion\">Graphic 68475 Version 10.0</div></div></div>"},"68478":{"type":"graphic_figure","displayName":"CDC BMI for age girls 2 to 20 years","title":"Body mass index-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Body mass index-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:549px; height:669px;\" src=\"images/PEDS/68478_BMI_age_girls_2_20_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; CDC: Centers for Disease Control.</div><div class=\"graphic_reference\">Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 68478 Version 5.0</div></div></div>"},"68479":{"type":"graphic_figure","displayName":"World trends in prevalence of childhood overweight","title":"Changes in prevalence of childhood overweight over time in selected countries","html":"<div class=\"graphic\"><div style=\"width: 717px\" class=\"figure\"><div class=\"ttl\">Changes in prevalence of childhood overweight over time in selected countries</div><div class=\"cntnt\"><img style=\"width:697px; height:339px;\" src=\"images/PEDS/68479_Wrld_trnd_prvlnc_chld_ovrwt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For this figure, the prevalence of overweight children is defined as the percent of children with body mass index (BMI) ≥85th percentile, using the standards from the International Obesity Task Force (IOTF). The countries are selected on the appropriateness and availability of the data. The surveys are not strictly comparable because of differences in age range and methodology. With the limited data available, prevalences are not age-standardized.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 World Obesity Federation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68479 Version 5.0</div></div></div>"},"68480":{"type":"graphic_picture","displayName":"Long term tubes","title":"Long-term tympanostomy tubes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long-term tympanostomy tubes</div><div class=\"cntnt\"><img style=\"width:288px; height:410px;\" src=\"images/PEDS/68480_Longtermtubes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term tympanostomy tubes are intended to remain in the eardrum for 15 months or longer. They include butterfly (B), Paparella (P), and T-tube (T).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 68480 Version 13.0</div></div></div>"},"68481":{"type":"graphic_figure","displayName":"Schematic of transmyocardial laser revascularization","title":"Schematic of percutaneous myocardial revascularization","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Schematic of percutaneous myocardial revascularization</div><div class=\"cntnt\"><img style=\"width:474px; height:303px;\" src=\"images/CARD/68481_Transmyocardial_laser_revas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous myocardial revascularization can be performed in the catheterization laboratory, via standard femoral artery access without general anesthesia, after a ventriculogram and coronary angiogram demonstrate the left ventricular and coroanry artery anatomy. A steerable catheter is delivered retrograde across the aortic valve; the energy delivery catheter is advanced through the guiding catheter and placed in the ventricular chamber. The steerable catheter allows access to the endocardial surface (left panel). The enlarged area (right panel) shows that intramyocardial channels are made by tissue ablation (red arrow) when the energy delivery catheter is in contact with the endocardium; the channels cause intramyocardial hemorrhage by transecting the microvasculature (blue arrow).</div><div class=\"graphic_footnotes\">V: epicardial vein; A: epicardial artery.</div><div class=\"graphic_reference\">Reproduced with permission from Kantor B, McKenna CJ, Caccitolo JA, et al. Mayo Clin Proc 1999; 74:585.</div><div id=\"graphicVersion\">Graphic 68481 Version 3.0</div></div></div>"},"68482":{"type":"graphic_table","displayName":"Metformin toxicity - Rapid overview","title":"Metformin toxicity: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metformin toxicity: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">General information</td> </tr> <tr> <td>Metformin is an antihyperglycemic agent whose major toxicity is lactic acidosis, which can occur with renal insufficiency, liver disease, and hemodynamic instability</td> </tr> <tr> <td>Metformin may exacerbate hypoglycemia caused by other agents; taken alone it almost never causes hypoglycemia</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Patients with metformin-induced lactic acidosis may complain of nausea and abdominal pain</td> </tr> <tr> <td>Examination findings may include tachycardia, tachypnea, and hyperpnea</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>For all poisoned patients, obtain: fingerstick glucose; ECG; acetaminophen and aspirin blood concentrations; serum pregnancy test in women of childbearing age</td> </tr> <tr> <td>For suspected metformin toxicity, obtain: basic serum electrolytes, BUN and creatinine, serum bicarbonate, and serum lactate</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Secure airway, breathing, and circulation</td> </tr> <tr> <td>For acute ingestions, give activated charcoal: 1 g/kg (generally 50 g in adults); Do <strong>not</strong> give activated charcoal to patients with chronic toxicity</td> </tr> <tr> <td>For patients with profound acidosis (pH &#60;7.10), consider sodium bicarbonate infusion (eg, give 1 to 2 meq/kg IV push; then put approximately 133 meq NaHCO3 in one liter D5W, run at 250 mL/hour in adults, or twice maintenance fluid infusion rate in children)</td> </tr> <tr> <td>For patients with profound acidosis, highly elevated lactate, renal disease, or critical illness, obtain immediate nephrology consultation; hemodialysis will correct metformin-induced acid-base disturbance and slightly increase metformin clearance</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68482 Version 7.0</div></div></div>"},"68483":{"type":"graphic_figure","displayName":"Ossification centers patella","title":"Saupe's classification of accessory ossification centers of the patella","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Saupe's classification of accessory ossification centers of the patella</div><div class=\"cntnt\"><img style=\"width:456px; height:168px;\" src=\"images/EM/68483_Ossification_centers_patell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type III accounts for 75 percent of bipartite patella (see text).</div><div id=\"graphicVersion\">Graphic 68483 Version 1.0</div></div></div>"},"68484":{"type":"graphic_figure","displayName":"Space between rectum and vagina","title":"Taking the uterosacral ligaments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Taking the uterosacral ligaments</div><div class=\"cntnt\"><img style=\"width:449px; height:304px;\" src=\"images/OBGYN/68484_Space_between_rectum_and_va.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharp dissection is used to incise the peritoneum between two uterosacral ligaments, and to develop the potential space between the posterior vagina and the anterior rectum. The uterosacral ligaments are then clamped laterally at their origin and divided, as is the posterior aspect of the parametrium.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68484 Version 1.0</div></div></div>"},"68485":{"type":"graphic_diagnosticimage","displayName":"US and intraop MCDK","title":"Multicystic dysplastic kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multicystic dysplastic kidney</div><div class=\"cntnt\"><img style=\"width:318px; height:316px;\" src=\"images/PEDS/68485_US_and_intraop_MCDK.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative multicystic dysplastic kidney and its corresponding ultrasound images.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 68485 Version 3.0</div></div></div>"},"68486":{"type":"graphic_figure","displayName":"Esophageal vs reflux parameters","title":"Reflux parameters in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reflux parameters in asthma</div><div class=\"cntnt\"><img style=\"width:246px; height:540px;\" src=\"images/PULM/68486_Esophageal_vs_reflux_parame.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower esophageal sphincter pressure (top panel) and reflux parameters, number of episodes per hour and percent time that esophageal pH was below 4.0 (middle and lower panels) in patients with asthma and control subjects. Compared to controls, asthmatics had significantly decreased lower esophageal sphincter pressure, more frequent reflux episodes, and higher esophageal acid contact times.</div><div class=\"graphic_reference\">Redrawn from Sontag SJ, O'Connell S, Khandelwal S. Gastroenterology 1990; 99:613.</div><div id=\"graphicVersion\">Graphic 68486 Version 2.0</div></div></div>"},"68487":{"type":"graphic_diagnosticimage","displayName":"RB ILD CT I","title":"Respiratory bronchiolitis-associated interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory bronchiolitis-associated interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:374px; height:220px;\" src=\"images/PULM/68487_RB_ILD_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan (5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion shows extensive ground-glass opacities. The plain chest film was normal. The diagnosis was confirmed by open lung biopsy. Symptoms improved following smoking cessation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 68487 Version 3.0</div></div></div>"},"68488":{"type":"graphic_picture","displayName":"Keratosis pilaris dark skin","title":"Keratosis pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68488_Keratosispilarisdarkskin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratosis pilaris. Close view of multiple follicularly-based, hyperpigmented papules on arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68488 Version 5.0</div></div></div>"},"68490":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid squamous metaplasia","title":"Ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/68490_Ocular_squamous_metaplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin, 100x. Note the squamous metaplasia, with loss of nuclei in the superficial layers of the conjunctival epithelium.</div><div id=\"graphicVersion\">Graphic 68490 Version 1.0</div></div></div>"},"68491":{"type":"graphic_diagnosticimage","displayName":"Pneumobilia due to gallstone ileus","title":"Pneumobilia due to gallstone ileus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumobilia due to gallstone ileus</div><div class=\"cntnt\"><img style=\"width:307px; height:391px;\" src=\"images/GAST/68491_Pneumobilia_gallstone_ileus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the abdomen showing air in the intrahepatic biliary tree (arrows) and dilated loops of small bowel. Pneumobilia implies either a patent cystic duct or a fistula involving the common bile duct. The gallstone cannot be identified on this film. This is a common finding that is due to two factors: most stones are radiolucent; and gas or bony structures can obscure gallstones outside the biliary tree.</div><div class=\"graphic_reference\">Courtesy of Nezam Afdhal, MD.</div><div id=\"graphicVersion\">Graphic 68491 Version 4.0</div></div></div>"},"68492":{"type":"graphic_picture","displayName":"Kidney glomerulus EHEC","title":"Renal lesion in fatal hemolytic-uremic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal lesion in fatal hemolytic-uremic syndrome</div><div class=\"cntnt\"><img style=\"width:315px; height:422px;\" src=\"images/ID/68492_Kidney_glomerulus_EHEC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thrombus (arrow) in a glomerular arteriole in a child who died with fulminant postdiarrhoeal hemolytic-uremic syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 68492 Version 3.0</div></div></div>"},"68493":{"type":"graphic_movie","displayName":"Dilated cardiomyopathy short axis echocardiogram","title":"Dilated cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilated cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68493_shaxdicmconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:271px; height:207px;\" src=\"images/CARD/68493_shaxdicm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short axis view from a 2-D echocardiogram of a dilated cardiomyopathy shows marked left dilatation of the left ventricle which is diffusely hypokinetic.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 68493 Version 2.0</div></div></div>"},"68495":{"type":"graphic_diagnosticimage","displayName":"Dobutamine stress CMR predicts lack of viable myocardium","title":"Dobutamine stress CMR predicts lack of viable myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dobutamine stress CMR predicts lack of viable myocardium</div><div class=\"cntnt\"><img style=\"width:444px; height:202px;\" src=\"images/CARD/68495_Dobutamine_MRI_LV_scar_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dobutamine stress CMR studies in a patient with three vessel disease and a prior anterior wall myocardial infarction.<br />(Left upper panel) At rest, the short axis CMR during diastole shows that the diastolic wall thickness (DWT) of the anteroseptal wall is significantly reduced (arrows).<br />(Left lower panel) The entire region shows a lack of systolic wall thickening (SWT).<br />(Middle lower panel) During a dobutamine infusion, there was no measurable increase in SWT of the anteroseptal wall, indicating scar tissue.<br />(Right upper and lower panel) Six months after successful bypass surgery (CABG), the reduction in DWT persisted (arrows, upper panel) there was no improvement in SWT.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance. </div><div class=\"graphic_reference\">Reprinted with permission from: The American College of Cardiology (Journal of the American College of Cardiology 1998; 31:1040).</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 68495 Version 5.0</div></div></div>"},"68496":{"type":"graphic_table","displayName":"First SCD risk Brugada syndrome","title":"Probability of SCD or VF during follow-up (mean 24 months) in 547 patients with type 1 Brugada syndrome with no prior history of SCD: Risk increased with syncope, spontaneously abnormal ECG, and inducible sustained ventricular arrhythmia at EP testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of SCD or VF during follow-up (mean 24 months) in 547 patients with type 1 Brugada syndrome with no prior history of SCD: Risk increased with syncope, spontaneously abnormal ECG, and inducible sustained ventricular arrhythmia at EP testing</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    \n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Noninducible, percent (95% CI)</td>\n\n      <td class=\"subtitle1\">Inducible, percent (95% CI)</td>\n\n    </tr>\n\n    <tr><td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Prior syncope</td></tr><tr>\n\n      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">ECG</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Spontaneously abnormal </td>\n\n      <td class=\"sublist_other\">4.1 (1.4-11.7)</td>\n\n      <td class=\"sublist_other\">27.2 (17.3-40.0)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Abnormal after drug challenge</td>\n\n      <td class=\"sublist_other\">1.2 (0.2-6.6)</td>\n\n      <td class=\"sublist_other\">9.7 (2.3-33.1)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">No prior syncope</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">ECG</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Spontaneously abnormal </td>\n\n      <td class=\"sublist_other\">1.8 (0.6-5.1)</td>\n\n      <td class=\"sublist_other\">14.0 (8.1-23.0)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Abnormal after drug challenge</td>\n\n      <td class=\"sublist_other\">0.5 (0.1-2.7)</td>\n\n      <td class=\"sublist_other\">4.5 (1.0-17.1)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Brugada J, Brugada R, Brugada P. Circulation 2003; 108:3092.</div><div id=\"graphicVersion\">Graphic 68496 Version 2.0</div></div></div>"},"68498":{"type":"graphic_picture","displayName":"Gonorrhea penis edema and discharge","title":"Gonococcal urethritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gonococcal urethritis</div><div class=\"cntnt\"><img style=\"width:436px; height:382px;\" src=\"images/DERM/68498_Gono_penis_edema_discharge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 23-year-old man complained of profuse and purulent penile discharge with dysuria five days after unprotected sexual contact. Gram stain of the urethral discharge showed polymorphonuclear cells with intracellular Gram negative diplococci.</div><div class=\"graphic_reference\">Copyright © SV Rakhesh, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 68498 Version 5.0</div></div></div>"},"68499":{"type":"graphic_figure","displayName":"Tirofiban unstable angina PRISM","title":"Tirofiban reduces mortality in unstable angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tirofiban reduces mortality in unstable angina</div><div class=\"cntnt\"><img style=\"width:366px; height:261px;\" src=\"images/CARD/68499_Tirofiban_unstable_angina_P.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PRISM study randomly assigned 3232 patients with unstable angina to therapy with heparin or tirofiban. Tirofiban was associated with a significant reduction in 30-day mortality.</div><div class=\"graphic_reference\">Data from The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.</div><div id=\"graphicVersion\">Graphic 68499 Version 1.0</div></div></div>"},"68500":{"type":"graphic_figure","displayName":"Kidney embryology","title":"Embryology of the kidney","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Embryology of the kidney</div><div class=\"cntnt\"><img style=\"width:534px; height:587px;\" src=\"images/PEDS/68500_Kidney_embryology.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68500 Version 2.0</div></div></div>"},"68501":{"type":"graphic_table","displayName":"Viral encephalitis mimics","title":"Conditions that mimic viral encephalitis (all of these conditions require specific therapy)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions that mimic viral encephalitis (all of these conditions require specific therapy)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Potential clues</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Bacterial infections</td> </tr> <tr> <td class=\"indent1\">Bacterial meningitis</td> <td>Meningeal signs; CSF pleocytosis with predominance of polymorphonuclear cells</td> </tr> <tr> <td class=\"indent1\">CNS tuberculosis</td> <td>Residing in, travel to, or exposure to contact from endemic areas (Asia, Africa, Latin America, Eastern Europe); contact with an adult with tuberculosis; lacunar infarction; hydrocephalus; low CSF glucose and elevated CSF protein</td> </tr> <tr> <td class=\"indent1\">Parameningeal infection</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Listeriosis</td> <td>Age &#60;1 month; immune compromise; rhomboencephalitis (ataxia, cranial nerve deficits, nystagmus)</td> </tr> <tr> <td class=\"indent1\">Cat scratch disease</td> <td>Cat bite/scratch; regional lymphadenopathy; neuroretinitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Parasitic infections</td> </tr> <tr> <td class=\"indent1\">Amoebiasis</td> <td>Immune compromise; swimming in lakes/brackish water; travel to an endemic area; change in taste or smell</td> </tr> <tr> <td class=\"indent1\">Cerebral malaria</td> <td>Travel to endemic area without prophylaxis</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> <td>Immune compromise; extrapyramidal symptoms and signs</td> </tr> <tr> <td class=\"indent1\">Cysticercosis</td> <td>Travel to endemic area; seizures, hydrocephalus; ingestion of undercooked pork</td> </tr> <tr> <td class=\"indent1\">Echinococcus (tapeworm)</td> <td>Hydatid cysts</td> </tr> <tr> <td class=\"indent1\">Trichinosis</td> <td>Gastrointestinal symptoms (abdominal pain, nausea, vomiting, diarrhea); ingestion of bear meat or other potentially contaminated foods</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fungal infections</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> <td>Residing in or travel to endemic area (eastern and central US and Canada)</td> </tr> <tr> <td class=\"indent1\">Blastomycosis</td> <td>Residing in or travel to endemic area (in the US, southeastern, central, and states bordering the Great Lakes)</td> </tr> <tr> <td class=\"indent1\">Cryptococcus</td> <td>Immune compromise; exposure to bird droppings</td> </tr> <tr> <td class=\"indent1\">Coccidiomycosis</td> <td>Residing in or travel to endemic areas, such as the southwestern United States</td> </tr> <tr> <td class=\"indent1\">Candidiasis</td> <td>Immune compromise</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rickettsial infection</td> </tr> <tr> <td class=\"indent1\">Rocky Mountain spotted fever</td> <td>Tick exposure in endemic region; maculopapular/petechial rash; intractable seizures</td> </tr> <tr> <td class=\"indent1\">Murine typhus</td> <td>Flea exposure</td> </tr> <tr> <td class=\"indent1\">Q fever</td> <td>Exposure to cats, sheep, goats (particularly placental tissue, parturient fluids, newborn animals)</td> </tr> <tr> <td class=\"subtitle2_left\">Ehrlichiosis</td> <td>Tick exposure, rash, leukopenia, thrombocytopenia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other central nervous system conditions</td> </tr> <tr> <td class=\"indent1\">Head trauma</td> <td>History of trauma (may be absent in child abuse)</td> </tr> <tr> <td class=\"indent1\">Hypertensive encephalopathy&nbsp;</td> <td>Hypertension; exclusion of other causes&nbsp;</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage</td> <td>Neuroimaging; intracranial hemorrhage may be an indication for lumbar puncture</td> </tr> <tr> <td class=\"indent1\">Intracranial thrombosis</td> <td>Neuroimaging</td> </tr> <tr> <td class=\"indent1\">Idiopathic intracranial hypertension (pseudotumor cerebri)</td> <td>Visual obscurations, diplopia, cranial nerve palsy; papilledema; increased opening pressure during lumbar puncture</td> </tr> <tr> <td class=\"indent1\">Status epilepticus (especially nonconvulsive seizures)</td> <td>Electroencephalogram</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> <td>Arthritis, nephritis, dermatitis, leukopenia</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa&nbsp;</td> <td>Fever, weight loss, dermatitis, eosinophilia</td> </tr> <tr> <td class=\"indent1\">Acute disseminated encephalomyelitis (ADEM, postinfectious encephalitis)</td> <td>History of recent infection or immunization; multifocal neurologic signs and symptoms; neuroimaging</td> </tr> <tr> <td class=\"indent1\">Tumor</td> <td>Neuroimaging; increased opening pressure during lumbar puncture (however, lumbar puncture usually is not performed if a tumor is suspected)</td> </tr> <tr> <td class=\"indent1\">Acute confusional migraine</td> <td>History of migraine headaches; exclusion of other causes</td> </tr> <tr> <td class=\"indent1\">Anti-N-methyl-D-asparate receptor&nbsp;encephalitis*</td> <td>No identifiable infectious etiology; encephalitis with psychiatric manifestations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> <td>Serum glucose</td> </tr> <tr> <td class=\"indent1\">Uremic encephalopathy</td> <td>Elevation of blood urea nitrogen, creatinine</td> </tr> <tr> <td class=\"indent1\">Hepatic encephalopathy</td> <td>Elevation of serum aminotransferases; increased opening pressure during lumbar puncture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Toxins</td> </tr> <tr> <td class=\"indent1\">Acute toxic ingestion</td> <td>Toxicology screening; pupillary changes</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> <td>History of lead exposure or pica; elevated blood lead level (confirmatory)</td> </tr> <tr> <td class=\"indent1\">Reye syndrome</td> <td>History of aspirin use; recent viral infection; increased opening pressure during lumbar puncture</td> </tr> <tr> <td><strong>Inborn errors of metabolism</strong> (eg, organic acidemia, urea cycle disorder, mitochondrial disorders, mitochondrial fatty acid oxidation disorders, etc)</td> <td>Abnormal laboratory findings (eg, hypoglycemia, hyperammonemia, acidosis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid.<br> * Associated with certain tumors (eg, ovarian teratoma).<br></div><div class=\"graphic_reference\">Courtesy of Hordur Hardarson, MD.</div><div id=\"graphicVersion\">Graphic 68501 Version 6.0</div></div></div>"},"68502":{"type":"graphic_picture","displayName":"Lactating breast abscess with skin compromise","title":"Lactating breast abscess with skin compromise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lactating breast abscess with skin compromise</div><div class=\"cntnt\"><img style=\"width:396px; height:349px;\" src=\"images/PC/68502_Skin_compromise_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the overlying skin is thinned or necrotic, the best procedure is incision and drainage.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 68502 Version 3.0</div></div></div>"},"68503":{"type":"graphic_picture","displayName":"Erythropoietic protoporphyria","title":"Erythropoietic protoporphyria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythropoietic protoporphyria</div><div class=\"cntnt\"><img style=\"width:273px; height:396px;\" src=\"images/ALLRG/68503_Erythro_protoporphyria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythematous infiltration of the nose with edema, petechial hemorrhage, and scattered atrophic scars on the side of the face with telangiectasia.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick T, Johnson R, Wolff K, et al. Color atlas and synopsis of clinical dermatology: Common and Serious Diseases, Third Edition, McGraw Hill, New York, 1997. Copyright © 1997 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 68503 Version 15.0</div></div></div>"},"68504":{"type":"graphic_table","displayName":"Drug interactions with NMBAs","title":"Potential drug interactions with NMBAs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential drug interactions with NMBAs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Enhance the neuromuscular effect of NMBAs</td> </tr> <tr> <td class=\"sublist2_start\">Acetylcholinesterase inhibitors*</td> </tr> <tr> <td class=\"sublist2\">Donepezil</td> </tr> <tr> <td class=\"sublist2\">Galantamine</td> </tr> <tr> <td class=\"sublist2\">Echothiophate iodine*</td> </tr> <tr> <td class=\"sublist2\">Neostigmine</td> </tr> <tr> <td class=\"sublist2\">Physostigmine</td> </tr> <tr> <td class=\"sublist2\">Pyridostigmine</td> </tr> <tr> <td class=\"sublist2\">Rivastigmine</td> </tr> <tr> <td class=\"sublist2\">Tacrine</td> </tr> <tr> <td class=\"sublist2_start\">Antibiotics</td> </tr> <tr> <td class=\"sublist2\">Aminoglycosides</td> </tr> <tr> <td class=\"sublist3\">Amikacin</td> </tr> <tr> <td class=\"sublist3\">Gentamicin</td> </tr> <tr> <td class=\"sublist3\">Kanamycin</td> </tr> <tr> <td class=\"sublist3\">Neomycin</td> </tr> <tr> <td class=\"sublist3\">Streptomycin</td> </tr> <tr> <td class=\"sublist3\">Tobramycin</td> </tr> <tr> <td class=\"sublist2\">Amphotericin B</td> </tr> <tr> <td class=\"sublist2\">Colistin</td> </tr> <tr> <td class=\"sublist2\">Lincosamides</td> </tr> <tr> <td class=\"sublist3\">Clindamycin</td> </tr> <tr> <td class=\"sublist3\">Lincomycin</td> </tr> <tr> <td class=\"sublist2\">Polymyxin B</td> </tr> <tr> <td class=\"sublist2_start\">Calcium channel blockers<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Amlodipine</td> </tr> <tr> <td class=\"sublist2\">Bepridil<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">Clevidipine</td> </tr> <tr> <td class=\"sublist2\">Diltiazem</td> </tr> <tr> <td class=\"sublist2\">Felodipine</td> </tr> <tr> <td class=\"sublist2\">Isradipine</td> </tr> <tr> <td class=\"sublist2\">Nicardipine</td> </tr> <tr> <td class=\"sublist2\">Nifedipine</td> </tr> <tr> <td class=\"sublist2\">Nilvadipine<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">Nimodipine</td> </tr> <tr> <td class=\"sublist2\">Nisoldipine, nitrendipine<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">Verapamil</td> </tr> <tr> <td>Cyclophosphamide*</td> </tr> <tr> <td class=\"sublist2_start\">Loop diuretics (low doses)</td> </tr> <tr> <td class=\"sublist2\">Bumetanide</td> </tr> <tr> <td class=\"sublist2\">Ethacrynic acid</td> </tr> <tr> <td class=\"sublist2\">Furosemide</td> </tr> <tr> <td class=\"sublist2\">Torsemide</td> </tr> <tr> <td class=\"indent1\">Magnesium Salts</td> </tr> <tr> <td class=\"indent1\">Phenelzine*</td> </tr> <tr> <td class=\"indent1\">Quinidine</td> </tr> <tr> <td class=\"indent1\">Quinine</td> </tr> <tr> <td class=\"indent1\">Trimebutine<sup>&#182;</sup><sup>&#916;</sup></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diminish the neuromuscular effect of NMBAs</td> </tr> <tr> <td class=\"sublist2_start\">Acetylcholinesterase inhibitors<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Donepezil</td> </tr> <tr> <td class=\"sublist2\">Galantamine</td> </tr> <tr> <td class=\"sublist2\">Neostigmine</td> </tr> <tr> <td class=\"sublist2\">Physostigmine</td> </tr> <tr> <td class=\"sublist2\">Pyridostigmine</td> </tr> <tr> <td class=\"sublist2\">Rivastigmine</td> </tr> <tr> <td class=\"sublist2\">Tacrine</td> </tr> <tr> <td class=\"sublist2_start\">Loop diuretics (high doses)</td> </tr> <tr> <td class=\"sublist2\">Bumetanide</td> </tr> <tr> <td class=\"sublist2\">Ethacrynic acid</td> </tr> <tr> <td class=\"sublist2\">Furosemide</td> </tr> <tr> <td class=\"sublist2\">Torsemide</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For more details, see specific drug information topic or Lexi-Interact (available to online readers from the main search page).</div><div class=\"graphic_footnotes\">* Succinylcholine only.<br />¶ Nondepolarizing NBMAs only.<br />Δ Not available in United States.</div><div id=\"graphicVersion\">Graphic 68504 Version 3.0</div></div></div>"},"68506":{"type":"graphic_figure","displayName":"Ornipressin on GFR in cirrhosis","title":"Ornipressin improves renal function in advanced hepatic cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ornipressin improves renal function in advanced hepatic cirrhosis</div><div class=\"cntnt\"><img style=\"width:356px; height:215px;\" src=\"images/GAST/68506_Ornipressin_on_GFR_in_cirrh.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of infusion of ornipressin, an analog of antidiuretic hormone that causes preferential splanchnic vasoconstriction, in patients with advanced hepatic cirrhosis and functional renal failure (the hepatorenal syndrome). Ornipressin raised the glomerular filtration rate (GFR) from 18 to 29 mL/min, lowered the plasma renin activity from 28 to 14 (normal equals less than 3 ng/mL per hour on a regular salt intake), and raised the fraction of the cardiac output delivered to the kidneys from 2 to 5 percent (normal equals 20 percent). Each of these abnormalities was only partially corrected, although it is not known if a greater response would be seen with less severe disease or with a higher dose.</div><div class=\"graphic_reference\">Data from Lenz, K, Hortnagl, H, Druml, W, et al, Gastroenterology 1991; 101:1060.</div><div id=\"graphicVersion\">Graphic 68506 Version 1.0</div></div></div>"},"68507":{"type":"graphic_movie","displayName":"Aortic valve homograft transesophageal echocardiogram","title":"Aortic valve homograft","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic valve homograft</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68507_teeavhomconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:233px; height:373px;\" src=\"images/CARD/68507_teeavhom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a normally functioning aortic valve homograft.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 68507 Version 2.0</div></div></div>"},"68510":{"type":"graphic_table","displayName":"Diseases associated with symptomatic IgM deficiency","title":"Diseases associated with symptomatic IgM deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases associated with symptomatic IgM deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td>Bronchitis, pneumonia, sinusitis, otitis media</td> </tr> <tr> <td>Increased atopy - allergic rhinitis, asthma</td> </tr> <tr> <td>Interstitial lung disease?*</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious disease</td> </tr> <tr> <td>Sepsis (meningococcal, others)</td> </tr> <tr> <td>Meningococcal naspharyngitis</td> </tr> <tr> <td>Generalized vaccinia</td> </tr> <tr> <td>Epidermodysplasia verruciformis</td> </tr> <tr> <td>Occupational small pox</td> </tr> <tr> <td>Recurrent staphylococcal pyoderma</td> </tr> <tr> <td>Disseminated molluscum contagiosum</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disease</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Hashimoto's thyroiditis</td> </tr> <tr> <td>Chronic idiopathic thrombocytopenic purpura</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic disease</td> </tr> <tr> <td>Clear cell sarcoma</td> </tr> <tr> <td>Prolymphocytic leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disease</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td>Bloom syndrome</td> </tr> <tr> <td>Inability to train (athlete)</td> </tr> <tr> <td>Splenomegaly</td> </tr> <tr> <td>Pulmonary interstitial disease?*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.<br />* Possible association.</div><div id=\"graphicVersion\">Graphic 68510 Version 3.0</div></div></div>"},"68514":{"type":"graphic_picture","displayName":"Vaginal retractors","title":"Vaginal retractors","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Vaginal retractors</div><div class=\"cntnt\"><img style=\"width:475px; height:317px;\" src=\"images/OBGYN/68514_Vaginal_retractors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Schieden retractor. (B) Auvard weighted speculum.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68514 Version 2.0</div></div></div>"},"68515":{"type":"graphic_table","displayName":"Periop hemostasis agents","title":"Perioperative management of agents affecting hemostasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of agents affecting hemostasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name or class of drug</td> <td class=\"subtitle1\">Clinical considerations</td> <td class=\"subtitle1\">Recommended strategy for surgery with brief NPO state</td> <td class=\"subtitle1\">Recommended strategy for surgery with prolonged NPO state</td> </tr> <tr> <td>Aspirin</td> <td> <p>Continuation may cause perioperative hemorrhage.</p> <p>Discontinuation may increase the risk of vascular complications.</p> <strong>Discussion with cardiologist appropriate for patients with cardiovascular indications.</strong></td> <td>Discontinue aspirin approximately&nbsp;seven days prior to noncardiovascular surgery.</td> <td>Resume with oral intake.</td> </tr> <tr> <td>P2Y12 receptor blockers (clopidogrel, prasugrel, ticlopidine, ticagrelor)</td> <td>When used after cardiac stenting procedure, if discontinued can cause cardiac ischemia perioperatively. If continued can result in bleeding complications. Should discuss management with cardiologist.</td> <td>Ideally, elective procedures should be delayed until the mandatory period of platelet inhibition with these agents is completed. When used for long-term stroke prophylaxis, should be discontinued 7 to 10 days. If discontinuing, stop clopidogrel and ticagrelor at least&nbsp;five days, prasugrel&nbsp;seven days, and ticlopidine 10 days before surgery. When restarting clopidogrel, consider using a loading dose.</td> <td>Resume with oral intake.</td> </tr> <tr> <td>Warfarin</td> <td colspan=\"3\">Refer to UpToDate topic on perioperative management of patients receiving anticoagulants.</td> </tr> <tr> <td>Dabigatran, rivaroxaban, apixaban, edoxaban</td> <td colspan=\"3\">Refer to UpToDate topic on perioperative management of patients receiving anticoagulants.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth).</div><div id=\"graphicVersion\">Graphic 68515 Version 13.0</div></div></div>"},"68516":{"type":"graphic_table","displayName":"Special studies skin biopsy","title":"Special studies for skin biopsies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Special studies for skin biopsies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Study</td>\n\n      <td class=\"subtitle1\">Fixative or solution</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Histopathology</td>\n\n      <td>10 percent buffered formalin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Direct immunofluorescence (blistering diseases and\nlupus erythematosus)</td>\n\n      <td>Michel's solution</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Electron microscopy</td>\n\n      <td>Electron microscopy fixative; glutaraldehyde</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bacterial or fungal cultures</td>\n\n      <td>Sterile container with nonbacteriostatic saline</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Viral cultures</td>\n\n      <td>Viral transport media</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">With permission from Alguire, PC, Mathes, BM, J Gen Intern Med 1998; 13:46.</div><div id=\"graphicVersion\">Graphic 68516 Version 1.0</div></div></div>"},"68517":{"type":"graphic_table","displayName":"Doses inhaled glucocorticoids","title":"Estimated comparative daily doses for inhaled glucocorticoids in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated comparative daily doses for inhaled glucocorticoids in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"6\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"2\">Low daily dose</td> <td class=\"subtitle1\" colspan=\"2\">Medium daily dose</td> <td class=\"subtitle1\" colspan=\"2\">High daily dose</td> </tr> <tr> <td class=\"subtitle2\">Child 0 to 4</td> <td class=\"subtitle2\">Child 5 to 11</td> <td class=\"subtitle2\">Child 0 to 4</td> <td class=\"subtitle2\">Child 5 to 11</td> <td class=\"subtitle2\">Child 0 to 4</td> <td class=\"subtitle2\">Child 5 to 11</td> </tr> <tr class=\"divider_bottom\"> <td>Beclomethasone HFA <p class=\"sublist1\">40 or 80 mcg/puff</p> </td> <td>NA</td> <td>40 mcg/puff - One to two puffs twice per day</td> <td>NA</td> <td> <p>40 mcg/puff - Two to four puffs twice per day</p> 80 mcg/puff - One to two puffs twice per day</td> <td>NA</td> <td>80 mcg/puff - Three to four puffs twice per day</td> </tr> <tr class=\"divider_bottom\"> <td>Budesonide DPI* (breath activated) <p class=\"sublist1\">90 or 180 mcg/inhalation</p> </td> <td>NA</td> <td>90 mcg/inhalation - One to two inhalations twice per day</td> <td>NA</td> <td>180 mcg/inhalation - One to two inhalations twice per day</td> <td>NA</td> <td>180 mcg/inhalation - Three to four inhalations twice per day</td> </tr> <tr class=\"divider_bottom\"> <td>Budesonide nebulization suspension<sup>&#182;</sup> <p class=\"sublist1\">0.25 mg/2 mL, 0.5 mg/2 mL, or 1 mg/2 mL</p> </td> <td>0.25 to 0.5 mg once daily or as two divided doses</td> <td>0.5 mg once daily or as two divided doses</td> <td>0.75 to 1 mg once daily or as two or three divided doses</td> <td>1 mg once daily or as two divided doses</td> <td>1.25 to 2 mg once daily or as two divided doses</td> <td>2 mg once daily or as two divided doses</td> </tr> <tr class=\"divider_bottom\"> <td>Ciclesonide HFA<sup>&#916;</sup> <p class=\"sublist1\">80 or 160 mcg/puff</p> </td> <td>NA</td> <td>80 mcg/puff - One to two puffs once daily</td> <td>NA</td> <td>80 mcg/puff - Three to four puffs once daily</td> <td>NA</td> <td> <p>80 mcg/puff - Five to six puffs once daily or as two divided doses</p> 160 mcg/puff - Three puffs once daily or as two divided doses</td> </tr> <tr class=\"divider_bottom\"> <td>Flunisolide HFA (built-in spacer)<sup>&#9674;</sup> <p class=\"sublist1\">80 mcg/puff</p> </td> <td>NA</td> <td>80 mcg/puff - One puff twice per day<sup>&#9674;</sup></td> <td>NA</td> <td>80 mcg/puff - Two puffs twice per day<sup>&#9674;</sup></td> <td>NA</td> <td>Not recommended<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Fluticasone HFA<sup>&#167;</sup> <p class=\"sublist1\">44, 110, or 220 mcg/puff</p> </td> <td>44 mcg/puff - Two puffs twice per day<sup>&#167;</sup></td> <td>44 mcg/puff - One to two puffs twice per day</td> <td> <p>44 mcg/puff - Two to four puffs twice per day</p> 110 mcg/puff - One puff in AM and two puffs in PM</td> <td> <p>44 mcg/puff - Two to four puffs twice per day</p> 110 mcg/puff - One puff in AM and two puffs in PM</td> <td> <p>110 mcg/puff - Two puffs twice per day</p> 220 mcg/puff - One puff twice per day</td> <td> <p>110 mcg/puff - Two puffs twice per day</p> 220 mcg/puff - One puff twice per day</td> </tr> <tr class=\"divider_bottom\"> <td>Fluticasone DPI (breath activated)<sup>&#165;</sup> <p class=\"sublist1\">50, 100, or 250 mcg/inhalation</p> </td> <td>NA</td> <td>50 mcg/inhalation - One to two inhalations twice per day</td> <td>NA</td> <td> <p>50 mcg/inhalation - Three to four inhalations twice per day</p> 100 mcg/inhalation - One inhalation in AM and two inhalations in PM to two inhalations twice per day</td> <td>NA</td> <td> <p>100 mcg/inhalation - Two inhalations in AM and three inhalations in PM</p> 250 mcg/inhalation - One inhalation twice per day</td> </tr> <tr> <td>Mometasone aerosol DPI (breath activated)* <p class=\"sublist1\">110 or 220 mcg/inhalation</p> </td> <td>NA</td> <td>110 mcg/inhalation - One inhalation once daily</td> <td>NA</td> <td>110 mcg/inhalation - Two to three inhalations once daily</td> <td>NA</td> <td> <p>110 mcg/inhalation - Four inhalations once daily or two inhalations twice per day</p> 220 mcg/inhalation - Two inhalations once daily or one inhalation twice per day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Some doses may be outside approved package labeling, especially in the high-dose range. Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States, which may differ from how strengths are described for products available in other countries. Consult local product information before use.</div><div class=\"graphic_footnotes\">HFA: hydrofluoroalkane; NA: not approved and no data available for this age group; DPI: dry-powder inhaler; AM: in morning; PM: in evening; US FDA: US Food and Drug Administration; MDI: metered-dose inhaler.<br />* Contains milk protein.<br />&#182; Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer. Use only jet nebulizers, as ultrasonic nebulizers are ineffective for suspensions.<br />&Delta; Ciclesonide is not approved by US FDA for use in children under 12. It is approved for use in children six years of age and older in Canada, some countries of Europe, and elsewhere.<br /><span class=\"lozenge\">&loz;</span> Doses shown are for flunisolide HFA MDI according to United States-approved product information. Dose equivalence to other inhaled glucocorticoids is not well established.<br />&sect; For fluticasone HFA, the low dose for children &lt;4 years is higher than for children 5 to 11 years of age due to lower dose delivered with facemask and data on efficacy in young children.<br />&yen; Contains lactose.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</li>&#xD;&#xA;    <li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2012. Available at <a href=\"http://www.ginasthma.org/\" target=\"_blank\">www.ginasthma.org</a>.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 68517 Version 13.0</div></div></div>"},"68520":{"type":"graphic_figure","displayName":"Splitting of a long arm cast","title":"Splitting of a long arm cast","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Splitting of a long arm cast</div><div class=\"cntnt\"><img style=\"width:473px; height:697px;\" src=\"images/EM/68520_Splitting-of-a-long-arm-cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long arm cast should be split as shown and then wrapped with an elastic bandage to permit swelling at the fracture site.</div><div id=\"graphicVersion\">Graphic 68520 Version 1.0</div></div></div>"},"68521":{"type":"graphic_diagnosticimage","displayName":"Hepatic hematoma rupture MRI","title":"Hepatic hematoma with rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hematoma with rupture</div><div class=\"cntnt\"><img style=\"width:297px; height:289px;\" src=\"images/GAST/68521_Hepatic_hematoma_rupture_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image from a pregnant woman with hepatic hematoma with rupture. This cut shows collected blood under the hepatic capsule running from the dome of the liver down along the right side, pushing the remaining normal parenchyma towards the midline.</div><div class=\"graphic_reference\">Reproduced with permission from Barton, JR, Sibai, BM, Am J Obstet Gynecol 1996; 174:1820.</div><div id=\"graphicVersion\">Graphic 68521 Version 2.0</div></div></div>"},"68523":{"type":"graphic_picture","displayName":"Scolex of Echinococcus","title":"Echinococcus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echinococcus</div><div class=\"cntnt\"><img style=\"width:359px; height:238px;\" src=\"images/ID/68523_Livercyst1withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wet mount of contents of hydatid cyst of liver (x400) shows a scolex of <EM>Echinococcus</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 68523 Version 3.0</div></div></div>"},"68524":{"type":"graphic_movie","displayName":"Mitral stenosis pulsed wave Doppler","title":"Mitral stenosis pulsed wave Doppler","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis pulsed wave Doppler</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68524_mspudop2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:311px; height:230px;\" src=\"images/CARD/68524_mspudop2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68524 Version 2.0</div></div></div>"},"68525":{"type":"graphic_table","displayName":"ANCA accuracy in GN in older adults","title":"ANCA results for pauci-immune crescentic glomerulonephritis in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ANCA results for pauci-immune crescentic glomerulonephritis in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Clinical presentation of patient</td>\n\n\t\t\t<td class=\"subtitle1\">Prevalence of PI-CGN</td>\n\n\t\t\t<td class=\"subtitle1\">PPV for PI-CGN</td>\n\n\t\t\t<td class=\"subtitle1\">NPV for PI-CGN</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Rapidly progressive glomerulonephritis*</td>\n\n\t\t\t<td>66 percent (82/124)</td>\n\n\t\t\t<td>99 percent</td>\n\n\t\t\t<td>65 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine &#62;3 mg/dL</td>\n\n\t\t\t<td>30 percent (147/497)</td>\n\n\t\t\t<td>95 percent</td>\n\n\t\t\t<td>89 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine 1.5-3 mg/dL</td>\n\n\t\t\t<td>11 percent (36/311)</td>\n\n\t\t\t<td>85 percent</td>\n\n\t\t\t<td>97 percent</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Hematuria, proteinuria, and creatinine &#60;1.5 mg/dL</td>\n\n\t\t\t<td>4 percent (7/195)</td>\n\n\t\t\t<td>66 percent</td>\n\n\t\t\t<td>99 percent</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=35071&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ANCA_accuracy_in_GN_in_elde.htm</title></head></div><div class=\"graphic_lgnd\">Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in older adults (&gt;50 years old) with different clinical presentations using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).</div><div class=\"graphic_footnotes\">* This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.</div><div class=\"graphic_reference\">Adapted from: Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53:796.</div><div id=\"graphicVersion\">Graphic 68525 Version 3.0</div></div></div>"},"68527":{"type":"graphic_table","displayName":"Diffusing capacity limitation","title":"Diffusing capacity in various obstructive diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diffusing capacity in various obstructive diseases</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td colspan=\"1\" class=\"subtitle1\">&nbsp;</td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Airflow\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n DLCO\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Bronchitis</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n <td>&#8596;</td>\r\n \r\n </tr>\r\n\r\n <tr>\r\n \r\n <td>Bronchiolitis</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Emphysema</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Asthma</td>\r\n \r\n <td>&#8595;</td>\r\n \r\n <td>&#8596; or &#8593;</td>\r\n \r\n </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=64334&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Diffusing_capacity_limitati.htm</title></head></div><div class=\"graphic_footnotes\">DLCO: diffusing capacity for carbon monoxide; ↓: decreased; ↔: within normal limits;&nbsp;↑: increased.</div><div id=\"graphicVersion\">Graphic 68527 Version 3.0</div></div></div>"},"68529":{"type":"graphic_figure","displayName":"Known mutations ZAP 70 protein","title":"Known mutations in the ZAP-70 protein","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Known mutations in the ZAP-70 protein</div><div class=\"cntnt\"><img style=\"width:704px; height:278px;\" src=\"images/ALLRG/68529_Known_mutations_ZAP_70_prtn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ZAP-70 protein diagram, showing N- and C-SH2 domains, interdomains, I-A and I-B, and kinase domain. Mutation sites in the family are bolded; previously reported mutations in combined immunodeficiency patients (all of which are loss of function) are italicized.</div><div class=\"graphic_footnotes\">ZAP-70: zeta chain-associated protein kinase 70; SH2: Src homology 2.</div><div class=\"graphic_reference\">Copyright &copy; 2016 Chan et al. Journal of Experimental Medicine. 213:155-165. doi:10.1084/jem.20150888. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 68529 Version 4.0</div></div></div>"},"68532":{"type":"graphic_table","displayName":"Braden scale for predicting risk of pressure-induced injury","title":"Braden scale for predicting risk of pressure-induced injury*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Braden scale for predicting risk of pressure-induced injury*</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Sensory perception\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Moisture\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Activity\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Mobility\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Nutrition\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Friction &#38; shear\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ability to respond meaningfully to pressure-related discomfort</td>\r\n  \r\n   <td>Degree to which skin is exposed to moisture</td>\r\n  \r\n   <td>Degree of physical activity</td>\r\n  \r\n   <td>Ability to change and control body position</td>\r\n  \r\n   <td>Usual food intake pattern</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Completely limited\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Constantly moist\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Bedfast\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Completely immobile\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Very poor\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   1. Problem\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Unresponsive (does not moan, flinch, or grasp) to painful stimuli, due to diminished level of consciousness or sedation</p>\n\t<p> \t \t\t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\t\tLimited ability to feel pain over most of body</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Skin is kept moist almost constantly by perspiration, urine, etc. Dampness is detected every time patient is moved or turned.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Confined to bed\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Does not make even slight changes in body or extremity position without assistance\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Never eats a complete meal. Rarely eats more than 1/3 of any food offered. Eats 2 servings or less of protein (meat or dairy products) per day. Takes fluids poorly. Does not take a liquid dietary supplement.</p>\n\t<p> \t \t\t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\t\tIs NPO and/or maintained on clear liquids or IV's for more than 5 days</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Requires moderate to maximum assistance in moving. Complete lifting without sliding against sheets is impossible. Frequently slides down in bed or chair, requiring frequent repositioning with maximum assistance. Spasticity, contractures or agitation leads to almost constant friction.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Very limited\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Very moist\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Chairfast\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Very limited\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Probably inadequate\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   2. Potential problem\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Responds only to painful stimuli</p>\n\t<p> \t \t\t\t\t\t\t\t\tCannot communicate discomfort except by moaning or restlessness</p>\n\t<p> \t \t\t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\t\tHas a sensory impairment which limits the ability to feel pain or discomfort over 1/2 of body</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Skin is often, but not always moist. Linen must be changed at least once a shift.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Ability to walk severely limited or non-existent. Cannot bear own weight and/or must be assisted into chair or wheelchair.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Makes occasional slight changes in body or extremity position but unable to make frequent or significant changes independently\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Rarely eats a complete meal and generally eats only about 1/2 of any food offered. Protein intake includes only 3 servings of meat or dairy products per day. Occasionally will take a dietary supplement.</p>\n\t<p> \t \t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\tReceives less than optimum amount of liquid diet or tube feeding</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Moves feebly or requires minimum assistance. During a move skin probably slides to some extent against sheets, chair, restraints or good position in chair or bed most of the time but occasionally slides down.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. Slightly limited\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. Occasionally moist\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. Walks occasionally\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. Slightly limited\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. Adequate\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   3. No apparent problem\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Responds to verbal commands, but cannot always communicate discomfort or the need to be turned</p>\n\t<p> \t \t\t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\t\tHas some sensory impairment which limits ability to feel pain or discomfort in 1 or 2 extremities</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Skin is occasionally moist, requiring an extra linen change approximately once a day\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Walks occasionally during day, but for very short distances, with or without assistance. Spends majority of each shift in bed or chair.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Makes frequent though slight changes in body or extremity position independently\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Eats over half of most meals. Eats a total of 4 servings of protein (meat, dairy products) per day. Occasionally will refuse a meal, but will usually take a supplement when offered.</p>\n\t<p> \t \t\t\t\t\t\t\t\t <strong>OR</strong> </p>\n\t<p> \t \t\t\t\t\t\t\t\tIs on a tube feeding or TPN regimen which probably meets most of nutritional needs</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Moves in bed and in chair independently and has sufficient muscle strength to lift up completely during move. Maintains good position in bed or chair.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   4. No impairment\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   4. Rarely moist\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   4. Walks frequently\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   4. No limitation\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\">\r\n  \r\n   4. Excellent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2_left\" rowspan=\"2\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   \t<p>Responds to verbal commands</p>\n\t<p> \t \t\t\t\t\t\t\t\tHas no sensory deficit which would limit ability to feel or voice pain or discomfort</p>\n\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Skin is usually dry, linen only requires changing at routine intervals\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Walks outside room at least twice a day and inside room at least once every two hours during waking hours\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Makes major and frequent changes in position without assistance\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Eats most of every meal. Never refuses a meal. Usually eats a total of 4 or more servings of meat and dairy products. Occasionally eats between meals. Does not require supplementation.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   <td><strong>Score:</strong> __________</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57674&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Braden_scale.htm</title></head></div><div class=\"graphic_footnotes\">* To calculate the Braden scale score, rank the patient in each of the subscales; sensory perception, mobility, activity, moisture, nutrition and friction and shear. Add the six subscale scores to yield a total Braden scale score. Lower scores are associated with a higher risk of developing pressure scores. A score of 18 or less indicates high risk. See www.bradenscale.com.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 1988 Barbara Braden and Nancy Bergstrom.</div><div id=\"graphicVersion\">Graphic 68532 Version 3.0</div></div></div>"},"68534":{"type":"graphic_table","displayName":"Review genetic testing","title":"The ACCE Model's list of targeted questions aimed at a comprehensive review of genetic testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The ACCE Model's list of targeted questions aimed at a comprehensive review of genetic testing</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Element</td>\n<td class=\"subtitle1\">Component</td>\n<td class=\"subtitle1\">Specific question</td>\n</tr>\n<tr>\n<td rowspan=\"7\"><strong>Disorder/setting</strong></td>\n<td rowspan=\"7\">&nbsp;</td>\n<td>1. What is the specific clinical disorder to be studied?</td>\n</tr>\n<tr>\n<td>2. What are the clinical findings defining this disorder?</td>\n</tr>\n<tr>\n<td>3. What is the clinical setting in which the test is to be performed?</td>\n</tr>\n<tr>\n<td>4. What DNA test(s) are associated with this disorder?</td>\n</tr>\n<tr>\n<td>5. Are preliminary screening questions employed?</td>\n</tr>\n<tr>\n<td>6. Is it a stand-alone test or is it one of a series of tests?</td>\n</tr>\n<tr>\n<td>7. If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only some tests performed on the basis of other results (series)?</td>\n</tr>\n<tr>\n<td rowspan=\"10\"><strong>Analytic validity</strong></td>\n <td>&nbsp;</td>\n<td>8. Is the test qualitative or quantitative?</td>\n</tr>\n<tr>\n<td>Sensitivity</td>\n<td>9. How often is the test positive when a mutation is present?</td>\n</tr>\n<tr>\n<td>Specificity</td>\n<td>10. How often is the test negative when a mutation is not present?</td>\n</tr>\n<tr>\n<td rowspan=\"7\">&nbsp;</td>\n<td>11. Is an internal QC program defined and externally monitored?</td>\n</tr>\n<tr>\n<td>12. Have repeated measurements been made on specimens?</td>\n</tr>\n<tr>\n<td>13. What is the within- and between-laboratory precision?</td>\n</tr>\n<tr>\n<td>14. If appropriate, how is confirmatory testing performed to resolve false positive results in a timely manner?</td>\n</tr>\n<tr>\n<td>15. What range of patient specimens have been tested?</td>\n</tr>\n<tr>\n<td>16. How often does the test fail to give a useable result?</td>\n</tr>\n<tr>\n<td>17. How similar are results obtained in multiple laboratories using the same, or different, technology?</td>\n</tr>\n<tr>\n<td rowspan=\"8\"><strong>Clinical validity</strong></td>\n<td>Sensitivity</td>\n<td>18. How often is the test positive when the disorder is present?</td>\n</tr>\n<tr>\n<td>Specificity</td>\n<td>19. How often is the test negative when a disorder is not present?</td>\n</tr>\n<tr><td>&nbsp;</td>\n<td>20. Are there methods to resolve clinical false positive results in a timely manner?</td>\n</tr>\n<tr>\n<td>Prevalence</td>\n<td>21. What is the prevalence of the disorder in this setting?</td>\n</tr>\n<tr>\n<td rowspan=\"4\">&nbsp;</td>\n<td>22. Has the test been adequately validated on all populations to which it may be offered?</td>\n</tr>\n<tr>\n<td>23. What are the positive and negative predictive values?</td>\n</tr>\n<tr>\n<td>24. What are the genotype/phenotype relationships?</td>\n</tr>\n<tr>\n<td>25. What are the genetic, environmental or other modifiers?</td>\n</tr>\n<tr>\n<td rowspan=\"16\"><strong>Clinical utility</strong></td>\n<td>Intervention</td>\n<td>26. What is the natural history of the disorder?</td>\n</tr>\n<tr>\n<td>Intervention</td>\n<td>27. What is the impact of a positive (or negative) test on patient care?</td>\n</tr>\n<tr>\n<td>Intervention</td>\n<td>28. If applicable, are diagnostic tests available?</td>\n</tr>\n<tr>\n<td>Intervention</td>\n<td>29. Is there an effective remedy, acceptable action, or other measurable benefit?</td>\n</tr>\n<tr>\n<td>Intervention</td>\n<td>30. Is there general access to that remedy or action?</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>31. Is the test being offered to a socially vulnerable population?</td>\n</tr>\n<tr>\n<td>Quality assurance</td>\n<td>32. What quality assurance measures are in place?</td>\n</tr>\n<tr>\n<td>Pilot trials</td>\n<td>33. What are the results of pilot trials?</td>\n</tr>\n<tr>\n<td>Health risks</td>\n<td>34. What health risks can be identified for follow-up testing and/or intervention?</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>35. What are the financial costs associated with testing?</td>\n</tr>\n<tr>\n<td>Economic</td>\n<td>36. What are the economic benefits associated with actions resulting from testing?</td>\n</tr>\n<tr>\n<td>Facilities</td>\n<td>37. What facilities/personnel are available or easily put in place?</td>\n</tr>\n<tr>\n<td>Education</td>\n<td>38. What educational materials have been developed and validated and which of these are available?</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>39. Are there informed consent requirements?</td>\n</tr>\n<tr>\n<td>Monitoring</td>\n<td>40. What methods exist for long-term monitoring?</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>41. What guidelines have been developed for evaluating program performance?</td>\n</tr>\n<tr>\n<td rowspan=\"3\"><strong>ELSI</strong></td>\n<td>Impediments</td>\n<td>42. What is known about stigmatization, discrimination, privacy/confidentiality and personal/family social issues?</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>43. Are there legal issues regarding consent, ownership of data and/or samples, patents, licensing, proprietary testing, obligation to disclose, or reporting requirements?</td>\n</tr>\n<tr>\n<td>Safeguards</td>\n<td>44. What safeguards have been described and are these safeguards in place and effective?</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Haddow JE, Palomaki GE. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In: Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Khoury, M, Little, J, Burke, W (Eds.), Oxford University Press 2003, p. 217.<br> Reproduced from Centers for Disease Control. Available at http://www.cdc.gov/genomics/gtesting/ACCE/acce_proj.htm#T1. Accessed on 2/24/2012.</div><div id=\"graphicVersion\">Graphic 68534 Version 2.0</div></div></div>"},"68535":{"type":"graphic_picture","displayName":"Sea lice print-Seabather's eruption","title":"Sea lice print (Seabather's eruption)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sea lice print (Seabather's eruption)</div><div class=\"cntnt\"><img style=\"width:288px; height:441px;\" src=\"images/PC/68535_Sea_lice_print.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Print of sea lice, Linuche unguiculata, at the contact area under the swimming suit.</div><div class=\"graphic_reference\">Reproduced with permission from: Junghanss T, Bodio M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &copy; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 68535 Version 3.0</div></div></div>"},"68536":{"type":"graphic_table","displayName":"Contraindications and complications of prone position","title":"Prone position: Contraindications and complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prone position: Contraindications and complications</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Shock (eg, persistent mean aterial pressure &#60;65 mmHg)</td> </tr> <tr> <td class=\"indent1\">Acute bleeding (eg, hemorrhagic shock, massive hemoptysis)</td> </tr> <tr> <td class=\"indent1\">Multiple fractures or trauma (eg, unstable fractures of femur, pelvis, face)</td> </tr> <tr> <td class=\"indent1\">Spinal instability</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Raised intracranial pressure &#62;30 mmHg or cerebral perfusion pressure &#60;60 mmHg</td> </tr> <tr> <td class=\"indent1\">Tracheal surgery or sternotomy within two weeks</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindictions</td> </tr> <tr> <td class=\"indent1\">Recent DVT treated for &#60;2 days*</td> </tr> <tr> <td class=\"indent1\">Anterior chest tube(s) with air leaks*</td> </tr> <tr> <td class=\"indent1\">Major abdominal surgery</td> </tr> <tr> <td class=\"indent1\">Recent pacemaker*</td> </tr> <tr> <td class=\"indent1\">Clinical conditions limiting life expectancy* (eg, oxygen or ventilator-dependent respiratory failure)</td> </tr> <tr> <td class=\"indent1\">Severe burns*</td> </tr> <tr> <td class=\"indent1\">Lung transplant recipient*</td> </tr> <tr> <td class=\"indent1\">Prior use of rescue therapies*<sup>&#182;</sup></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Complications</td> </tr> <tr> <td class=\"indent1\">Nerve compression (eg, brachial plexus injury)</td> </tr> <tr> <td class=\"indent1\">Crush injury</td> </tr> <tr> <td class=\"indent1\">Venous stasis (eg, facial edema)</td> </tr> <tr> <td class=\"indent1\">Dislodging endotracheal tube</td> </tr> <tr> <td class=\"indent1\">Diaphragm limitation</td> </tr> <tr> <td class=\"indent1\">Pressure sores (eg, facial)</td> </tr> <tr> <td class=\"indent1\">Dislodging vascular catheters or drainage tubes</td> </tr> <tr> <td class=\"indent1\">Retinal damage</td> </tr> <tr> <td class=\"indent1\">Transient reduction in arterial oxygen saturation</td> </tr> <tr> <td class=\"indent1\">Vomiting</td> </tr> <tr> <td class=\"indent1\">Transient arrhythmias</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis.<br />* Based upon exclusion criteria from the Prone Postioning in Severe ARDS trial (PROSEVA).<br />¶ Patients in whom benefit is not assured include: patients on inhaled nitric oxide, on almitrine bimesyalte, extracorporeal membrane oxygeneation (ECMO), or noninvasive ventilation (NIV) prior to intubation.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ryan DW, Pelosi P. The prone position in acute respiratory distress syndrome. BMJ 1996; 312:860.</li>&#xD;&#xA;    <li>Gu&eacute;rin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368:2159.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 68536 Version 4.0</div></div></div>"},"68538":{"type":"graphic_picture","displayName":"Left neck lymphodenopathy","title":"Left neck cervical lymphadenopathy with draining sinuses (patient 12","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Left neck cervical lymphadenopathy with draining sinuses (patient 12</div><div class=\"cntnt\"><img style=\"width:468px; height:306px;\" src=\"images/ID/68538_Left_neck_lymphodenopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Phillips, P, Bonner, S, Gataric, N, et al. Nontuberculous Mycobacterial Immune Reconstitution Syndrome in HIV-infected patients spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483. Copyright &#169; 2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 68538 Version 1.0</div></div></div>"},"68540":{"type":"graphic_figure","displayName":"Age at onset of renal disease in SCD","title":"Age of presentation of renal disease in patients with sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age of presentation of renal disease in patients with sickle cell disease</div><div class=\"cntnt\"><img style=\"width:450px; height:254px;\" src=\"images/NEPH/68540_Ageatonsetofrenaldzin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As shown in this bar graph, the age at presentation of the different manifestations of renal disease varies widely among patients with sickle cell disease.</div><div class=\"graphic_reference\">Data from Saborio P, Scheinman JI. Sickle&nbsp;cell&nbsp;nephropathy.&nbsp;J Am Soc Nephrol 1999; 10:187</div><div id=\"graphicVersion\">Graphic 68540 Version 4.0</div></div></div>"},"68541":{"type":"graphic_waveform","displayName":"Doppler restrictive CM I","title":"Doppler in restrictive cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Doppler in restrictive cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:482px; height:242px;\" src=\"images/CARD/68541_Doppler_restrictive_CM_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulse wave Doppler in a patient with an idiopathic restrictive cardiomyopathy demonstrates an increased E/A ratio (2.4), with shortened deceleration time (DT = 128 milliseconds).</div><div class=\"graphic_reference\">Courtesy of Naser Ammash MD.</div><div id=\"graphicVersion\">Graphic 68541 Version 2.0</div></div></div>"},"68545":{"type":"graphic_table","displayName":"Management of NK cell deficiencies","title":"Management of natural killer (NK) cell deficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of natural killer (NK) cell deficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Reported or theoretical benefit</td> <td class=\"subtitle1\">Risks</td> </tr> <tr> <td>Antiviral agents</td> <td>Decrease incidence of disease</td> <td> <p>Adverse drug reactions</p> Resistance</td> </tr> <tr> <td>IVIG</td> <td>Decrease incidence of disease</td> <td> <p>Adverse drug reactions</p> <p>Infections/neurodegeneration</p> Inconvenience</td> </tr> <tr> <td>IL-2</td> <td>Increase NK cell function</td> <td> <p>Adverse drug reactions</p> Autoimmunity</td> </tr> <tr> <td>IFN-alfa</td> <td>Increase NK cell function</td> <td> <p>Adverse drug reactions</p> Autoimmunity</td> </tr> <tr> <td>Stem cell transplantation</td> <td>Correction of defect</td> <td> <p>Defect not corrected</p> Transplant-related mortality or morbidity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin; IL-2: interleukin-2; NK: natural killer; IFN-alfa: interferon-alfa.</div><div id=\"graphicVersion\">Graphic 68545 Version 5.0</div></div></div>"},"68547":{"type":"graphic_table","displayName":"Etiology of arteriovenous fistulas","title":"Etiology of arteriovenous fistulas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of arteriovenous fistulas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"sublist1_start\">Vessel injury*</td> </tr> <tr> <td class=\"sublist1\">Traumatic</td> </tr> <tr> <td class=\"sublist1\">Iatrogenic</td> </tr> <tr> <td class=\"sublist2\">Femoral catheterization</td> </tr> <tr> <td class=\"sublist2\">Post-surgical</td> </tr> <tr> <td class=\"sublist2\">Following biopsy</td> </tr> <tr> <td class=\"sublist2\">Hemodialysis vascular access</td> </tr> <tr> <td class=\"sublist2\">Lumbar spine surgery (leading to aortocaval or iliocaval fistula)</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td>Patent ductus arteriosus</td> </tr> <tr> <td>Pulmonary AV fistula (Osler-Weber-Rendu syndrome)</td> </tr> <tr> <td>Klippel-Trenaunay syndrome</td> </tr> <tr> <td>Central nervous system or vertebral fistulas</td> </tr> <tr> <td>Angiomas</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: arteriovenous.<br> * Most common etiologies.</div><div id=\"graphicVersion\">Graphic 68547 Version 3.0</div></div></div>"},"68548":{"type":"graphic_table","displayName":"Cancer risks BRCA1 and BRCA2","title":"Estimated cancer risks associated with <em>BRCA1</em> and <em>BRCA2</em> mutations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated cancer risks associated with <em>BRCA1</em> and <em>BRCA2</em> mutations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cancer type</td> <td class=\"subtitle1\">Risk in <em>BRCA1/2</em> carriers to age 70 years</td> <td class=\"subtitle1\">General population risk to age 70 years</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Breast</td> <td>40 to 75 percent</td> <td>7 percent</td> <td> <p>The range of risk reported in the literature is wide. In most studies, risk in <em>BRCA1</em> carriers is higher than that observed in <em>BRCA2</em> carriers.</p> The incidence of breast cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers compared&nbsp;with <em>BRCA2</em> carriers, but both groups have an increased risk of premenopausal breast cancer, as well as increased lifetime risks.</td> </tr> <tr> <td>Contralateral (opposite) breast</td> <td> <p><em>BRCA1</em>: up to 65 percent</p> <em>BRCA2</em>: up to 50 percent</td> <td>0.5 to 1 percent per year after diagnosis</td> <td> <p>Risk is affected by other factors such as tamoxifen use and oophorectomy (ovary removal).</p> For <em>BRCA1/2</em> carriers who have had lumpectomy: Risk of developing a second breast cancer in the affected breast appears to be elevated over long follow-up periods.</td> </tr> <tr> <td>Ovarian </td> <td> <p><em>BRCA1</em>: Approximately 40 percent</p> <em>BRCA2</em>: Approximately 15 percent</td> <td>&#60;1 percent</td> <td> <p>The risk estimates provided here are representative of findings from multiple studies.</p> The incidence of ovarian cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers, and overall rare in all carriers younger than 40 years old; risk of fallopian tube cancer is also substantially elevated.</td> </tr> <tr> <td>Colon</td> <td>Unclear</td> <td>2 percent</td> <td>If elevated, risk is small; studies have not been consistent about whether risk is elevated.</td> </tr> <tr> <td>Prostate</td> <td>Elevated; absolute risk not well defined</td> <td> <p>8 percent Whites</p> 12 percent African Americans</td> <td>Risk appears to be higher in <em>BRCA2</em> carriers and possibly in men younger than 65 years old.</td> </tr> <tr> <td>Male breast</td> <td>Elevated but &#60;10 percent</td> <td>&#60;1 percent</td> <td>Risk appears to be higher in <em>BRCA2</em> carriers; rarely occurs in men younger than age 50.</td> </tr> <tr> <td>Pancreatic</td> <td>Elevated but &#60;10 percent</td> <td>&#60;1 percent</td> <td>Risk appears to be higher in <em>BRCA2</em> carriers.</td> </tr> <tr> <td>Other sites</td> <td>To be determined</td> <td>Varied</td> <td>These sites may include cancer of the stomach and skin (melanoma).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These risks are estimates based upon review of the literature. Specific studies have reported risks that are lower or higher than the ranges or estimates quoted; however, the estimates reported here are representative of findings from high-quality studies. Risks will also vary based on an individual's current age and other risk factors.</div><div id=\"graphicVersion\">Graphic 68548 Version 8.0</div></div></div>"},"68549":{"type":"graphic_table","displayName":"Plaques","title":"Differential diagnosis of plaques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of plaques</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td>Acanthosis nigricans</td></tr>\n\t\t\t\t\t\t<tr><td>Candidiasis</td></tr>\n\t\t\t\t\t\t<tr><td>Cellulitis</td></tr>\n\t\t\t\t\t\t<tr><td>Deep fungal infections</td></tr>\n\t\t\t\t\t\t<tr><td>Dermatomyositis</td></tr>\n\t\t\t\t\t\t<tr><td>Diaper dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Eczematous dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Erythrasma</td></tr>\n\t\t\t\t\t\t<tr><td>Tinea infections</td></tr>\n\t\t\t\t\t\t<tr><td>Granuloma annulare</td></tr>\n\t\t\t\t\t\t<tr><td>Ichthyosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lichen planus</td></tr>\n\t\t\t\t\t\t<tr><td>Lichen sclerosus</td></tr>\n\t\t\t\t\t\t<tr><td>Lupus erythematosus</td></tr>\n\t\t\t\t\t\t<tr><td>Lyme disease</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td>Lymphoma (cutaneous T cell)</td></tr>\n\t\t\t\t\t\t<tr><td>Morphea</td></tr>\n\t\t\t\t\t\t<tr><td>Myxedema</td></tr>\n\t\t\t\t\t\t<tr><td>Necrobiosis lipoidica diabeticorum</td></tr>\n\t\t\t\t\t\t<tr><td>Paget's disease</td></tr>\n\t\t\t\t\t\t<tr><td>Pityriasis rosea</td></tr>\n\t\t\t\t\t\t<tr><td>Psoriasis</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Seborrheic dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Sweet's syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Syphilis</td></tr>\n\t\t\t\t\t\t<tr><td>Tinea versicolor</td></tr>\n\t\t\t\t\t\t<tr><td>Vasculitis</td></tr>\n\t\t\t\t\t\t<tr><td>Xanthelasma</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68549 Version 1.0</div></div></div>"},"68551":{"type":"graphic_picture","displayName":"Severe varicose veins","title":"Severe varicose veins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe varicose veins</div><div class=\"cntnt\"><img style=\"width:216px; height:294px;\" src=\"images/PC/68551_Severe_varicose_veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prominently dilated and tortuous varicose veins associated with moderate hyperpigmentation.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 68551 Version 1.0</div></div></div>"},"68552":{"type":"graphic_figure","displayName":"Continuous aspiration system","title":"Device for continuous aspiration of subglottic secretions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Device for continuous aspiration of subglottic secretions</div><div class=\"cntnt\"><img style=\"width:292px; height:312px;\" src=\"images/PULM/68552_Continuous_aspiration_syste.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of a specially designed endotracheal tube that permits the drainage of subglottic secretions. Hi-Lo EVAC tube (Mallinckrodt).</div><div class=\"graphic_reference\">Redrawn from Valles J, Artigas A, Rello J, et al. Ann Intern Med 1995; 122:179.</div><div id=\"graphicVersion\">Graphic 68552 Version 2.0</div></div></div>"},"68554":{"type":"graphic_table","displayName":"IV temsirolimus regimen","title":"Temsirolimus for the initial treatment of poor-prognosis metastatic renal cell carcinoma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Temsirolimus for the initial treatment of poor-prognosis metastatic renal cell carcinoma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: Weekly.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Temsirolimus</strong></td> <td>25 mg IV*</td> <td>Dilute in 250 mL normal saline (NS) and infuse via an infusion pump over 60 minutes for the first dose<sup>&#916;</sup>. Subsequent doses may be given over 30 minutes if tolerated.</td> <td>Once weekly</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW (10 to 30 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Temsirolimus has caused hypersensitivity reactions, including anaphylaxis, which can occur with the initial as well as subsequent infusions. Premedication with an H1-antagonist such as diphenhydramine is recommended. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Not applicable. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver dysfunction:</strong> For patients with liver dysfunction (bilirubin &#62;1.5 to 1.5 times the upper limit of normal [ULN] or AST &#62;ULN with a normal bilirubin), the dose of temsirolimus should be reduced to 15 mg. Temsirolimus is contraindicated for bilirubin &#62;1.5 times the ULN<sup>[2]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Serum electrolytes at baseline then every two to four weeks.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Serum glucose, cholesterol, and triglycerides at baseline then every four weeks.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Temsirolimus should not be administered if the absolute neutrophil count (ANC) is &#60;1000/microL and/or platelet count is &#60;50,000/microL. Withhold treatment until myelotoxicity resolves to grade 2 or less (ANC &#62;1000/microL, platelets &#62;50,000/microL), then restart with a 5 mg per week dose reduction (minimum dose is 15 mg per week)<sup>[2]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; AST: aspartate aminotransferase; CBC: complete blood count.<br />* Total dose, not adjusted for weight or body surface area.<br />&Delta; Administer through an inline 5-micron (or smaller), polyethersulfone filter. Do not use DEHP-containing (PVC) containers or administration sets<sup>[2]</sup>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Hudes G, et al. N Engl J Med 2007; 356:2271. </LI>&#xD;&#xA;<LI>Temsirolimus injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011). </LI></OL></div><div id=\"graphicVersion\">Graphic 68554 Version 16.0</div></div></div>"},"68555":{"type":"graphic_diagnosticimage","displayName":"HRCT bronchiectasis child","title":"Computerized tomography (CT) scan in a pediatric patient with bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computerized tomography (CT) scan in a pediatric patient with bronchiectasis</div><div class=\"cntnt\"><img style=\"width:299px; height:234px;\" src=\"images/PEDS/68555_HRCT_bronchiect_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dilated and thickened airways have a tram-track-like appearance in the periphery of the lung (arrows).</div><div class=\"graphic_reference\">Courtesy of: Drs. Khoulood Fakhoury and Adaobi Kanu.</div><div id=\"graphicVersion\">Graphic 68555 Version 4.0</div></div></div>"},"68556":{"type":"graphic_figure","displayName":"Thigh foot angle","title":"Determination of the thigh-foot angle","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Determination of the thigh-foot angle</div><div class=\"cntnt\"><img style=\"width:520px; height:407px;\" src=\"images/PEDS/68556_Thigh_foot_angle_rev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thigh-foot angle (TFA) is the angular difference between the axis of the foot and thigh when the patient is in a prone position with the knees flexed 90 degrees and the foot and ankle are in neutral position. The TFA is external (or positive) when the foot points away from the midline (left) and internal (or negative) when the foot points toward the midline (right). The TFA normally ranges from +10 to +15 degrees.</div><div id=\"graphicVersion\">Graphic 68556 Version 4.0</div></div></div>"},"68559":{"type":"graphic_diagnosticimage","displayName":"Lipoma terminal ileum CT","title":"Lipoma of terminal ileum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipoma of terminal ileum</div><div class=\"cntnt\"><img style=\"width:321px; height:288px;\" src=\"images/GAST/68559_Lipoma_terminal_ileum_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the lower abdomen demonstrates a soft tissue mass of fat density in the lumen of the terminal ileum (arrow). These characteristics are diagnostic for a lipoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 68559 Version 3.0</div></div></div>"},"68560":{"type":"graphic_table","displayName":"Lynch syndrome SGO criteria","title":"Lynch syndrome risk assessment: Society of Gynecologic Oncology guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lynch syndrome risk assessment: Society of Gynecologic Oncology guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with an increased likelihood of Lynch syndrome and for whom genetic assessment is recommended.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients with endometrial or colorectal cancer with evidence of microsatellite instability or loss of a DNA mismatch repair protein (MLH1, MSH2, MSH6, PMS2) on immunohistochemistry. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients with a first-degree relative* affected with endometrial or colorectal cancer who was either diagnosed before age 60 years or who is identified to be at risk for Lynch syndrome by a systematic clinical screen that incorporates a focused personal and medical history. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Patients with a first or second degree relative* with a known mutation in a mismatch repair gene. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* First degree relatives are parents, siblings and Children. Second degree relatives are aunts, uncles, nieces, nephews, grandparents and grandchildren.</div><div class=\"graphic_reference\">Reproduced from: Lancaster JM, Powell CB, Chen, L, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015; 136:3. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68560 Version 2.0</div></div></div>"},"68562":{"type":"graphic_figure","displayName":"Femoral anteversion","title":"Femoral anteversion","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Femoral anteversion</div><div class=\"cntnt\"><img style=\"width:507px; height:432px;\" src=\"images/PEDS/68562_Femoral-anteversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral anteversion is the angle formed by the axis of the femoral neck and the transcondylar axis of the femur.</div><div id=\"graphicVersion\">Graphic 68562 Version 1.0</div></div></div>"},"68563":{"type":"graphic_figure","displayName":"Construction of a double barrel end colostomy","title":"Construction of a double barrel end colostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a double barrel end colostomy</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/68563_Double-barrel-end-colostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the divided proximal and distal limbs exteriorized through the same abdominal wall aperture.</div><div id=\"graphicVersion\">Graphic 68563 Version 1.0</div></div></div>"},"68566":{"type":"graphic_table","displayName":"Pseudoallergen-free diet for CSU: Prohibited foodstuffs","title":"Pseudoallergen-free diet for chronic spontaneous urticaria: Prohibited foodstuffs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pseudoallergen-free diet for chronic spontaneous urticaria: Prohibited foodstuffs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Foodstuff</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Additives</td> <td>E100-E1518, preservatives or artificial colors, gelling agents, thickening matter, humectant, emulsifiers, flavor potentiators, antioxidants, separating agents, sweeteners, baking agents, modified starches, foaming agents, stabilizers, flavoring agents.</td> </tr> <tr> <td>Spices and herbs</td> <td>Salt and chives allowed. Avoid all others.</td> </tr> <tr> <td>Egg products</td> <td>Eggs, pasta made with eggs, cake, biscuits, mayonnaise.</td> </tr> <tr> <td>Meat and seafood</td> <td>Smoked meats, seafood.</td> </tr> <tr> <td>Vegetables</td> <td>Tomatoes, artichokes, peas, mushrooms, spinach, rhubarb, olives, sweet peppers.</td> </tr> <tr> <td>Fruit</td> <td>Fresh fruits, dried fruits, fruit juices.</td> </tr> <tr> <td>Breads</td> <td>Breads with additional grains, herbs, or other such added ingredients. Packaged bread is preferable to bakery breads because the ingredients are listed on the label.</td> </tr> <tr> <td>Miscellaneous, candies</td> <td>Alcohol, herbal teas, margarine, sesame, potato chips, chewing gum, candy.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adopting a diet free of pseudoallergens is an alternative approach to managing chronic spontaneous urticaria. All of the items listed above should be avoided. Patients may eat fresh or deep-frozen forms of any foods that are NOT listed above, without any additives. Chemical and common names for additives listed by E number above may be found online at <A href=\"http://www.food.gov.uk/safereating/chemsafe/additivesbranch/enumberlist\" target=_blank>www.food.gov.uk/safereating/chemsafe/additivesbranch/enumberlist</A>.<br />The author of this review and the editors of UpToDate do not routinely recommend a pseudoallergen-free diet to patients with chronic urticaria for the reasons discussed in the topic on standard management and patient education in chronic urticaria. However, there may be patients who are interested in this information.</div><div class=\"graphic_reference\">Adapted from: Magerl M, Pisarevskaja D, Scheufele R, et al. Effects of a pseudoallergen free diet on chronic spontaneous urticaria: a prospective trial. Allergy 2010; 65:78.</div><div id=\"graphicVersion\">Graphic 68566 Version 7.0</div></div></div>"},"68567":{"type":"graphic_diagnosticimage","displayName":"Complete CBD transection II","title":"Complete transection of common bile duct after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete transection of common bile duct after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:352px;\" src=\"images/GAST/68567_Complete_CBD_transection_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ERCP shows complete transection of the comon bile duct.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 68567 Version 3.0</div></div></div>"},"68569":{"type":"graphic_picture","displayName":"Mycobacterium marinum nodules","title":"<EM>Mycobacterium marinum</EM> infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Mycobacterium marinum</EM> infection</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/ID/68569_Mycobacterium_marinum_nodul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerative nodules on the arm.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.145.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 68569 Version 8.0</div></div></div>"},"68570":{"type":"graphic_table","displayName":"Cysts in children","title":"Renal cystic diseases in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal cystic diseases in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Polycystic kidney diseases</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Autosomal recessive polycystic kidney disease</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Autosomal dominant polycystic kidney disease</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Cystic renal dysplasia</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Microcystic kidney</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Cystic dysplasia with obstruction</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Medullary cystic diseases</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Nephronophthisis-medullary cystic disease</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Medullary sponge kidney</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Cortical cystic diseases</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Glomerular cysts</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Cortical microcysts with interstitial nephritis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Renal cysts in malformative syndromes</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Simple and multilocular renal cysts</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Other</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> von Hippel-Lindau disease</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Tuberous sclerosis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td> Acquired cystic disease of the kidney</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68570 Version 1.0</div></div></div>"},"68572":{"type":"graphic_picture","displayName":"Choriocarcinoma histo","title":"Choriocarcinoma histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choriocarcinoma histology</div><div class=\"cntnt\"><img style=\"width:354px; height:396px;\" src=\"images/OBGYN/68572_Choriocarcinoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Choriocarcinoma. The syncytiotrophoblast cell surrounds a cluster of cytotrophoblast cells. Hemorrhage is evident in the adjacent tissue.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68572 Version 1.0</div></div></div>"},"68573":{"type":"graphic_table","displayName":"Immune globulin for intravenous administration (IVIG or IGIV)","title":"Immune globulin products for intravenous administration (IVIG or IGIV)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immune globulin products&nbsp;for intravenous administration (IVIG or IGIV)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><span style=\"color: #ff0000;\"></span>Trade name<br /> (United States)</td> <td class=\"subtitle1\">Manufacturer<br /> (processed by)</td> <td class=\"subtitle1\">Available form</td> <td class=\"subtitle1\">Concentration, %<br /> (grams IgG per 100 mL)</td> <td class=\"subtitle1\">Sugar</td> <td class=\"subtitle1\">Sodium</td> <td class=\"subtitle1\">Other*</td> <td class=\"subtitle1\">mOsms*</td> <td class=\"subtitle1\">IgA content</td> <td class=\"subtitle1\">Viral reduction steps</td> </tr> <tr class=\"divider_bottom\"> <td>Bivigam</td> <td>Biotest Pharmaceuticals</td> <td>Liquid</td> <td>10</td> <td>None</td> <td>Sodium chloride 0.1 to 0.14 mol/L</td> <td> <p>Glycine 0.2 to 0.29 mol/L</p> Polysorbate 80 1.5 to 2.5 mg/mL</td> <td>&#60;510 mOsm/kg</td> <td>&#8804;200 mcg/mL</td> <td>Precipitation, cold ethanol fractionation, S/D, nanofiltration, low pH</td> </tr> <tr class=\"divider_bottom\"> <td>Carimune NF</td> <td>CSL Behring</td> <td>Lyophilized</td> <td>3, 6, 12</td> <td>1.67 gram sucrose per gram protein</td> <td>Sodium chloride &#60;20 mg per gram IgG</td> <td>None</td> <td>192 to 1074<sup>&#182;</sup> mOsm/kg</td> <td>1000 to 2000 mcg/mL</td> <td>pH 4/pepsin treatment, nanofiltration, TSE removal</td> </tr> <tr class=\"divider_bottom\"> <td>Flebogamma DIF</td> <td>Grifols</td> <td>Liquid</td> <td>5, 10</td> <td>50 mg/mL sorbitol</td> <td>Trace </td> <td> <p>5%: PEG &#8804;3 mg/mL&nbsp;</p> <p>10%: PEG &#8804;6 mg/mL</p> </td> <td>240 to 370 mOsm/kg</td> <td> <p>5%: &#60;50 mcg/mL</p> <p>10%: &#60;100&nbsp;mcg/mL</p> </td> <td>Cold ethanol fractionation, PEG precipitation, ion exchange chromatography,&nbsp;low pH, pasteurization, S/D, nanofiltration, TSE removal</td> </tr> <tr class=\"divider_bottom\"> <td>Gammagard Liquid</td> <td>Baxalta/Shire</td> <td>Liquid</td> <td>10</td> <td>None</td> <td>Not detectable</td> <td>Glycine 0.25 mol/L</td> <td>240 to 300 mOsm/kg</td> <td>37 mcg/mL</td> <td>S/D, low pH treatment, nanofiltration</td> </tr> <tr class=\"divider_bottom\"> <td>Gammagard S/D (not available in United States; available in some other countries)</td> <td>Baxalta/Shire</td> <td>Lyophilized</td> <td>5, 10</td> <td>20 mg/mL glucose when prepared as a 5% solution<sup>&#916;</sup></td> <td>8.5 mg/mL when prepared as a 5% solution<sup>&#916;</sup></td> <td> <p>When prepared as a 5% solution<sup>&#916;</sup>:</p> <p>Glycine 22.5 mg/mL</p> <p>PEG 2 mg/mL</p> <p>Polysorbate 80 100 mcg/mL</p> Albumin 3 mg/mL</td> <td>636 mOsm/L when prepared as a 5% solution<sup>&#916;</sup></td> <td>&#8804;2.2 mcg/mL when prepared as 5% solution<sup>&#916;</sup></td> <td>S/D, cold ethanol fractionation</td> </tr> <tr class=\"divider_bottom\"> <td>Gammagard S/D Less IgA</td> <td>Baxalta/Shire</td> <td>Lyophilized</td> <td>5, 10</td> <td>20 mg/mL glucose when prepared as a 5% solution<sup>&#916;</sup></td> <td>8.5 mg/mL when prepared as a 5% solution<sup>&#916;</sup></td> <td> <p>When prepared as a 5%<sup> </sup>solution<sup>&#916;</sup>:</p> <p>Glycine 22.5 mg/mL</p> <p>PEG 2 mg/mL</p> <p>Polysorbate 80 100 mcg/mL</p> Albumin 3 mg/mL</td> <td>636 mOsm/L when prepared as a 5% solution<sup>&#916;</sup></td> <td>&#60;1 mcg/mL when prepared as 5% solution<sup>&#916;</sup></td> <td>S/D, cold ethanol fractionation</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Gammaked</p> </td> <td>Grifols</td> <td>Liquid</td> <td>10</td> <td>None</td> <td>Trace &#60;7 mEq/L</td> <td>Glycine 0.16 to 0.24 mol/L</td> <td>258 mOsm/kg</td> <td>46 mcg/mL (average)</td> <td>Caprylate chromatography purified, low pH incubation, TSE removal</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Gammaplex 5%</p> <p>Gammaplex 10%</p> </td> <td>Bio Products Laboratory</td> <td>Liquid</td> <td>5, 10</td> <td> <p>5%: 50 mg/mL D-sorbitol</p> <p>10%: None</p> </td> <td> <p>5%: Sodium acetate 2 mg/mL and sodium chloride 3 mg/mL</p> <p>10%: &#60;0.3 mmol/mL</p> <p>&nbsp;</p> </td> <td> <p>5%: Glycine 6 mg/mL and polysorbate 80 approximately 0.05 mg/mL</p> <p>10%: Glycine 0.2 to&nbsp;0.3 mmol/mL and polysorbate 80 approximately 0.01 to&nbsp;0.06 mg/mL</p> </td> <td> <p>5%: 420 to 500 mOsm/kg</p> <p>10%: Approximately 280 mOsm/kg</p> </td> <td> <p>5%: &#60;10 mcg/mL</p> <p>10%: &#60;20 mcg/mL</p> </td> <td>S/D, nanofiltration, low pH incubation</td> </tr> <tr class=\"divider_bottom\"> <td>Gamunex-C</td> <td>Grifols</td> <td>Liquid</td> <td>10</td> <td>None</td> <td>Trace &#60;7 mEq/L</td> <td>Glycine 0.15 grams/kg</td> <td>258 mOsm/kg</td> <td>46 mcg/mL</td> <td>Caprylate chromatography purified, low pH incubation, TSE removal</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Octagam 5%</p> <p>Octagam 10%</p> </td> <td>Octapharma</td> <td>Liquid</td> <td>5, 10</td> <td> <p>5%: 100 mg/mL maltose</p> 10%: 90 mg/mL</td> <td>&#8804;30 mmol/L</td> <td>Not reported</td> <td>310 to 380 mOsm/kg</td> <td> <p>5%: &#8804;200 mcg/mL</p> 10%: 106 mcg/mL (average)</td> <td>Cold ethanol fractionation, S/D, pH 4 treatment</td> </tr> <tr> <td>Privigen<sup>&#9674;</sup></td> <td>CSL Behring</td> <td>Liquid</td> <td>10</td> <td>None</td> <td>Trace &#8804;1 mmol/L</td> <td>L-proline<sup>&#9674;</sup> 250 mmol/L</td> <td>220 to 440 mOsm/kg</td> <td>&#8804;25 mcg/mL</td> <td>pH 4 incubation, 20 nm virus filtration, depth filtration, TSE removal</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For information on products available for subcutaneous or intramuscular use, <SPAN style=\"COLOR: black\">please refer to the separate table: Immune globulin products available in the United States or Canada for subcutaneous and intramuscular use.</SPAN></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgA: immunoglobulin A; S/D: solvent/detergent-treated; NF: nanofiltration; TSE: transmissible spongiform encephalopathy; <FONT color=black>DIF: dual inactivation and filtration;</FONT><FONT color=black> PEG: polyethylene glycol.</FONT><br />* Units as reported by manufacturer. Other stabilizing components may be present. Consult product labeling.<br />¶&nbsp;Osmolality varies depending on diluent type, volume, and protein concentration.<br />Δ When prepared as a 10% solution, the content of all components including IgA will be twice the values reported in the table for a 5% solution.<br /><FONT class=lozenge>◊</FONT> Privigen is contraindicated in patients with hyperprolinemia.</div><div class=\"graphic_reference\">Data from: United States Food &amp; Drug Administration licensed product information accessible at: <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a> or data available upon request from manufacturer's medical information department.</div><div id=\"graphicVersion\">Graphic 68573 Version 37.0</div></div></div>"},"68574":{"type":"graphic_figure","displayName":"HLA-B27 induce AS","title":"Three different HLA-B27 structures and hypotheses as to how they might induce disease processes in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Three different HLA-B27 structures and hypotheses as to how they might induce disease processes in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:526px; height:586px;\" src=\"images/RHEUM/68574_HLA-B27_induce_AS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HLA-B27 are first generated as free heavy chains, which inside the cells become associated and folded with the beta-2-microglobulin and antigenic peptide, and then become expressed on the cell surface as a trimolecular complex. It can also be expressed on the cell surface as homodimers of heavy chains without the beta-2-microglobulin.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Reprinted by permission from: MacMillan Publishers Ltd: Tam, LS, Jieruo, G, Yu, D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010; 6:399. Copyright © 2010 MacMillan Publishers Ltd.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 68574 Version 3.0</div></div></div>"},"68576":{"type":"graphic_picture","displayName":"Psoriasis on the face","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68576_Psoriasis_on_the_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques are present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68576 Version 3.0</div></div></div>"},"68577":{"type":"graphic_table","displayName":"Features of high risk abdominal pain","title":"Features of high risk abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of high risk abdominal pain</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   History\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Age over 65</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Immunocompromised (eg, HIV, chronic glucocorticoid treatment)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Alcoholism (risk of hepatitis, cirrhosis, pancreatitis)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiovascular disease (eg, CAD, PVD, hypertension, atrial fibrillation)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Major comorbidities (eg, cancer, diverticulosis, gallstones, IBD, pancreatitis, renal failure)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prior surgery or recent GI instrumentation (risk of obstruction, perforation)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Early pregnancy (risk of ectopic pregnancy)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Pain characteristics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sudden onset</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Maximal at onset</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pain then subsequent vomiting</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Constant pain of less than two days duration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td   class=\"subtitle1_single\">\r\n  \r\n   Exam findings\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tense or rigid abdomen</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Involuntary guarding</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Signs of shock</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">CAD: coronary artery disease; HIV: human immunodeficiency virus; IBD: inflammatory bowel disease; PVD: peripheral vascular disease.</div><div id=\"graphicVersion\">Graphic 68577 Version 2.0</div></div></div>"},"68579":{"type":"graphic_table","displayName":"Prophylactic medication CVS","title":"Prophylactic or preventive medications* in CVS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prophylactic or preventive medications* in CVS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Children 2 to 5 years old</td> </tr> <tr> <td class=\"subtitle2_single\">Antihistamines: cyproheptadine (first choice) and pizotifen (available in UK, Canada)</td> </tr> <tr> <td class=\"indent1\">Cyproheptadine 0.25-0.5 mg/kg/day orally divided twice daily or three times daily (maximum 12 mg per 24 hours). (Available in 2 mg/5 mL liquid).</td> </tr> <tr> <td class=\"indent1\">Side effects: increased appetite, weight gain, sedation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternatives: pizotifen (available in UK, Canada)</td> </tr> <tr> <td class=\"subtitle2_single\">Beta-blockers: propranolol (second choice)</td> </tr> <tr> <td class=\"indent1\">Propranolol 0.25-1 mg/kg/day orally divided twice daily or three times daily, most often 10 mg twice daily or three times daily. Initiate at 0.25 mg/kg/day and increase every 1-4 weeks in increments of 0.25 mg/kg/day as needed and tolerated. (&#60;35 kg maximum 60 mg per 24 hours. &#8805;35 kg maximum 120 mg per 24 hours). (Available in liquid).</td> </tr> <tr> <td class=\"indent1\">Monitor: resting heart rate maintain &#8805;60 bpm</td> </tr> <tr> <td class=\"indent1\">Side effects: lethargy, reduced exercise intolerance</td> </tr> <tr> <td class=\"indent1\">Contraindications: asthma, diabetes, heart disease, depression</td> </tr> <tr> <td class=\"indent1\">Discontinuation: tapered for 1-2 weeks</td> </tr> <tr> <td class=\"subtitle1_single\">Children older than 5 years</td> </tr> <tr> <td class=\"subtitle2_single\">Tricyclic antidepressants: amitriptyline (first choice)</td> </tr> <tr> <td class=\"indent1\">Amitriptyline begin at 0.25-0.5 mg/kg/day orally at bedtime, increase every 1-4 weeks as needed and tolerated by 5-10 mg, until 1-1.5 mg/kg/day (maximum 75 mg per 24 hours). (For dose &#62;1 mg/kg/day, divide twice daily).</td> </tr> <tr> <td class=\"indent1\">Monitor: &#8730;EKG QT<sub>c</sub> interval before starting and 10 days after peak dose</td> </tr> <tr> <td class=\"indent1\">Side effects: constipation, sedation, arrhythmia, behavioral changes (especially in young children)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternatives: nortriptyline<sup>&#182;</sup> (available in 10 mg/5 mL liquid)</td> </tr> <tr> <td class=\"subtitle2_single\">Beta-blockers: propranolol (second choice) - see above</td> </tr> <tr> <td class=\"subtitle1_single\">Other agents</td> </tr> <tr> <td class=\"subtitle2_single\">Anticonvulsants: phenobarbital<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Phenobarbital 2 mg/kg/day orally administered at bedtime (maximum 40 mg per 24 hours)</td> </tr> <tr> <td class=\"indent1\">Side effects: sedation, cognitive impairment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Alternatives: topiramate, valproic acid, gabapentin, levetiracetam - consult Pediatric neurologist</td> </tr> <tr> <td class=\"subtitle2_single\">Supplements<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">L-carnitine 50-100 mg/kg/day orally divided twice daily or three times daily (maximum 1 g three times daily)</td> </tr> <tr> <td class=\"indent1\">Coenzyme Q<sub>10</sub> 10 mg/kg/day orally divided twice daily or three times daily (maximum 100 mg three times daily)</td> </tr> <tr> <td class=\"indent1\">Side effects: diarrhea, fishy body odor (for L-carnitine)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All medication recommendations are made for off-label use.<br />¶ Limited or no published experience regarding efficacy.</div><div class=\"graphic_reference\">Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68579 Version 11.0</div></div></div>"},"68580":{"type":"graphic_figure","displayName":"Collimaters comp b","title":"Schema of collimator and compensators","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Schema of collimator and compensators</div><div class=\"cntnt\"><img style=\"width:532px; height:238px;\" src=\"images/ONC/68580_Collimaters_comp_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A customized collimator/compensator used in proton radiosurgery.</div><div class=\"graphic_reference\">Courtesy of Clark C Chen, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68580 Version 1.0</div></div></div>"},"68581":{"type":"graphic_figure","displayName":"Nasality relationships","title":"Functional and anatomical relationships in nasality","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Functional and anatomical relationships in nasality</div><div class=\"cntnt\"><img style=\"width:539px; height:593px;\" src=\"images/PEDS/68581_Nasality_relationships.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normally, the soft palate reaches the posterior pharyngeal wall during production of sibilant and plosive sounds (solid arrow, top diagram). With other sounds, the passage is open enough for normal nasal resonance (dashed arrow, top diagram). Large adenoids (bottom left diagram) interfere with airflow and produce hyponasality. Velopharyngeal insufficiency, as in submucous cleft, lets sound escape through the nose and produces hypernasality (bottom right diagram).</div><div id=\"graphicVersion\">Graphic 68581 Version 5.0</div></div></div>"},"68584":{"type":"graphic_diagnosticimage","displayName":"Ferrous sulfate overdose","title":"Abdominal radiograph in iron overdose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal radiograph in iron overdose</div><div class=\"cntnt\"><img style=\"width:215px; height:287px;\" src=\"images/PULM/68584_Ferrous_sulfate_overdose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal radiograph showing radiopaque iron (ferrous sulfate) tablets visualized in the stomach of an intentional overdose patient (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael J Burns, MD.</div><div id=\"graphicVersion\">Graphic 68584 Version 2.0</div></div></div>"},"68585":{"type":"graphic_diagnosticimage","displayName":"Mistaken Dx joint effusion MRI","title":"Magnetic resonance imaging of markedly obese patient with mistaken clinical diagnosis of joint effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of markedly obese patient with mistaken clinical diagnosis of joint effusion</div><div class=\"cntnt\"><img style=\"width:324px; height:280px;\" src=\"images/RHEUM/68585_Mistaken_dx_joint_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">False clinical impression of joint effusion in a markedly obese patient with rheumatoid arthritis. Axial T1 weighted image through the mid-patella shows no significant joint effusion. The normal collapsed medial recess of the knee joint is denoted by arrow heads. As can be seen by the hypothetical needle tract (long arrow), a 1.5-inch needle could not reach this patient's joint via a medial approach. However, a lateral approach could be successful.</div><div class=\"graphic_footnotes\">M: medial side; L: lateral side.</div><div class=\"graphic_reference\">Reproduced with permission from: Roberts,WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 68585 Version 3.0</div></div></div>"},"68587":{"type":"graphic_figure","displayName":"Sectioned kidney","title":"Sectioned kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sectioned kidney</div><div class=\"cntnt\"><img style=\"width:425px; height:426px;\" src=\"images/NEPH/68587_Sectioned_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Neill, WC. Atlas of renal ultrasonography, 1st ed, W.B. Saunders Company, Philadelphia 2000. Copyright ©2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 68587 Version 1.0</div></div></div>"},"68589":{"type":"graphic_figure","displayName":"Dextro type of transposition of the great arteries","title":"Diagram of the dextro type of transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of the dextro type of transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:336px; height:441px;\" src=\"images/PEDS/68589_Transposgreatarteriesedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram of the dextro type of transposition of the great arteries showing the abnormal position of the aorta (Ao) and the pulmonary artery (PA).</div><div class=\"graphic_footnotes\">Ao: aorta; LA: left atrium; LV: left ventricle; PA: pulmonary artery; RA: right atrium; RV: right ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from: Multimedia Library of Congenital Heart Disease, Children's Hospital, Boston, editor Robert Geggel MD, www.childrenshospital.org/mml/cvp.</div><div id=\"graphicVersion\">Graphic 68589 Version 4.0</div></div></div>"},"68593":{"type":"graphic_table","displayName":"Symptoms GI lymphoma","title":"Symptoms in gastrointestinal lymphoma according to involved site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms in gastrointestinal lymphoma according to involved site</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Stomach (n=277)</td> <td class=\"subtitle1\">Small bowel (n=32)</td> <td class=\"subtitle1\">Ileocecal (n=26)</td> <td class=\"subtitle1\">Multiple sites (n=24)</td> </tr> <tr> <td>Pain</td> <td>78</td> <td>75</td> <td>77</td> <td>58</td> </tr> <tr> <td>Loss of appetite</td> <td>47</td> <td>41</td> <td>23</td> <td>58</td> </tr> <tr> <td>Weight loss</td> <td>24</td> <td>34</td> <td>15</td> <td>25</td> </tr> <tr> <td>Bleeding</td> <td>19</td> <td>6</td> <td>12</td> <td>8</td> </tr> <tr> <td class=\"space\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td>Vomiting</td> <td>18</td> <td>31</td> <td>8</td> <td>21</td> </tr> <tr> <td>Night sweats</td> <td>11</td> <td>12 </td> <td>19</td> <td>46</td> </tr> <tr> <td>Diarrhea</td> <td>4</td> <td>12</td> <td>19</td> <td>29</td> </tr> <tr> <td>Constipation</td> <td>3</td> <td>25</td> <td>23</td> <td>12</td> </tr> <tr> <td class=\"space\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td>Fever</td> <td>2</td> <td>6</td> <td>8</td> <td>4</td> </tr> <tr> <td>Perforation</td> <td>2 </td> <td>9</td> <td>-</td> <td>-</td> </tr> <tr> <td>Ileus</td> <td>-</td> <td>38</td> <td>19</td> <td>4</td> </tr> <tr> <td>No symptoms</td> <td>4</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the percent of patients with the listed symptom at each of the four major sites of disease.</div><div class=\"graphic_reference\">Data from Koch P, et al. J Clin Oncol 2001; 19:3861.</div><div id=\"graphicVersion\">Graphic 68593 Version 2.0</div></div></div>"},"68594":{"type":"graphic_table","displayName":"Giant cell v Takayasu arteritis","title":"Distinguishing features of giant cell versus Takayasu arteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features of giant cell versus Takayasu arteritis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Finding\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Giant cell arteritis\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Takayasu arteritis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Female-to-male ratio</td>\r\n  \r\n   <td>3:2</td>\r\n  \r\n   <td>7:1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Age at onset</td>\r\n  \r\n   <td>&#62;50 years</td>\r\n  \r\n   <td>&#60;40 years</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ethnic ancestry</td>\r\n  \r\n   <td>European</td>\r\n  \r\n   <td>Asian</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Histopathology</td>\r\n  \r\n   <td>Granulomatous inflammation</td>\r\n  \r\n   <td>Granulomatous inflammation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Primary vessels involved</td>\r\n  \r\n   <td>External carotid artery branches</td>\r\n  \r\n   <td>Aorta and branches</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Renovascular hypertension</td>\r\n  \r\n   <td>Rare</td>\r\n  \r\n   <td>Common</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>HLA association</td>\r\n  \r\n   <td>HLA-DR4</td>\r\n  \r\n   <td>HLA-Bw52</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Course</td>\r\n  \r\n   <td>Self-limited</td>\r\n  \r\n   <td>Chronic</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Response to corticosteroids</td>\r\n  \r\n   <td>Excellent</td>\r\n  \r\n   <td>Excellent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Surgical intervention needed</td>\r\n  \r\n   <td>Rare</td>\r\n  \r\n   <td>Common</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">15.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=71086&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Giant_cell_v_Takayasu_arter.htm</title></head></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Adapted from Michel, BA, Arend, WP, Hunder, GG. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 1996; 23:106.</div><div id=\"graphicVersion\">Graphic 68594 Version 2.0</div></div></div>"},"68596":{"type":"graphic_figure","displayName":"Port placement laparoscopic esophageal myotomy","title":"Port placement laparoscopic Heller myotomy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Port placement laparoscopic Heller myotomy</div><div class=\"cntnt\"><img style=\"width:503px; height:587px;\" src=\"images/SURG/68596_Port_placement_laparoscopic_Heller_myotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the locations of the trocars for laparoscopic esophageal myotomy.</div><div id=\"graphicVersion\">Graphic 68596 Version 2.0</div></div></div>"},"68597":{"type":"graphic_picture","displayName":"Juvenile xanthogranuloma multiple scalp","title":"Juvenile xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68597_JXG_multiple_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-orange papules and plaques on the scalp of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Kate Püttgen.</div><div id=\"graphicVersion\">Graphic 68597 Version 2.0</div></div></div>"},"68598":{"type":"graphic_diagnosticimage","displayName":"EUS-guided cholangiography","title":"EUS-guided cholangiography","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">EUS-guided cholangiography</div><div class=\"cntnt\"><img style=\"width:601px; height:599px;\" src=\"images/GAST/68598_EUS-guided_cholang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) EUS-guided cholangiography for antegrade access to the bile duct following unsuccessful retrograde access with ERCP. Two large filling defects consistent with choledocholithiasis are seen on the cholangiogram.<br />(B) A guidewire is passed through the fine-needle aspiration needle into the bile duct and across the major duodenal papilla into the second portion of the duodenum in preparation for a \"rendezvous\" procedure.<br />(C) The guidewire is then snared and withdrawn through a side-viewing duodenoscope, allowing access to the bile duct for completion of the \"rendezvous\" procedure. Stone extraction is then performed using conventional ERCP techniques.</div><div class=\"graphic_footnotes\">EUS: endoscopic ultrasound; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 68598 Version 3.0</div></div></div>"},"68600":{"type":"graphic_diagnosticimage","displayName":"Calcified pancreas CT","title":"Chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:313px; height:252px;\" src=\"images/GAST/68600_Calcified_pancreas_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of a patient with chronic pancreatitis demonstrates coarse calcifications (arrow) distributed throughout the body and tail of the pancreas.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 68600 Version 4.0</div></div></div>"},"68602":{"type":"graphic_figure","displayName":"Relationship between GFR and PTH","title":"Relationship between GFR and PTH with and without dietary phosphate restriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relationship between GFR and PTH with and without dietary phosphate restriction</div><div class=\"cntnt\"><img style=\"width:432px; height:238px;\" src=\"images/NEPH/68602_Low_PO4_prevents_PTH_in_CRF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between GFR and the plasma PTH concentration in two groups of dogs which developed renal failure: one maintained on a regular diet (solid line); and one treated with dietary phosphate restriction (dashed line). A decline in GFR led to a progressive rise in PTH levels with the regular diet; limiting phosphate intake prevented both phosphate retention and the development of secondary hyperparathyroidism.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; PTH: parathyroid hormone.</div><div class=\"graphic_reference\">Data from Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.&nbsp;J Clin Invest 1971; 50:492.</div><div id=\"graphicVersion\">Graphic 68602 Version 4.0</div></div></div>"},"68607":{"type":"graphic_figure","displayName":"T shaped uterus 1","title":"Diethylstilbestrol (DES)-related anomalies: T-shaped uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diethylstilbestrol (DES)-related anomalies: T-shaped uterus</div><div class=\"cntnt\"><img style=\"width:356px; height:202px;\" src=\"images/OBGYN/68607_Tshapeduterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68607 Version 16.0</div></div></div>"},"68608":{"type":"graphic_figure","displayName":"Operative repair of the perforated cervical esophagus","title":"Operative repair of the perforated cervical esophagus - approach through the left neck","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Operative repair of the perforated cervical esophagus - approach through the left neck</div><div class=\"cntnt\"><img style=\"width:468px; height:421px;\" src=\"images/SURG/68608_Repair_perf_cerv_eso_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the lateral retraction of the sternocleidomastoid muscle to expose the esophagus. The middle thyroid vein and the omohyoid muscle are divided and the trachea and esophagus are retracted medially.</div><div id=\"graphicVersion\">Graphic 68608 Version 5.0</div></div></div>"},"68609":{"type":"graphic_figure","displayName":"Auricular blood supply","title":"Auricular blood supply","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Auricular blood supply</div><div class=\"cntnt\"><img style=\"width:516px; height:481px;\" src=\"images/EM/68609_Auricular-blood-supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior blood supply comes from the superficial temporal artery. The posterior auricle is fed by the posterior auricular artery. There is a supplemental blood supply from branches of the occipital artery. The superficiall temporal artery and posterior auricular artery communicate via the helical arcade; this arcade is the basis for single pedicle reimplantation of a total avulsion of the auricle.</div><div id=\"graphicVersion\">Graphic 68609 Version 2.0</div></div></div>"},"68610":{"type":"graphic_picture","displayName":"Acute generalized exanthematous pustulosis (AGEP) detail","title":"Acute generalized exanthematous pustulosis (AGEP) detail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute generalized exanthematous pustulosis (AGEP) detail</div><div class=\"cntnt\"><img style=\"width:425px; height:319px;\" src=\"images/ALLRG/68610_AGEP_detail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonfollicular, pinhead-sized pustules on a background of edematous erythema are characteristic of AGEP.</div><div class=\"graphic_reference\">Courtesy of Werner J Pichler, MD.</div><div id=\"graphicVersion\">Graphic 68610 Version 9.0</div></div></div>"},"68612":{"type":"graphic_picture","displayName":"Monofilament in diabetic foot","title":"Monofilament estimation of pressure sensation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monofilament estimation of pressure sensation</div><div class=\"cntnt\"><img style=\"width:378px; height:262px;\" src=\"images/ENDO/68612_Monofilament_in_diabetic_fo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use of the monofilament pressure esthesiometer for quantitative assessment of the cutaneous pressure perception threshold in the foot. The filament (arrow) is placed at a right angle to the skin on the plantar surface of the foot; pressure is then gradually increased until the filament buckles, indicating that a known amount of pressure (determined by the stiffness of the filament) has been applied. The patient is asked if the pressure has been felt. Diabetic patients with insensitivity to the monofilament are at increased risk for foot ulcers.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 68612 Version 1.0</div></div></div>"},"68615":{"type":"graphic_picture","displayName":"Foreign bodies A","title":"Examples of organic foreign bodies removed from children and adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of organic foreign bodies removed from children and adults</div><div class=\"cntnt\"><img style=\"width:334px; height:320px;\" src=\"images/PULM/68615_Foreign_bodies_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 68615 Version 2.0</div></div></div>"},"68617":{"type":"graphic_picture","displayName":"Dynamic Y stent","title":"Dynamic Y-stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dynamic Y-stent</div><div class=\"cntnt\"><img style=\"width:388px; height:215px;\" src=\"images/PULM/68617_Rusch_Y_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Dynamic™ Y stent has a rigid anterior wall comprised of horseshoe-shaped metal struts. The posterior wall is silicone.</div><div id=\"graphicVersion\">Graphic 68617 Version 4.0</div></div></div>"},"68618":{"type":"graphic_picture","displayName":"Lymph infiltr nerve vessel","title":"Chronic lymphocytic inflammation in blood vessel supplying a nerve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic inflammation in blood vessel supplying a nerve</div><div class=\"cntnt\"><img style=\"width:396px; height:286px;\" src=\"images/RHEUM/68618_Lymph_infiltr_nerve_vessel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nerve biopsy revealing chronic lymphocytic inflammation and fibrinoid necrosis within the wall of an artery/arteriole supplying a peripheral nerve.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 68618 Version 1.0</div></div></div>"},"68620":{"type":"graphic_table","displayName":"Elements comp geri assess","title":"Elements of a comprehensive geriatric assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elements of a comprehensive geriatric assessment</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Parameter assessed </td>\r\n            <td class=\"subtitle1\">Elements of the assessment </td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"4\">Function </td>\r\n            <td>Performance status</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Activities of daily living</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Instrumental activities of daily living</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Timed Get Up and Go</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Comorbidity </td>\r\n            <td>Number of comorbid conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Severity of comorbid conditions (comorbidity index)</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Socioeconomic conditions </td>\r\n            <td>Living conditions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Presence and adequacy of a caregiver</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">Cognition </td>\r\n            <td>Folstein's Mini-mental Status</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Other tests</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Emotional conditions</td>\r\n            <td>Geriatric Depression Scale</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"3\">Pharmacy </td>\r\n            <td>Number of medications</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Appropriateness of medications</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Risk of drug interactions</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Nutrition</td>\r\n            <td>Mini-Nutritional Assessment</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"6\">Geriatric syndromes </td>\r\n            <td>Dementia</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Delirium</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Depression</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Falls</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Neglect and abuse</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Spontaneous bone fractures</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced and modified with permission from: Kohne CH, Folprecht G, Goldberg RM, et al. Chemotherapy in Elderly Patients with Colorectal Cancer. The Oncologist 2008; 13:390. Copyright &#169; 2008 AlphaMed Press.</div><div id=\"graphicVersion\">Graphic 68620 Version 2.0</div></div></div>"},"68621":{"type":"graphic_picture","displayName":"Petroleum gauze dressing PI","title":"Circumcised penis wrapped in petroleum gauze dressing","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Circumcised penis wrapped in petroleum gauze dressing</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/PI/68621_Petroleum_gauze_dressing_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 68621 Version 1.0</div></div></div>"},"68626":{"type":"graphic_figure","displayName":"AGA Nasoenteric routes","title":"Possible routes for feeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Possible routes for feeding</div><div class=\"cntnt\"><img style=\"width:402px; height:445px;\" src=\"images/GAST/68626_AGA_Nasoenteric_routes.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEG: percutaneous endoscopic gastrostomy; PEJ: percutaneous endoscopic jejunostomy.</div><div class=\"graphic_reference\">Adapted from: American Gastroenterological Association Medical Position Statement: guidelines for the use of enteral nutrition. Gastroenterology 1995; 108:1282.</div><div id=\"graphicVersion\">Graphic 68626 Version 3.0</div></div></div>"},"68628":{"type":"graphic_figure","displayName":"HLA-B27 peptide presentation","title":"HLA-B27 peptide presentation","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">HLA-B27 peptide presentation</div><div class=\"cntnt\"><img style=\"width:468px; height:566px;\" src=\"images/RHEUM/68628_HLA-B27_peptide_presentatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel (A): The three-dimensional structure of the alpha-1 and alpha-2 domains of HLA-B*2705. Numbers identify polymorphic residues among B27 subtypes. A peptide (green) intimately interacts with the groove through hydrogen bonds. Each of six pockets (A-F) can bind the side chain of an individual amino acid. Lower panel: (B) Schematic diagram showing binding of antigenic peptides to HLA-B27 and recognition by the T-cell receptor. The side-chains of peptide \"anchor\" residues P2, P3 and P9 (C-terminal) are bound in pockets. The side-chains of P1, P4, and P8, which extend out of the peptide-binding groove, are critical for T-cell recognition.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: Lopez-Larrea, C, Gonzalez, S, Martinez-Borra, J. The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. Molecular Medicine Today 1998; 4:540. Copyright © 1998 Elsevier Science.<br> (B) Reproduced with permission from: Bowness, P, Zaccai, N, Bird, J, Jones, FY. HLA-B27 and disease pathogenesis: new structural and functional insights. Exp Rev Mol Med. Cambridge University Press 1999. Copyright © 1999 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 68628 Version 4.0</div></div></div>"},"68629":{"type":"graphic_figure","displayName":"Muscle compartments of the leg","title":"Muscle compartments of the leg","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Muscle compartments of the leg</div><div class=\"cntnt\"><img style=\"width:525px; height:532px;\" src=\"images/SURG/68629_Muscle-compartments-of-the-leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compartments of the leg:<br /><UL>&#xD;&#xA;<LI>Anterior compartment (blue) — Tibialis anterior, extensor muscles of the foot, and fibularis (peroneus) tertius muscles. The anterior tibial artery and deep fibular (peroneal) nerve supply the anterior compartment. </LI>&#xD;&#xA;<LI>Lateral compartment (green) — Fibularis (peroneus) longus and fibularis (peroneus) brevis muscles. The superficial fibular (peroneal) nerve and branches from the anterior tibial artery supply these muscles. </LI>&#xD;&#xA;<LI>Superficial posterior compartment (purple) — Gastrocnemius, soleus and plantaris muscles. Tibial nerve branches supply these muscles. The arteries which supply these muscles descend from the popliteal artery. The sural arteries (medial, lateral) supply the gastrocnemius. The soleus is variably supplied by the popliteal artery, posterior tibial artery and fibular (peroneal) artery. </LI>&#xD;&#xA;<LI>Deep posterior compartment (pink) — Tibialis posterior, flexor muscles of the foot and popliteus muscles. The deep posterior compartment is innervated by the tibial nerve and supplied by the posterior tibial and fibular (peroneal) arteries. </LI></UL></div><div id=\"graphicVersion\">Graphic 68629 Version 5.0</div></div></div>"},"68630":{"type":"graphic_diagnosticimage","displayName":"MR cholangiogram showing common bile duct stones","title":"MR cholangiogram showing common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MR cholangiogram showing common bile duct stones</div><div class=\"cntnt\"><img style=\"width:432px; height:388px;\" src=\"images/SURG/68630_MR_chol_bileduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiogram showing common bile duct stones (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Maier, RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68630 Version 2.0</div></div></div>"},"68631":{"type":"graphic_diagnosticimage","displayName":"Color Doppler flow mapping of right and left ventricular outflow","title":"Color Doppler flow mapping of right and left ventricular outflow tracts","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Color Doppler flow mapping of right and left ventricular outflow tracts</div><div class=\"cntnt\"><img style=\"width:494px; height:400px;\" src=\"images/OBGYN/68631_Color_Dopp_RV_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As indexed by the color bar on the right side, the flow toward the transducer is encoded in red and flow away from the transducer is encoded in blue. Note the mosaic color pattern in the LVOT indicating aliasing because of the high velocity of the blood flow.</div><div class=\"graphic_footnotes\">RV and LV: right and left ventricles, respectively; IVS: interventricular septum; RVOT and LVOT: right and left ventricular outflow tracts, respectively.</div><div class=\"graphic_reference\">Courtesy of Dev Maulik, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68631 Version 4.0</div></div></div>"},"68632":{"type":"graphic_picture","displayName":"Milking maneuver for elbow medial collateral ligament","title":"Milking maneuver for the elbow medial collateral ligament","html":"<div class=\"graphic\"><div style=\"width: 914px\" class=\"figure\"><div class=\"ttl\">Milking maneuver for the elbow medial collateral ligament</div><div class=\"cntnt\"><img style=\"width:894px; height:362px;\" src=\"images/EM/68632_Mlk_mnv_elbw_mdl_clltrl_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Milking maneuver places valgus stress on the medial (or ulnar) collateral ligament of the elbow in a throwing position. With the patient's affected extremity in 90 degrees of shoulder abduction and maximal external rotation, elbow flexed to about 90 degrees, and forearm supinated, the clinician grasps the patient's thumb and applies valgus stress to the elbow by pulling on the thumb. A soft endpoint or increased medial elbow widening compared to the unaffected extremity marks a positive test.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD and Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 68632 Version 4.0</div></div></div>"},"68633":{"type":"graphic_table","displayName":"Pt variability BTMs","title":"Determinants of the preanalytical variability of bone turnover","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determinants of the preanalytical variability of bone turnover</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Controllable determinants</td> </tr> <tr> <td class=\"indent1\">Circadian variation</td> </tr> <tr> <td class=\"indent1\">Menstrual variation</td> </tr> <tr> <td class=\"indent1\">Seasonal variation</td> </tr> <tr> <td class=\"indent1\">Fasting and food intake (serum beta-CTX-1)</td> </tr> <tr> <td class=\"indent1\">Exercise and physical activity</td> </tr> <tr> <td class=\"subtitle1_single\">Determinants that cannot be easily modified</td> </tr> <tr> <td class=\"indent1\">Age</td> </tr> <tr> <td class=\"indent1\">Sex</td> </tr> <tr> <td class=\"indent1\">Menopausal status</td> </tr> <tr> <td class=\"indent1\">Vitamin D deficit and secondary hyperparathyroidism</td> </tr> <tr> <td class=\"sublist2_start\">Diseases characterized by an acceleration of bone turnover</td> </tr> <tr> <td class=\"sublist2\">Primary hyperparathyroidism</td> </tr> <tr> <td class=\"sublist2\">Thyrotoxicosis</td> </tr> <tr> <td class=\"sublist2\">Acromegaly</td> </tr> <tr> <td class=\"sublist2\">Paget disease</td> </tr> <tr> <td class=\"sublist2\">Bone metastases</td> </tr> <tr> <td class=\"sublist2_start\">Diseases characterized by a dissociation of bone turnover</td> </tr> <tr> <td class=\"sublist2\">Cushing's disease</td> </tr> <tr> <td class=\"sublist2\">Multiple myeloma</td> </tr> <tr> <td class=\"sublist2_start\">Diseases characterized by a low bone turnover</td> </tr> <tr> <td class=\"sublist2\">Hypothyroidism</td> </tr> <tr> <td class=\"sublist2\">Hypoparathyroidism</td> </tr> <tr> <td class=\"sublist2\">Hypopituitarism</td> </tr> <tr> <td class=\"sublist2\">Growth hormone deficit</td> </tr> <tr> <td class=\"indent1\">Renal impairment (depending on the stage)</td> </tr> <tr> <td class=\"indent1\">Recent fracture</td> </tr> <tr> <td class=\"sublist2_start\">Chronic diseases associated with limited mobility</td> </tr> <tr> <td class=\"sublist2\">Stroke</td> </tr> <tr> <td class=\"sublist2\">Hemiplegia</td> </tr> <tr> <td class=\"sublist2\">Dementia</td> </tr> <tr> <td class=\"sublist2\">Alzheimer disease</td> </tr> <tr> <td class=\"sublist2_start\">Medications</td> </tr> <tr> <td class=\"sublist2\">Oral corticosteroids</td> </tr> <tr> <td class=\"sublist2\">Inhaled corticosteroids (only osteocalcin)</td> </tr> <tr> <td class=\"sublist2\">Aromatase inhibitors (anti-aromatases)</td> </tr> <tr> <td class=\"sublist2\">GnRH agonists</td> </tr> <tr> <td class=\"sublist2\">Antiepileptic drugs</td> </tr> <tr> <td class=\"sublist2\">Thiazolidinediones</td> </tr> <tr> <td class=\"sublist2\">Heparin</td> </tr> <tr> <td class=\"sublist2\">Vitamin K antagonists</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTX: C-telopeptide of type&nbsp;I collagen; GnRH: gonadotropin-releasing hormone.</div><div class=\"graphic_reference\">Szulc P, Delmas PD. 2008 Biochemical Markers of Bone Turnover in Osteoporosis. In: Rosen C (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed. Copyright &copy; 2008. Reproduced with permission of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 68633 Version 10.0</div></div></div>"},"68634":{"type":"graphic_picture","displayName":"Preeclampsia immunofluorescence microscopy","title":"IgM deposition in preeclampsia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgM deposition in preeclampsia</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/68634_Preeclampsia_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy in preeclampsia showing diffuse&nbsp;immunoglobulin M&nbsp;(IgM) deposition. This represents nonspecific entrapment of larger proteins in the more permeable glomerular capillary wall, rather than the formation of discrete immune complexes. There is, for example, generally no deposition of immunoglobulin G (IgG).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 68634 Version 3.0</div></div></div>"},"68635":{"type":"graphic_table","displayName":"Fetal reticulocyte count by GA","title":"Reticulocyte count, 10<sup>12</sup>/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reticulocyte count, 10<sup>12</sup>/L</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">GA</td>\n<td class=\"subtitle1\">5th percentile</td>\n<td class=\"subtitle1\">Mean</td>\n<td class=\"subtitle1\">95th percentile</td>\n</tr>\n<tr>\n<td>20</td>\n<td>0.15</td>\n<td>0.33</td>\n<td>0.73</td>\n</tr>\n<tr>\n<td>22</td>\n<td>0.13</td>\n<td>0.30</td>\n<td>0.66</td>\n</tr>\n<tr>\n<td>24</td>\n<td>0.12</td>\n<td>0.27</td>\n<td>0.60</td>\n</tr>\n<tr>\n<td>26</td>\n<td>0.11</td>\n<td>0.25</td>\n<td>0.55</td>\n</tr>\n<tr>\n<td>28</td>\n<td>0.10</td>\n<td>0.22</td>\n<td>0.50</td>\n</tr>\n<tr>\n<td>30</td>\n<td>0.09</td>\n<td>0.20</td>\n<td>0.46</td>\n</tr>\n<tr>\n<td>32</td>\n<td>0.08</td>\n<td>0.19</td>\n<td>0.41</td>\n</tr>\n<tr>\n<td>34</td>\n<td>0.08</td>\n<td>0.17</td>\n<td>0.38</td>\n</tr>\n<tr>\n<td>36</td>\n<td>0.07</td>\n<td>0.15</td>\n<td>0.35</td>\n</tr>\n<tr>\n<td>38</td>\n<td>0.06</td>\n<td>0.14</td>\n<td>0.32</td>\n</tr>\n<tr>\n<td>40</td>\n<td>0.06</td>\n<td>0.13</td>\n<td>0.29</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68635 Version 1.0</div></div></div>"},"68637":{"type":"graphic_figure","displayName":"Causes CKD children age","title":"Distribution of the etiology of chronic kidney disease (CKD) in pediatric renal transplant recipients based on age at transplantation","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Distribution of the etiology of chronic kidney disease (CKD) in pediatric renal transplant recipients based on age at transplantation</div><div class=\"cntnt\"><img style=\"width:532px; height:601px;\" src=\"images/PEDS/68637_Causes_CKD_children_age_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FSGS: focal segmental glomerulosclerosis; GN: glomerulonephritis; Structural: structural anomalies of the kidney and urinary tract.</div><div class=\"graphic_reference\">Reproduced with permission from: NAPRTCS: 2010 Annual Report, Rockville, MD. Full report available at: <a href=\"https://web.emmes.com/study/ped/annlrept/2010_Report.pdf\" style=\"font-style: italic;\" target=\"_blank\">https://web.emmes.com/study/ped/annlrept/2010_Report.pdf</a>.</div><div id=\"graphicVersion\">Graphic 68637 Version 5.0</div></div></div>"},"68640":{"type":"graphic_picture","displayName":"Erythema multiforme target","title":"Typical target lesion of erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical target lesion of erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68640_Erythema_multiforme_target.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plaque from a patient with erythema multiforme shows a central erosion on an erythematous base, surrounded by a pale edematous rim and a peripheral erythematous halo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68640 Version 4.0</div></div></div>"},"68642":{"type":"graphic_figure","displayName":"Op hip and gonadal steroids","title":"Relationship between hip osteoporosis and gonadal steroids","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Relationship between hip osteoporosis and gonadal steroids</div><div class=\"cntnt\"><img style=\"width:573px; height:455px;\" src=\"images/ENDO/68642_Ophipandgonadalsteroids.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of hip osteoporosis (T-score &lt;-2.5, red bars) and incidence of rapid hip bone loss (&gt;3%/year, blue bars) in relation to total testosterone, bioavailable testosterone, total estradiol, and bioavailable estradiol levels in men age 65 or older.</div><div class=\"graphic_footnotes\">T: testosterone; E: estradiol.</div><div class=\"graphic_reference\">Adapted with permission from: Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908. http://jcem.endojournals.org/. Copyright © 2006 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 68642 Version 7.0</div></div></div>"},"68646":{"type":"graphic_table","displayName":"Selection for bullectomy","title":"Patient selection for resection of giant bullae: More favorable and less favorable characteristics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient selection for resection of giant bullae: More favorable and less favorable characteristics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Favorable</td> <td class=\"subtitle1\">Less favorable</td> </tr> <tr> <td rowspan=\"3\"><strong>Clinical</strong></td> <td>Age &#8804;60 years</td> <td>Age &#62;60 years</td> </tr> <tr> <td>Progressive dyspnea despite maximal medical therapy</td> <td>Comorbid illness (eg, coronary heart disease, heart failure)*</td> </tr> <tr> <td>Ex-smoker</td> <td>Current smoker</td> </tr> <tr> <td rowspan=\"6\"><strong>Physiological</strong></td> <td>FEV<sub>1</sub> &#8805;40 percent predicted</td> <td>FEV<sub>1</sub> &#60;40 percent predicted</td> </tr> <tr> <td>Hyperinflation (eg, TLC &#62;100 percent predicted, RV &#62;150 percent predicted)</td> <td>Absence of hyperinflation</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td>DLCO &#60;40 percent predicted</td> </tr> <tr> <td>PaCO<sub>2</sub> &#62;45 mmHg</td> </tr> <tr> <td>Pulmonary hypertension (PA systolic &#62;45 mmHg, PA mean &#62;35 mmHg)</td> </tr> <tr> <td>Unable to participate in pulmonary rehabilitation</td> </tr> <tr> <td rowspan=\"3\"><strong>Imaging</strong></td> <td>CXR: bulla &#8805;30 percent of hemithorax in a symptomatic patient</td> <td>CXR: poorly defined bulla(e)</td> </tr> <tr> <td>HRCT: large and localized bulla with compressed parenchyma and vascular crowding adjacent to the bulla</td> <td>HRCT: homogeneous, diffuse emphysema without a single large bulla</td> </tr> <tr> <td>Isotope scan: well-localized matching defect with normal uptake and washout for the rest of the lung<sup>&#182;</sup></td> <td>Isotope scan: absence of target zones, poor washout in rest of the lung<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table describes characteristics that are more or less favorable for clinical improvement following resection of giant bullae, but are not absolute criteria for bullectomy.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second; TLC: total lung capacity; RV: residual volume; DLCO: diffusing capacity for carbon monoxide; PA: pulmonary artery; PaCO<SUB>2</SUB>: arterial tension of carbon dioxide; CXR: chest radiograph; HRCT: high resolution computed tomography.<br />* Comorbid illnesses may be considered relative contraindications depending on degree of severity.<br />¶&nbsp;Isotope scanning&nbsp;is rarely performed, having been replaced by HRCT scanning.</div><div class=\"graphic_reference\">Data from: www.thoracic.org/COPD.</div><div id=\"graphicVersion\">Graphic 68646 Version 4.0</div></div></div>"},"68648":{"type":"graphic_diagnosticimage","displayName":"Splenic injury on computed tomography of the abdomen","title":"Splenic injury on computed tomography of the abdomen","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Splenic injury on computed tomography of the abdomen</div><div class=\"cntnt\"><img style=\"width:500px; height:397px;\" src=\"images/SURG/68648_Perisplenic_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial image on abdominal CT demonstrates splenic injury and perihepatic fluid. Abnormal densities in and around the&nbsp;spleen&nbsp;may represent intrasplenic or perisplenic hematoma. Pools of contrast (white puddles and streaks) in the spleen suggest active extravasation and/or pseudoaneurysm formation.</div><div class=\"graphic_footnotes\">CT: computed tomography</div><div class=\"graphic_reference\">Courtesy of Lewis J Kaplan, MD</div><div id=\"graphicVersion\">Graphic 68648 Version 3.0</div></div></div>"},"68649":{"type":"graphic_picture","displayName":"Heliotrope eruption on eyelid in dermatomyositis","title":"Heliotrope eruption in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heliotrope eruption in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68649_Derm_heliotrope_eruption.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous erythema and edema is present on the upper eyelid in this patient with dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68649 Version 6.0</div></div></div>"},"68651":{"type":"graphic_figure","displayName":"Biventricular pacemaker PI","title":"Biventricular pacemaker","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Biventricular pacemaker</div><div class=\"cntnt\"><img style=\"width:523px; height:641px;\" src=\"images/PI/68651_Biventricular-pacemaker-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A biventricular (or &quot;BiV&quot;) pacemaker is a device that is used to treat some types of heart failure. The device uses electrical signals to help the heart pump better. The electrical signals travel from a battery to the heart through 3 wires (called &quot;leads&quot;) that are put in different parts of the heart. The right atrial lead carries electrical signals to the right upper chamber (right atrium). The coronary sinus and right ventricular leads carry electrical signals to the heart's lower chambers (ventricles).</div><div id=\"graphicVersion\">Graphic 68651 Version 3.0</div></div></div>"},"68654":{"type":"graphic_picture","displayName":"A haemolyticum rash","title":"Rash of <EM>Arcanobacterium haemolyticum </EM>infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash of <EM>Arcanobacterium haemolyticum </EM>infection</div><div class=\"cntnt\"><img style=\"width:371px; height:259px;\" src=\"images/PEDS/68654_A_haemolyticum_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Academy of Pediatrics. Red Book Online: Photo of the week. Available at: aapredbook.aappublications.org/week/iotw012808.shtml. Copyright © 2008 American Academy of Pediatrics.</div><div id=\"graphicVersion\">Graphic 68654 Version 13.0</div></div></div>"},"68655":{"type":"graphic_table","displayName":"High risk conditions for invasive pneumococcal disease","title":"Underlying medical conditions that are indications for pneumococcal polysaccharide vaccination among children, by risk group - Advisory Committee on Immunization Practices, United States, 2010","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Underlying medical conditions that are indications for pneumococcal polysaccharide vaccination among children, by risk group - Advisory Committee on Immunization Practices, United States, 2010</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\">Condition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Immunocompetent children</td> <td>Chronic heart disease*</td> </tr> <tr> <td>Chronic lung disease<sup>&#182;</sup></td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Cerebrospinal fluid leaks</td> </tr> <tr class=\"divider_bottom\"> <td>Cochlear implant</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Children with functional or anatomic asplenia</td> <td>Sickle cell disease and other hemoglobinopathies</td> </tr> <tr class=\"divider_bottom\"> <td>Congenital or acquired asplenia, or splenic dysfunction</td> </tr> <tr> <td rowspan=\"4\">Children with immunocompromising conditions</td> <td>HIV infection</td> </tr> <tr> <td>Chronic renal failure and nephrotic syndrome</td> </tr> <tr> <td>Diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; or solid organ transplantation</td> </tr> <tr> <td>Congenital immunodeficiency<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Particularly cyanotic congenital heart disease and cardiac failure.<br />¶ Including asthma if treated with prolonged high-dose oral corticosteroids.<br />Δ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).</div><div class=\"graphic_reference\">Data from: Centers for Disease Control and Prevention. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children–Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59:260.</div><div id=\"graphicVersion\">Graphic 68655 Version 9.0</div></div></div>"},"68658":{"type":"graphic_table","displayName":"Accuracy of US diverticulitis","title":"Sensitivity and specificity of ultrasonography in the detection of diverticulitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of ultrasonography in the detection of diverticulitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> <td class=\"subtitle1\">PPV</td> <td class=\"subtitle1\">NPV</td> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td class=\"centered\">130</td> <td class=\"centered\">98</td> <td class=\"centered\">98</td> <td class=\"centered\">96</td> <td class=\"centered\">99</td> <td class=\"centered\">[1]</td> <td class=\"centered\">Schwerk WB, et al</td> <td class=\"centered\">1992</td> </tr> <tr> <td class=\"centered\">161</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">96</td> <td class=\"centered\">99</td> <td class=\"centered\">[2]</td> <td class=\"centered\">Schwerk WB, et al</td> <td class=\"centered\">1993</td> </tr> <tr> <td class=\"centered\">143</td> <td class=\"centered\">84</td> <td class=\"centered\">93</td> <td class=\"centered\">93</td> <td class=\"centered\">84</td> <td class=\"centered\">[3]</td> <td class=\"centered\">Zielke A, et al</td> <td class=\"centered\">1997</td> </tr> <tr> <td class=\"centered\">64</td> <td class=\"centered\">85</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">84</td> <td class=\"centered\">[4]</td> <td class=\"centered\">Pradel JA, et al</td> <td class=\"centered\">1997</td> </tr> <tr> <td class=\"centered\">934</td> <td class=\"centered\">91</td> <td class=\"centered\">100</td> <td class=\"centered\">96</td> <td class=\"centered\">100</td> <td class=\"centered\">[5]</td> <td class=\"centered\">Chou YH, et al</td> <td class=\"centered\">2001</td> </tr> <tr> <td class=\"centered\">NE</td> <td class=\"centered\">77</td> <td class=\"centered\">99</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[6]</td> <td class=\"centered\">Hollerweger A, et al</td> <td class=\"centered\">2001</td> </tr> <tr> <td class=\"centered\">247</td> <td class=\"centered\">97</td> <td class=\"centered\">76</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[7]</td> <td class=\"centered\">Moll R, et al</td> <td class=\"centered\">2002</td> </tr> <tr> <td class=\"centered\">203</td> <td class=\"centered\">94</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[8]</td> <td class=\"centered\">Ripolles T, et al</td> <td class=\"centered\">2003</td> </tr> <tr> <td class=\"centered\">63</td> <td class=\"centered\">97</td> <td class=\"centered\">97</td> <td class=\"centered\">NE</td> <td class=\"centered\">NE</td> <td class=\"centered\">[9]</td> <td class=\"centered\">Farag SM, et al</td> <td class=\"centered\">2004</td> </tr> <tr> <td class=\"centered\">328 (18)</td> <td class=\"centered\">89</td> <td class=\"centered\">100</td> <td class=\"centered\">94</td> <td class=\"centered\">99</td> <td class=\"centered\">[10]</td> <td class=\"centered\">Lee MW, et al</td> <td class=\"centered\">2009</td> </tr> <tr> <td class=\"centered\">1021 (118)</td> <td class=\"centered\">61</td> <td class=\"centered\">99</td> <td class=\"centered\">90</td> <td class=\"centered\">95</td> <td class=\"centered\">[11]</td> <td class=\"centered\">Van Randen A, et al</td> <td class=\"centered\">2011</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Parentheses indicate the number of patients with proven diverticulitis, if noted.</div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value; NE: not evaluable.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Schwerk WB, Schwarz S, Rothmund M. Sonography in acute colonic diverticulitis. A prospective study. Dis Colon Rectum 1992; 35:1077.</LI>&#xD;&#xA;<LI>Schwerk WB, Schwarz S, Rothmund M, Arnold R. Colon diverticulitis: imaging diagnosis with ultrasound--a prospective study. Z Gastroenterol 1993; 31:294.</LI>&#xD;&#xA;<LI>Zielke A, Hasse C, Nies C, Kisker O, Voss M, Sitter H et al. Prospective evaluation of ultrasonography in acute colonic diverticulitis. Br J Surg 1997; 84:385.</LI>&#xD;&#xA;<LI>Pradel JA, Adell JF, Taourel P, Djafari M, Monnin-Delhom E, Bruel JM. Acute colonic diverticulitis: prospective comparative evaluation with US and CT. Radiology 1997; 205:503.</LI>&#xD;&#xA;<LI>Chou YH, Chiou HJ, Tiu CM, Chen JD, Hsu CC, Lee CH et al. Sonography of acute right side colonic diverticulitis. Am J Surg 2001; 181:122.</LI>&#xD;&#xA;<LI>Hollerweger A, Macheiner P, Rettenbacher T, Brunner W, Gritzmann N. Colonic diverticulitis: diagnostic value and appearance of inflamed diverticula-sonographic evaluation. Eur Radiol 2001; 11:1956.</LI>&#xD;&#xA;<LI>Moll R, Mittelkotter U, Reith HB, Schindler G, Thiede A. Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomography. Zentralbl Chir 2002; 127:297.</LI>&#xD;&#xA;<LI>Ripolles T, Agramunt M, Martinez MJ, Costa S, Gomez-Abril SA, Richart J. The role of ultrasound in the diagnosis, management and evolutive prognosis of acute left-sided colonic diverticulitis: a review of 208 patients. Eur Radiol 2003; 13:2587.</LI>&#xD;&#xA;<LI>Farag SM, Wustner M, Sturm J, Werner A, Diehl SJ, Duber C et al. Primary diagnostics of acute diverticulitis of the sigmoid. Ultraschall Med 2004; 25:342.</LI>&#xD;&#xA;<LI>Lee MW, Kim YJ, Jeon HJ, Park SW, Jung SI, Yi JG. Sonography of acute right lower quadrant pain: importance of increased intraabdominal fat echo. AJR Am J Roentgenol. 2009; 192:174.</LI>&#xD;&#xA;<LI>Van Randen A, Laméris W, van Es HW, van Heesewijk HP, van Ramshorst B, Ten Hove W, Bouma WH, van Leeuwen MS, van Keulen EM, Bossuyt PM, Stoker J, Boermeester MA; OPTIMA Study Group. A comparison of the accuracy of ultrasound and computed tomography in common diagnoses causing acute abdominal pain. Eur Radiol. 2011; 21: 1535.</LI>&#xD;&#xA;<OL></OL></OL></div><div id=\"graphicVersion\">Graphic 68658 Version 2.0</div></div></div>"},"68659":{"type":"graphic_diagnosticimage","displayName":"Intussusception ultrasound","title":"Intussusception ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception ultrasound</div><div class=\"cntnt\"><img style=\"width:423px; height:342px;\" src=\"images/GAST/68659_Intussusception_Ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography shows a typical appearance of &quot;coiled spring&quot; pattern.</div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 68659 Version 3.0</div></div></div>"},"68660":{"type":"graphic_table","displayName":"Vascular disease in Behçet's syndrome","title":"Vascular disease in 728 patients with Behçet's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vascular disease in 728 patients with Beh&ccedil;et's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of patients</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Venous disease</td> </tr> <tr> <td class=\"indent1\">Deep venous thrombosis</td> <td>221</td> </tr> <tr> <td class=\"indent1\">Subcutaneous thrombophlebitis</td> <td>205</td> </tr> <tr> <td class=\"indent1\">SVC occlusion</td> <td>122</td> </tr> <tr> <td class=\"indent1\">IVC occlusion</td> <td>93</td> </tr> <tr> <td class=\"indent1\">Cerebral sinus thrombosis</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Budd-Chiari syndrome</td> <td>17</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other venous occlusion*</td> <td>24</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Arterial disease</td> </tr> <tr> <td class=\"indent1\">Pulmonary artery occlusion or aneurysm</td> <td>36</td> </tr> <tr> <td class=\"indent1\">Aortic aneurysm</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Extremity arterial occlusion or aneurysm</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Other arterial occlusion or aneurysm<sup>&#182;</sup></td> <td>42</td> </tr> <tr> <td class=\"indent1\">Right ventricular thrombus</td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVC: superior vena cava; IVC: inferior vena cava.<br />* Other veins included subclavian, iliac, portal, renal, innominate, brachiocephalic.<br />&para; Other arteries included iliac, subclavian, renal, carotid, cerebral, coronary, innominate, mesenteric, aorta, basilar, splenic.</div><div class=\"graphic_reference\">Review of 728 cases from Koc, Y, Gullu, I, Akpek, G, et al. J Rheumatol 1992; 19:402.</div><div id=\"graphicVersion\">Graphic 68660 Version 4.0</div></div></div>"},"68661":{"type":"graphic_picture","displayName":"Bronchoscopic image of stent through bronchial wall","title":"Bronchoscopic image of a stent through the bronchial wall revealing lung parenchyma with severe emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic image of a stent through the bronchial wall revealing lung parenchyma with severe emphysema</div><div class=\"cntnt\"><img style=\"width:278px; height:288px;\" src=\"images/PULM/68661_Bronch_img_stent_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Cardoso, PFG, Snell, GI. Hopkins, P, et al. Clinical application of airway bypass with paclitaxel-eluting stents: Early results. J Thorac Cardiovasc Surg 2007; 134:974. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68661 Version 1.0</div></div></div>"},"68662":{"type":"graphic_movie","displayName":"Atheroma on CT","title":"Atheroma on CT","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atheroma on CT</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/68662_AtherormaCTmoviePR.mp4\" style=\"width:384px;height:400px\"></div><img style=\"width:432px; height:432px;\" src=\"images/SURG/68662_AtheromaonCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive, partly calcified plaque in the descending thoracic and abdominal aorta visualized by axial CT imaging.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Dr. Pierre Maldjian.</div><div id=\"graphicVersion\">Graphic 68662 Version 1.0</div></div></div>"},"68663":{"type":"graphic_table","displayName":"Differential diagnosis of thromboangiitis obliterans","title":"Differential diagnosis of thromboangiitis obliterans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of thromboangiitis obliterans</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lower extremity</td> </tr> <tr> <td>Peripheral artery disease</td> </tr> <tr> <td>Atheroembolism/microthromboembolism (blue toe syndrome, trash foot)</td> </tr> <tr> <td class=\"sublist1_start\">Hypercoagulability</td> </tr> <tr> <td class=\"sublist1\">Polycythemia vera</td> </tr> <tr> <td class=\"sublist1\">Essential thrombocytosis</td> </tr> <tr> <td class=\"sublist1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis/collagen vascular disease</td> </tr> <tr> <td class=\"sublist1\">Polyarteritis nodosa (or other small to medium-sized vessel vasculitis)</td> </tr> <tr> <td>Nonatherosclerotic vascular disease (adventitial cystic disease, popliteal entrapment)</td> </tr> <tr> <td>Frostbite</td> </tr> <tr> <td>Ergot poisoning</td> </tr> <tr> <td>Cannabis arteritis</td> </tr> <tr> <td class=\"subtitle1_single\">Upper extremity</td> </tr> <tr> <td>Peripheral artery disease (arteriosclerosis)</td> </tr> <tr> <td class=\"sublist1_start\">Atheroembolism/thromboembolism</td> </tr> <tr> <td class=\"sublist1\">Arterial thoracic outlet syndrome</td> </tr> <tr> <td class=\"sublist1\">Subclavian aneurysm</td> </tr> <tr> <td class=\"sublist1\">Hypothenar hammer syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis/collagen vascular disease</td> </tr> <tr> <td class=\"sublist1\">Scleroderma/CREST</td> </tr> <tr> <td class=\"sublist1\">Polyarteritis nodosa and similar forms of vasculitis</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease</td> </tr> <tr> <td class=\"sublist1\">Cocaine or amphetamine vasculitis</td> </tr> <tr> <td class=\"sublist1_start\">Prothrombotic states</td> </tr> <tr> <td class=\"sublist1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Vasospasm</td> </tr> <tr> <td class=\"sublist1\">Pernio</td> </tr> <tr> <td class=\"sublist1\">Diseases related to vibratory tools</td> </tr> <tr> <td class=\"sublist1\">Ergot poisoning</td> </tr> <tr> <td>Frostbite</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68663 Version 1.0</div></div></div>"},"68664":{"type":"graphic_figure","displayName":"Closed reduction of a supracondylar fracture","title":"Manipulative supracondylar closed reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manipulative supracondylar closed reduction</div><div class=\"cntnt\"><img style=\"width:396px; height:404px;\" src=\"images/EM/68664_SC_closed_reduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Traction is applied with the elbow in extension and the forearm in supination. The assistant stabilizes the proximal fragment. After traction has been applied and the length regained, the fracture is hyperextended to obtain apposition of the fragments. B) With traction being maintained, the varus or valgus angulation along with the rotation of the distal fragment is corrected.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68664 Version 11.0</div></div></div>"},"68665":{"type":"graphic_figure","displayName":"Rx of ectopic ACTH secretion","title":"Treatment of ectopic ACTH syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of ectopic ACTH syndrome</div><div class=\"cntnt\"><img style=\"width:406px; height:202px;\" src=\"images/ENDO/68665_Rx_of_ectopic_ACTH_secretio.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68665 Version 1.0</div></div></div>"},"68666":{"type":"graphic_table","displayName":"Need for anesthesia consult","title":"Indications for antenatal anesthesia consultation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for antenatal anesthesia consultation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\"><strong>Patients should ideally be referred for anesthesiology consultation by 32 weeks gestation, or earlier if premature birth is anticipated.</strong></td> </tr> <tr> <td> <ol> <li><strong>Cardiac issues</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Valvular disease (excluding asymptomatic mitral valve prolapse) </li> <li>History of chest pain without cardiac workup </li> <li>History of arrhythmias (specifically SVT, atrial fibrillation, VT) </li> <li>Complex congenital cardiac defects </li> <li>Pacemakers/ICDs </li> <li>History of cardiomyopathy or IHSS </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li><strong>Pulmonary disease</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Asthma - poorly controlled or worsening during pregnancy </li> <li>History of pulmonary hypertension </li> <li>Other pulmonary disease (eg, previous chest surgery, cystic fibrosis, sarcoid) that compromises ability to perform usual ADLs </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li><strong>Neurologic/neurosurgical disease</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Current or prior history of intracranial vascular malformation, hemorrhage, tumor or any mass lesion </li> <li>Arnold chiari malformation </li> <li>Multiple sclerosis (compromising ability to perform ADLs) </li> <li>Spinal anatomy concerns: Hardware (eg, lumbar drains, nerve stimulators for chronic pain), prior surgery (including Harrington Rod placement), major or minor paralysis, diagnosed spina bifida, low back pain if it significantly compromises ability to perform ADLs </li> <li>Neuromuscular disease (eg, multiple sclerosis or myasthenia gravis) that compromises ability to perform ADLs </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li><strong>Hematologic</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>History of thrombocytopenia (platelet count &#60;100,000/microL) </li> <li>History of bleeding disorder </li> <li>Anticoagulation therapy </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"5\"> <li><strong>Chronic pain syndrome involving visits to pain clinics or neurologists</strong> </li> </ol> </td> </tr> <tr> <td> <ol start=\"6\"> <li><strong>Severe obesity</strong> </li> </ol> </td> </tr> <tr> <td> <ol start=\"7\"> <li><strong>Allergy to local anesthetics</strong> (eg, lidocaine, novocaine)<br /> <strong>or opioids</strong> (eg, morphine, fentanyl, hydromorphone, meperidine, codeine) </li> </ol> </td> </tr> <tr> <td> <ol start=\"8\"> <li><strong>History of anesthetic complications or problems in the patient or in a family member</strong> <ol style=\"list-style-type: lower-alpha;\"> <li>Malignant hyperthermia </li> <li>Airway concerns (history of difficult intubation, history of oral or facial surgery) </li> </ol> </li> </ol> </td> </tr> <tr> <td> <ol start=\"9\"> <li><strong>Specific questions, special requests, or significant anxiety regarding anesthesia care</strong> (eg, complicated birth plans or requests for general anesthesia) </li> </ol> </td> </tr> <tr> <td> <ol start=\"10\"> <li><strong>Refusal of transfusion, including Jehovah's Witness</strong> </li> </ol> </td> </tr> <tr> <td> <ol start=\"11\"> <li><strong>Opioid abuse disorder, not on stable methadone or buprenorphine regimen</strong> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; VT: ventricular tachycardia; ICD: implantable cardioverter-defibrillator; IHSS: idiopathic hypertrophic subaortic stenosis; ADL: activity of daily living.</div><div id=\"graphicVersion\">Graphic 68666 Version 3.0</div></div></div>"},"68667":{"type":"graphic_picture","displayName":"Histology normal breast tissue","title":"Histology of normal breast tissue of a premenopausal woman","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of normal breast tissue of a premenopausal woman</div><div class=\"cntnt\"><img style=\"width:384px; height:534px;\" src=\"images/ONC/68667_Histology_normal_breast_tis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper panel, low power photomicrograph, showing several lobules and a few extralobular ducts (arrow); lower panel, high power photomicrograph of several acini of a lobule.</div><div class=\"graphic_reference\">Reproduced with permission from: Schnitt SJ. Normal anatomy and development, In: Atlas of Breast Cancer, Hayes, DF (Ed). Harcourt Publishers Ltd. 2000, p.3.3. Copyright &#169; 2000 Mosby.</div><div id=\"graphicVersion\">Graphic 68667 Version 1.0</div></div></div>"},"68668":{"type":"graphic_table","displayName":"Mod osteosarcoma protocols","title":"Methotrexate dose, duration of infusion, and leucovorin rescue for several contemporary osteosarcoma protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methotrexate dose, duration of infusion, and leucovorin rescue for several contemporary osteosarcoma protocols</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Author, year</td>\r\n            <td class=\"subtitle1\">Methotrexate (MTX) dose</td>\r\n            <td class=\"subtitle1\">Duration of methotrexate (MTX) infusion</td>\r\n            <td class=\"subtitle1\">Leucovorin rescue dose</td>\r\n            <td class=\"subtitle1\">Start of leucovorin*</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Souhami R; 1997<sup>[1]</sup></td>\r\n            <td>8 g/m<sup>2</sup> (12 g/m<sup>2</sup> for children &#60;12 years old)</td>\r\n            <td>NR</td>\r\n            <td>12 mg/m<sup>2</sup> IV or 15 mg/m<sup>2</sup> orally&nbsp;every six&nbsp;hours&nbsp;for 10 doses</td>\r\n            <td>24</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Meyers P; 1998<sup>[2]</sup></td>\r\n            <td>\r\n            <p>8 g/m<sup>2</sup> (&#62;12 years old)</p>\r\n            <p>12 g/m<sup>2</sup> (&#8804;12 years old)</p>\r\n            </td>\r\n            <td>NR</td>\r\n            <td>NR</td>\r\n            <td>20</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Fuchs N; 1998<sup>[3]</sup></td>\r\n            <td>12 g/m<sup>2</sup> (maximum 20 gm)</td>\r\n            <td>NR</td>\r\n            <td>15 mg/m<sup>2</sup>&nbsp;every six&nbsp;hours&nbsp;for 12 doses</td>\r\n            <td>NR</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Bacci G; 2001<sup>[4]</sup></td>\r\n            <td>12 g/m<sup>2</sup> (escalate to 14 g/m2 if the 6-hour serum level &#60;1 micromol/L)</td>\r\n            <td>6</td>\r\n            <td>15 mg&nbsp;every six&nbsp;hours&nbsp;for 11 doses</td>\r\n            <td>24</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Goorin A; 2003<sup>[5]</sup></td>\r\n            <td>12 g/m<sup>2</sup></td>\r\n            <td>4</td>\r\n            <td>15 mg&nbsp;every six&nbsp;hours&nbsp;for 10 doses</td>\r\n            <td>24</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Ferrari S; 2005<sup>[6]</sup></td>\r\n            <td>12 g/m<sup>2</sup></td>\r\n            <td>4</td>\r\n            <td>8 mg/m<sup>2</sup>&nbsp;every six&nbsp;hours&nbsp;for 11 doses</td>\r\n            <td>24</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47058&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">NR: not reported.<br>* After start of methotrexate (MTX) infusion.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911.</LI>&#xD;&#xA;<LI>Meyers PA, Gorlick R, Heller G et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16:2452. </LI>&#xD;&#xA;<LI>Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9:893. </LI>&#xD;&#xA;<LI>Bacci G, Briccoli A, Ferrari S et al.&nbsp;Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 2001; 37:2030. </LI>&#xD;&#xA;<LI>Goorin, AM Schwartzentruber DJ, Devidas M et al.&nbsp;Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.&nbsp;J Clin Oncol 2003; 21:1574. </LI>&#xD;&#xA;<LI>Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23:8845.</LI></OL></div><div id=\"graphicVersion\">Graphic 68668 Version 2.0</div></div></div>"},"68670":{"type":"graphic_figure","displayName":"Ages foster care","title":"Ages of children in foster care, United States 2015","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ages of children in foster care, United States 2015</div><div class=\"cntnt\"><img style=\"width:422px; height:468px;\" src=\"images/PEDS/68670_Agesfstrcare.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Adoption and Foster Care Analysis and Reporting System (AFCARS) FY 2015 data. Available at: <a href=\"http://www.acf.hhs.gov/programs/cb/research-data-technology/statistics-research/afcars\"  target=\"_blank\">www.acf.hhs.gov/programs/cb/research-data-technology/statistics-research/afcars</a> (Accessed on October 16, 2017).</div><div id=\"graphicVersion\">Graphic 68670 Version 5.0</div></div></div>"},"68672":{"type":"graphic_diagnosticimage","displayName":"Transverse femur fracture","title":"Transverse femoral shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse femoral shaft fracture</div><div class=\"cntnt\"><img style=\"width:314px; height:504px;\" src=\"images/EM/68672_Transverse_femur_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 68672 Version 2.0</div></div></div>"},"68673":{"type":"graphic_figure","displayName":"Thyroid physiology in the fetus and newborn","title":"Thyroid physiology in the fetus and newborn","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Thyroid physiology in the fetus and newborn</div><div class=\"cntnt\"><img style=\"width:626px; height:614px;\" src=\"images/PEDS/68673_Thyr_physiol_fetus_newborn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal patterns of change for thyroid-stimulating hormone (TSH), total T<sub>4</sub>, and total T<sub>3</sub> are depicted for the fetus (beginning at 12 weeks gestation) and continuing for the first four weeks of life in the newborn.<br /><strong>NOTE:</strong> To convert T<sub>3</sub> in ng/dL to nmol/L, multiply by 0.01536. To convert T<sub>4</sub> in mcg/dL to nmol/L, multiply by 12.87.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Thorpe-Beeston JG, Nicolaides KH, Felton CB, et al. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med 1991; 324:532. </li>&#xD;&#xA;    <li>Fisher DA. Thyroid physiology in the perinatal period and during childhood. In: Werner's and Ingbar's The Thyroid, Braverman LE, Utiger RD (Eds), Lippincott-Raven, Philadelphia, 1996. p.974. </li>&#xD;&#xA;    <li>Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. J Clin Endocrinol Metab 2004; 89:5314.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 68673 Version 3.0</div></div></div>"},"68674":{"type":"graphic_table","displayName":"Associations with webs","title":"Conditions associated with esophageal webs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with esophageal webs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Dermatologic diseases</td> </tr> <tr> <td class=\"sublist1_start\">Epidermolysis bullosa (EB)</td> </tr> <tr> <td class=\"sublist1\">EB dystrophica</td> </tr> <tr> <td class=\"sublist1\">EB junctional</td> </tr> <tr> <td class=\"sublist1\">EB simplex</td> </tr> <tr> <td class=\"sublist1\">EB acquisita</td> </tr> <tr> <td>Bullous pemphigoid</td> </tr> <tr> <td>Pemphigus vulgaris</td> </tr> <tr> <td>Stevens-Johnson syndrome (toxic epidermal necrolysis)</td> </tr> <tr> <td>Psoriasis </td> </tr> <tr> <td class=\"subtitle1_single\">Immunologic disorders</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68674 Version 2.0</div></div></div>"},"68675":{"type":"graphic_table","displayName":"Hypercoagulability in IBD","title":"Hypercoagulability in inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypercoagulability in inflammatory bowel disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Clinical characteristics\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Unusual sites</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Associated with active disease and better when disease controlled</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Associated with use of steroids (possibly indicating active disease)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Recurrent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Serious</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Younger age</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Abnormalities described\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abnormal fibrinolysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Abnormal platelet aggregation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Activated protein C increased</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Circulating immune complexes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased antithrombin III</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Factor V Leiden mutation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased cytokines (interleukin-6, thrombopoietin)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased factors V and VIII</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased plasminogen activator inhibitor</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased sedimentation rate, fibrinogen</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lupus anticoagulant</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thrombocytosis and leukocytosis (uniformly present in most studies)</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 68675 Version 1.0</div></div></div>"},"68676":{"type":"graphic_picture","displayName":"Mild acute rejection","title":"ITx mild acute rejection (high power view)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ITx mild acute rejection (high power view)</div><div class=\"cntnt\"><img style=\"width:432px; height:280px;\" src=\"images/GAST/68676_Mild_acute_rejection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mononuclear inflammatory infiltrate is present with crypt inflammation.</div><div class=\"graphic_reference\">Courtesy of Farrukh Khan, MD.</div><div id=\"graphicVersion\">Graphic 68676 Version 1.0</div></div></div>"},"68677":{"type":"graphic_diagnosticimage","displayName":"Hysterosalpingogram a","title":"Hysterosalpingogram","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram</div><div class=\"cntnt\"><img style=\"width:496px; height:329px;\" src=\"images/OBGYN/68677_Hysterosalpingogram_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hysterosalpingogram on a 29-year-old woman with infertility demonstrates occlusion of both fallopian tubes (arrows).</div><div id=\"graphicVersion\">Graphic 68677 Version 2.0</div></div></div>"},"68678":{"type":"graphic_diagnosticimage","displayName":"Tracheal papillomatosis","title":"Tracheobronchial papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheobronchial papillomatosis</div><div class=\"cntnt\"><img style=\"width:400px; height:502px;\" src=\"images/PULM/68678_Tracheal_papillomatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper image shows computed tomographic scan with multiple intraluminal tracheal filling defects in conjunction with parenchymal nodules and cavities. Bronchoscopy (lower image) confirmed the presence of tracheobronchial papillomatosis.</div><div class=\"graphic_reference\">Bronchoscopic image courtesy of James Harrell, MD.</div><div id=\"graphicVersion\">Graphic 68678 Version 5.0</div></div></div>"},"68680":{"type":"graphic_figure","displayName":"Vascular supply of the spleen","title":"Vascular supply of the spleen","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Vascular supply of the spleen</div><div class=\"cntnt\"><img style=\"width:533px; height:422px;\" src=\"images/SURG/68680_Vascular-supply-of-the-spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The splenic artery is a branch of the celiac trunk. It traverses along the superior margin of the pancreas toward the spleen, branching to form up to six major arteries before entering the spleen. The splenic vein joins the superior mesenteric vein to form the portal vein.</div><div id=\"graphicVersion\">Graphic 68680 Version 4.0</div></div></div>"},"68681":{"type":"graphic_diagnosticimage","displayName":"MRI of Chiari I malformation","title":"Chiari I malformation showing descent of the cerebellar tonsils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chiari I malformation showing descent of the cerebellar tonsils</div><div class=\"cntnt\"><img style=\"width:432px; height:453px;\" src=\"images/NEURO/68681_Chiari-tonsils-descent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T1-weighted MRI of the brain shows the low-lying and elongated cerebellar tonsils (arrow), which are displaced below the level of the foramen magnum.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 68681 Version 6.0</div></div></div>"},"68682":{"type":"graphic_picture","displayName":"Stevens-Johnson syndrome (SJS)","title":"Stevens-Johnson syndrome (SJS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stevens-Johnson syndrome (SJS)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68682_SJS_oral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions and crusts are present on the lips of this patient with SJS.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68682 Version 4.0</div></div></div>"},"68683":{"type":"graphic_table","displayName":"Doses of beta agonists for asthma exacerbations","title":"Doses of beta agonists for asthma exacerbations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of beta agonists for asthma exacerbations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Medication</td> <td class=\"subtitle1\" colspan=\"3\">Doses</td> </tr> <tr> <td class=\"subtitle2\">Child dose*</td> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Inhaled short-acting beta<sub>2</sub>-agonists (SABA)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Albuterol (salbutamol)</td> </tr> <tr> <td class=\"indent2\">Nebulizer solution<br /> (0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg/3 mL, 5 mg/mL)</td> <td>0.15 mg/kg (minimum 2.5 mg, maximum 5 mg) every 20 minutes for three doses then 0.15 to 0.3 mg/kg up to 10 mg every one to four hours as needed, or 0.5 mg/kg/hour by continuous nebulization (maximum 20 mg per hour).</td> <td>2.5 to 5 mg every 20 minutes for three doses, then 2.5 to 10 mg every one to four hours as needed, or 10 to 15 mg/hour continuously.</td> <td>Only selective beta<sub>2</sub>-agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6 to 8 L/min. Use large volume nebulizers for continuous administration. May mix with ipratropium nebulizer solution.</td> </tr> <tr> <td class=\"indent2\">MDI<br /> (90 microgram/puff)</td> <td>Four to eight puffs every 20 minutes for three doses, then every one to four hours as needed. Use VHC; add mask in children less than four years.</td> <td>Four to eight puffs every 20 minutes up to four hours, then every one to four hours as needed.</td> <td>In mild-to-moderate exacerbations, MDI plus VHC is as effective as nebulized therapy with appropriate administration technique and coaching by trained personnel.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Levalbuterol (R-albuterol, levosalbutamol)</td> </tr> <tr> <td class=\"indent2\">Nebulizer solution<br /> (0.63 mg/3 mL, 1.25 mg/0.5 mL 1.25 mg/3 mL)</td> <td>0.075 mg/kg (minimum 1.25 mg, maximum 2.5 mg) every 20 minutes for three doses, then 0.075 to 0.15 mg/kg up to 5 mg every one to four hours as needed.</td> <td>1.25 to 2.5 mg every 20 minutes for three doses, then 1.25 to 5 mg every one to four hours as needed.</td> <td rowspan=\"2\">Levalbuterol administered in one-half the mg dose of albuterol provides comparable efficacy and safety. Has not been evaluated by continuous nebulization.</td> </tr> <tr> <td class=\"indent2\">MDI<br /> (45 microgram/puff)</td> <td>See albuterol MDI dose.</td> <td>See albuterol MDI dose.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Bitolterol<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Nebulizer solution<br /> (2 mg/mL)</td> <td>See albuterol dose (thought to be half as potent as albuterol on mg basis).</td> <td>See albuterol dose (thought to be half as potent as albuterol on mg basis).</td> <td>Has not been studied in severe asthma exacerbations. Do not mix with other drugs.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">MDI<br /> (370 microgram/puff)</td> <td>See albuterol MDI dose.</td> <td>See albuterol MDI dose.</td> <td>Has not been studied in severe asthma exacerbations.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Systemic (injected) beta<sub>2</sub>-agonists<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle3_left\">Terbutaline</td> <td> <p>0.01 mg/kg (maximum 0.4 mg) every 20 minutes for three doses then every two to six hours as needed subcutaneously or intramuscularly.</p> <strong>OR</strong> as intravenous infusion initiated with 10 microgram/kg (maximum 0.4 mg) bolus over 10 minutes followed by 0.3 to 0.5 microgram/kg per minute. Every 30 minutes infusion may be increased if needed by 0.1 to 0.5 microgram/kg/minute up to maximum 10 microgram/kg per minute.<sup>&#9674;</sup></td> <td>0.25 mg every 20 minutes for three doses, subcutaneously or intramuscularly.</td> <td> <p>Subcutaneous/intramuscular administration is reserved for patients with poor inspiratory flow or who cannot cooperate with inhaled therapy. No proven advantage over aerosol.</p> Intravenous terbutaline is rarely indicated. Selected patients who are poorly responsive to standard therapies may receive parenteral terbutaline or epinephrine, NOT both. See text.</td> </tr> <tr> <td class=\"subtitle3_left\">Epinephrine<br /> 1:1000 (1 mg/mL)</td> <td>0.01 mg/kg (maximum 0.4 mg) every 20 minutes for three doses, subcutaneously or intramuscularly.</td> <td>0.3 mg every 20 minutes for three doses, subcutaneously or intramuscularly.</td> <td>Subcutaneous/intramuscular administration is reserved for patients with anaphylaxis or poor inspiratory flow or who cannot cooperate with inhaled therapy. No proven advantage of systemic epinephrine over aerosol except in the treatment of anaphylaxis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDI: metered dose inhaler; VHC: valved holding chamber.<br />* Children ≤12 years of age.<br />¶ Not available in the United States or Canada.<br />Δ The use of systemic terbutaline or epinephrine requires cardiopulmonary monitoring, such as that available in a critical care setting. Orally administered systemic beta<SUB>2</SUB>-agonists are not recommended.<br /><FONT class=lozenge>◊</FONT> For patients who require doses of intravenous terbutaline above 3 microgram/kg per minute, prompt transfer to an intensive care unit is advisable due to potential cardiac toxicity and respiratory failure.</div><div class=\"graphic_reference\">Adapted from: National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>.</div><div id=\"graphicVersion\">Graphic 68683 Version 7.0</div></div></div>"},"68686":{"type":"graphic_figure","displayName":"Impact of age on adverse cerebral outcomes after CABG","title":"Impact of age on adverse cerebral outcomes after coronary bypass surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impact of age on adverse cerebral outcomes after coronary bypass surgery</div><div class=\"cntnt\"><img style=\"width:442px; height:281px;\" src=\"images/CARD/68686_Cerebral_outcomes_after_CAB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence of adverse cerebral events after coronary artery bypass surgery is 6.1 percent, of which half are type I (focal injury, coma, or stupor at discharge) and half are type II (deterioration in intellectual function, memory defect, or seizures). The incidence of both type I and II events increase with age.</div><div class=\"graphic_reference\">Data from Roach GW, Kanchuger M, Mangano M, et al, and the Ischemia Research and Education Foundation Investigators. N Engl J Med 1996; 335:1857.</div><div id=\"graphicVersion\">Graphic 68686 Version 4.0</div></div></div>"},"68692":{"type":"graphic_diagnosticimage","displayName":"CBD stones MRCP I","title":"Common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common bile duct stones</div><div class=\"cntnt\"><img style=\"width:320px; height:288px;\" src=\"images/GAST/68692_CBD_stones_MRCP_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography image shows two small stones in the distal common bile duct (arrows) immediately adjacent to the duodenal bulb (Duo). Note the normal-appearing, nondistended pancreatic duct (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 68692 Version 3.0</div></div></div>"},"68694":{"type":"graphic_table","displayName":"Classification of pediatric hemorrhagic shock","title":"Classification of hemorrhagic shock in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of hemorrhagic shock in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Class I, very mild</td> <td class=\"subtitle1\">Class II, mild</td> <td class=\"subtitle1\">Class III, moderate</td> <td class=\"subtitle1\">Class IV, severe</td> </tr> <tr> <td>Percent blood volume loss</td> <td>&#60;15%</td> <td>15-30%</td> <td>30-40%</td> <td>&#62;40%</td> </tr> <tr> <td>Heart rate</td> <td>Normal</td> <td>Slightly increased</td> <td>Moderately increased</td> <td>Markedly increased</td> </tr> <tr> <td>Respiratory rate</td> <td>Normal</td> <td>Slightly increased</td> <td>Moderately increased</td> <td>Markedly increased, markedly decreased, or absent</td> </tr> <tr> <td>Blood pressure</td> <td>Normal or slightly increased</td> <td>Normal or slightly decreased</td> <td>Decreased</td> <td>Decreased</td> </tr> <tr> <td>Pulses</td> <td>Normal</td> <td>Normal or decreased peripheral</td> <td>Weak or absent peripheral</td> <td>Absent peripheral, weak or absent central</td> </tr> <tr> <td>Skin</td> <td>Warm and pink</td> <td>Cool extremities, mottled</td> <td>Cool mottling extremities, or pallor</td> <td>Cold extremities with pallor or cyanosis</td> </tr> <tr> <td>Capillary refill</td> <td>Normal</td> <td>Prolonged</td> <td>Markedly prolonged</td> <td>Markedly prolonged</td> </tr> <tr> <td>Mental status</td> <td>Slightly anxious</td> <td>Mildly anxious, confused, combative</td> <td>Very anxious, confused, or lethargic</td> <td>Very confused, lethargic, or comatose</td> </tr> <tr> <td>Urine output</td> <td>Normal</td> <td>Slightly decreased</td> <td>Moderately decreased</td> <td>Markedly decreased or anuria</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Hazinski, MF, Barkin, RM. Shock. In: Pediatric emergency medicine: Concepts and clinical practice, Barkin, RM (Ed), Mosby-Yearbook Inc, St. Louis, MO 1997. p. 118; and Waltzman, ML, Mooney, DP. Major trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p. 1354.</div><div id=\"graphicVersion\">Graphic 68694 Version 5.0</div></div></div>"},"68695":{"type":"graphic_figure","displayName":"Superficial retinal hemorrhages","title":"Superficial retinal hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial retinal hemorrhages</div><div class=\"cntnt\"><img style=\"width:408px; height:407px;\" src=\"images/PEDS/68695_Superficial_retinal_hem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial retinal hemorrhages are small, linear, flame-shaped, red streaks in the fundi. They are shaped by the superficial bundles of nerve fibers that radiate from the optic disc in the pattern illustrated. Sometimes the hemorrhages occur in clusters and then simulate a larger hemorrhage, but the linear streaking at the edges shows their true nature. An occasional superficial hemorrhage has a white center consisting of fibrin.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68695 Version 2.0</div></div></div>"},"68697":{"type":"graphic_picture","displayName":"Tongue retaining device","title":"Tongue retaining device (four views)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tongue retaining device (four views)</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/PULM/68697_Tongue_retaining_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When inserted into the suction cavity of this oral appliance, the tongue is held forward to maintain airway patency. (Tongue Retaining Device, Professional Positioners, Inc, Racine, WI)</div><div id=\"graphicVersion\">Graphic 68697 Version 2.0</div></div></div>"},"68698":{"type":"graphic_diagnosticimage","displayName":"DISH radiograph thoracic spine","title":"Radiographs of thoracic spine in diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographs of thoracic spine in diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><img style=\"width:445px; height:427px;\" src=\"images/RHEUM/68698_DISHradiographthoracicsp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ossification of the anterior longitudinal ligament, similar in appearance to flowing candle wax (arrow), is seen in the lateral view of the thoracic spine (left radiograph) in a patient with DISH. The changes are predominantly on the right side, particularly in mid-thoracic spine (anteroposterior view, right radiograph). There is both complete and incomplete bridging of the spurs.</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 68698 Version 3.0</div></div></div>"},"68699":{"type":"graphic_diagnosticimage","displayName":"Thyroid nodule with degeneration and bright spot","title":"Thyroid nodule with degeneration and bright spot","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Thyroid nodule with degeneration and bright spot</div><div class=\"cntnt\"><img style=\"width:477px; height:254px;\" src=\"images/ENDO/68699_Thyroid_nod_bright_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an image of a thyroid nodule (arrowheads) that shows areas of cystic/hemorrhagic degeneration (black areas) and a bright spot with a trailing plume or comet tail (arrow) that is suggestive of colloid.</div><div class=\"graphic_reference\">Courtesy of John Bonavita, MD, Department of Radiology, NYU Langone Medical Center.</div><div id=\"graphicVersion\">Graphic 68699 Version 5.0</div></div></div>"},"68701":{"type":"graphic_diagnosticimage","displayName":"Mild fetal ventriculomegaly","title":"Mild fetal ventriculomegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild fetal ventriculomegaly</div><div class=\"cntnt\"><img style=\"width:432px; height:359px;\" src=\"images/OBGYN/68701_Mild_ventriculomegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of fetal head demonstrating mild ventriculomegaly. The ventricle is measured in the axial plane, at the level of the frontal horns and cavum septi pellucidi. The calipers are positioned at the level of the internal margin of the medial and lateral walls of the atria, at the level of the glomus of the choroid plexus, on an axis perpendicular to the long axis of the lateral ventricle.</div><div class=\"graphic_reference\">Courtesy of Mary E Norton, MD.</div><div id=\"graphicVersion\">Graphic 68701 Version 2.0</div></div></div>"},"68702":{"type":"graphic_diagnosticimage","displayName":"Periosteal osteosarcoma","title":"Periosteal osteosarcoma involving femoral diaphysis in 14-year-old boy who presented with painful thigh mass","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periosteal osteosarcoma involving femoral diaphysis in 14-year-old boy who presented with painful thigh mass</div><div class=\"cntnt\"><img style=\"width:504px; height:247px;\" src=\"images/ONC/68702_Periosteal_osteosarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior radiograph of femur shows cortical thickening (with Codman triangles [solid arrows] superiorly and inferiorly) that is eroded by a broad-based soft-tissue mass, with involvement of the underlying preexisting cortex (open arrow). Perpendicular periosteal reaction extends into the soft-tissue mass (arrowheads).<br />(B) Bone scintigram (anterior projection) shows marked and eccentric increased radionuclide uptake (*).<br />(C) Coronal T1-weighted MR image (650/17) also shows thickened cortex, which is extrinsically eroded centrally (r) by the broad-based intermediate-signal-intensity soft-tissue mass (m). The marrow shows focal areas of decreased signal intensity (arrows) that are separated from the soft-tissue mass by normal intervening cortex.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphey MD, Robbin MR, McRae GA, et al. The many faces of osteosarcoma. Radiographics 1997; 17:1205. Copyright &copy; Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 68702 Version 4.0</div></div></div>"},"68703":{"type":"graphic_table","displayName":"WHO classification CRC","title":"World Health Organization classification of carcinomas of the colon and rectum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization classification of carcinomas of the colon and rectum</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Adenocarcinoma</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; Cribriform comedo-type adenocarcinoma&nbsp;</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; Medullary carcinoma</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; Micropapillary carcinoma </td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp; Mucinous (colloid) adenocarcinoma (&#62;50% mucinous)</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serrated adenocarcinoma</td> </tr> <tr> <td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signet-ring cell carcinoma (&#62;50% signet-ring cells)</td> </tr> <tr> <td>Adenosquamous carcinoma</td> </tr> <tr> <td>Spindle cell carcinoma</td> </tr> <tr> <td>Squamous cell (epidermoid) carcinoma</td> </tr> <tr> <td>Undifferentiated carcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68703 Version 3.0</div></div></div>"},"68705":{"type":"graphic_table","displayName":"Drugs causing tinnitus","title":"Some of the drugs that cause or exacerbate tinnitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some of the drugs that cause or exacerbate tinnitus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Aminoglycoside antibiotics</td>\n</tr>\n<tr>\n<td>Angiotensin converting enzyme (ACE) inhibitors</td>\n</tr>\n<tr>\n<td>Antimalarial drugs (eg, chloroquine, hydroxychloroquine)</td>\n</tr>\n<tr>\n<td>Benzodiazepines</td>\n</tr>\n<tr>\n<td>Bismuth</td>\n</tr>\n<tr>\n<td>Calcium channel blockers</td>\n</tr>\n<tr>\n<td>Carbamazepine</td>\n</tr>\n<tr>\n<td>Chlordiazepoxide</td>\n</tr>\n<tr>\n<td>Cisplatin</td>\n</tr>\n<tr>\n<td>Clarithromycin</td>\n</tr>\n<tr>\n<td>COX-2 inhibitors</td>\n</tr>\n<tr>\n<td>Cyclobenzaprine</td>\n</tr>\n<tr>\n<td>Dapsone</td>\n</tr>\n<tr>\n<td>Doxazosin</td>\n</tr>\n<tr>\n<td>Doxepin</td>\n</tr>\n<tr>\n<td>Fluoroquinolone antibiotics</td>\n</tr>\n<tr>\n<td>Isotretinoin</td>\n</tr>\n<tr>\n<td>Lidocaine and other local anesthetics</td>\n</tr>\n<tr>\n<td>Loop diuretics</td>\n</tr>\n<tr>\n<td>Nitroprusside</td>\n</tr>\n<tr>\n<td>Prazosin</td>\n</tr>\n<tr>\n<td>Proton pump inhibitors</td>\n</tr>\n<tr>\n<td>Quinidine</td>\n</tr>\n<tr>\n<td>Salicylates and nonsteroidal antiinflammatory drugs (NSAIDs)</td>\n</tr>\n<tr>\n<td>Sertraline</td>\n</tr>\n<tr>\n<td>Sibutramine</td>\n</tr>\n<tr>\n<td>Tricyclic antidepressants</td>\n</tr>\n<tr>\n<td>Tolbutamide</td>\n</tr>\n<tr>\n<td>Valproic acid</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68705 Version 1.0</div></div></div>"},"68706":{"type":"graphic_picture","displayName":"Fluorosc stent placement","title":"EUS-guided pancreatic pseudocyst drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EUS-guided pancreatic pseudocyst drainage</div><div class=\"cntnt\"><img style=\"width:360px; height:372px;\" src=\"images/GAST/68706_Fluorosc_stent_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image demonstrating insertion of a stent introduction catheter into the pseudocyst over the previously placed guidewire following balloon dilatation.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 68706 Version 1.0</div></div></div>"},"68708":{"type":"graphic_figure","displayName":"Insertion of lever pessary","title":"Insertion of lever vaginal pessary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of lever vaginal pessary</div><div class=\"cntnt\"><img style=\"width:329px; height:330px;\" src=\"images/OBGYN/68708_Insertion_of_lever_pessary.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Milex Products, Inc., Chicago, IL.</div><div id=\"graphicVersion\">Graphic 68708 Version 2.0</div></div></div>"},"68710":{"type":"graphic_picture","displayName":"Juvenile papillomatosis bronch","title":"Juvenile papillomatosis before and after argon plasma coagulation","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Juvenile papillomatosis before and after argon plasma coagulation</div><div class=\"cntnt\"><img style=\"width:537px; height:262px;\" src=\"images/PULM/68710_Juvenile_papillomatosis_bro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Juvenile papillomatosis of the glottic and subglottic region in a 16-year-old boy is seen before (left panel) and after (right panel) treatment with argon plasma coagulation.</div><div class=\"graphic_reference\">Courtesy of Heinrich Becker, MD.</div><div id=\"graphicVersion\">Graphic 68710 Version 3.0</div></div></div>"},"68711":{"type":"graphic_figure","displayName":"PaO2 div FiO2 proning schedule","title":"Course of PaO<sub>2</sub>/FiO<sub>2</sub> during four consecutive 24-hour periods of prone positioning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Course of PaO<sub>2</sub>/FiO<sub>2</sub> during four consecutive 24-hour periods of prone positioning</div><div class=\"cntnt\"><img style=\"width:445px; height:297px;\" src=\"images/PULM/68711_PaO2_div_FiO2_proning_sched.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In each period, patients were prone (p) 20 hours and supine (s) 4 hours. A benefit from prone positioning was observed during repeated transitions from supine to prone position.</div><div class=\"graphic_reference\">Data from Fridrich, P, Krafft, P, Hochleuthner, H, et al., Anesth Analg 1996; 83:1206.</div><div id=\"graphicVersion\">Graphic 68711 Version 1.0</div></div></div>"},"68712":{"type":"graphic_picture","displayName":"Cholangioscopy-directed biopsy","title":"Cholangioscopy-directed biopsy of a stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangioscopy-directed biopsy of a stricture</div><div class=\"cntnt\"><img style=\"width:360px; height:334px;\" src=\"images/GAST/68712_Cholangiosc_directed_bio_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fiberoptic cholangioscopy showing biopsy forceps obtaining a tissue sample from an ulcerated stricture due to cholangiocarcinoma.</div><div id=\"graphicVersion\">Graphic 68712 Version 2.0</div></div></div>"},"68713":{"type":"graphic_table","displayName":"Requirements for off-site surgical backup","title":"ACCF/AHA/SCAI expert consensus document requirements for off-site surgical backup","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCF/AHA/SCAI expert consensus document requirements for off-site surgical backup</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>1.</strong> Interventional cardiologists establish a working relationship with cardiac surgeons at the receiving facility</td> </tr> <tr> <td><strong>2.</strong> Cardiac surgeon must have privileges at the referring facility to allow review of treatment options as time allows</td> </tr> <tr> <td><strong>3.</strong> Cardiac surgeon and receiving hospital agree to provide cardiac surgical backup for urgent cases at all hours and for elective cases at mutually agreed hours</td> </tr> <tr> <td><strong>4.</strong> Surgeon and receiving facility ensure that patients will be accepted based on medical condition, capacity of surgeon to provide services at the time of request, and availability of resources. If this cannot be ensured before the start of an elective procedure, the case should not be done at this time.</td> </tr> <tr> <td><strong>5.</strong> Interventional cardiologists must review with surgeons the immediate needs and status of any patient transferred for urgent surgery</td> </tr> <tr> <td><strong>6.</strong> Hospital administrations from both facilities endorse transfer agreement</td> </tr> <tr> <td><strong>7.</strong> Transferring and receiving facilities establish a rigorous protocol for rapid transfer of patients, including the proper personnel with appropriate experience</td> </tr> <tr> <td><strong>8.</strong> A transport provider is available to begin transport within 20 min of the request and provide vehicle/helicopter with necessary life-sustaining equipment, including IABP and monitoring capability</td> </tr> <tr> <td><strong>9.</strong> Transferring physician obtains consent for surgery from patient or appropriate surrogate</td> </tr> <tr> <td><strong>10.</strong> Initial informed consent for PCI discloses that the procedure is being done without on-site surgical backup and acknowledges the possibility of risks related to transfer. The consent process should include the risk of urgent surgery (approximately 0.3 percent) and state that a written plan for transfer exists.</td> </tr> <tr> <td><strong>11.</strong> As part of the local continuous quality improvement program, a regular review of all patients transferred for emergency surgery with the outcome of surgery and identification of any improvement opportunities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IABP: intra-aortic balloon pump; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions.</div><div class=\"graphic_reference\">From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68713 Version 2.0</div></div></div>"},"68717":{"type":"graphic_table","displayName":"Management of ICH after thrombolysis for ischemic stroke","title":"Management of intracerebral hemorrhage after thrombolysis for ischemic stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of intracerebral hemorrhage after thrombolysis for ischemic stroke</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Consider bleeding the likely cause of neurologic worsening after use of a thrombolytic drug until a brain scan confirms or refutes hemorrhage.</td> </tr> <tr> <td>2. Immediately discontinue ongoing infusion of thrombolytic drug.</td> </tr> <tr> <td>3. Obtain emergent head CT or MRI stat.</td> </tr> <tr> <td>4. Obtain blood samples for type and crossmatch, prothrombin time, activated partial thromboplastin time, platelet count, and fibrinogen.</td> </tr> <tr> <td class=\"sublist1_start\">5. If intracerebral hemorrhage is confirmed by imaging:</td> </tr> <tr> <td class=\"sublist1\">- Give 10 units of cryoprecipitate to increase the levels of fibrinogen and factor VIII</td> </tr> <tr> <td class=\"sublist1\">- Give 6 to 8 units of platelets</td> </tr> <tr> <td class=\"sublist1\">- In patients receiving unfractionated heparin (UFH) for any reason, consider giving 1 mg of protamine for every 100 U of UFH received in the preceding four hours</td> </tr> <tr> <td>6. Obtain neurosurgical consultation and consider evacuation of the hematoma.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68717 Version 3.0</div></div></div>"},"68718":{"type":"graphic_diagnosticimage","displayName":"Bladder tumor cystogram","title":"Characteristics of bladder cancer on IVP","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Characteristics of bladder cancer on IVP</div><div class=\"cntnt\"><img style=\"width:504px; height:277px;\" src=\"images/ONC/68718_Bladder_tumor_cystogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravenous pyelogram (IVP) study, which demonstrates a bladder tumor (arrows) on the cystogram (panel A) and postvoid phases (panel B).</div><div class=\"graphic_reference\">Courtesy of Machele Donat, MD.</div><div id=\"graphicVersion\">Graphic 68718 Version 2.0</div></div></div>"},"68719":{"type":"graphic_table","displayName":"GI priming in preterm infants","title":"Advantages of gastrointestinal priming (trophic feeding) in preterm infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages of gastrointestinal priming (trophic feeding) in preterm infants</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Shortens time to regain birth weight</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Improves feeding tolerance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduces duration of parenteral nutrition</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enhances enzyme maturation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduces intestinal permeability</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Improves gastrointestinal motility</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Matures hormone responses</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Improves mineral absorption and mineralization</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduces duration of phototherapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lowers incidence of cholestasis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68719 Version 2.0</div></div></div>"},"68720":{"type":"graphic_table","displayName":"Normal growth rates children","title":"Normal growth rates in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal growth rates in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Age group</td>\n<td class=\"subtitle1\">Height velocity</td>\n<td class=\"subtitle1\">Weight velocity</td>\n</tr>\n<tr>\n<td>Infancy (0 to 12 months)</td>\n<td>25 cm/y</td>\n<td>7 kg/y</td>\n</tr>\n<tr>\n<td>Toddler (12 to 24 months)</td>\n<td>11 cm/y</td>\n<td>2.5 kg/y</td>\n</tr>\n<tr>\n<td>Preschool/school age</td>\n<td>6 cm/y</td>\n<td>2.5 kg/y</td>\n</tr>\n<tr>\n<td>Adolescent</td>\n<td>3-4 cm/6 mo</td>\n<td>3 kg/6 mo</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68720 Version 1.0</div></div></div>"},"68721":{"type":"graphic_table","displayName":"Pediatric RIFLE Classification of AKI","title":"Pediatric RIFLE Classification of acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric RIFLE Classification of acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">pRIFLE stage</td> <td class=\"subtitle1\">Estimated creatinine clearance (eCCl)</td> <td class=\"subtitle1\">Urine output</td> </tr> <tr> <td>R = Risk for renal dysfunction</td> <td>eCCl decreased by 25 percent</td> <td>&#60;0.5 mL/kg per hour for 8 hours</td> </tr> <tr> <td>I = Injury to the kidney</td> <td>eCCl decreased by 50 percent</td> <td>&#60;0.5 mL/kg per hour for 16 hours</td> </tr> <tr> <td>F = Failure of kidney function</td> <td>eCCl decreased by 75 percent or eCCl &#60;35 mL/min per 1.73 m<sup>2</sup></td> <td>&#60;0.3 mL/kg per hour for 24 hours or anuria for 12 hours</td> </tr> <tr> <td>L = Loss of kidney function</td> <td>Persistent failure &#62;4 weeks</td> <td>&nbsp;</td> </tr> <tr> <td>E = End-stage renal disease</td> <td>Persistent failure &#62;3 months</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68721 Version 3.0</div></div></div>"},"68722":{"type":"graphic_diagnosticimage","displayName":"Lateral view of comminuted midshaft femur fracture","title":"Lateral view of comminuted midshaft femur fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral view of comminuted midshaft femur fracture</div><div class=\"cntnt\"><img style=\"width:289px; height:355px;\" src=\"images/EM/68722_Femur_fx_mid_lat_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph shows a comminuted midshaft femur fracture prior to operative repair.</div><div class=\"graphic_reference\">Courtesy of Thomas J Mezzanotte, MD.</div><div id=\"graphicVersion\">Graphic 68722 Version 3.0</div></div></div>"},"68723":{"type":"graphic_figure","displayName":"Serology acute to chronic HCV","title":"Serologic pattern of acute HCV infection with progression of chronic infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serologic pattern of acute HCV infection with progression of chronic infection</div><div class=\"cntnt\"><img style=\"width:410px; height:325px;\" src=\"images/GAST/68723_Serology_acute_to_chronic_H.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Figure provided by the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 68723 Version 1.0</div></div></div>"},"68724":{"type":"graphic_picture","displayName":"CML marrow","title":"Bone marrow aspirate in chronic myelogenous leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate in chronic myelogenous leukemia</div><div class=\"cntnt\"><img style=\"width:414px; height:288px;\" src=\"images/HEME/68724_CML_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with chronic myelogenous leukemia shows hyperplasia of elements of the granulocytic series (eg, promyelocytes, myelocytes, metamyelocytes, band forms, and mature granulocytes).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and Anna J Mitus, MD.</div><div id=\"graphicVersion\">Graphic 68724 Version 2.0</div></div></div>"},"68725":{"type":"graphic_diagnosticimage","displayName":"Left atrial myxoma TTE TEE II","title":"Left atrial myxoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><img style=\"width:381px; height:286px;\" src=\"images/CARD/68725_Left_atrial_myxoma_TTE_TE1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis precordial view from a transthoracic echocardiography shows the tumor as a vague mass just behind the aortic root (panel A). The apical four chamber view (panel B) shows the mass attached to the interatrial septum. A transesophageal echocardiography (panels C and D) reveals that the myxoma is highly mobile and at surgery, the tumor had the consistency of jelly and fragmented easily.</div><div id=\"graphicVersion\">Graphic 68725 Version 3.0</div></div></div>"},"68727":{"type":"graphic_picture","displayName":"Intubation with rigid bronch","title":"Intubation with rigid bronchoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intubation with rigid bronchoscope</div><div class=\"cntnt\"><img style=\"width:305px; height:209px;\" src=\"images/PULM/68727_Intubation_with_rigid_bronc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is intubated with an Efer-Dumon rigid bronchoscope. The mouth is being packed with gauze to prevent leakage of oxygen or anesthesia gases.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD.</div><div id=\"graphicVersion\">Graphic 68727 Version 2.0</div></div></div>"},"68729":{"type":"graphic_picture","displayName":"Dermatofibroma - dark skin","title":"Dermatofibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatofibroma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68729_Dermatofibroma_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This oval, hyperpigmented, firm papule is a dermatofibroma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68729 Version 3.0</div></div></div>"},"68731":{"type":"graphic_waveform","displayName":"Atrial tach with block tutorial","title":"Atrial tachycardia with atrioventricular block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial tachycardia with atrioventricular block</div><div class=\"cntnt\"><img style=\"width:401px; height:145px;\" src=\"images/CARD/68731_Atrial_tach_with_block_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this arrhythmia, an ectopic atrial focus is the dominant pacemaker and activates the atrial myocardium at a rate of 140 to 220 beats per minute. Due to changes in the electrophysiologic properties of the atrioventricular node, however, there is a slowing of impulse conduction through and prolongation of the refractory period of the AV node, resulting in failure of the node to conduct some of the atrial impulses. In this case, the atrial rate is 220 beats per minute and the failure to conduct occurs in a repeating 2:1 pattern.</div><div id=\"graphicVersion\">Graphic 68731 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"68733":{"type":"graphic_diagnosticimage","displayName":"SLS MRI 5 16 35 months","title":"Brain MRI (at 5, 16, and 35 months) of a patient with Sjogren-Larsson syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Brain MRI (at 5, 16, and 35 months) of a patient with Sjogren-Larsson syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:167px;\" src=\"images/NEURO/68733_SLS_MRI_5_16_35_months.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MR images (3100/98 [TR/TE]). There is a delay in the maturation of the white matter on all three images.<br />(A) At five months of age, the unmyelinated periventricular white matter shows no abnormal signal intensities.<br />(B and C) Images obtained at 16 (B) and 35 (C) months of age show nonprogressive, slight signal-intensity abnormalities in the periventricular white matter that mainly involve the occipital trigones.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Reproduced with permission from: Willemsen, MA, Van Der, Graaf M, Van Der, Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649. Copyright &copy;2004 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 68733 Version 3.0</div></div></div>"},"68734":{"type":"graphic_picture","displayName":"Atypical nevi","title":"Atypical melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atypical melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:360px; height:306px;\" src=\"images/ONC/68734_Atypical_nevi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple melanocytic nevi on the posterior trunk, some of which are large in size (&gt;6 mm) and/or have variegated pigmentation.</div><div class=\"graphic_reference\">Courtesy of Clara Curiel-Lewandrowski, MD.</div><div id=\"graphicVersion\">Graphic 68734 Version 3.0</div></div></div>"},"68736":{"type":"graphic_picture","displayName":"String pull technique","title":"String pull technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">String pull technique</div><div class=\"cntnt\"><img style=\"width:401px; height:337px;\" src=\"images/PEDS/68736_String_pull_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One end of a 20-inch length of suture or umbilical tape is passed under the ring and pulled so that the two ends are of equal length. The finger and ring are lubricated with a water-soluble lubricant. The string is grasped 5 to 10 cm from the ring and pulled distally in a circular fashion along the axis of the finger, permitting the ring gradually to be removed.</div><div id=\"graphicVersion\">Graphic 68736 Version 2.0</div></div></div>"},"68737":{"type":"graphic_picture","displayName":"Insulinoma Light","title":"Insulinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insulinoma</div><div class=\"cntnt\"><img style=\"width:396px; height:271px;\" src=\"images/ENDO/68737_Insulinoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular insulinoma (left) abutting on normal pancreatic tissue (x 6).</div><div class=\"graphic_reference\">Courtesy of F John Service, MD.</div><div id=\"graphicVersion\">Graphic 68737 Version 1.0</div></div></div>"},"68738":{"type":"graphic_diagnosticimage","displayName":"Upright abdominal x-ray of small bowel obstruction","title":"Upright abdominal x-ray of small bowel obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Upright abdominal x-ray of small bowel obstruction</div><div class=\"cntnt\"><img style=\"width:396px; height:363px;\" src=\"images/GAST/68738_Dilated_sm_bowel_air_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain, upright abdominal&nbsp;radiograph shows dilated loops of small bowel with air-fluid levels consistent with a diagnosis of small bowel obstruction.</div><div class=\"graphic_reference\">Courtesy of Richard A Hodin, MD.</div><div id=\"graphicVersion\">Graphic 68738 Version 4.0</div></div></div>"},"68739":{"type":"graphic_diagnosticimage","displayName":"Simple hepatic cyst series","title":"Images of a simple hepatic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Images of a simple hepatic cyst</div><div class=\"cntnt\"><img style=\"width:382px; height:268px;\" src=\"images/GAST/68739_Simple_hepatic_cyst_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Abdominal CT scan shows a well-defined, low-attenuation lesion in the left hepatic lobe.<br />(B) Abdominal ultrasound demonstrates an unilocular space with internal echoes consistent with bleeding into the cyst cavity.<br />(C) T2-weighted magnetic resonance imaging, demonstrating a typical high-intensity signal.<br />(D) Surgical view showing wide unroofing of the cyst.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright &copy; 2001 American College of Surgeons.</div><div id=\"graphicVersion\">Graphic 68739 Version 4.0</div></div></div>"},"68740":{"type":"graphic_table","displayName":"Results of phlebotomy in HH","title":"Results of therapeutic phlebotomy in patients with hemochromatosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of therapeutic phlebotomy in patients with hemochromatosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complications of iron overload</td> <td class=\"subtitle1\">Expected treatment outcome</td> </tr> <tr> <td>None</td> <td>Prevention of complications of iron overload; normal life expectancy</td> </tr> <tr> <td>Weakness, fatigue, lethargy</td> <td>Improvement in majority of patients</td> </tr> <tr> <td>Elevated serum concentrations of hepatic enzymes</td> <td>Resolution or marked improvement</td> </tr> <tr> <td>Hepatomegaly</td> <td>Resolution often occurs</td> </tr> <tr> <td>Hepatic cirrhosis</td> <td>No change</td> </tr> <tr> <td>Increased risk for primary liver cancer</td> <td>No change*</td> </tr> <tr> <td>Right upper quadrant pain</td> <td>Resolution or marked improvement<sup>&#182;</sup></td> </tr> <tr> <td>Arthropathy</td> <td>Improvement in arthralgias sometimes occurs; change in joint deformity is rare; progression is sometimes seen</td> </tr> <tr> <td>Hypogonadotrophic hypogonadism</td> <td>Resolution is rare</td> </tr> <tr> <td>Diabetes mellitus</td> <td>Occasional improvement, often temporary</td> </tr> <tr> <td>Hypothyroidism, hypogonadism</td> <td>Resolution is rare</td> </tr> <tr> <td>Cardiomyopathy</td> <td>Resolution sometimes occurs</td> </tr> <tr> <td>Hyperpigmentation</td> <td>Resolution usually occurs</td> </tr> <tr> <td>Hyperferritinemia</td> <td>Resolution</td> </tr> <tr> <td>Excess absorption and storage of nonferrous metals<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Infection with Vibrio vulnificus or other bacteria</td> <td>Little or no change</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Increased risk occurs only in persons with cirrhosis.<br />¶ Right upper quadrant pain in persons with hemochromatosis is often related to hepatic iron overload. In these cases, therapeutic phlebotomy usually results in marked improvement or resolution. However, right upper quadrant pain may also be caused by primary liver cancer, portal vein thrombosis, gallbladder disease, lesions in the hepatic flexure, or nephrolithiasis. Iron depletion alone will not alleviate right upper quadrant pain due to these causes.<br />Δ Cobalt, maganese, zinc, and lead.</div><div class=\"graphic_reference\">Adapted from: Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.</div><div id=\"graphicVersion\">Graphic 68740 Version 7.0</div></div></div>"},"68741":{"type":"graphic_picture","displayName":"Wet AMD with hemorrhage","title":"Wet type age-related macular degeneration (AMD) with subretinal hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wet type age-related macular degeneration (AMD) with subretinal hemorrhage</div><div class=\"cntnt\"><img style=\"width:351px; height:290px;\" src=\"images/PC/68741_Wet_AMD_with_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large area of subretinal hemorrhage is present.</div><div class=\"graphic_reference\">Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.</div><div id=\"graphicVersion\">Graphic 68741 Version 2.0</div></div></div>"},"68742":{"type":"graphic_diagnosticimage","displayName":"Advanced sarcoidosis PA","title":"Long standing sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long standing sarcoidosis</div><div class=\"cntnt\"><img style=\"width:360px; height:306px;\" src=\"images/PULM/68742_Advanced_sarcoidosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph shows interstitial opacities with upper zone predominance, volume loss, and advanced fibrosis (Stage IV).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68742 Version 4.0</div></div></div>"},"68744":{"type":"graphic_picture","displayName":"Pharyngitis in a patient with PFAPA syndrome","title":"Pharyngitis in a patient with periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pharyngitis in a patient with periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/68744_Pharyngitis_PFAPA_syndr.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68744 Version 1.0</div></div></div>"},"68745":{"type":"graphic_picture","displayName":"Frozen shoulder motion restrictions","title":"Frozen shoulder: Restrictions in motion","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Frozen shoulder: Restrictions in motion</div><div class=\"cntnt\"><img style=\"width:620px; height:555px;\" src=\"images/EM/68745_Frozen_shoulder_motion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above&#160;show common motion restrictions&#160;that are found with frozen shoulder. Note how the affected left shoulder is limited in external rotation (A), abduction (B), and internal rotation (C), compared to the unaffected shoulder (photographs D, E, and F).&#160;Photographs A, B, D, and E&#160;depict passive glenohumeral motion while the scapula is stabilized.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 68745 Version 3.0</div></div></div>"},"68746":{"type":"graphic_picture","displayName":"Atopic dermatitis infant","title":"Atopic dermatitis - infantile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis - infantile</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/68746_Atopic_dermatitis_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diaper area is relatively spared in this infant with widespread atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68746 Version 4.0</div></div></div>"},"68747":{"type":"graphic_picture","displayName":"Aspergillus silver stain","title":"<EM>Aspergillus fumigatus</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Aspergillus fumigatus</EM></div><div class=\"cntnt\"><img style=\"width:366px; height:240px;\" src=\"images/ID/68747_Aspergillussilverstain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Silver stain of lung tissue (x400) shows septate hyphae with acute angle branching characteristic of <EM>Aspergillus fumigatus</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 68747 Version 5.0</div></div></div>"},"68752":{"type":"graphic_figure","displayName":"Abdominal sacrocolpopexy","title":"Transabdominal sacrocolpopexy for transverse defect repair","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Transabdominal sacrocolpopexy for transverse defect repair</div><div class=\"cntnt\"><img style=\"width:534px; height:432px;\" src=\"images/OBGYN/68752_Abdominal_sacrocolpopexy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with a prior hysterectomy without identifiable uterosacral ligaments, abdominal sacrocolpopexy can be used to resuspend the vagina. Each arm of the Y-shaped permanent mesh graft is attached to the muscularis of the anterior and posterior vagina. The base of the mesh graft is then attached to the periosteum of the sacrum, thereby suspending both the anterior and posterior vaginal walls, as well as the vaginal apex.</div><div id=\"graphicVersion\">Graphic 68752 Version 3.0</div></div></div>"},"68753":{"type":"graphic_figure","displayName":"Retroflexion of endoscope within the stomach","title":"Retroflexion of endoscope within the stomach","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Retroflexion of endoscope within the stomach</div><div class=\"cntnt\"><img style=\"width:528px; height:508px;\" src=\"images/GAST/68753_Retroflexion-of-endoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroflexion of the endoscope permits visualization of portions of the stomach that are not well seen during forward-viewing with the endoscope.</div><div id=\"graphicVersion\">Graphic 68753 Version 1.0</div></div></div>"},"68754":{"type":"graphic_picture","displayName":"Photodamage scale","title":"Photonumeric scale for cutaneous photodamage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photonumeric scale for cutaneous photodamage</div><div class=\"cntnt\"><img style=\"width:299px; height:743px;\" src=\"images/DERM/68754_Photo_damage_scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photonumeric scale used for the assessment of cutaneous photodamage. Five photographic standards (en face and 45 degree oblique) illustrating increasing severity of photodamage, where grade 0 represents no damage; grade 2, mild damage; grade 4, moderate damage; grade 6, moderate/severe damage; and grade 8, severe damage.</div><div class=\"graphic_reference\">Reproduced with permission from: Regents of the University of Michigan. Copyright © 1991.</div><div id=\"graphicVersion\">Graphic 68754 Version 2.0</div></div></div>"},"68755":{"type":"graphic_diagnosticimage","displayName":"Displaced proximal humeral fracture","title":"Displaced proximal humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced proximal humeral fracture</div><div class=\"cntnt\"><img style=\"width:443px; height:360px;\" src=\"images/EM/68755_Displacedproxhumeralfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) AP x-ray of displaced, shortened fracture of the proximal humerus. Panel B) Axillary image of same. Panel C) Intramedullary fixation using retrograde technique. Note the satisfactory restoration of alignment. Panel D) Postoperative lateral view.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scapula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68755 Version 14.0</div></div></div>"},"68756":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber echo right atrial thrombus","title":"Apical 4 chamber echocardiogram showing right atrial thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber echocardiogram showing right atrial thrombus</div><div class=\"cntnt\"><img style=\"width:327px; height:251px;\" src=\"images/CARD/68756_4_chamber_right_atrial_thro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view show a thrombus that was in transit from the lower extremities and temporarily became lodged in the right atrium (RA). Additionally, the right ventricle (RV) is enlarged, implying that other emboli have reached the pulmonary circulation, resulting in raised pulmonary vascular resistance.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 68756 Version 4.0</div></div></div>"},"68758":{"type":"graphic_form","displayName":"Parent questionnaire B","title":"Questionnaire for parents (continued)","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Questionnaire for parents (continued)</div><div class=\"cntnt\"><img style=\"width:533px; height:650px;\" src=\"images/PEDS/68758_Parent_questionnaire_B.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 68758 Version 2.0</div></div></div>"},"68759":{"type":"graphic_table","displayName":"Clinical features of vaginitis","title":"Clinical findings in women with vaginitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in women with vaginitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Normal findings</td> <td class=\"subtitle1\">Vulvovaginal candidiasis</td> <td class=\"subtitle1\">Bacterial vaginosis</td> <td class=\"subtitle1\">Trichomoniasis</td> </tr> <tr class=\"divider_bottom\"> <td>Symptoms</td> <td>None or mild, transient</td> <td>Pruritus, soreness, dyspareunia</td> <td>Malodorous discharge, no dyspareunia</td> <td>Malodorous discharge, burning, postcoital bleeding, dyspareunia, dysuria</td> </tr> <tr class=\"divider_bottom\"> <td>Signs</td> <td>Normal vaginal discharge consists of 1 to 4 mL fluid (per 24 hours), which is white or transparent, thin or thick, and mostly odorless</td> <td>Vulvar erythema and/or edema. Discharge may be white and clumpy and may or may not adhere to vagina.</td> <td>Off-white/gray thin discharge that coats the vagina</td> <td>Thin green-yellow discharge, vulvovaginal erythema</td> </tr> <tr class=\"divider_bottom\"> <td>Vaginal pH</td> <td>4.0 to 4.5</td> <td>4.0 to 4.5</td> <td>&#62;4.5</td> <td>5.0 to 6.0</td> </tr> <tr class=\"divider_bottom\"> <td>Amine test</td> <td>Negative</td> <td>Negative</td> <td>Positive (in 70 to 80% of patients)</td> <td>Often positive</td> </tr> <tr class=\"divider_bottom\"> <td>Saline microscopy</td> <td>PMN:EC ratio &#60;1; rods dominate; squames +++</td> <td>PMN:EC ratio &#60;1; rods dominate; squames +++; pseudohyphae (present in about 40% of patients); budding yeast for nonalbicans <em>Candida</em></td> <td>PMN:EC &#60;1; loss of rods; increased coccobacilli; clue cells comprise at least 20% of epithelial cells (present in &#62;90% of patients)</td> <td>PMN ++++; mixed flora; motile trichomonads (present in about 60% of patients)</td> </tr> <tr class=\"divider_bottom\"> <td>10% potassium hydroxide microscopy</td> <td>Negative</td> <td>Pseudohyphae (in about 70% of patients)</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td>Other tests</td> <td>&ndash;</td> <td>If microscopy nondiagnostic: <ul class=\"decimal_heading\"> <li>Culture </li> <li>DNA hybridization probe (eg, Affirm VP III) </li> </ul> </td> <td> <p>Quantitative Gram stain (eg, Nugent criteria, Hay/Ison criteria)</p> <p>DNA hybridization probe (eg, Affirm VPIII)</p> Culture of <strong>no</strong> value</td> <td>If microscopy nondiagnostic: <ul class=\"decimal_heading\"> <li>Culture (eg, InPouch TV culture system) </li> <li>Rapid antigen test (eg, OSOM Trichomonas Rapid Test) </li> <li>Nucleic acid amplification test (eg, APTIMA Trichomonas vaginalis test) </li> <li>DNA Hybridization probe (eg, Affirm VPIII) </li> </ul> </td> </tr> <tr> <td>Differential diagnosis</td> <td>Physiologic leukorrhea</td> <td>Contact irritant or allergic vulvar dermatitis, chemical irritation, focal vulvitis (vulvodynia)</td> <td>Elevated pH in trichomoniasis, atrophic vaginitis, and desquamative inflammatory vaginitis</td> <td>Purulent vaginitis, desquamative inflammatory vaginitis, atrophic vaginitis, erosive lichen planus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocytes; EC: vaginal epithelial cells.</div><div id=\"graphicVersion\">Graphic 68759 Version 12.0</div></div></div>"},"68760":{"type":"graphic_diagnosticimage","displayName":"Adenoid cystic carcinoma CT","title":"Adenoid cystic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenoid cystic carcinoma</div><div class=\"cntnt\"><img style=\"width:389px; height:525px;\" src=\"images/PULM/68760_Adenoid_cystic_carcinoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scans reveal an irregular tracheal mass that originates from the posterior wall.</div><div id=\"graphicVersion\">Graphic 68760 Version 3.0</div></div></div>"},"68761":{"type":"graphic_diagnosticimage","displayName":"Central lung tumor PA","title":"Central bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:380px; height:344px;\" src=\"images/PULM/68761_Central_lung_tumor_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with advanced lung cancer. Chest radiograph shows complete atelectasis of the right lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 68761 Version 2.0</div></div></div>"},"68762":{"type":"graphic_table","displayName":"B cell subsets","title":"Characteristics of B cell subsets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of B cell subsets</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">B-1a</td>\n<td class=\"subtitle1\">B-1b</td>\n<td class=\"subtitle1\">B-2, \"Conventional\"</td>\n</tr>\n<tr>\n<td>CD5</td>\n<td>Constitutive</td>\n<td>Inducible</td>\n<td>Inducible</td>\n</tr>\n<tr>\n<td>CD11b/CD18</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>CD45RA</td>\n<td>Low</td>\n<td>Low</td>\n<td>High</td>\n</tr>\n<tr>\n<td rowspan=\"4\">Immunoglobulins</td>\n<td>Low-affinity</td>\n<td>High-affinity</td>\n<td>High-affinity</td>\n</tr>\n<tr>\n\n<td>Polyreactive</td>\n<td>Specific</td>\n<td>Specific</td>\n</tr>\n<tr>\n\n<td>Germline VH, VL</td>\n<td>Mutated VH, VL</td>\n<td>Mutated VH, VL</td>\n</tr>\n<tr>\n\n<td>IgM</td>\n<td>IgG, IgA, IgE</td>\n<td>IgG, IgA, IgE</td>\n</tr>\n<tr>\n<td>Origin</td>\n<td>Self-replenishing</td>\n<td>Bone marrow</td>\n<td>Bone marrow</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Location</td>\n<td>Blood</td>\n<td>Blood</td>\n<td>Blood</td>\n</tr>\n<tr>\n\n<td>Peritoneal cavity</td>\n<td>Follicular mantle</td>\n<td>Follicular mantle</td>\n</tr>\n<tr>\n<td>CD5 ligation</td>\n<td>Induce TNF and IL-2R</td>\n<td>Apoptosis</td>\n<td>Apoptosis</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">VH: heavy chain variable region genes; VL: light chain variable region genes; TNF: tumor necrosis factor; IL-2R: interleukin-2 receptor. CD45A is the high molecular weight form of CD45 (leukocyte common antigen).</div><div class=\"graphic_reference\">Data from Youinou, P, Jamin, C, Lydyard, PM. Immunol Today 1999; 20:312. (page 314, table2).</div><div id=\"graphicVersion\">Graphic 68762 Version 1.0</div></div></div>"},"68763":{"type":"graphic_figure","displayName":"QT dispersion VT","title":"QT dispersion in patients with and without ventricular tachycardia is variable","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">QT dispersion in patients with and without ventricular tachycardia is variable</div><div class=\"cntnt\"><img style=\"width:568px; height:266px;\" src=\"images/CARD/68763_QT_dispersion_VT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A summary of studies evaluating QT dispersion in patients with (red) and without (blue) ventricular tachyarrhythmias demonstrates a great degree of overlap in the mean QT dispersion. Some, but not all studies, have shown that the mean QT dispersion is greater in patients with ventricular arrhythmias compared to those without ventricular arrhythmia.</div><div class=\"graphic_footnotes\">NS: nonsignificant.<br>* p = 0.05.</div><div id=\"graphicVersion\">Graphic 68763 Version 1.0</div></div></div>"},"68766":{"type":"graphic_figure","displayName":"First aid snake bites","title":"First aid for snake bites - pressure-immobilization method","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">First aid for snake bites - pressure-immobilization method</div><div class=\"cntnt\"><img style=\"width:558px; height:758px;\" src=\"images/ID/68766_First_aid_snake_bites.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Ken Winkel, MD. First aid for snake bites: Pressure-Immobilization Method. Australian Venom Research Unit. Copyright Dr. Ken Winkel, Australian Venom Research Unit.</div><div id=\"graphicVersion\">Graphic 68766 Version 1.0</div></div></div>"},"68768":{"type":"graphic_figure","displayName":"VF complete HH","title":"Visual fields: Complete Homonymous Hemianopia","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Visual fields: Complete Homonymous Hemianopia</div><div class=\"cntnt\"><img style=\"width:521px; height:454px;\" src=\"images/NEURO/68768_VF_complete_HH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field showing a left complete homonymous hemianopia.</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68768 Version 12.0</div></div></div>"},"68770":{"type":"graphic_diagnosticimage","displayName":"Normal postoperative CT scan after gastric bypass","title":"Normal postoperative CT scan after gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Normal postoperative CT scan after gastric bypass</div><div class=\"cntnt\"><img style=\"width:541px; height:274px;\" src=\"images/SURG/68770_Norm_postop_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This computed tomography (CT) scan shows gastrojejunostomy and Roux limb (arrowhead) anterior to the gastric remnant (arrow) which has some fluid in it and small bowel anterior to colon. In Image B, the arrowhead shows contrast-filled Roux limb medial to the biliopancreatic limb (arrow). This is a normal study on an antegastric antecolic gastric bypass.</div><div id=\"graphicVersion\">Graphic 68770 Version 7.0</div></div></div>"},"68772":{"type":"graphic_table","displayName":"Efficacy of Rx for anovulation","title":"Approximate ovulation and pregnancy rates following ovulation induction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate ovulation and pregnancy rates following ovulation induction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Ovulation rate, percent</td> <td class=\"subtitle1\">Cumulative pregnancy rate, percent</td> </tr> <tr> <td>Clomiphene</td> <td>80</td> <td>50</td> </tr> <tr> <td>Gonadotropins</td> <td>72</td> <td>50</td> </tr> <tr> <td>Pulsatile GnRH*</td> <td>90</td> <td>80</td> </tr> <tr> <td>Dopamine agonists<sup>&#182;</sup></td> <td>80</td> <td>70</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; WHO: World Health Organization.<br />* Indicated only for women with hypogonadotropic hypogonadal anovulation (WHO class 1).<br />¶ Indicated only for women with hyperprolactinemia-induced anovulation.</div><div id=\"graphicVersion\">Graphic 68772 Version 3.0</div></div></div>"},"68773":{"type":"graphic_figure","displayName":"Autoabsorption method","title":"Autoabsorption method to detect alloantibody in the presence of autoantibody","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Autoabsorption method to detect alloantibody in the presence of autoantibody</div><div class=\"cntnt\"><img style=\"width:588px; height:346px;\" src=\"images/HEME/68773_Autoabsorption_method.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68773 Version 1.0</div></div></div>"},"68775":{"type":"graphic_picture","displayName":"NSIP lung biopsy","title":"Nonspecific interstitial pneumonitis (NSIP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonspecific interstitial pneumonitis (NSIP)</div><div class=\"cntnt\"><img style=\"width:392px; height:518px;\" src=\"images/PEDS/68775_NSIP_lung_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative fields of a lung biopsy specimen from a child with NSIP. A low-power view of the lung biopsy specimen (top) demonstrates a mixed pattern of inflammation and fibrosis, with moderately dilated and tortuous air spaces. The high-power view (bottom) demonstrates a mixed inflammatory infiltrate of lymphocytes, histiocytes, and plasma cells, as well as regions of brightly eosinophilic material within the alveolar septae. Patchy intraalveolar macrophages are visible within the air spaces. The alveolar walls are variably thickened by collagen bundles, fibroblasts, and epithelial hyperplasia.</div><div class=\"graphic_reference\">Courtesy of Cynthia Epstein, MD and Leland L Fan, MD.</div><div id=\"graphicVersion\">Graphic 68775 Version 2.0</div></div></div>"},"68777":{"type":"graphic_picture","displayName":"Normal retina","title":"Normal retina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal retina</div><div class=\"cntnt\"><img style=\"width:324px; height:234px;\" src=\"images/PC/68777_Normal_retina.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jeffrey W Berger Retina Teaching Set. Copyrighted by the Scheie Eye Institute and the University of Pennsylvania.</div><div id=\"graphicVersion\">Graphic 68777 Version 1.0</div></div></div>"},"68778":{"type":"graphic_figure","displayName":"Noncontact map sinus rhythm","title":"Noncontact endocardial map during sinus rhythm","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Noncontact endocardial map during sinus rhythm</div><div class=\"cntnt\"><img style=\"width:541px; height:252px;\" src=\"images/CARD/68778_Noncontactmapsinusrhythm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sequence of isopotential maps of the left ventricular endocardium (purple) is modeled to the ventricular chamber dimensions. The location of the multielectrode array is represented by the orange ellipsoid. Surface ECG lead I and selected virtual electrograms from a line following fascicular activation are shown beneath each map. Initial activation (arrow, panel A) occurs in the upper part of the fascicles and then progresses toward the apex (arrow, panel B). At the apex, fascicular activation initiates ventricular activation (white area, panel C).</div><div class=\"graphic_reference\">Data from: Peters NS, Jackman WM, Schilling RJ, et al. Circulation 1997; 95:1658.</div><div id=\"graphicVersion\">Graphic 68778 Version 3.0</div></div></div>"},"68779":{"type":"graphic_table","displayName":"Noninfectious causes fever","title":"Noninfectious causes of fever in the intensive care unit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious causes of fever in the intensive care unit</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Important causes</td></tr>\n\t\t\t\t\t\t<tr><td>Acalculous cholecystitis</td></tr>\n\t\t\t\t\t\t<tr><td>Adrenal insufficiency</td></tr>\n\t\t\t\t\t\t<tr><td>Benign post-operative fever</td></tr>\n\t\t\t\t\t\t<tr><td>Drug fever</td></tr>\n\t\t\t\t\t\t<tr><td>Pancreatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Thyroid storm</td></tr>\n\t\t\t\t\t\t<tr><td>Transfusion reaction</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Other causes</td></tr>\n\t\t\t\t\t\t<tr><td>Acute respiratory distress syndrome (late)</td></tr>\n\t\t\t\t\t\t<tr><td>Burns</td></tr>\n\t\t\t\t\t\t<tr><td>Drug overdose (eg, aspirin anticholinergic drugs)</td></tr>\n\t\t\t\t\t\t<tr><td>Drug withdrawal</td></tr>\n\t\t\t\t\t\t<tr><td>Gout</td></tr>\n\t\t\t\t\t\t<tr><td>Heat stroke</td></tr>\n\t\t\t\t\t\t<tr><td>Intracranial hemorrhage</td></tr>\n\t\t\t\t\t\t<tr><td>Ischemic colitis</td></tr>\n\t\t\t\t\t\t<tr><td>Malignancy</td></tr>\n\t\t\t\t\t\t<tr><td>Malignant hyperthermia</td></tr>\n\t\t\t\t\t\t<tr><td>Myocardial infarction</td></tr>\n\t\t\t\t\t\t<tr><td>Neuroleptic malignant syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Pheochromocytoma</td></tr>\n\t\t\t\t\t\t<tr><td>Seizures</td></tr>\n\t\t\t\t\t\t<tr><td>Serotonin syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Thromboembolic disease</td></tr>\n\t\t\t\t\t\t<tr><td>Vasculitis</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68779 Version 1.0</div></div></div>"},"68780":{"type":"graphic_figure","displayName":"AHT drug and HF ALLHAT","title":"Amlodipine, lisinopril, chlorthalidone, and rates of heart failure (HF) in hypertensive patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amlodipine, lisinopril, chlorthalidone, and rates of heart failure (HF) in hypertensive patients</div><div class=\"cntnt\"><img style=\"width:434px; height:233px;\" src=\"images/NEPH/68780_AHT_drug_and_HF_ALLHAT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the ALLHAT trial, cumulative event rates for the development of heart failure (HF) according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there were significant increases in the six year rate of HF with both amlodipine (10.2 versus 7.7 percent, relative risk 1.38, 95 percent CI 1.25 to 1.52) and lisinopril (8.7 versus 7.7 percent, relative risk 1.19 95 percent CI 1.07 to 1.31).</div><div class=\"graphic_reference\">Data from The ALLHAT Officers, JAMA 2002; 288:2981.</div><div id=\"graphicVersion\">Graphic 68780 Version 2.0</div></div></div>"},"68781":{"type":"graphic_diagnosticimage","displayName":"Parainfluenza pneumonia chest CT","title":"Chest CT findings in hematopoietic cell transplant recipients with parainfluenza pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest CT findings in hematopoietic cell transplant recipients with parainfluenza pneumonia</div><div class=\"cntnt\"><img style=\"width:408px; height:408px;\" src=\"images/ID/68781_Paraflu_PNA_in_chest_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) High-resolution CT scan of the lungs of patient 1 that show peribronchial nodules &lt;5 mm, 5 to 10 mm, and &gt;10 mm in diameter. (B) High-resolution CT scan of the lungs of patient 1 that show nodules with associated consolidation. (C) High-resolution CT scan of the lungs of patient 3 that shows very small (&lt;5 mm) peribronchial nodules in the left upper lobe. (D) High-resolution CT scan of the lungs of patient 5 that show multiple small (≤5 mm) peribronchial nodules and the appearance of ground-glass consolidation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Ferguson PE, Sorrell TC, Bradstock KF, et al. Parainfluenza virus type 3 pneumonia in bone marrow transplant recipients: Multiple small nodules in high-resolution lung computed tomography scans provide a radiological clue to diagnosis. Clin Infect Dis 2009; 48:905. Copyright ©2009 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 68781 Version 5.0</div></div></div>"},"68784":{"type":"graphic_table","displayName":"Contraindications to fibrinolytic therapy","title":"Absolute and relative contraindications to the use of thrombolytic therapy in patients with acute ST elevation myocardial infarction*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absolute and relative contraindications to the use of thrombolytic therapy in patients with acute ST elevation myocardial infarction*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute contraindications</td> </tr> <tr> <td class=\"indent1\">History of any intracranial hemorrhage</td> </tr> <tr> <td class=\"indent1\">History of ischemic stroke within the preceding three months, with the important exception of acute ischemic stroke seen within three hours, which may be treated with thrombolytic therapy</td> </tr> <tr> <td class=\"indent1\">Presence of a cerebral vascular malformation or a primary or metastatic intracranial malignancy</td> </tr> <tr> <td class=\"indent1\">Symptoms or signs suggestive of an aortic dissection</td> </tr> <tr> <td class=\"indent1\">A bleeding diathesis or active bleeding, with the exception of menses; thrombolytic therapy may increase the risk of moderate bleeding, which is offset by the benefits of thrombolysis</td> </tr> <tr> <td class=\"indent1\">Significant closed-head or facial trauma within the preceding three months</td> </tr> <tr> <td class=\"subtitle1_single\">Relative contraindications</td> </tr> <tr> <td class=\"indent1\">History of chronic, severe, poorly controlled hypertension or uncontrolled hypertension at presentiaton (blood pressure &#62;180 mmHg systolic and/or &#62;110 mmHg diastolic; severe hypertension at presentation can be an absolute contraindication in patients at low risk)</td> </tr> <tr> <td class=\"indent1\">History of ischemic stroke more than three months previously</td> </tr> <tr> <td class=\"indent1\">Dementia</td> </tr> <tr> <td class=\"indent1\">Any known intracranial disease that is not an absolute contraindication</td> </tr> <tr> <td class=\"indent1\">Traumatic or prolonged (&#62;10 min) cardiopulmonary resuscitation</td> </tr> <tr> <td class=\"indent1\">Major surgery within the preceding three weeks</td> </tr> <tr> <td class=\"indent1\">Internal bleeding within the preceding two to four weeks or an active peptic ulcer</td> </tr> <tr> <td class=\"indent1\">Noncompressible vascular punctures</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Current warfarin therapy - the risk of bleeding increases as the INR increases</td> </tr> <tr> <td class=\"indent1\">For streptokinase or anistreplase - a prior exposure (more than five days previously) or allergic reaction to these drugs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">INR: International Normalized Ratio.<BR>* May not be all-inclusive or definitive.</div><div class=\"graphic_reference\">Data from: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.</div><div id=\"graphicVersion\">Graphic 68784 Version 9.0</div></div></div>"},"68785":{"type":"graphic_figure","displayName":"Midpontine syndrome","title":"Midpontine syndrome","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Midpontine syndrome</div><div class=\"cntnt\"><img style=\"width:521px; height:598px;\" src=\"images/NEURO/68785_Midpontine_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 68785 Version 1.0</div></div></div>"},"68786":{"type":"graphic_figure","displayName":"Positive and negative remodel","title":"Positive and negative arterial remodeling extremes of the remodeling response","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Positive and negative arterial remodeling extremes of the remodeling response</div><div class=\"cntnt\"><img style=\"width:519px; height:381px;\" src=\"images/CARD/68786_Positive_and_negative_remod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sections through vessel segments show positively and negatively remodeled lesions. The lumen diameter is maintained with positive remodeling, while there is significant luminal narrowing with negative remodeling.</div><div class=\"graphic_footnotes\">EEM: external elastic membrane; RR: remodeling ratio (EEM area lesion/EEM area proximal reference).</div><div class=\"graphic_reference\">Reprinted with permission from Schoenhagen P, Ziada KM, Vince DC, et al. J Am Coll Cardiol 2001; 38:297. Copyright &#169; 2001 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 68786 Version 2.0</div></div></div>"},"68787":{"type":"graphic_picture","displayName":"Lentigo maligna cheek","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/68787_Lentigo_maligna_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68787 Version 1.0</div></div></div>"},"68789":{"type":"graphic_algorithm","displayName":"Diagnosis of dementia","title":"Diagnosis of dementia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnosis of dementia</div><div class=\"cntnt\"><img style=\"width:410px; height:538px;\" src=\"images/PC/68789_Diagnosis_of_dementia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* If diagnosis of depression is uncertain, neuropsychologic testing can be helpful to distinguish from cognitive impairment due to dementia.</div><div class=\"graphic_reference\">Adapted from: Corey-Bloom J, Thal LJ, Galasko D, et al. Diagnosis and evaluation of dementia. Neurology 1995; 45:211.</div><div id=\"graphicVersion\">Graphic 68789 Version 2.0</div></div></div>"},"68791":{"type":"graphic_figure","displayName":"Test lumbar nerve root comp","title":"Testing for lumbar nerve root compromise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing for lumbar nerve root compromise</div><div class=\"cntnt\"><img style=\"width:426px; height:549px;\" src=\"images/PC/68791_Test_lumbar_nerve_root_comp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Bigos S, Bowyer O, Braen G, et al. Acute Low Back Problems in Adults. Clinical Practice Guideline, Quick Reference Guide Number. 14. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Pub. No. 95-0643. December 1994.</div><div id=\"graphicVersion\">Graphic 68791 Version 6.0</div></div></div>"},"68792":{"type":"graphic_waveform","displayName":"ECG Managed ventricular pacing","title":"Electrocardiogram (ECG) showing managed ventricular pacing","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) showing managed ventricular pacing</div><div class=\"cntnt\"><img style=\"width:533px; height:218px;\" src=\"images/CARD/68792_Normal_Managed_V_Pace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Managed ventricular pacing: a normal response for the algorithm when intrinsic ventricular conduction does not occur.</div><div id=\"graphicVersion\">Graphic 68792 Version 3.0</div></div></div>"},"68793":{"type":"graphic_picture","displayName":"Mucosal inflammation after FBA","title":"Airway foreign body in right mainstem bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway foreign body in right mainstem bronchus</div><div class=\"cntnt\"><img style=\"width:436px; height:229px;\" src=\"images/PULM/68793_Mucosal_inflammation_after.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Peanut impacted in the right mainstem bronchus of a 13-month old child for four hours. Right: After 28 hours, the oily peanut has caused severe mucosal inflammation with bulky granulation tissue.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 68793 Version 4.0</div></div></div>"},"68796":{"type":"graphic_picture","displayName":"Osler nodes in infective endocarditis","title":"Osler nodes in infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osler nodes in infective endocarditis</div><div class=\"cntnt\"><img style=\"width:247px; height:283px;\" src=\"images/ID/68796_Oslers_nodes_in_IE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osler nodes are tender papulopustules located on the pulp of the finger in a patient with bacterial endocarditis caused by <EM>Staphylococcus aureus</EM>.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 68796 Version 9.0</div></div></div>"},"68797":{"type":"graphic_diagnosticimage","displayName":"TB pneumonia","title":"Expansile pneumonia caused by tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expansile pneumonia caused by tuberculosis</div><div class=\"cntnt\"><img style=\"width:396px; height:388px;\" src=\"images/ID/68797_TB_pneumonia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This two-year-old toddler, infected by his mother, has an expansile pneumonia caused by tuberculosis and, perhaps, a secondary infection. The child presented with high fever, cough, and weight loss. The clinical symptoms improved with conventional antibiotics, but cultures of the gastric aspirates grew <EM>Mycobacterium tuberculosis</EM>. A subsequent computed tomography scan of the chest revealed extensive right-sided hilar adenopathy with obstruction of the main bronchus to the right upper lobe.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 68797 Version 5.0</div></div></div>"},"68801":{"type":"graphic_figure","displayName":"Pulmonary vein velocity schematic","title":"Schematic of normal pulmonary venous flow velocity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic of normal pulmonary venous flow velocity</div><div class=\"cntnt\"><img style=\"width:403px; height:342px;\" src=\"images/CARD/68801_Pulmonaryvenousflowveloc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulmonary venous velocity time integrals in systole (VTIs) and diastole (VTId) are determined by planimetry. The VTIs consists of two peaks due to early and late systolic atrial filling; the VTId contains a short pulmonary venous flow reversal after atrial contraction. A predominantly negative VTIs (VTIs &lt;0) translates into VTIs/VTId &lt;0, compatible with significant mitral regurgitation.</div><div class=\"graphic_reference\">Data from Seiler C, Aeschbacher BC, Meier B. J Am Coll Cardiol 1998; 31:1383.</div><div id=\"graphicVersion\">Graphic 68801 Version 3.0</div></div></div>"},"68802":{"type":"graphic_figure","displayName":"Lateral rectal ligaments","title":"Lateral rectal ligaments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral rectal ligaments</div><div class=\"cntnt\"><img style=\"width:340px; height:337px;\" src=\"images/SURG/68802_Lateral-rectal-ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure A. The upper rectum is mobilized laterally by identifying the lateral rectal ligaments. The ligaments contain the middle hemorrhoidal vessels.<br> Figure B. The lateral ligament is divided between two clamps and the pedicle secured with ligatures.</div><div id=\"graphicVersion\">Graphic 68802 Version 1.0</div></div></div>"},"68803":{"type":"graphic_picture","displayName":"Bridge","title":"Bridges","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bridges</div><div class=\"cntnt\"><img style=\"width:432px; height:253px;\" src=\"images/EM/68803_Bridge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on your back on the floor. Keep the feet on the floor and bend both knees. Place the hands about 12 inches to the side of the body (on the floor). Lift the buttocks 6 to 8 inches off the floor. Hold for 5 seconds, then slowly release. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets. To increase the difficulty, keep the right foot on the floor and lift the left foot off the floor, keeping the left leg straight. Raise the buttocks using the right foot to support the lower body. Switch sides. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 68803 Version 2.0</div></div></div>"},"68804":{"type":"graphic_waveform","displayName":"12 lead ECG orthodromic AVRT","title":"12-lead electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway","html":"<div class=\"graphic normal\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:539px; height:351px;\" src=\"images/CARD/68804_12_lead_ECG_orthodromic_AVR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG from a patient with Wolff-Parkinson-White shows a regular tachycardia. However, in contrast to the QRS pattern during sinus rhythm, the QRS complexes are narrow, without evidence of a delta wave or preexcitation; this is due to the fact that antegrade ventricular activation occurs via the normal atrioventricular node-His Purkinje pathway while retrograde atrial activation is via the accessory pathway. Therefore, this is called an orthodromic atrioventricular reentrant tachycardia (OAVRT).</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 68804 Version 4.0</div></div><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">ECG in Wolff-Parkinson-White</div><div class=\"cntnt\"><img style=\"width:538px; height:365px;\" src=\"images/CARD/67181_12leadWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 67181 Version 3.0</div></div></div>"},"68806":{"type":"graphic_figure","displayName":"Hemoglobin electrophoresis at alkaline pH","title":"Hemoglobin electrophoresis (alkaline pH)","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Hemoglobin electrophoresis (alkaline pH)</div><div class=\"cntnt\"><img style=\"width:501px; height:355px;\" src=\"images/HEME/68806_Hemoglobin_electrophoresis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of hemoglobin electrophoresis run at alkaline pH on cellulose acetate. The electrophoretic positions of the more common hemoglobins are shown on the right.<br>   Lane 1 is a commercial standard containing approximately equal amounts of hemoglobins A, F, S, and C.<br>  Lanes 2, 3, 4, 6, 8, and 10 are from normal subjects (Hb A only).<br>  Lanes 7 and 9 are from subjects with sickle cell trait (Hbs A and S).<br>  Lane 5 is from a subject with homozygous sickle cell anemia (Hbs F and S).<br>  Lane 11 is from a subject with hemoglobin SC disease (Hbs S and C).</div><div class=\"graphic_reference\">Electrophoretogram kindly supplied by Dr. Radek Bieniek, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 68806 Version 4.0</div></div></div>"},"68808":{"type":"graphic_picture","displayName":"Peripapillary staphyloma","title":"Peripapillary staphyloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripapillary staphyloma</div><div class=\"cntnt\"><img style=\"width:342px; height:298px;\" src=\"images/PEDS/68808_Peripapillary_staphyloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The optic disc itself is relatively normal in size and shape. The surrounding retina is deeply excavated and the retinal pigment epithelium and choroid are atrophic.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 68808 Version 2.0</div></div></div>"},"68809":{"type":"graphic_picture","displayName":"Pre post exstrophy","title":"Preoperative and postoperative pictures of a male infant with bladder exstrophy","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Preoperative and postoperative pictures of a male infant with bladder exstrophy</div><div class=\"cntnt\"><img style=\"width:554px; height:374px;\" src=\"images/PEDS/68809_Pre_post_exstrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photographs showing frontal view of a male infant with bladder exstrophy prior to repair as a newborn and several weeks following complete primary repair of bladder exstrophy.</div><div class=\"graphic_reference\">Courtesy of Joseph Borer, MD.</div><div id=\"graphicVersion\">Graphic 68809 Version 4.0</div></div></div>"},"68810":{"type":"graphic_table","displayName":"Common tremors","title":"Common tremors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common tremors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Resting tremor </td> </tr> <tr> <td>Parkinson disease</td> </tr> <tr> <td>Parkinsonian syndromes</td> </tr> <tr> <td>Midbrain (rubral) tremor</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Severe essential tremor</td> </tr> <tr> <td class=\"subtitle1_single\">Postural-action tremor </td> </tr> <tr> <td>Enhanced physiologic tremors (eg, drug-induced and toxic tremors)</td> </tr> <tr> <td>Essential tremor</td> </tr> <tr> <td>Task-specific tremors</td> </tr> <tr> <td class=\"sublist1_start\">Other extrapyramidal disorders </td> </tr> <tr> <td class=\"sublist1\">Parkinson disease </td> </tr> <tr> <td class=\"sublist1\">Wilson disease </td> </tr> <tr> <td class=\"sublist1\">Dystonia </td> </tr> <tr> <td>Cerebellar disease</td> </tr> <tr> <td>Neuropathic tremor</td> </tr> <tr> <td class=\"subtitle1_single\">Intention tremor (cerebellar outflow) </td> </tr> <tr> <td>Cerebellar disease</td> </tr> <tr> <td>Multiple sclerosis</td> </tr> <tr> <td>Midbrain stroke</td> </tr> <tr> <td>Midbrain trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68810 Version 3.0</div></div></div>"},"68811":{"type":"graphic_picture","displayName":"Bronchocentric granuloma High","title":"Bronchocentric granulomatosis in a patient with ABPA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchocentric granulomatosis in a patient with ABPA</div><div class=\"cntnt\"><img style=\"width:392px; height:294px;\" src=\"images/PULM/68811_Bronchocentric_granuloma_Hi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Higher magnification photomicrograph (original magnification 200x) from&nbsp;a specimen showing transition from respiratory epithelium to granulomatous inflammation.</div><div id=\"graphicVersion\">Graphic 68811 Version 2.0</div></div></div>"},"68812":{"type":"graphic_table","displayName":"Chemical exposure antigen in HP","title":"Hypersensitivity pneumonitides associated with plastic manufacturing, painting, electronics industry, and other chemicals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with plastic manufacturing, painting, electronics industry, and other chemicals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Environmental source</td> <td class=\"subtitle1\">Major causative antigen</td> </tr> <tr> <td rowspan=\"2\">Chemical worker's lung</td> <td>Diphenylmethane diisocyanate (MDI)</td> </tr> <tr> <td>Toluene diisocyanate (TDI)</td> </tr> <tr> <td>Detergent worker's lung (washing powder lung)</td> <td>Bacillus subtilis enzymes</td> </tr> <tr> <td>Pauli's reagent alveolitis</td> <td>Sodium diazobenzene sulfate</td> </tr> <tr> <td>Vineyard sprayer's lung</td> <td>Copper sulfate (bordeaux mixture)</td> </tr> <tr> <td>Pyrethrum (pesticide)</td> <td>Pyrethrum</td> </tr> <tr> <td>Epoxy resin lung</td> <td>Phthalic anhydride (heated epoxy resin)</td> </tr> <tr> <td>Bible printer's lung</td> <td>Moldy typesetting water</td> </tr> <tr> <td rowspan=\"3\">Machine operator's lung </td> <td>Pseudomonas fluorescens</td> </tr> <tr> <td>Mycobacterium immunogenum</td> </tr> <tr> <td>Aerosolized metal working fluid</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68812 Version 2.0</div></div></div>"},"68813":{"type":"graphic_table","displayName":"Molecular test brain lesion","title":"Molecular tests for infectious causes of intracranial mass lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular tests for infectious causes of intracranial mass lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Availability*</td> <td class=\"subtitle1\">When inclusion of NAT is indicated</td> <td class=\"subtitle1\">Preferred testing method(s)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bacteria</td> </tr> <tr> <td class=\"indent1\">Abscess<sup>&#916;</sup></td> <td>Limited</td> <td>Gram stain positive, culture negative; prior antibacterial therapy</td> <td>Gram stain, culture prior to antibacterial therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em><sup>&#9674;</sup></td> <td>Yes</td> <td>Potentially</td> <td>AFB stain, culture, histologic exam, and NAT</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viruses</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (primary central nervous system lymphoma)</td> <td>Yes</td> <td>Yes</td> <td>NAT, preferably quantitative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">JC virus (progressive multifocal leukoencephalopathy)</td> <td>Yes</td> <td>Yes</td> <td>NAT, preferably quantitative</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Spirochetes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Treponema pallidum </em>(syphilis)</td> <td>Limited</td> <td>No</td> <td>Serology, CSF VDRL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fungal</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus</em></td> <td>Yes</td> <td>No</td> <td>Antigen detection, culture</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td>Limited</td> <td>Rarely</td> <td>Culture, serology, histologic exam</td> </tr> <tr> <td class=\"subtitle2_left\">Parasites</td> <td>Limited</td> <td>Rarely (eg, amebic brain abscess or immunocompromised hosts)</td> <td>Stains, serology, histologic exam, and NAT for select pathogens</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPV: positive predictive value; PCR: polymerase chain reaction; CDC: Centers for Disease Control and Prevention; NAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid-fast bacilli; VDRL: Venereal Disease Research Laboratories.<br />* Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, CDC or research groups).<br />¶ Testing on brain mass tissue.<br />Δ 16s rDNA \"universal\" PCR.<br /><FONT class=lozenge>◊</FONT> Limited experience, presumably poor sensitivity, high PPV.</div><div id=\"graphicVersion\">Graphic 68813 Version 7.0</div></div></div>"},"68814":{"type":"graphic_movie","displayName":"TR four chamber color Doppler echo 1","title":"Tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/68814_4chcotr1conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:242px; height:223px;\" src=\"images/CARD/68814_4chcotr1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram with color flow Doppler shows significant tricuspid regurgitation. There is enlargement of the left atrium and limited mobility of the mitral valve which shows doming in diastole, suggesting that tricuspid regurgitation is the result of pulmonary hypertension due to mitral stenosis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 68814 Version 2.0</div></div></div>"},"68815":{"type":"graphic_picture","displayName":"Late chronic papilledema","title":"Late chronic papilledema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late chronic papilledema</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/NEURO/68815_Late_chronic_papilledema.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 68815 Version 1.0</div></div></div>"},"68816":{"type":"graphic_table","displayName":"Cervical length twins and PTB","title":"Prediction of preterm birth before 32 weeks of gestation in twins by sonographically determined cervical length","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prediction of preterm birth before 32 weeks of gestation in twins by sonographically determined cervical length</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Cut-off for cervical length (mm)\n   </td>\n   <td  class=\"subtitle1\">\n   Sensitivity (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   Specificity (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   PPV (percent)\n   </td>\n   <td  class=\"subtitle1\">\n   NPV (percent)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"5\">\n   Assessment at 21 to 24 weeks of gestation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   20\n   </td>\n   <td>42</td>\n   <td>85</td>\n   <td>22</td>\n   <td>94</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   25\n   </td>\n   <td>54</td>\n   <td>86</td>\n   <td>27</td>\n   <td>95</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   30\n   </td>\n   <td>46</td>\n   <td>89</td>\n   <td>19</td>\n   <td>97</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"5\">\n   Assessment at 25 to 28 weeks of gestation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   20\n   </td>\n   <td>56</td>\n   <td>76</td>\n   <td>16</td>\n   <td>95</td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   25\n   </td>\n   <td>63 to 100</td>\n   <td>70 to 84</td>\n   <td>13 to 18</td>\n   <td>96 to 100</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42196&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Cervical_length_twins_and_P.htm</title></head></div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value.</div><div class=\"graphic_reference\">Data adapted from:<br />1. Goldenberg RL, Iams JD, Miodovnik M, et al. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1996; 175:1047.<br />2. Guzman ER, Walters C, O'Reilly-Green C, et al. Use of cervical ultrasonography in prediction of spontaneous preterm birth in twin gestations. Am J Obstet Gynecol 2000; 183:1103.<br />3. Vayssiere C, Favre R, Audibert F, et al. Cervical length and funneling at 22 and 27 weeks to predict spontaneous birth before 32 weeks in twin pregnancies: a French prospective multicenter study. Am J Obstet Gynecol 2002; 187:1596.</div><div id=\"graphicVersion\">Graphic 68816 Version 2.0</div></div></div>"},"68817":{"type":"graphic_figure","displayName":"Cecocolic rotation","title":"Normal rotation of the cecocolic loop","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Normal rotation of the cecocolic loop</div><div class=\"cntnt\"><img style=\"width:524px; height:561px;\" src=\"images/PEDS/68817_Cecocolic_rotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;The starting point of the cecum is directly inferior to the superior mesenteric artery (SMA). <br />(B) The cecum has rotated 90 degrees counterclockwise. <br />(C) The cecum continues to rotate around the SMA, now 180 degrees from its starting point and directly ventral to the SMA. <br />(D) The final position the cecum, after 270 degrees counterclockwise rotation, is to the right of the SMA.</div><div id=\"graphicVersion\">Graphic 68817 Version 2.0</div></div></div>"},"68819":{"type":"graphic_figure","displayName":"BMD after liver transplantation","title":"Bone loss after liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone loss after liver transplantation</div><div class=\"cntnt\"><img style=\"width:446px; height:322px;\" src=\"images/GAST/68819_BMD_after_liver_transpl_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rate of change in LS BMD after orthotopic liver transplantation in 105 women with primary biliary cholangitis. Most women had a substantial loss of LS BMD (mean rate 18.1 percent per year) at three months. Measurements at 12, 24, and 36 months showed stable BMD with evidence for recovery of bone loss in some women at 12 months.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; LS: lumbar spine.</div><div class=\"graphic_reference\">Data from: Eastell R, Dickson ER, Hodgson SF, et al. Hepatology 1996; 14:296.</div><div id=\"graphicVersion\">Graphic 68819 Version 6.0</div></div></div>"},"68820":{"type":"graphic_picture","displayName":"Angioedema tongue","title":"Unilateral angioedema of the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unilateral angioedema of the tongue</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/68820_Angioedema_tongue_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68820 Version 5.0</div></div></div>"},"68821":{"type":"graphic_picture","displayName":"Esoph superficial dissecans","title":"Esophagitis dissecans superficialis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophagitis dissecans superficialis</div><div class=\"cntnt\"><img style=\"width:396px; height:339px;\" src=\"images/GAST/68821_Esoph_superficial_dissecans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper endoscopy showing a denuded esophagus in esophagitis dissecans superficialis.</div><div class=\"graphic_reference\">Courtesy of S. Ian Gan, MD, and Daniel Wild, MD.</div><div id=\"graphicVersion\">Graphic 68821 Version 2.0</div></div></div>"},"68824":{"type":"graphic_diagnosticimage","displayName":"Pinning of displaced radial head fracture","title":"Pinning of displaced radial head fracture","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Pinning of displaced radial head fracture</div><div class=\"cntnt\"><img style=\"width:514px; height:244px;\" src=\"images/EM/68824_Pin_displa_rad_head_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Lateral view of elbow with displaced radial head fracture.<br> (B) Anatomic reduction with pinning.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 68824 Version 2.0</div></div></div>"},"68825":{"type":"graphic_picture","displayName":"Congenital cutaneous candidiasis","title":"Congenital cutaneous candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital cutaneous candidiasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/68825_Cong_cutan_candidiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Kaufman DA. Neonatal candidiasis: Clinical manifestations, management, and prevention strategies. J Pediatr 2010; 156:S55. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68825 Version 3.0</div></div></div>"},"68826":{"type":"graphic_diagnosticimage","displayName":"2D TTE short axis LV mitral valve","title":"Two-dimensional transthoracic echocardiogram (2D TTE) in short axis plane of left ventricle (LV) at the level of the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) in short axis plane of left ventricle (LV) at the level of the mitral valve</div><div class=\"cntnt\"><img style=\"width:374px; height:260px;\" src=\"images/CARD/68826_Short_axis_LV_mitral_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis image of the left ventricle (LV), at the level of the mitral valve, shows the tips of the mitral leaflets.</div><div id=\"graphicVersion\">Graphic 68826 Version 4.0</div></div></div>"},"68827":{"type":"graphic_figure","displayName":"Schematic representation of endochondral bone formation","title":"Schematic representation of endochondral bone formation","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Schematic representation of endochondral bone formation</div><div class=\"cntnt\"><img style=\"width:624px; height:467px;\" src=\"images/ENDO/68827_Schemat_repres_bone_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial phase of long bone development occurs through mesenchymal condensation to form a cartilage model. Following chondrocytes hypertrophy, the cartilaginous template is calcified by osteoblasts and then partially resorbed by osteoclasts, resulting in the formation of the primary and the secondary ossification centers. Through additional cycles of remodeling, the cartilage of the primary and secondary ossification centers is converted to the trabecular bone of the metaphysis and epiphysis, respectively. Longitudinal bone growth occurs at the growth plates and results from the elongation of the cartilaginous template. In adult bones, the growth plate is fully resorbed, so that one marrow cavity extends the full length of the bone.</div><div class=\"graphic_reference\">Reproduced with permission from: Baron R. Chapter 1: Anatomy and ultrastructure of bone - Histogenesis, growth and remodeling. In: Diseases of bone and mineral metabolism, Singer F (Ed). Copyright © 2008 WWW.ENDOTEXT.ORG website, Version of 09/26/2012, published by MDTEXT.COM, Inc, South Dartmouth, MA. <A spellcheck=true href=\"http://www.endotext.org/chapter/anatomy-and-ultrastructure-of-bone-histogenesis-growth-and-remodeling\" target=_blank>http://www.endotext.org/chapter/anatomy-and-ultrastructure-of-bone-histogenesis-growth-and-remodeling</A>.</div><div id=\"graphicVersion\">Graphic 68827 Version 6.0</div></div></div>"},"68828":{"type":"graphic_picture","displayName":"Lentigo maligna dermoscopy","title":"Dermoscopic features of lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of lentigo maligna</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/68828_Lentigo_maligna_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical pseudonetwork, annular-granular pattern and slate-gray areas are characteristics of lentigo maligna.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68828 Version 3.0</div></div></div>"},"68829":{"type":"graphic_picture","displayName":"Rocky mountain wood tick","title":"An adult female <EM>Dermacentor andersoni</EM> (Rocky Mountain wood tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female <EM>Dermacentor andersoni</EM> (Rocky Mountain wood tick)</div><div class=\"cntnt\"><img style=\"width:222px; height:190px;\" src=\"images/ID/68829_Rocky_mountain_wood_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 68829 Version 4.0</div></div></div>"},"68830":{"type":"graphic_table","displayName":"Secondary prophylaxis for rheumatic fever - Selection of therapy","title":"Secondary prophylaxis for rheumatic fever - Selection of therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary prophylaxis for rheumatic fever - Selection of therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Continuous regimen</td> </tr> <tr> <td class=\"subtitle2\">Adults &#62;27 kg</td> <td class=\"subtitle2\">Children &#8804;27 kg</td> </tr> <tr> <td><strong>Penicillin G benzathine intramuscular (Bicillin LA, benzathine benzylpenicillin)</strong></td> <td>1.2 million units every 21 to 28 days*</td> <td>600,000 units every 21 to 28 days*</td> </tr> <tr> <td><strong>Penicillin V oral</strong></td> <td>250 mg orally twice daily</td> <td>250 mg orally twice daily</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><strong>Allergy to penicillin and sulfonamide antimicrobials:</strong></td> </tr> <tr> <td class=\"sublist1\">Azithromycin<sup>&#182;</sup></td> <td class=\"sublist_other\">250 mg orally once daily</td> <td class=\"sublist_other\">5 mg/kg orally once daily (up to 250 mg)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Parenteral penicillin by deep intramuscular injection<SUP>Δ</SUP> is preferred for all patients receiving secondary prophylaxis. Oral medication is considered second line.</div><div class=\"graphic_footnotes\">* The shorter interval (21 days)&nbsp;is recommended in high-risk situations (eg, a patient has had an episode of recurrent acute rheumatic fever despite adherence to once every 28 day regimen). Refer to UpToDate topic on treatment and prevention&nbsp;of acute rheumatic fever.<br />¶&nbsp;Erythromycin is an acceptable alternative to azithromycin, although the latter has fewer adverse effects and permits once daily dosing. Erythromycin dosing for adults: 250 mg (base)&nbsp;orally twice daily. Dosing for children: 20 mg/kg/day divided twice daily (maximum 500 mg per day).&nbsp;Skin testing and penicillin desensitization for immediate hypersensitivity type reaction may also be an option.<br />Δ Close adherence to preparation and administration instructions for benzathine penicillin suspension is necessary. Injection in more superficial muscle or failure to adhere to reconstitution and site selection instructions can decrease serum concentrations.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009; 119:1541.</LI>&#xD;&#xA;<LI>Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol 2014; 63:e57.</LI></OL></div><div id=\"graphicVersion\">Graphic 68830 Version 13.0</div></div></div>"},"68831":{"type":"graphic_figure","displayName":"Insertion track","title":"Location of insertion site for implanon","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Location of insertion site for implanon</div><div class=\"cntnt\"><img style=\"width:518px; height:433px;\" src=\"images/OBGYN/68831_Insertion_track.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure above reflects the manufacturer's recommendations. The author finds the procedure is easier when the arm is extended. This allows full exposure of the insertion site at the crease between the biceps and triceps muscles. We identify an insertion site approximately three fingerbreadths (6 to 8 cm) superior and lateral to the medial epicondyle of the humerus.</div><div id=\"graphicVersion\">Graphic 68831 Version 1.0</div></div></div>"},"68833":{"type":"graphic_table","displayName":"Disorders with cancer risk","title":"Common hereditary disorders associated with childhood cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common hereditary disorders associated with childhood cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Disorder</td>\n\n      <td class=\"subtitle1\">Type of malignancy</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Chromosomal Disorders</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Down syndrome</td>\n\n      <td>Leukemia, testicular, retinoblastoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Turner syndrome</td>\n\n      <td>Neurogenic, gonadal, endometrial</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Klinefelter syndrome</td>\n\n      <td>Leukemia, germ cell tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Other sex aneuploidy</td>\n\n      <td>Retinoblastoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">XY gonadal dysgenesis</td>\n\n      <td>Gonadoblastoma, dysgerminoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Trisomy 13</td>\n\n      <td>Teratoma, leukemia, neurogenic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Trisomy 18</td>\n\n      <td>Neurogenic, Wilm's tumor</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">XYY, XYY mosaic</td>\n\n      <td>Osteosarcoma, medulloblastoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Other Genetic Disorders</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Xeroderma pigmentosum</td>\n\n      <td>Basal, squamous cell carcinoma, melanoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bloom syndrome</td>\n\n      <td>Leukemia, lymphoma, gastrointestinal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fanconi anemia</td>\n\n      <td>Leukemia, hepatoma, squamous cell carcinoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ataxia-telangiectasia</td>\n\n      <td>Lymphoma, leukemia, Hodgkin's disease, brain, gastric, ovarian, other epithelial</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Neurofibromatosis type 1</td>\n\n      <td>Gliomas, malignant peripheral nerve sheath tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Tuberous sclerosis</td>\n\n      <td>Brain tumors, rhabdomyosarcomas</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Von Hippel-Lindau disease</td>\n\n      <td>Renal cell carcinoma, pheochromocytoma</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68833 Version 1.0</div></div></div>"},"68835":{"type":"graphic_diagnosticimage","displayName":"Nonfunctioning thyroid nodule","title":"Nonfunctioning thyroid nodule: Appearance on thyroid scintigraphy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonfunctioning thyroid nodule: Appearance on thyroid scintigraphy</div><div class=\"cntnt\"><img style=\"width:360px; height:266px;\" src=\"images/ENDO/68835_Coldthyroidnodulescan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-I thyroid scan demonstrating typical appearance of a large, 3.5 cm hypofunctioning (&quot;cold&quot;) nodule in the left upper lobe of the thyroid. The position of the nodule is outlined in white.</div><div class=\"graphic_footnotes\">SSN: suprasternal notch; 123-I: iodine-123.</div><div class=\"graphic_reference\">Courtesy of Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 68835 Version 4.0</div></div></div>"},"68836":{"type":"graphic_figure","displayName":"Caudal retraction panniculus","title":"Caudal retraction of panniculus","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Caudal retraction of panniculus</div><div class=\"cntnt\"><img style=\"width:479px; height:233px;\" src=\"images/SURG/68836_Caudal_retraction_panniculu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panniculus retracted caudad and a supraumbilical incision made.</div><div id=\"graphicVersion\">Graphic 68836 Version 2.0</div></div></div>"},"68837":{"type":"graphic_picture","displayName":"Micrograph of VAIN","title":"Vaginal intraepithelial neoplasia 2 compared to normal vaginal epithelium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal intraepithelial neoplasia&nbsp;2 compared to normal vaginal epithelium</div><div class=\"cntnt\"><img style=\"width:439px; height:231px;\" src=\"images/OBGYN/68837_Micrograph_of_VAIN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal; (B) VAIN 2.</div><div class=\"graphic_reference\">Courtesy of Christine Holschneider, MD.</div><div id=\"graphicVersion\">Graphic 68837 Version 5.0</div></div></div>"},"68838":{"type":"graphic_table","displayName":"Adverse drug effects in HF","title":"Drugs associated with increased risk of adverse effects in patients with heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs associated with increased risk of adverse effects in patients with heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug/drug class</td> <td class=\"subtitle1\">Adverse effect(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anti-inflammatory medications</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids</td> <td>Sodium retention (particularly with fludrocortisone, hydrocortisone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">NSAIDs<sup>&#182;</sup></td> <td>Sodium retention and peripheral vasocontriction; blunted response to diuretics and angiotensin converting enzyme inhibitors</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiovascular medications</td> </tr> <tr> <td class=\"indent1\">Class I antiarrhythmic agents*<sup>&#182;</sup></td> <td>Negative inotropy; proarrhythmia; increased mortality with IA and IC agents in post-MI trials</td> </tr> <tr> <td class=\"indent1\">Class III antiarrhythmic agents (included sotalol and ibutalide)*<sup>&#182;</sup></td> <td>Proarrhythmia</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers (other than amlodipine or felodipine)*<sup>&#182;</sup></td> <td>Negative inotropy; neurohumoral activation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Minoxidil*<sup>&#182;</sup></td> <td>Sodium retention; neurohumoral activation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Diabetes medications</td> </tr> <tr> <td class=\"indent1\">Metformin</td> <td>Lactic acidosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thiazolidinediones<sup>&#182;</sup></td> <td>Sodium retention</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Phosphdiesterase inhibitors</td> </tr> <tr> <td class=\"indent1\">Anagrelide</td> <td>Palpitations; tachycardia; sodium retention; induction or exacerbation of HF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cilostazol</td> <td>Ventricular tachyarrhythmias</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic and psychiatric medications</td> </tr> <tr> <td class=\"indent1\">Amphetamines*<sup>&#182;</sup></td> <td>Sympathetic agonist activity; hypertension; tachycardia; tachyarrhythmias</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td>Negative inotropic effect; bradyarrhythmias</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> <td>Development of myocarditis and cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Ergot alkaloids (ergotamine, dihydroergotamine)</td> <td>Sympathetic agonist activity; valve fibrosis</td> </tr> <tr> <td class=\"indent1\">Pergolide (not available in the US)</td> <td>Valve fibrosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tricyclic antidepressants</td> <td>Negative inotropic effect; proarrhythmia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Beta-2 agonists</td> <td>Sympathetic agonist activity; tachyarrhythmias; hypokalemia</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> <td>Risk of hyperkalemia or acute kidney injury&nbsp;when taken with ACE inhibitor or ARB<br /> Risk of hyperkalemia when taken with MRA</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> <td>Negative inotropic effect; also can increase serum digoxin concentrations</td> </tr> <tr> <td class=\"indent1\">Licorice</td> <td>Mineralocorticoid excess: sodium retention and hypokalemia</td> </tr> <tr> <td class=\"indent1\">Sodium-containing preparations (eg, Fleet PhosPho soda)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sodium load QT-prolonging drugs (eg, haloperidol, erythromycin)</td> <td>Proarrhythmia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs; MI: myocardial infarction;&nbsp;HF: heart failure; ACE: angiotensin-converting enzyme; ARB: angiotension II receptor blockers; MRA: mineralocorticoid receptor antagonist.<br />* Evidence from randomized placebo controlled trials.<br />¶ Increased risk noted in American College of Cardiology/American Heart Association heart failure guidelines (Hunt SA, et al. Circulation 2005; 112:e154.).</div><div class=\"graphic_reference\">Data modified from Amabile CM, Spencer AP. Arch Intern Med 2004; 164:709.</div><div id=\"graphicVersion\">Graphic 68838 Version 6.0</div></div></div>"},"68841":{"type":"graphic_picture","displayName":"UIP histology","title":"Usual interstitial pneumonia pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Usual interstitial pneumonia pattern</div><div class=\"cntnt\"><img style=\"width:229px; height:520px;\" src=\"images/PULM/68841_UIP_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Patchy fibrosis with remodeling of the lung architecture shows a striking subpleural distribution. Interstitial chronic inflammation is mild with a few lymphoid aggregares. Areas of &quot;normal&quot; lung are present that lack active lesions of other interstitial lung disorders. (B) There is marked fibrosis consisting of dense collagenous scarring with remodeling of the lung architecture and cystic changes. (C) The dense collagenous scar is juxtaposed with a fibroblastic focus of loose organizing connective tissue.</div><div id=\"graphicVersion\">Graphic 68841 Version 2.0</div></div></div>"},"68842":{"type":"graphic_picture","displayName":"LIFT","title":"Ligation of the intersphincteric fistula tract (LIFT)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ligation of the intersphincteric fistula tract (LIFT)</div><div class=\"cntnt\"><img style=\"width:392px; height:345px;\" src=\"images/SURG/68842_AULIFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the probe inserted into the secondary external opening and extending into the internal primary opening of the fistula tract.</div><div class=\"graphic_reference\">Courtesy of R Kumar, MD.</div><div id=\"graphicVersion\">Graphic 68842 Version 5.0</div></div></div>"},"68843":{"type":"graphic_table","displayName":"Approach to management of fetal tachycardia","title":"Factors to consider prior to treatment of fetal tachycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors to consider prior to treatment of fetal tachycardia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Favoring treatment</td> <td class=\"subtitle1\">Favoring observation</td> <td class=\"subtitle1\">Favoring delivery</td> </tr> <tr> <td><strong>Tachycardia rate</strong> (bpm)</td> <td>&#62;220</td> <td>&#8804;200</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Persistence</strong></td> <td>&#62;50 percent of the day</td> <td>&#8804;20-25 percent of the day</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Gestational age</strong> (weeks)</td> <td>&#60;34</td> <td>&#8805;34</td> <td>Term; mature lungs</td> </tr> <tr> <td><strong>Hydrops</strong></td> <td>Yes</td> <td>No</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Preeclampsia</strong></td> <td>No</td> <td>&nbsp;</td> <td>For maternal safety</td> </tr> <tr> <td><strong>Mechanism</strong></td> <td>Atrial flutter</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Typical SVT</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Nonsustained ectopic atrial tachycardia</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>PJRT (slow, frequently terminating)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BPM: beats per minute; SVT: supraventricular tachycardia; PJRT: persistent junctional reciprocating tachycardia.</div><div id=\"graphicVersion\">Graphic 68843 Version 2.0</div></div></div>"},"68844":{"type":"graphic_diagnosticimage","displayName":"Salter II fracture","title":"Salter II fracture","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Salter II fracture</div><div class=\"cntnt\"><img style=\"width:526px; height:333px;\" src=\"images/EM/68844_Salter_II_fracture_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique and lateral views of the right ankle. Salter Harris type II fracture through the posterior aspect of the distal tibial metaphysis with extension of the fracture line through the physis (arrowhead). The resultant metaphyseal wedge in this fracture is called the Thurston Holland fragment (arrow).</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 68844 Version 3.0</div></div></div>"},"68846":{"type":"graphic_waveform","displayName":"Atypical atrial flutter","title":"Electrocardiogram in atypical atrial flutter","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in atypical atrial flutter</div><div class=\"cntnt\"><img style=\"width:435px; height:175px;\" src=\"images/CARD/68846_Atrial_flutter_Type_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are three findings that distinguish this arrhythmia from&nbsp;typical atrial flutter: the flutter rate is faster at 375 beats/minute; there is no isoelectric interval between the flutter waves; and there is more apparent positivity in leads II, III, and avF. The high degree of AV block is due to digoxin and some underlying AV nodal disease.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 68846 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"68848":{"type":"graphic_figure","displayName":"Dialysis amyloidosis in older adults","title":"Increased frequency of dialysis-related amyloidosis in older adults","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased frequency of dialysis-related amyloidosis in older adults</div><div class=\"cntnt\"><img style=\"width:411px; height:290px;\" src=\"images/NEPH/68848_Dialysis_amyloidosis_in_eld.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative risk of radiologic signs of bone amyloidosis according to age and membrane type. The risk is increased in older patients and those treated with bioincompatible cellulosic membranes. Patients who are over age 60 at the start of dialysis have a fivefold increase in likelihood of developing bone amyloidosis if they are dialyzed with cellulosic membranes compared&nbsp;with high-flux biocompatible AN 69 membranes.</div><div class=\"graphic_reference\">Data from van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis: The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.</div><div id=\"graphicVersion\">Graphic 68848 Version 3.0</div></div></div>"},"68849":{"type":"graphic_picture","displayName":"Lamellar osmophilic inclusions","title":"Electron micrograph showing lamellar osmophilic inclusions in a glomerular podocyte","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph showing lamellar osmophilic inclusions in a glomerular podocyte</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/NEPH/68849_Lamellarosmophilicinclusi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The foot processes are intact. (Original magnification X20,000).</div><div class=\"graphic_reference\">Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha- galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68849 Version 8.0</div></div></div>"},"68850":{"type":"graphic_figure","displayName":"Sites anter vaginal defects","title":"Sites of anterior vaginal defects","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sites of anterior vaginal defects</div><div class=\"cntnt\"><img style=\"width:504px; height:464px;\" src=\"images/OBGYN/68850_Sites_anter_vaginal_defects.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Karram, MM. Vaginal Operations for Prolapse. In: Atlas of pelvic anatomy and gynecologic surgery, Baggish MS, Karram, MM (Eds). WB Saunders Company, Philadelphia 2001. p. 378 (Original Figure #1 on p. 381). Copyright &#169;2001 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 68850 Version 1.0</div></div></div>"},"68851":{"type":"graphic_picture","displayName":"Iridodialysis I","title":"Iridodialysis I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iridodialysis I</div><div class=\"cntnt\"><img style=\"width:372px; height:243px;\" src=\"images/EM/68851_Iridodialysis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a patient following blunt trauma. There is a hyphema in the form of a blood clot in the anterior chamber. A small iridodialysis is at&nbsp;three o'clock&nbsp;at the iris insertion.</div><div class=\"graphic_reference\">Photo courtesy of Kathryn A Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 68851 Version 3.0</div></div></div>"},"68853":{"type":"graphic_picture","displayName":"Nodular basal cell carcinoma pathology 10x","title":"Nodular basal cell carcinoma (10x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma (10x)</div><div class=\"cntnt\"><img style=\"width:432px; height:311px;\" src=\"images/ONC/68853_Nodular_BCC_10x.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gary Goldenberg, MD.</div><div id=\"graphicVersion\">Graphic 68853 Version 3.0</div></div></div>"},"68854":{"type":"graphic_figure","displayName":"Retinal layers","title":"Retinal layers","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Retinal layers</div><div class=\"cntnt\"><img style=\"width:570px; height:422px;\" src=\"images/PEDS/68854_Retinal_layers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laminar organization of the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: Bear, MF, Connors, BW, and Parasido, MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68854 Version 1.0</div></div></div>"},"68855":{"type":"graphic_figure","displayName":"Scanning geometry helical CT","title":"Helical CT scanning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Helical CT scanning</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/68855_Scanning_geometry_helical_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the scanning geometry for helical CT.</div><div class=\"graphic_reference\">Adapted from Kalender, WA, Sissler, W, Klotz, E, Vock, P. Radiology 1990; 176:181.</div><div id=\"graphicVersion\">Graphic 68855 Version 1.0</div></div></div>"},"68856":{"type":"graphic_picture","displayName":"Medial plica of the knee","title":"Medial plica of the knee","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial plica of the knee</div><div class=\"cntnt\"><img style=\"width:360px; height:253px;\" src=\"images/RHEUM/68856_Medial_plica_of_the_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medial plica of the knee from an autopsy specimen.</div><div class=\"graphic_reference\">Reproduced with permission from Roberts, WN, Hayes, CW, Breitbach, SA, et al, Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 68856 Version 1.0</div></div></div>"},"68858":{"type":"graphic_figure","displayName":"Position for left thoracotomy","title":"Intra-operative positioning for left thoracotomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Intra-operative positioning for left thoracotomy</div><div class=\"cntnt\"><img style=\"width:538px; height:310px;\" src=\"images/SURG/68858_Left-thoracotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the intra-operative positioning of the patient in preparation for a left thoracotomy. For perforations of the distal esophagus, the left thoractomy approach is used. For a mid-esophageal perforation, a right thoracotomy is used.</div><div id=\"graphicVersion\">Graphic 68858 Version 1.0</div></div></div>"},"68859":{"type":"graphic_algorithm","displayName":"Contacts diphtheria protocol","title":"Respiratory diphtheria: Recommendations for case management and investigation of close contacts","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Respiratory diphtheria: Recommendations for case management and investigation of close contacts</div><div class=\"cntnt\"><img style=\"width:564px; height:488px;\" src=\"images/ID/68859_Contacts_dipht_prot_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Strict isolation should be maintained until two cultures are negative at least 24 hours apart after completion of antimicrobial therapy.<br> <span class=bullet>&#8226;</span> Equine diphtheria antitoxin can be obtained from either the Centers for Disease Control and Prevention (1-404-639-2889), or Connaught Laboratories, Swiftwater, PA. Before administration, patients should be tested for sensitivity to horse serum and, if necessary, desensitized. The recommended dosage and route of administration depend on the extent and duration of disease.<br> &#916; See text for dosing.<br> <span class=lozenge>&#9674;</span> Close contacts include household members and other persons with a history of direct contact with a case-patient (eg, caretakers, relatives, or friends who regularly visit the home) as well as medical staff exposed to oral or respiratory secretions of a case-patient.<br> &#167; See text for dosing.</div><div id=\"graphicVersion\">Graphic 68859 Version 2.0</div></div></div>"},"68861":{"type":"graphic_picture","displayName":"Crescentic GN Light High","title":"Light micrograph showing crescentic glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing crescentic glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/68861_RPGN_Light_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power light micrograph in crescentic glomerulonephritis. The hypercellular circumferential crescent (arrows) is compressing the glomerular tuft in the center of the glomerulus and closing the capillary lumens.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 68861 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"68863":{"type":"graphic_table","displayName":"Survival by LN ratio INT 0089","title":"Five-year survival rates for resected colon cancer according to lymph node ratio in INT-0089","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five-year survival rates for resected colon cancer according to lymph node ratio in INT-0089</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Endpoint</td> <td class=\"subtitle1\" colspan=\"4\">Lymph node ratio (total positive/total examined)</td> </tr> <tr> <td class=\"subtitle2\">&#60;0.05</td> <td class=\"subtitle2\">0.05-0.19</td> <td class=\"subtitle2\">0.2-0.39</td> <td class=\"subtitle2\">0.4-1.0</td> </tr> <tr> <td>Overall survival, %</td> <td>79</td> <td>73</td> <td>63</td> <td>52</td> </tr> <tr> <td>Cause-specific survival, %</td> <td>84</td> <td>79</td> <td>69</td> <td>57</td> </tr> <tr> <td>Disease-free survival, %</td> <td>77</td> <td>70</td> <td>62</td> <td>50</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Berger AC et al. J Clin Oncol 2005; 23:8706.</div><div id=\"graphicVersion\">Graphic 68863 Version 3.0</div></div></div>"},"68864":{"type":"graphic_table","displayName":"Timing of tissue damage","title":"Timing of tissue damage and repair after caustic injury of the esophagus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of tissue damage and repair after caustic injury of the esophagus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Injury</td>\n<td class=\"subtitle1\">Time</td>\n</tr>\n<tr>\n<td>Acute injury</td>\n<td>Day 0</td>\n</tr>\n<tr>\n<td>Inflammation, vascular thrombosis</td>\n<td>1 to 7 days</td>\n</tr>\n<tr>\n<td>Granulation tissue</td>\n<td>10 to 21 days</td>\n</tr>\n<tr>\n<td>Fibrosis/stricture</td>\n<td>3 weeks</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68864 Version 2.0</div></div></div>"},"68865":{"type":"graphic_figure","displayName":"Construction of an ostomy cruciate incision fascia","title":"Construction of an ostomy - cruciate incision anterior rectus fascia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of an ostomy - cruciate incision anterior rectus fascia</div><div class=\"cntnt\"><img style=\"width:447px; height:585px;\" src=\"images/SURG/68865_Ostomy-cruciate-incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the full thickness excision of skin in preparation for the ostomy (colostomy or ileostomy). A cruciate incision is made through the anterior rectus fascia.</div><div id=\"graphicVersion\">Graphic 68865 Version 1.0</div></div></div>"},"68866":{"type":"graphic_figure","displayName":"Acidosis and K distribution","title":"Ion redistribution after acid load","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ion redistribution after acid load</div><div class=\"cntnt\"><img style=\"width:358px; height:275px;\" src=\"images/NEPH/68866_Acidosis_and_K_distribution.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of an HCl load on the distribution of Cl, Na, and K. As H enters the cells to be buffered, intracellular Na and K leave the cells and move into the extracellular fluid, tending to raise the plasma potassium concentration. These ion shifts are reversed when H ions are removed from the extracellular fluid.</div><div id=\"graphicVersion\">Graphic 68866 Version 2.0</div></div></div>"},"68867":{"type":"graphic_table","displayName":"Drugs prevent ERCP pancreatitis","title":"Pharmaceutical agents evaluated for the prevention of post-ERCP amylase elevation and/or pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmaceutical agents evaluated for the prevention of post-ERCP amylase elevation and/or pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Postulated mechanism of action</td> <td class=\"subtitle1\">Agents</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Inhibition of pancreatic secretion</td> <td>Somatostatin</td> </tr> <tr> <td>Octreotide</td> </tr> <tr> <td>Glucagon</td> </tr> <tr> <td class=\"divider_bottom\">Calcitonin</td> </tr> <tr class=\"divider_bottom\"> <td>Stimulation of pancreatic secretion and reduction of sphincter tone</td> <td>Secretin</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Reduction of sphincter tone</td> <td>Nifedipine</td> </tr> <tr> <td>Nitroglycerin</td> </tr> <tr> <td>Botulinum toxin</td> </tr> <tr> <td class=\"divider_bottom\">Lidocaine</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Inhibition of protease activation</td> <td>Aprotinin</td> </tr> <tr> <td>Gabexate mesilate</td> </tr> <tr> <td>C1-esterase inhibitor</td> </tr> <tr> <td>Heparins</td> </tr> <tr> <td>Ulinastatin</td> </tr> <tr> <td>Nafamostat</td> </tr> <tr> <td class=\"divider_bottom\">Magnesium sulphate</td> </tr> <tr class=\"divider_bottom\"> <td>Antimicrobial agents</td> <td>Antibiotics</td> </tr> <tr class=\"divider_bottom\"> <td>Steroidal anti-inflammatory agents</td> <td>Glucocorticoids</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Nonsteroidal anti-inflammatory agents</td> <td>Diclofenac</td> </tr> <tr> <td>Indomethacin</td> </tr> <tr> <td class=\"divider_bottom\">Valdecoxib</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\">Other anti-inflammatory agents</td> <td>Allopurinol</td> </tr> <tr> <td>Epinephrine spray</td> </tr> <tr> <td>Interleukin-10</td> </tr> <tr> <td>Pentoxifylline</td> </tr> <tr> <td>Platelet-activating factor-acetylhydrolase</td> </tr> <tr> <td>Semapimod</td> </tr> <tr> <td>Aprepitant</td> </tr> <tr> <td class=\"divider_bottom\">Risperidone</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Antioxidants</td> <td>Beta-carotene</td> </tr> <tr> <td>N-acetyl cysteine (acetylcysteine)</td> </tr> <tr> <td class=\"divider_bottom\">Sodium selenite</td> </tr> <tr> <td>Antimetabolites</td> <td>5-fluorouracil</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">With the exception of rectally administered non-selective NSAIDs (eg, indomethacin), pharmacologic prophylaxis is not a routinely recommended strategy for minimizing the risk of post-ERCP pancreatitis. Most pharmaceutical agents evaluated have not demonstrated efficacy for this use, and several listed in this table are not available for clinical use. Refer to topic.</div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Courtesy of Silvano Loperfido, MD.</div><div id=\"graphicVersion\">Graphic 68867 Version 7.0</div></div></div>"},"68868":{"type":"graphic_table","displayName":"Endoscopic criteria malignancy","title":"Endoscopic criteria suggesting malignancy of a polyp","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic criteria suggesting malignancy of a polyp</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Firm consistency</td>\n</tr>\n<tr>\n<td>Adherence</td>\n</tr>\n<tr>\n<td>Ulceration</td>\n</tr>\n<tr>\n<td>Friability</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68868 Version 1.0</div></div></div>"},"68869":{"type":"graphic_figure","displayName":"TPO or c-Mpl deficiency","title":"Importance of thrombopoietin (TPO) and its receptor (MPL) in deficient mice","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Importance of thrombopoietin (TPO) and its receptor (MPL) in deficient mice</div><div class=\"cntnt\"><img style=\"width:328px; height:327px;\" src=\"images/HEME/68869_TPO_or_c_Mpl_deficiency.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platelet counts in thrombopoietin (TPO) or c-Mpl (MPL, the TPO receptor) homozygous (-/-) or heterozygous (+/-) deficient mice compared with normal (+/+) mice. The platelet count is 10 to 20 percent of normal in homozygous TPO or c-Mpl deficient mice, and 65 percent of normal in heterozygous TPO deficient mice.</div><div class=\"graphic_reference\">Data from: Gurney AL, Carver-Moore K, de Sauvage FJ, et al. Science 1994; 265:1445 and de Sauvage FJ, Carver-Moore K, Luoh SM, et al. J Exp Med 1996; 183:651.</div><div id=\"graphicVersion\">Graphic 68869 Version 3.0</div></div></div>"},"68872":{"type":"graphic_figure","displayName":"LTE4 excretion in asthma","title":"Increased urinary LTE4 excretion in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased urinary LTE4 excretion in asthma</div><div class=\"cntnt\"><img style=\"width:275px; height:232px;\" src=\"images/PULM/68872_LTE4_excretion_in_asthma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urinary excretion of leukotriene E4 (LTE4) in normal subjects and patients with acute asthma. Approximately two-thirds of asthmatics have increased LTE4 excretion during an acute episode.</div><div class=\"graphic_reference\">Data from Drazen, JM, O'Brien, J, Sparrow, D, et al, Am Rev Respir Dis 1992; 146:104.</div><div id=\"graphicVersion\">Graphic 68872 Version 1.0</div></div></div>"},"68873":{"type":"graphic_figure","displayName":"Plasma AAT after IV replacement","title":"Efficacy of weekly infusions of alpha-1 antitrypsin","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Efficacy of weekly infusions of alpha-1 antitrypsin</div><div class=\"cntnt\"><img style=\"width:496px; height:261px;\" src=\"images/PULM/68873_Plasma_AAT_after_IV_replace.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum alpha-1 antitrypsin (AAT) levels by immunodiffusion after once weekly administration of 60 mg/kg of active AAT to patients with the ZZ homozygous form of AAT deficiency. The dashed line represents the protective threshold. Weekly infusions (arrows) maintained the serum A1AT levels above this threshold. Values are in commercial standard units of mg/dL; the true standard levels in &#181;mol/L can be&nbsp;estimated by dividing the&nbsp;immunodiffusion value by 7.3.</div><div class=\"graphic_reference\">Redrawn from Hubbard RC, Crystal RG. Am J Med 1988; 84(Suppl 6A):52.</div><div id=\"graphicVersion\">Graphic 68873 Version 2.0</div></div></div>"},"68874":{"type":"graphic_figure","displayName":"Collar and cuff sling","title":"Collar and cuff sling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collar and cuff sling</div><div class=\"cntnt\"><img style=\"width:285px; height:329px;\" src=\"images/RHEUM/68874_Collar_and_cuff_sling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The combination of a sling around the neck (collar) and a cuff around the wrist allows for some traction which may be useful in managing some proximal or midshaft fractures of the humerus.</div><div id=\"graphicVersion\">Graphic 68874 Version 2.0</div></div></div>"},"68875":{"type":"graphic_figure","displayName":"Ureterouretostomy","title":"Ureterouretostomy","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Ureterouretostomy</div><div class=\"cntnt\"><img style=\"width:470px; height:465px;\" src=\"images/SURG/68875_Ureterouretostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts anastomosis of the spatulated ends of the proximal and distal portion of the ureter. The anastomosis is performed with an interrupted, absorbable suture.</div><div id=\"graphicVersion\">Graphic 68875 Version 1.0</div></div></div>"},"68876":{"type":"graphic_diagnosticimage","displayName":"Biliary ascariasis","title":"Biliary ascariasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliary ascariasis</div><div class=\"cntnt\"><img style=\"width:221px; height:360px;\" src=\"images/GAST/68876_Ascaris_lumbricoides_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram obtained during endoscopic retrograde cholangiopancreatography shows a linear filling defect (arrow) that was later identified as an adult <EM>Ascaris lumbricoides </EM>worm.</div><div class=\"graphic_reference\">Courtesy of D Ngeshwar Reddy, MD.</div><div id=\"graphicVersion\">Graphic 68876 Version 8.0</div></div></div>"},"68877":{"type":"graphic_picture","displayName":"Rash in secondary syphilis","title":"Secondary syphilis: Rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis: Rash</div><div class=\"cntnt\"><img style=\"width:352px; height:252px;\" src=\"images/ID/68877_Rash_in_secondary_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of secondary syphilis characteristically involves the palms and soles. It may have a variety of appearances but is usually pigmented and macular.</div><div class=\"graphic_reference\">Courtesy of Charles B Hicks, MD.</div><div id=\"graphicVersion\">Graphic 68877 Version 4.0</div></div></div>"},"68878":{"type":"graphic_diagnosticimage","displayName":"Spinal epidural abscess MRI","title":"Spinal epidural abscess","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Spinal epidural abscess</div><div class=\"cntnt\"><img style=\"width:764px; height:615px;\" src=\"images/ID/68878_Spnl_epdrl_abscess_MRI_edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spinal epidural abscess in a 73-year-old patient. T1-weighted MRI shows epidural lesions (arrow) with surrounding contrast enhancement located at (A) C3/C4 and (B) T7–T9. Insets show corresponding axial sections.<EM> Staphylococcus aureus</EM> was identified in blood and cerebrospinal fluid.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Pfister HW, Klein M, Tunkel AR, Scheld WM. Epidural abscess. In: Infections of the Central Nervous System, 4th ed, Scheld WM, Whitley RJ, Marra CM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright © 2014 Wolters Kluwer Health. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68878 Version 4.0</div></div></div>"},"68882":{"type":"graphic_picture","displayName":"Ichthyosis vulgaris 3","title":"Ichthyosis vulgaris, sparing of flexural areas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ichthyosis vulgaris, sparing of flexural areas</div><div class=\"cntnt\"><img style=\"width:432px; height:327px;\" src=\"images/DERM/68882_Ichthyosis_vulgaris_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ichthyosis vulgaris. This patient has atopic dermatitis and ichthyosis vulgaris lesions that resemble fish scales. Note the characteristic sparing of the popliteal fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68882 Version 1.0</div></div></div>"},"68883":{"type":"graphic_table","displayName":"Pancreatic diabetes","title":"Approximate frequency of diabetes mellitus in different types of pancreatic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate frequency of diabetes mellitus in different types of pancreatic disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Disease</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Total pancreactectomy</td>\n\n      <td>100</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Pancreatectomy</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Distal pancreatectomy</td>\n\n      <td class=\"sublist_other\">20 to 40</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">40 to 80 percent resection</td>\n\n      <td class=\"sublist_other\">40</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">80 to 90 percent resection</td>\n\n      <td class=\"sublist_other\">&#62;60</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Pancreatitis</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Acute</td>\n\n      <td class=\"sublist_other\">2 to 18</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chronic calcifying</td>\n\n      <td class=\"sublist_other\">60 to 70</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chronic noncalcifying</td>\n\n      <td class=\"sublist_other\">15 to 30</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">Hemachromatosis</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Primary</td>\n\n      <td class=\"sublist_other\">75</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Secondary</td>\n\n      <td class=\"sublist_other\">16</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carcinoma</td>\n\n      <td>40 to 50</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cystic fibrosis</td>\n\n      <td>10</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15635&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Pancreatic_diabetes.htm</title></head></div><div class=\"graphic_reference\">Data from: Del Prato S, Tiengo A. Diabetes Reviews 1993; 1:260.</div><div id=\"graphicVersion\">Graphic 68883 Version 2.0</div></div></div>"},"68885":{"type":"graphic_table","displayName":"Tissue stains for endoscopy","title":"Tissue stains used during gastrointestinal endoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tissue stains used during gastrointestinal endoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"16%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stain type</td> <td class=\"subtitle1\">What is stained</td> <td class=\"subtitle1\">Mechanism of staining</td> <td class=\"subtitle1\">Positive staining</td> <td class=\"subtitle1\">Clinical uses in GI</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vital stains</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Lugol's solution (iodine + potassium iodide)</td> <td rowspan=\"3\">Normal glycogen containing squamous cells</td> <td rowspan=\"3\">Binds iodine in non-keratinized cells</td> <td rowspan=\"3\">Dark brown</td> <td>1) Squamous cell esophageal cancer (non-staining)</td> </tr> <tr> <td>2) Columnar epithelium in the esophagus, including residual Barrett's esophagus following mucosal ablation (non-staining)</td> </tr> <tr> <td>3) Reflux esophagitis (non-staining)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Methylene blue (methylthionine chloride)</td> <td rowspan=\"5\">Small or large intestinal cells or intestinal metaplasia</td> <td rowspan=\"5\">Active absorption into cells</td> <td rowspan=\"5\">Blue</td> <td>1) Specialized epithelium (intestinal metaplasia) in Barrett's esophagus*</td> </tr> <tr> <td>2) Intestinal metaplasia in the stomach</td> </tr> <tr> <td>3) Early gastric cancer<sup>&#182;</sup></td> </tr> <tr> <td>4) Gastric metaplasia in the duodenum (non-staining)</td> </tr> <tr> <td>5) Celiac and tropical sprue</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Toluidine blue (tolonium chloride or dimethylamino-toluphenazothioni-chloride)</td> <td class=\"divider_bottom\" rowspan=\"2\">Nuclei of columnar (gastric and intestinal-type) cells</td> <td class=\"divider_bottom\" rowspan=\"2\">Diffuses into cell</td> <td class=\"divider_bottom\" rowspan=\"2\">Blue</td> <td>1) Squamous cell carcinoma of the esophagus</td> </tr> <tr class=\"divider_bottom\"> <td>2) Gastric or intestinal metaplasia in Barrett's esophagus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Reactive stains</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Congo red (biphenylene-napthadene sulfornic acid)</td> <td rowspan=\"2\">Acid-containing gastric cells</td> <td rowspan=\"2\">Acid pH &#60;3.0 results in color change</td> <td rowspan=\"2\">Turns red to dark blue or black</td> <td>1) Acid-secreting gastric mucosa (including ectopic locations)</td> </tr> <tr> <td>2) Gastric cancer (nonstaining); (may be combined with methylene blue to outline intestinal metaplasia)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phenol red (phenolsulfonphthalein)</td> <td>H. pylori-infected gastric cells</td> <td>Alkaline pH (from hydrolysis of urea to NH3 and CO2 by urease) results in color change</td> <td>Turns yellow to red</td> <td>Diagnose Helicobacter pylori infection (positive color change) and map its distribution in the stomach</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Contrast stain</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Indigo carmine<sup>&#916;</sup></td> <td rowspan=\"2\">Cells are not stained</td> <td rowspan=\"2\">Pools in crevices and valleys between mucosal projections</td> <td rowspan=\"2\">Blue (indigo)</td> <td>1) Colon, gastric, duodenal, esophageal lesions</td> </tr> <tr> <td>2) Barrett's esophagus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Methylene blue does not stain non-specialized or gastric metaplasia; specialized columnar epithelium stains blue, but highly dysplastic or malignant specialized columnar epithelium in Barrett's esophagus generally takes up little to no dye; low grade dysplasia in Barrett's esophagus may or may not take up stain.<br />¶ With or without Congo red.<br />Δ Also used in combination with high resolution or high magnification endoscopy; may be used with or without crystal violet (for early colorectal cancers).</div><div class=\"graphic_reference\">Reproduced with permission from: Canto M. Staining in Gastrointestinal Endoscopy: The Basics. Endoscopy 1999; 31:479. Copyright &copy; 1999 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 68885 Version 9.0</div></div></div>"},"68886":{"type":"graphic_table","displayName":"Hysterectomy outcome PI","title":"Frequency of common, severe symptoms before and after hysterectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of common, severe symptoms before and after hysterectomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Symptom</td>\n\n\n      <td class=\"subtitle1\">Frequency before, percent</td>\n\n      <td class=\"subtitle1\">Frequency after, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vaginal bleeding</td>\n\n\n      <td>59</td>\n\n      <td>&#60;1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pelvic pain</td>\n\n\n      <td>63</td>\n\n      <td>8</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Back pain</td>\n\n\n      <td>43</td>\n\n      <td>17</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Activity limitation</td>\n\n\n      <td>58</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sleep disturbance</td>\n\n\n      <td>41</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fatigue</td>\n\n\n      <td>70</td>\n\n      <td>25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal bloating</td>\n\n\n      <td>48</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary incontinence</td>\n\n\n      <td>20</td>\n\n      <td>8</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=49189&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Hysterectomy_outcome_PI.htm</title></head></div><div class=\"graphic_reference\">Data from:&nbsp;Kjerulff KH, Langenberg PW, Rhodes JS, et al. Effectiveness of hysterectomy. Obstet Gynecol 2000; 95:319.</div><div id=\"graphicVersion\">Graphic 68886 Version 2.0</div></div></div>"},"68887":{"type":"graphic_table","displayName":"Mimics of sepsis","title":"Noninfectious mimics of sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious mimics of sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Acute myocardial infarction</td>\n</tr>\n<tr>\n<td>Acute pulmonary embolus</td>\n</tr>\n<tr>\n<td>Acute pancreatitis</td>\n</tr>\n<tr>\n<td>Fat emboli syndrome</td>\n</tr>\n<tr>\n<td>Acute adrenal insufficiency</td>\n</tr>\n<tr>\n<td>Acute gastrointestinal hemorrhage</td>\n</tr>\n<tr>\n<td>Overzealous diuresis</td>\n</tr>\n<tr>\n<td>Transfusion reactions</td>\n</tr>\n<tr>\n<td>Adverse drug reactions</td>\n</tr>\n<tr>\n<td>Procedure-related transient bacteremia</td>\n</tr>\n<tr>\n<td>Amniotic fluid embolism</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Cuhna, BA, Crit Care Clin 1998; 14:1</div><div id=\"graphicVersion\">Graphic 68887 Version 1.0</div></div></div>"},"68890":{"type":"graphic_picture","displayName":"Unstable UCL","title":"Ulnar collateral ligament: Unstable","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulnar collateral ligament: Unstable</div><div class=\"cntnt\"><img style=\"width:343px; height:432px;\" src=\"images/EM/68890_Unstable_UCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abduction stress placed upon the ulnar collateral ligament in the photograph above reveals increased motion, which may be due to a partial ligament tear. Patient history and comparison with the opposite thumb can determine the nature of such increased motion.</div><div id=\"graphicVersion\">Graphic 68890 Version 1.0</div></div></div>"},"68892":{"type":"graphic_table","displayName":"Chronic tension-type headache criteria","title":"Chronic tension-type headache diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic tension-type headache diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Description:</strong> A disorder evolving from frequent episodic tension-type headache, with daily or very frequent episodes of headache, typically bilateral, pressing or tightening in quality and of mild to moderate intensity, lasting hours to days, or unremitting. The pain does not worsen with routine physical activity, but may be associated with mild nausea, photophobia or phonophobia.</td> </tr> <tr> <td class=\"subtitle2_left\">Diagnostic criteria:</td> </tr> <tr> <td class=\"indent1\">A. Headache occurring on &#8805;15 days per month on average for more than three months (&#8805;180 days per year) and fulfilling criteria B through D</td> </tr> <tr> <td class=\"indent1\">B. <span style=\"font-size: 11pt; font-family: calibri,sans-serif;\">Lasting hours to days, or unremitting</span></td> </tr> <tr> <td class=\"indent1\">C. At least two of the following characteristics:</td> </tr> <tr> <td class=\"indent2\">1. Bilateral location</td> </tr> <tr> <td class=\"indent2\">2. Pressing or tightening (non-pulsating) quality</td> </tr> <tr> <td class=\"indent2\">3. Mild or moderate intensity</td> </tr> <tr> <td class=\"indent2\">4. Not aggravated by routine physical activity such as walking or climbing stairs</td> </tr> <tr> <td class=\"indent1\">D. Both of the following:</td> </tr> <tr> <td class=\"indent2\">1. No more than one of photophobia, phonophobia or mild nausea</td> </tr> <tr> <td class=\"indent2\">2. Neither moderate or severe nausea nor vomiting</td> </tr> <tr> <td class=\"indent1\">E. Not better accounted for by another ICHD-3 diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICHD-3: International Classification of Headache Disorders, 3rd edition</div><div class=\"graphic_reference\">Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 68892 Version 4.0</div></div></div>"},"68893":{"type":"graphic_waveform","displayName":"Twins FHR tracings","title":"Twins","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Twins</div><div class=\"cntnt\"><img style=\"width:540px; height:108px;\" src=\"images/OBGYN/68893_Twins_FHR_tracings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fetal monitors are picking up two (dark tracing, light tracing) easily discernable fetal heart rate patterns.</div><div id=\"graphicVersion\">Graphic 68893 Version 2.0</div></div></div>"},"68894":{"type":"graphic_table","displayName":"Doses antiemetic drugs","title":"Recommended adult doses of antiemetic drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended adult doses of antiemetic drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" rowspan=\"2\">Trade name</td> <td class=\"subtitle1\" colspan=\"2\">Dose and schedule</td> </tr> <tr> <td class=\"subtitle2\">Prechemotherapy</td> <td class=\"subtitle2\">Postchemotherapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Agents with a higher therapeutic index</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>5-HT3 receptor antagonists</strong>*</td> </tr> <tr> <td class=\"indent2\">Ondansetron IV</td> <td>Zofran</td> <td>8 mg or 0.15 mg/kg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Ondansetron oral</td> <td>Zofran</td> <td>8 mg by mouth twice daily.</td> <td>8 mg by mouth twice daily on days 2 and 3 for moderately emetogenic chemotherapy with the potential for delayed emesis.</td> </tr> <tr> <td class=\"indent2\">Ondansetron oral dissolving tablet (ODT)</td> <td>Zofran ODT</td> <td>&nbsp;</td> <td>8 mg dissolved in mouth every 12 hours as needed.</td> </tr> <tr> <td class=\"indent2\">Ondansetron oral soluble film</td> <td>Zuplenz</td> <td>&nbsp;</td> <td>8 mg dissolved in mouth every 12 hours as needed.</td> </tr> <tr> <td class=\"indent2\">Granisetron IV</td> <td>Kytril</td> <td>1 mg or 0.01 mg/kg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Granisetron oral</td> <td>Granisol</td> <td>1 to 2 mg by mouth once.</td> <td>1 mg by mouth twice daily on days 2 and 3 for moderately emetogenic chemotherapy with the potential for delayed emesis.</td> </tr> <tr> <td class=\"indent2\">Granisetron SQ extended release</td> <td>Sustol</td> <td>10 mg SQ once at least 30 minutes before chemotherapy.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Granisetron transdermal patch</td> <td>Sancuso</td> <td>Apply 24 to 48 hours prior to chemotherapy. Releases 3.1 mg per 24 hours.</td> <td>Remove 24 hours or more after last chemotherapy dose. Maximum 7 days depending on regimen.</td> </tr> <tr> <td class=\"indent2\">Dolasetron oral ONLY<sup>&#182;</sup></td> <td>Anzemet</td> <td>100 mg by mouth once.</td> <td>100 mg by mouth daily on days 2 and 3 for moderately emetogenic chemotherapy with potential for delayed emesis.</td> </tr> <tr> <td class=\"indent2\">Palonosetron IV</td> <td>Aloxi</td> <td>0.25 mg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Palonosetron oral</td> <td>Aloxi</td> <td>0.5 mg by mouth once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Tropisetron IV<sup>&#916;</sup></td> <td>Navoban</td> <td>5 mg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Tropisetron oral<sup>&#916;</sup></td> <td>Navoban</td> <td>&nbsp;</td> <td>5 mg by mouth daily for up to 5 days.</td> </tr> <tr> <td class=\"indent2\">Ramosetron<sup>&#916;</sup></td> <td>Irribow, Nasea</td> <td>300 mcg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Azasetron oral<sup>&#916;</sup></td> <td>Serotone</td> <td>10 mg by mouth once.</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Glucocorticoids</strong></td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"4\">Dexamethasone</td> </tr> <tr> <td class=\"indent3\" rowspan=\"2\" colspan=\"2\"> <ul> <li>With a Neurokinin-1 antagonist </li> </ul> </td> <td>12 mg IV or orally for highly emetogenic chemotherapy.</td> <td>8 mg by mouth daily (usually as 4 mg twice daily) on days 2, 3, and 4 for highly emetogenic chemotherapy (except patients receiving AC for breast cancer).</td> </tr> <tr> <td>8 mg IV or orally for moderately emetogenic chemotherapy.</td> <td>8 mg by mouth daily (usually as 4 mg twice daily) on days 2 and 3 for moderately emetogenic chemotherapy with the potential for delayed emesis.</td> </tr> <tr> <td class=\"indent3\" rowspan=\"2\" colspan=\"2\"> <ul> <li>Without a Neurokinin-1 antagonist </li> </ul> </td> <td>20 mg IV for highly emetogenic chemotherapy.</td> <td>16 mg by mouth daily (usually as 8 mg twice daily)&nbsp;on days 2, 3, and 4 for highly emetogenic chemotherapy.</td> </tr> <tr> <td>8 mg orally for moderately emetogenic chemotherapy.</td> <td>8 mg by mouth daily (usually as 4 mg twice daily)&nbsp;on days 2 and 3 for moderately emetogenic chemotherapy with the potential for delayed emesis.</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Neurokinin-1 antagonists</strong></td> </tr> <tr> <td class=\"indent2\">Aprepitant oral</td> <td>Emend</td> <td>125 mg by mouth once.</td> <td>80 mg by mouth daily for two days starting 24 hours after the start of chemotherapy.</td> </tr> <tr> <td class=\"indent2\">Aprepitant IV<sup>&#9674;</sup>&nbsp;</td> <td>Cinvanti</td> <td> <p>130 mg IV once (single-dose regimen for highly emetogenic chemotherapy).</p> <p>100 mg IV on day 1(moderately emetogenic chemotherapy).</p> </td> <td>Aprepitant capsules (80 mg) are given orally on days 2 and 3 for&nbsp;moderately emetogenic chemotherapy only.</td> </tr> <tr> <td class=\"indent2\">Fosaprepitant IV (single dose)</td> <td>Emend IV</td> <td>150 mg IV once.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Rolapitant</td> <td>Varubi</td> <td>180 mg by mouth once or 166.5 mg IV once.</td> <td>&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Combination products</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">NEPA (netupitant 300 mg plus palonsetron 0.5 mg)</td> <td>Akynzeo</td> <td>One tablet by mouth once prechemotherapy.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">Agents with a lower therapeutic index<sup>&#167;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Dopaminergic antagonists</strong></td> </tr> <tr> <td class=\"indent2\">Metoclopramide IV (high dose)</td> <td>Reglan</td> <td>1 to 2 mg/kg IV.</td> <td>Repeat IV dose 2 hours postchemotherapy; oral 0.5 mg/kg every 6 hours on days 2 to 4, starting 24 hours after start of chemotherapy, for moderately emetogenic chemotherapy with the potential for delayed emesis.</td> </tr> <tr> <td class=\"indent2\">Prochlorperazine IV</td> <td>Compazine</td> <td>5 to 10 mg IV every 6 to 8 hours as needed (maximum 40 mg per day).</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Prochlorperazine oral</td> <td>Compazine</td> <td>10 mg by mouth.</td> <td>10 mg by mouth every 6 to 8 hours as needed.</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Cannabinoids</strong></td> </tr> <tr> <td class=\"indent2\">Nabilone oral</td> <td>Cesamet</td> <td>1 to 2 mg by mouth once.</td> <td>1 to 2 mg twice daily or as needed (maximum 6 mg divided in 3 doses per day).</td> </tr> <tr> <td class=\"indent2\">Dronabinol oral</td> <td> <p>Marinol</p> <p>Syndros (oral liquid)</p> </td> <td>5 mg/m<sup>2</sup> by mouth.</td> <td>5 mg/m<sup>2</sup> by mouth every 2 to 4 hours as needed (maximum 15 mg/m<sup>2</sup> per dose, up to 6 doses per day).</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\" colspan=\"4\"><strong>Antipsychotics</strong></td> </tr> <tr> <td class=\"indent2\">Olanzapine</td> <td>Zyprexa</td> <td>5 to 10 mg by mouth once for highly emetogenic chemotherapy<sup>&#165;</sup>.</td> <td>5 to 10 mg by mouth daily on days 2 to 4 for highly emetogenic chemotherapy<sup>&#165;</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; SQ: subcutaneous; AC: cyclophosphamide plus doxorubicin.<br />* Prechemotherapy dosing of 5-HT3 receptor antagonists shown is based on a three-drug combination including dexamethasone and a neurokinin-1 antagonist for highly emetogenic chemotherapy, or the combination of palonosetron with dexamethasone for moderately emetogenic chemotherapy. Refer to text.<br />¶ IV use of dolasetron is contraindicated because of the potential for fatal cardiac arrhythmias.<br />Δ Not available in the United States.<br /><FONT class=lozenge>◊</FONT> Cinvanti is a fosaprepitant biosimilar that does not contain polysorbate 80 and is associated with a lower risk of&nbsp;systemic infusion reactions and local infusion site discomfort.<br />§ In general, use of agents with a low therapeutic index is reserved for patients intolerant or refractory to first-line agents. If used, they should be combined with more effective, higher therapeutic index antiemetics.<br />¥ To minimize sedation, the 5 mg olanzapine dose is preferred.</div><div class=\"graphic_reference\">Modified from: Hesketh PJ. Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2008; 358:2482.<br />Additional data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 21:4189.</LI>&#xD;&#xA;<LI>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119.</LI></OL></div><div id=\"graphicVersion\">Graphic 68894 Version 19.0</div></div></div>"},"68895":{"type":"graphic_picture","displayName":"Becker's nevus","title":"Becker's nevus (Becker's melanosis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Becker's nevus (Becker's melanosis)</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/PEDS/68895_Beckers_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the hypertrichosis and &quot;islands&quot; of hyperpigmentation.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 68895 Version 2.0</div></div></div>"},"68896":{"type":"graphic_picture","displayName":"Dentinogenesis imperfecta in patient with osteogenesis imperfect","title":"Dentinogenesis imperfecta in a patient with osteogenesis imperfecta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dentinogenesis imperfecta in a patient with osteogenesis imperfecta</div><div class=\"cntnt\"><img style=\"width:386px; height:265px;\" src=\"images/PEDS/68896_Dentinogenesis_imperfecta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked discoloration and severe attrition of the primary dentition are seen in this child with dentinogenesis imperfecta type II.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.</div><div id=\"graphicVersion\">Graphic 68896 Version 4.0</div></div></div>"},"68897":{"type":"graphic_figure","displayName":"SCFE epiphyseal shaft angle","title":"Epiphyseal-shaft angle of Southwick","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Epiphyseal-shaft angle of Southwick</div><div class=\"cntnt\"><img style=\"width:487px; height:218px;\" src=\"images/PEDS/68897_SCFE_epiphyseal_shaft_angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One line is drawn between the anterior and posterior tips of the epiphysis at the level of the growth plate. A second line is drawn perpendicular to the first. A third line is drawn along the mid-axis of the femoral shaft. The epiphyseal-shaft angle is measured at the intersection of the second and third lines. It is measured for both hips. The magnitude of slip displacement is the angle of the involved hip minus the angle of the contralateral normal hip (or minus 12 degrees if the slip is bilateral).</div><div id=\"graphicVersion\">Graphic 68897 Version 1.0</div></div></div>"},"68898":{"type":"graphic_picture","displayName":"Retinal microaneurysms","title":"Background diabetic retinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Background diabetic retinopathy</div><div class=\"cntnt\"><img style=\"width:293px; height:288px;\" src=\"images/ENDO/68898_Retinal_microaneurysms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Background diabetic retinopathy showing microaneurysms (small arrows) and hard exudates. The blood vessels can be seen running over the hard exudates (large arrow), indicating that the exudates are due to leakage in the deeper retinal layers (in contrast to soft exudates, which are microinfarcts in the superficial retinal layers with obliterated blood vessels). Many of the hard exudates are clustered around the macula, which is at the periphery at about four o'clock.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 68898 Version 1.0</div></div></div>"},"68899":{"type":"graphic_picture","displayName":"Pearly penile papules","title":"Pearly penile papules","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Pearly penile papules</div><div class=\"cntnt\"><img style=\"width:556px; height:392px;\" src=\"images/GAST/68899_Pearly_penile_papules_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Small white papules are oriented in a few rows on the corona of the penis.<br> (B) Whitish pink cobblestone appearance in a few rows with central dotted or comma-like vessels in each papule. The papules are further surrounded by whitish crescent-shaped rims.<br> (C) Prominent structures of hyperplastic papillary dermis and dilatation of vascular spaces. The epidermis shows mild acanthosis with orthokeratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Ozeki M, Saito R, Tanaka M. Dermoscopic features of pearly penile papules. Dermatology 2008; 217:21. Copyright © 2008 S. Karger AG.</div><div id=\"graphicVersion\">Graphic 68899 Version 8.0</div></div></div>"},"68903":{"type":"graphic_diagnosticimage","displayName":"Radiographic features of pelvic instability","title":"Radiographic features of pelvic instability","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Radiographic features of pelvic instability</div><div class=\"cntnt\"><img style=\"width:582px; height:298px;\" src=\"images/PC/68903_Indirect_feat_pelvic_instab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A standing AP radiograph of pelvis shows findings associated with underlying pelvic instability: (1) pelvic tilt secondary to leg length discrepancy; (2) degenerative changes at the symphysis pubis which include joint space narrowing, articular cortical irregularity and subchondral sclerosis; (3) slight pubic malalignment with associated traction osteophyte at the superior joint margin; (4) widening of the right sacroiliac joint inferiorly (arrowhead); and (5) ossification at the left adductor origin secondary to an old tear (arrow). Not all such changes are seen in all cases.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Read JW. Groin disruption injury. Sports Medicine Imaging. For more information, visit <a href=\"http://www.sportsmedicineimaging.com/\" class=\"ApplyClass\" target=\"_blank\">http://www.sportsmedicineimaging.com/</a>. Copyright &copy; 2009 SportsMedicineImaging.com. All rights reserved.</div><div id=\"graphicVersion\">Graphic 68903 Version 6.0</div></div></div>"},"68904":{"type":"graphic_picture","displayName":"Generalized morphea - legs","title":"Generalized morphea on the legs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized morphea on the legs</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/DERM/68904_Generalized_morphea_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symmetric, hypopigmented, sclerotic plaques are present on the legs of this patient with generalized morphea.</div><div id=\"graphicVersion\">Graphic 68904 Version 2.0</div></div></div>"},"68906":{"type":"graphic_picture","displayName":"Polymorphic eruption of pregnancy halo","title":"Polymorphic eruption of pregnancy (pruritic urticarial papules and plaques of pregnancy)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphic eruption of pregnancy (pruritic urticarial papules and plaques of pregnancy)</div><div class=\"cntnt\"><img style=\"width:432px; height:332px;\" src=\"images/DERM/68906_PUPPP_halo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In fair-skinned patients with polymorphic eruption of pregnancy (PEP),&nbsp;formerly called pruritic urticarial papules and plaques of pregnancy (PUPPP), a white halo may be present around the erythematous papules and plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68906 Version 5.0</div></div></div>"},"68907":{"type":"graphic_table","displayName":"Disorders that affect TSH","title":"Disorders that affect serum TSH concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that affect serum TSH concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low serum TSH </td> </tr> <tr> <td>Primary hyperthyroidism</td> </tr> <tr> <td>Incomplete recovery from hyperthyroidism</td> </tr> <tr> <td>Nonthyroidal illness</td> </tr> <tr> <td>High levels of chorionic gonadotropin - early pregnancy, molar pregnancy, choriocarcinoma</td> </tr> <tr> <td>Drugs - dopamine agonists, glucocorticoids, somatostatin analogs</td> </tr> <tr> <td>Central hypothyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">High serum TSH </td> </tr> <tr> <td>Primary hypothyroidism</td> </tr> <tr> <td>Recovery from nonthyroidal illness</td> </tr> <tr> <td>Drugs - dopamine antagonists, amiodarone, oral cholecystogram dye (sodium ipodate)</td> </tr> <tr> <td>TSH-producing pituitary adenoma</td> </tr> <tr> <td>Adrenal insufficiency</td> </tr> <tr> <td>Heterophilic antibody interference</td> </tr> <tr> <td>Generalized thyroid hormone resistance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 68907 Version 3.0</div></div></div>"},"68908":{"type":"graphic_picture","displayName":"Beta hemolysis 2","title":"<em>Streptococcus pyogenes</em> on blood agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Streptococcus pyogenes</em> on blood agar</div><div class=\"cntnt\"><img style=\"width:363px; height:240px;\" src=\"images/ID/68908_Beta_hemolysis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Culture of <EM>Streptococcus pyogenes</EM> on blood agar showing large zones of clear beta-hemolysis around the small colonies. The susceptibility of this organism to bacitracin is demonstrated by the zone of inhibition around the bacitracin-containing disc (A) on the left side of the plate.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 68908 Version 4.0</div></div></div>"},"68911":{"type":"graphic_figure","displayName":"Forceps of aftercoming head 2","title":"Forceps delivery of after-coming head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forceps delivery of after-coming head</div><div class=\"cntnt\"><img style=\"width:426px; height:308px;\" src=\"images/OBGYN/68911_Forceps_of_aftercoming_he1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &#169;1980 McGraw Hill. p.1071.</div><div id=\"graphicVersion\">Graphic 68911 Version 1.0</div></div></div>"},"68914":{"type":"graphic_figure","displayName":"Precut over pancreatic stent","title":"Precut papillotomy over a pancreatic stent","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Precut papillotomy over a pancreatic stent</div><div class=\"cntnt\"><img style=\"width:498px; height:461px;\" src=\"images/GAST/68914_Precut_over_pancreatic_sten.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Martin L Freeman, MD.</div><div id=\"graphicVersion\">Graphic 68914 Version 3.0</div></div></div>"},"68916":{"type":"graphic_table","displayName":"Prevalence thrombophilia defects","title":"Prevalence of thrombophilic defects in venous thrombosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of thrombophilic defects in venous thrombosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Prevalence, percent*</td> </tr> <tr> <td>Activated protein C resistance (factor V Leiden)</td> <td>12 to 40<sup>&#182;</sup></td> </tr> <tr> <td>Prothrombin G20210A gene mutation</td> <td>6 to 18<sup>&#182;</sup></td> </tr> <tr> <td>Deficiencies of Antithrombin, protein C, protein S</td> <td>5 to 15</td> </tr> <tr> <td>Antiphospholipid antibody syndrome</td> <td>5 to 10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Note: The lower percentage for each condition is for unselected patients; the higher percentage is for those with first events prior to age 50 or with a history of venous thrombosis in first-degree relatives.<br />¶&nbsp;Prevalence restricted to Caucasian populations.</div><div id=\"graphicVersion\">Graphic 68916 Version 2.0</div></div></div>"},"68917":{"type":"graphic_picture","displayName":"Auricular biopsy in RPC","title":"Auricular biopsy in relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auricular biopsy in relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:237px; height:357px;\" src=\"images/RHEUM/68917_Auricular_biopsy_in_RPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Auricular biopsy of an early active lesional site in a patient with relapsing polychondritis. Histopathology reveals a pleomorphic cellular infiltrate at the chondro-dermal junction in conjunction with proteoglycan depletion.</div><div class=\"graphic_reference\">Courtesy of Jerome H Herman, MD.</div><div id=\"graphicVersion\">Graphic 68917 Version 3.0</div></div></div>"},"68918":{"type":"graphic_table","displayName":"Malignant hyperthermia rapid response","title":"Malignant hyperthermia rapid response","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignant hyperthermia rapid response</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical presentation and signs</td> </tr> <tr> <td class=\"indent1\"><strong>Increasing end-tidal carbon dioxide:</strong> Metabolic acidosis may be delayed</td> </tr> <tr> <td class=\"indent1\"><strong>Prolonged masseter muscle spasm after succinylcholine administration:</strong> Early sign of MH in many patients</td> </tr> <tr> <td class=\"indent1\"><strong>Generalized body muscle rigidity</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Tachypnea/tachycardia:</strong> Nonspecific</td> </tr> <tr> <td class=\"indent1\"><strong>Unexpected cardiac arrest in a young patient:</strong> Presume hyperkalemia and treat (see below); may be due to an occult myopathy</td> </tr> <tr> <td class=\"indent1\"><strong>Hyperthermia:</strong> Not usually one of the presenting findings</td> </tr> <tr> <td class=\"indent1\"><strong>Myoglobinuria:</strong> Brown urine, hemoglobin on dipstick without RBCs</td> </tr> <tr> <td class=\"subtitle1_single\">Acute treatment</td> </tr> <tr> <td class=\"indent1\"><strong>Call for help:</strong> Call for MH equipment and drug cart; notify the surgeon; complete surgical procedure as soon as feasible; call <span class=\"red\"><span style=\"color: black;\">MH Hotline: </span><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap; color: black;\">1-800-644-9737<a href=\"#\" title=\"Call: 1-800-644-9737\"><img alt=\"\" title=\"Call: 1-800-644-9737\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></span> (US); outside US: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-209-417-3722<a href=\"#\" title=\"Call: 1-209-417-3722\"><img alt=\"\" title=\"Call: 1-209-417-3722\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr> <td class=\"indent1\"><strong>Initiate support:</strong> Discontinue inhalational agents and succinylcholine; hyperventilate with 100% oxygen; use non-triggering agents for the remainder of the procedure; intubate with endotracheal tube</td> </tr> <tr> <td class=\"indent1\"><span class=\"red\"><strong><span style=\"color: black;\">Give dantrolene:</span></strong><span style=\"color: black;\"> Initial bolus dose 2.5 mg/kg&nbsp;IV rapid continuous push. Continue to administer dantrolene in 1-mg/kg increments until symptoms abate (ie, hypercarbia and/or rigidity resolve).</span></span> <ul class=\"decimal_heading\"> <li>Some formulations of dantrolene (eg, Dantrium and Revonto) contain 20 mg lyophilized dantrolene per vial and each vial requires reconstitution with <strong>60 mL</strong> sterile preservative-free (non-bacteriostatic) water; shake vial until solution is clear. </li> <li>A highly concentrated formulation of dantrolene (Ryanodex) is also available, which contains 250 mg per vial and each vial requires reconstitution with only <strong>5 mL</strong> sterile preservative-free (non-bacteriostatic) water, thus facilitating rapid treatment, especially in larger patients; shake vial until uniform orange-colored suspension is formed; do not further dilute or transfer to another container prior to administering. </li> <li>Example of dantrolene initial bolus of 2.5 mg/kg for a 72 kg patient: </li> </ul> <p class=\"indent3\">Using <strong>20 mg vials</strong> (Dantrium, Revonto): Immediately reconstitute nine 20 mg vials and administer 180 mg bolus (540 mL) in IV catheter with freely running 0.9% saline, or 5% dextrose in water followed by saline flush (use a large-bore IV if possible);</p> <p class=\"indent4\"><strong>-OR-</strong></p> <p class=\"indent3\">Using <strong>250 mg vials</strong> (Ryanodex): Immediately reconstitute one 250 mg vial and administer 180 mg bolus (3.6 mL) in IV catheter with freely running 0.9% saline or 5% dextrose in water followed by saline flush</p> <ul class=\"decimal_heading\"> <li>Watch for reversal of clinical signs (end tidal CO<sub>2</sub> should begin to normalize); repeat as needed. Cumulative total doses up to or exceeding 10 mg/kg may occasionally be required. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Get blood gas/labs:</strong> Venous gas (femoral) may be better than arterial gas to follow hypermetabolism</td> </tr> <tr> <td class=\"indent1\"><strong>Give bicarbonate for acidosis:</strong> Sodium bicarbonate 1 to 2 mEq/kg IV push over 5 to 10 minutes</td> </tr> <tr> <td class=\"indent1\"><strong>Cool the patient:</strong> Start when core temp &#62;39&#176;C; stop when core temp &#60;38&#176;C; cold saline for infusion; ice to body surface; lavage body cavities (eg, stomach, bladder, rectum)</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Treat hyperkalemia:</strong> Hyperventilate, stabilize cardiac membranes with calcium</td> </tr> <tr> <td class=\"indent2\"> <p><strong>Calcium chloride:</strong> Adults: 0.5 to 1 gram (5 to 10 mL of 10% solution) per dose; pediatric: 10 to 20 mg/kg (0.1 to 0.2 mL/kg 10% solution), maximum of 2 grams (20 mL) per dose; &nbsp;repeat after five minutes if ECG changes persist; </p> <p><strong>-OR-</strong></p> <strong>Calcium gluconate:</strong> Adult: 1.5 to 3 g IV (15 to 30 mL of 10% solution) per dose; pediatric: 60 to 100 mg/kg (0.6 to 1 mL/kg 10% solution), maximum of 3 grams (30 mL) per dose</td> </tr> <tr> <td class=\"indent2\"><strong>Sodium bicarbonate:</strong> 1 to 2 mEq/kg IV push over 5 to 10 minutes (maximum 100 mEq per dose); do not give sodium bicarbonate in the same line as calcium</td> </tr> <tr> <td class=\"indent2\"><strong>Insulin and dextrose:</strong> Adult: 10 units regular insulin IV push with 50 mL of 50% dextrose; pediatric: 0.1 units insulin/kg IV push with 0.5 grams/kg dextrose (eg, 1 mL/kg 50% dextrose or 2 mL/kg 25% dextrose); monitor fingerstick glucose closely</td> </tr> <tr> <td class=\"indent1\"><strong>Treat dysrhythmias:</strong> Dysrhythmias usually respond to treatment of acidosis and hyperkalemia; use standard ACLS protocols</td> </tr> <tr> <td class=\"subtitle1_single\">Ongoing care</td> </tr> <tr> <td><span class=\"red\"><strong><span style=\"color: black;\">Continue dantrolene:</span></strong></span> Once acute MH is under control, administer 1 mg/kg every four to six hours.&nbsp;Maintain dantrolene interval dosing for at least 24 hours; further dosing may be indicated. Protect dantrolene from light; once reconstituted, dantrolene is stable for six hours.</td> </tr> <tr> <td class=\"subtitle2_single\">Follow:</td> </tr> <tr> <td class=\"indent1\">Urine output: Maintain at 1 to 2 cc/kg/hour; insert Foley catheter if patient's consciousness is depressed</td> </tr> <tr> <td class=\"indent1\">Temperature: Maintain &#60;39&#176;C aggressively;&nbsp;be wary of hypothermia if temperature decreases below 38&#176;C&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Blood gas: Normalize pH; optimize pCO<sub>2</sub> and pO<sub>2</sub></td> </tr> <tr> <td class=\"indent1\">Electrolytes: Normalize</td> </tr> <tr> <td class=\"indent1\">Glucose: Check hourly and correct</td> </tr> <tr> <td class=\"indent1\">Creatine kinase: Check CK every 8 to 12 hours; alkalinize urine and increase flow &#62;1 to 2 mL/kg/hour if CK &#62;10,000 international units/L</td> </tr> <tr> <td class=\"indent1\">Coagulation parameters: Watch for disseminated intravascular coagulation (DIC), especially if hyperthermia is &#62;42&#176;C</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Dr. Ronald Litman with additional data from Managing an MH Crisis. The Malignant Hyperthermia Association of the United States website. Avaiable at: <a href=\"http://www.mhaus.org/healthcare-professionals/managing-a-crisis\" target=\"_blank\">http://www.mhaus.org/healthcare-professionals/managing-a-crisis</a>; and Dantrolene sodium US prescribing information available at <a href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/index.cfm</a> (both accessed December 4, 2014).</div><div id=\"graphicVersion\">Graphic 68918 Version 9.0</div></div></div>"},"68919":{"type":"graphic_figure","displayName":"End versus side pancreatic fistulas","title":"End versus side pancreatic fistulas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">End versus side pancreatic fistulas</div><div class=\"cntnt\"><img style=\"width:440px; height:522px;\" src=\"images/SURG/68919_End_vs_side_pancreatic_fistulas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic fistulas are characterized by their anatomic relationship to the pancreatic duct as either an end (A) or side (B) fistula. In an end fistula, continuity of the upstream secreting pancreas is completely lost to the remaining gastrointestinal tract by either disconnection or obstruction. End fistulas are unlikely to close without repair. A side pancreatic fistula can be treated with a pancreatic duct stent.</div><div id=\"graphicVersion\">Graphic 68919 Version 3.0</div></div></div>"},"68920":{"type":"graphic_picture","displayName":"PCLBCL-LT clinical presentation I","title":"Primary cutaneous diffuse large B-cell lymphoma, leg type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous diffuse large B-cell lymphoma, leg type</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/HEME/68920_PCLBCL_LT_clin_pres_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with localized skin tumors on the left leg. Most patients present with red or bluish nodules or tumors on one or both legs, preferentially the lower legs. Ten to 15 percent will develop outside of the lower extremities.</div><div id=\"graphicVersion\">Graphic 68920 Version 1.0</div></div></div>"},"68921":{"type":"graphic_figure","displayName":"Relative risks of major complications of CKD","title":"Relative risks of major complications of chronic kidney disease based upon categorical meta-analysis","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Relative risks of major complications of chronic kidney disease based upon categorical meta-analysis</div><div class=\"cntnt\"><img style=\"width:508px; height:804px;\" src=\"images/NEPH/68921_Summary_risks_categorical_ma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Summary of categorical meta-analysis (adjusted relative risk) for general population cohorts with ACR. Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. eGFR and albuminuria are expressed as categorical variables. All results are adjusted for covariates and compared with the Ref. Each cell represents a pooled RR from a meta-analysis; bold numbers indicate statistical significance at p&lt;0.05. Incidence rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for CVD mortality, 0.04 for kidney failure, 0.98 for AKI, and 2.02 for kidney disease progression. Absolute risk can be computed by multiplying the RRs in each cell by the incidence rate in the reference cell. Colors reflect the ranking of adjusted RR. The point estimates for each cell were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with rank numbers 1 through 8 are green; rank numbers 9 through 14 are yellow; rank numbers 15 through 21 are orange; and trank numbers 22 through 28 are colored red. (For the outcome of kidney disease progression, two cells with RR of 1.0 are also green, leaving fewer cells as orange.)</div><div class=\"graphic_footnotes\">RR: relative risk; ACR: albumin creatinine ratio; eGFR: estimated glomerular filtration rate; Ref: reference cell; ESRD: end-stage renal disease; AKI: acute kidney injury; CKD: chronic kidney disease; CVD: cardiovascular disease.<br />* Dipstick included (-, &plusmn;, +, &ge;++).</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; 80:17. Copyright &copy; 2010.</div><div id=\"graphicVersion\">Graphic 68921 Version 9.0</div></div></div>"},"68922":{"type":"graphic_diagnosticimage","displayName":"Crohns disease fistula US","title":"Crohn's disease fistula on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn's disease fistula on ultrasound</div><div class=\"cntnt\"><img style=\"width:382px; height:268px;\" src=\"images/GAST/68922_Crohns_disease_fistula_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">B-mode transabdominal ultrasound in a patient with Crohn's disease of the right colon showing a hypoechoic bowel wall thickening and transmural inflammatory reaction and blind ending fistula (mes) in direction to the abdominal wall (abd wall). The lumen (Lu) is not seen due to mucosal swelling.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 68922 Version 3.0</div></div></div>"},"68923":{"type":"graphic_figure","displayName":"Nervus intermedius","title":"Anatomy of nervus intermedius","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Anatomy of nervus intermedius</div><div class=\"cntnt\"><img style=\"width:544px; height:528px;\" src=\"images/NEURO/68923_Nervus_intermedius.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68923 Version 2.0</div></div></div>"},"68924":{"type":"graphic_figure","displayName":"Perinatal complications of maternal diabetic nephropathy","title":"Perinatal complications in infants born to mothers with diabetic nephropathy (2001 to 2012)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perinatal complications in infants born to mothers with diabetic nephropathy (2001 to 2012)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/68924_Perinatal_complicat_nephrop.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001; 24:1739.</li>&#xD;&#xA;    <li>Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr 2011; 5:137.</li>&#xD;&#xA;    <li>Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006; 19:513.</li>&#xD;&#xA;    <li>Yogev Y, Chen R, Ben-Haroush A, et al. Maternal overweight and pregnancy outcome in women with Type-1 diabetes mellitus and different degrees of nephropathy. J Matern Fetal Neonatal Med 2010; 23:999.</li>&#xD;&#xA;    <li>Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32:38.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 68924 Version 3.0</div></div></div>"},"68926":{"type":"graphic_figure","displayName":"Roux en Y gastric bypass PI","title":"Roux-en-Y gastric bypass (RYGB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Roux-en-Y gastric bypass (RYGB)</div><div class=\"cntnt\"><img style=\"width:422px; height:572px;\" src=\"images/PI/68926_Roux_en_Y_gastric_bypass_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows how the stomach will look after gastric bypass.</div><div id=\"graphicVersion\">Graphic 68926 Version 2.0</div></div></div>"},"68928":{"type":"graphic_picture","displayName":"Pierre Robin sequence","title":"Pierre Robin sequence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pierre Robin sequence</div><div class=\"cntnt\"><img style=\"width:504px; height:374px;\" src=\"images/PEDS/68928_Pierre_Robin_sequence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The small, undershot chin and mandible give a birdlike facial appearance. The resultant inspiratory ball valve airway obstruction caused by glossoptosis within these tiny jaw confines made tracheostomy necessary.<br />(B) Isolated cleft palate.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright ©2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68928 Version 3.0</div></div></div>"},"68930":{"type":"graphic_table","displayName":"Actions of cholecystokinin","title":"Actions of cholecystokinin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Actions of cholecystokinin</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Contracts the gallbladder</td>\n</tr>\n<tr>\n<td>Stimulates pancreatic enzyme secretion</td>\n</tr>\n<tr>\n<td>Delays gastric emptying</td>\n</tr>\n<tr>\n<td>Induces satiety</td>\n</tr>\n<tr>\n<td>Potentiates insulin secretion</td>\n</tr>\n<tr>\n<td>Regulates intestinal motility</td>\n</tr>\n<tr>\n<td>Neurotransmitter</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68930 Version 1.0</div></div></div>"},"68931":{"type":"graphic_diagnosticimage","displayName":"Large adenoma CT","title":"Large hepatic adenomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large hepatic adenomas</div><div class=\"cntnt\"><img style=\"width:324px; height:311px;\" src=\"images/GAST/68931_Large_adenoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This contrast enhanced CT scan demonstrates a large complex enhancing mass (X) in the left lobe of the liver displacing vessels (arrowheads). A smaller, low attenuation mass is also noted in the right lobe of the right lobe of the liver (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 68931 Version 5.0</div></div></div>"},"68932":{"type":"graphic_figure","displayName":"Enterotomy for metastatic CA","title":"Enterotomies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enterotomies</div><div class=\"cntnt\"><img style=\"width:354px; height:503px;\" src=\"images/OBGYN/68932_Enterotomy_for_metastatic_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 68932 Version 1.0</div></div></div>"},"68933":{"type":"graphic_picture","displayName":"Erythroid precursors marrow","title":"Erythroid precursors in the bone marrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythroid precursors in the bone marrow</div><div class=\"cntnt\"><img style=\"width:430px; height:288px;\" src=\"images/HEME/68933_Erythroid_precursors_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal bone marrow shows an erythropoietic island with a large proerythroblast (blue arrow) surrounded by basophilic (yellow arrow), polychromatophilic (red arrow), and orthochromic (black arrow) normoblasts.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68933 Version 2.0</div></div></div>"},"68934":{"type":"graphic_figure","displayName":"View of the carpal tunnel ","title":"View of the carpal tunnel ","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">View of the carpal tunnel </div><div class=\"cntnt\"><img style=\"width:516px; height:397px;\" src=\"images/SURG/68934_View_of_the_carpal_tunnel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">View of the carpal tunnel of the left hand. The median nerve and flexor tendons, which are in the tunnel, lie below the transverse carpal ligament that forms the roof of the tunnel.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68934 Version 2.0</div></div></div>"},"68935":{"type":"graphic_figure","displayName":"Anatomy of the ulnar nerve at the elbow","title":"Anatomy of the ulnar nerve at the elbow","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anatomy of the ulnar nerve at the elbow</div><div class=\"cntnt\"><img style=\"width:538px; height:429px;\" src=\"images/NEURO/68935_Anatomy-of-theulnar-nerve-at-the-ebow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the relationship between the ulnar nerve at the elbow and musculoskeletal anatomy. Note the position of the nerve relative to the medial epicondyle and the aponeurosis of the flexor carpi ulnaris which forms the roof of the true cubital tunnel.</div><div id=\"graphicVersion\">Graphic 68935 Version 1.0</div></div></div>"},"68936":{"type":"graphic_figure","displayName":"Mechanism of angulation of proximal phalangeal shaft fractures","title":"Mechanism of angulation of proximal phalangeal shaft fractures","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Mechanism of angulation of proximal phalangeal shaft fractures</div><div class=\"cntnt\"><img style=\"width:524px; height:236px;\" src=\"images/SURG/68936_Mech_angl_prox_shaft_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The deforming forces on a proximal phalanx fracture are the intrinsic tendons and the extrinsic extensor tendons. A proximal phalanx fracture will typically develop an apex volar angulation. The reduction of a proximal phalangeal fracture requires metacarpophalangeal joint (MCPJ) flexion and wrist extension along with axial traction.</div><div id=\"graphicVersion\">Graphic 68936 Version 4.0</div></div></div>"},"68937":{"type":"graphic_diagnosticimage","displayName":"Percutaneous drainage of pseudocyst","title":"Percutaneous drainage of pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Percutaneous drainage of pseudocyst</div><div class=\"cntnt\"><img style=\"width:583px; height:451px;\" src=\"images/SURG/68937_Percut_drainage_pseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial non-contrast CT scan of the upper abdomen demonstrates a pseudocyst in a patient with pancreatitis.<br />(B) Axial non-contrast CT scan of the upper abdomen demonstrates a pigtail catheter within the infected pseudocyst.<br />(C) Plain x-ray demonstrates the pigtail catheter in the left upper quadrant of the abdomen. Note the presence of an IVC filter just to the right of the spine.</div><div class=\"graphic_footnotes\">CT: computed tomography; IVC: inferior vena cava.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 68937 Version 3.0</div></div></div>"},"68938":{"type":"graphic_picture","displayName":"Dystrophic epidermolysis bullosa","title":"Dystrophic epidermolysis bullosa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dystrophic epidermolysis bullosa</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/68938_Dystrophic_epiderm_bullosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple bullae and erosions are present in this infant with dystrophic epidermolysis bullosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 68938 Version 1.0</div></div></div>"},"68939":{"type":"graphic_figure","displayName":"Distal clavicle fracture type I","title":"Distal clavicle fracture type I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distal clavicle fracture type I</div><div class=\"cntnt\"><img style=\"width:418px; height:410px;\" src=\"images/EM/68939_Clav_fx_dist_type1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts a type I fracture of the distal clavicle (group II). The intact ligaments hold the fragments in place.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood CA Jr, Green DP, Bucholz RW, Heckman JD (Eds). Rockwood and Green's Fractures in Adults, 4th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68939 Version 5.0</div></div></div>"},"68942":{"type":"graphic_picture","displayName":"Hereditary nephritis EM","title":"Hereditary nephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hereditary nephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:244px;\" src=\"images/NEPH/68942_Hereditary_nephritis_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph from a patient with hereditary nephritis (Alport's syndrome) shows the characteristic thickening, fraying, and laminations (arrow) of the glomerular basement membrane (GBM).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 68942 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"68944":{"type":"graphic_figure","displayName":"Ectopic ureter pathogenesis","title":"Embryology of a complete uretal duplication and ectopic ureter","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Embryology of a complete uretal duplication and ectopic ureter</div><div class=\"cntnt\"><img style=\"width:502px; height:698px;\" src=\"images/PEDS/68944_Ectopic_ureter_pathogenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic embryologic development of a complete duplex renal system with the formation of two ureteral buds. Note that the cranial ureteral bud drains the lower pole of the kidney and the caudal ureter bud the upper renal unit. In general, pathology occurs when the caudal ureteral bud inserts in an abnormal distal ectopic location in the bladder (ie, ectopic ureter) or caudal to the bladder causing upper pole ureteral obstruction. When the cranial ureter inserts abnormally, lower pole ureteral reflux can occur.</div><div id=\"graphicVersion\">Graphic 68944 Version 1.0</div></div></div>"},"68945":{"type":"graphic_diagnosticimage","displayName":"Parasternal long axis color flow Doppler II","title":"Parasternal long axis view with color flow Doppler mapping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis view with color flow Doppler mapping</div><div class=\"cntnt\"><img style=\"width:384px; height:285px;\" src=\"images/CARD/68945_Long_axis_color_flow_Dopp1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seen is the long axis parasternal view of the left ventricular outflow tract during systole; a normal color flow signal (red-orange) is seen in the left ventricular outflow tract. The occasional blue patches in the signal represent aliasing and suggest that the signal is at or exceeds the Nyquist limit.</div><div class=\"graphic_footnotes\">Ao: aorta; IVS: interventricular septum; LA: left atrium; LV: left ventricle; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 68945 Version 7.0</div></div></div>"},"68946":{"type":"graphic_table","displayName":"Heart in hypothyroidism","title":"Hypothyroidism and the heart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypothyroidism and the heart</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Parameter</td>\n\n      <td class=\"subtitle1\">Finding</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Systemic vascular resistance</td>\n\n      <td>Increased</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac output</td>\n\n      <td>Decreased</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"sublist1_start\">Blood pressure</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Systolic</td>\n\n      <td class=\"sublist_other\">Decreased or normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Diastolic</td>\n\n      <td class=\"sublist_other\">Increased or normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart rate</td>\n\n      <td>Decreased or normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac contractility</td>\n\n      <td>Decreased</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac mass</td>\n\n      <td>Decreased</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blood volume</td>\n\n      <td>Decreased</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ventricular arrhythmias</td>\n\n      <td>Can induce or worsen</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68946 Version 1.0</div></div></div>"},"68947":{"type":"graphic_picture","displayName":"Colostomy allergic contact","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/GAST/68947_Colostomy_allergic_contact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergic reactions can occur with any of the products used to protect the peristomal skin or to assure adhesion of the pouching system; allergic reactions are characterized by pruritus, erythema, and blistering in the area corresponding to contact with the offending agent.</div><div class=\"graphic_reference\">Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.</div><div id=\"graphicVersion\">Graphic 68947 Version 1.0</div></div></div>"},"68948":{"type":"graphic_figure","displayName":"Fibrinogen molecule schematic","title":"Schematic model of fibrinogen and fibrin","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Schematic model of fibrinogen and fibrin</div><div class=\"cntnt\"><img style=\"width:458px; height:397px;\" src=\"images/HEME/68948_Fibrinogen_molecule_schemat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrinogen consists of three pairs of polypeptide chains, Aα, Bβ, and γ. The amino-terminal regions of all six chains are joined in the central domain (E domain) by disulfide bonds and form a dimeric structure. The E domain contains the FPA and FPB sequences that are cleaved by thrombin (factor IIa). Carbohydrate groups (O) are located at one site on each of the&nbsp;γ and Bβ chains. Thrombin-catalyzed conversion of fibrinogen to fibrin involves release of FPA and FPB. A nonsubstrate (\"secondary\") binding site for thrombin is present in the E domain of a,β-fibrin, and depends largely, if not entirely, on the presence of the b15-42 sequence. The binding sites for thrombin, t-PA, factor XIII, and α2-PI are indicated on the fibrinogen or fibrin molecule. The regions in the fibrinogen/fibrin molecule containing the platelet-binding HHLGGAKQAGDV or RGD sequences are indicated by the arrowheads.</div><div class=\"graphic_footnotes\">FPA: fibrinopeptides A; FPB: fibrinopeptides B; α2-PI: alpha 2 plasmin inhibitor; t-PA: tissue plasminogen activator.</div><div class=\"graphic_reference\">Reproduced with permission from: Mosesson, MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:179. Copyright © 1992 Elsevier.</div><div id=\"graphicVersion\">Graphic 68948 Version 2.0</div></div></div>"},"68949":{"type":"graphic_picture","displayName":"Platelet clumping in EDTA","title":"Pseudothrombocytopenia due to platelet clumping in EDTA","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudothrombocytopenia due to platelet clumping in EDTA</div><div class=\"cntnt\"><img style=\"width:430px; height:288px;\" src=\"images/HEME/68949_PlateletclumpinginEDTA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This peripheral blood smear shows platelet clumping (arrows) in an EDTA-anticoagulated blood sample. This patient had an EDTA-dependent platelet agglutinin which caused in vitro platelet clumping, resulting in an artifactually low platelet count (ie, &quot;pseudothrombocytopenia&quot;). No platelet clumping was seen, and the platelet count was normal, in a blood sample from this patient anticoagulated with sodium citrate.</div><div class=\"graphic_footnotes\">EDTA: ethylenediaminetetraacetic acid.</div><div class=\"graphic_reference\">Reproduced with permission from Beutler, E, Lichtman, MA, Coller, BS, et al, Hematology, 5<SUP>th</SUP> ed, McGraw-Hill, New York, 1995.</div><div id=\"graphicVersion\">Graphic 68949 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"68950":{"type":"graphic_figure","displayName":"Outcome beta blocker amiodarone","title":"Beta blocker plus amiodarone improves survival after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Beta blocker plus amiodarone improves survival after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:502px; height:313px;\" src=\"images/CARD/68950_Outcome_beta_blocker_amioda.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pooled analysis of patients in the EMIAT and CAMIAT trials shows that all-cause mortality after a myocardial infarction is lower with a combination of amiodarone and a beta blocker compared with beta blocker alone or no beta blocker with or without amiodarone.</div><div class=\"graphic_reference\">Data from Boutitie F, Boissel JP, Connolly SJ, et al. Circulation 1999; 99:2268.</div><div id=\"graphicVersion\">Graphic 68950 Version 2.0</div></div></div>"},"68952":{"type":"graphic_figure","displayName":"Endovascular repair of popliteal artery aneurysm","title":"Endovascular repair of popliteal artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Endovascular repair of popliteal artery aneurysm</div><div class=\"cntnt\"><img style=\"width:465px; height:536px;\" src=\"images/SURG/68952_Pop_repair_stent.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68952 Version 2.0</div></div></div>"},"68953":{"type":"graphic_table","displayName":"Randomized trials of novel agents in advanced pancreatic NETs","title":"Randomized trials of molecularly targeted agents in advanced pancreatic neuroendocrine tumors (NETs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials of molecularly targeted agents in advanced pancreatic neuroendocrine tumors (NETs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Tumor response rate<br /> (percent)</td> <td class=\"subtitle1\">Median TTP or PFS<br /> (months)</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>Sunitinib</td> <td class=\"centered\">86</td> <td class=\"centered\">9</td> <td class=\"centered\">11.4</td> <td class=\"divider_bottom\" rowspan=\"3\">Raymond et al, 2011</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">versus</td> </tr> <tr class=\"divider_bottom\"> <td>Placebo</td> <td class=\"centered\">85</td> <td class=\"centered\">0</td> <td class=\"centered\">5.5</td> </tr> <tr> <td>Everolimus</td> <td class=\"centered\">207</td> <td class=\"centered\">5</td> <td class=\"centered\">11</td> <td class=\"divider_bottom\" rowspan=\"3\">Yao et al, 2011 (RADIANT-3)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">versus</td> </tr> <tr class=\"divider_bottom\"> <td>Placebo</td> <td class=\"centered\">203</td> <td class=\"centered\">2</td> <td class=\"centered\">4.6</td> </tr> <tr> <td>Everolimus</td> <td class=\"centered\">75</td> <td class=\"centered\">12</td> <td class=\"centered\">14</td> <td rowspan=\"3\">Kulke et al, 2015 (Alliance)</td> </tr> <tr> <td class=\"sublist1\" colspan=\"4\">versus</td> </tr> <tr> <td>Everolimus + Bevacizumab</td> <td class=\"centered\">75</td> <td class=\"centered\">31</td> <td class=\"centered\">16.7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFS: progression-free survival; TTP: time to progression.</div><div id=\"graphicVersion\">Graphic 68953 Version 6.0</div></div></div>"},"68954":{"type":"graphic_figure","displayName":"Relationship of medication errors and adverse drug events","title":"Relationship among medication errors, adverse drug events, preventable adverse drug events, close-call adverse drug events, and adverse drug reactions","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Relationship among medication errors, adverse drug events, preventable adverse drug events, close-call adverse drug events, and adverse drug reactions</div><div class=\"cntnt\"><img style=\"width:520px; height:314px;\" src=\"images/PC/68954_Relationshipmederrors.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Gandhi TK, Seger DL, Bates DW. Identifying drug safety issues: from research to practice. Int J Qual Health Care 2000; 12:69, by permission of Oxford University Press. Copyright © 2000.</div><div id=\"graphicVersion\">Graphic 68954 Version 10.0</div></div></div>"},"68956":{"type":"graphic_figure","displayName":"Cardiac risk increases with the number of risk factors","title":"Incidence of major cardiac complications increases with the number of risk factors","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Incidence of major cardiac complications increases with the number of risk factors</div><div class=\"cntnt\"><img style=\"width:523px; height:273px;\" src=\"images/CARD/68956_Cardiac_risk_index_major_ev.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 4513 patients, the incidence of a major cardiac complication increases with a higher cardiac risk index (1 to 4), which is based upon six independent predictors, including high-risk type of surgery, history of ischemic heart disease, history of heart failure, history of cerebrovascular disease, preoperative treatment with insulin, and preoperative serum creatinine &gt;2.0 mg/dL (177 mol/L). By definition, patients undergoing abdominal aortic aneurysm (AAA), thoracic, and abdominal procedures were excluded from class I. In all subsets, except patients undergoing AAA, there was a statistically significant trend toward greater risk with higher risk class.</div><div class=\"graphic_reference\">Data from Lee TH, Marcantonio ER, Mangione CM, et al. Circulation 1999; 100:1043.</div><div id=\"graphicVersion\">Graphic 68956 Version 4.0</div></div></div>"},"68962":{"type":"graphic_figure","displayName":"Glucose metabolism","title":"Glucose metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glucose metabolism</div><div class=\"cntnt\"><img style=\"width:296px; height:330px;\" src=\"images/ENDO/68962_Glycogen_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the major regulatory steps in hepatic gluconeogenesis (arrows that point upward) and glycolysis (arrows that point downward). The circles with positive or negative signs represent the reactions that are stimulated or inhibited by glucagon. Glucagon promotes gluconeogenesis and blocks glycolysis by decreasing the activity of phosphofructokinase (PFK) and pyruvate kinase (PK). The sites of entry of the gluconeogenetic precursors&nbsp;(glycerol, alanine, and lactate) are shown. Muscle cells lack glucose-6-phosphatase (G6Pase); they can therefore use glycogen for energy but cannot convert it to glucose for release into the systemic circulation. In pancreatic beta cells, glucokinase (GK) acts as the glucose sensor that regulates insulin release.</div><div id=\"graphicVersion\">Graphic 68962 Version 3.0</div></div></div>"},"68963":{"type":"graphic_table","displayName":"Gastrointestinal peptides used in clinical practice","title":"Gastrointestinal peptides used in clinical practice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastrointestinal peptides used in clinical practice</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Peptide</td> <td class=\"subtitle1\">Clinical utility</td> </tr> <tr> <td rowspan=\"7\">Somatostatin</td> <td>Gastrointestinal hormone secreting tumors</td> </tr> <tr> <td>Diagnostic radiology</td> </tr> <tr> <td>Variceal hemorrhage</td> </tr> <tr> <td>Bleeding ulcers</td> </tr> <tr> <td>HIV-associated diarrhea</td> </tr> <tr> <td>Other chronic diarrheal syndromes</td> </tr> <tr> <td>Reducing fistula output</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Secretin</td> <td>Diagnosis of Zollinger-Ellison syndrome</td> </tr> <tr> <td>Diagnostic radiology</td> </tr> <tr> <td>Pancreatic function testing</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Cholecystokinin</td> <td>Diagnostic radiology (biliary scintigraphy)</td> </tr> <tr> <td>Pancreatic function testing</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Glucagon</td> <td>Therapeutic endoscopy</td> </tr> <tr> <td>Diagnostic radiology</td> </tr> <tr> <td>Treatment of severe hypoglycemia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Pentagastrin</td> <td>Quantitation of gastric acid output</td> </tr> <tr> <td>Diagnosis and monitoring of medullary thyroid cancer</td> </tr> <tr> <td>Diagnosis of carcinoid syndrome</td> </tr> <tr class=\"divider_top\"> <td>GLP-1-like agents</td> <td>Treatment of diabetes mellitus</td> </tr> <tr class=\"divider_top\"> <td>Motilin-like agents</td> <td>Treatment of gastroparesis, dysmotility</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=17524&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; GLP: glucagon-like peptides.</div><div id=\"graphicVersion\">Graphic 68963 Version 5.0</div></div></div>"},"68964":{"type":"graphic_figure","displayName":"Long term outcome streptokinase","title":"Benefit from streptokinase persists for 10 years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit from streptokinase persists for 10 years</div><div class=\"cntnt\"><img style=\"width:375px; height:264px;\" src=\"images/CARD/68964_Long_term_outcome_streptoki.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among patients entered into GISSI-1 who were treated within one hour of symptoms of a myocardial infarction and were discharged alive, life-table estimates show that the 10-year survival of patients allocated to streptokinase was greater compared to the control group. Most of the survival benefit was seen early, due to the reduction in in-hospital mortality; there was an insignificant trend toward further benefit after discharge.</div><div class=\"graphic_reference\">Data from Franzosi MG, Santoro E, De Vita C, et al. Circulation 1998; 98:2659.</div><div id=\"graphicVersion\">Graphic 68964 Version 2.0</div></div></div>"},"68967":{"type":"graphic_diagnosticimage","displayName":"Spigelian hernia imaging","title":"Spigelian hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spigelian hernia</div><div class=\"cntnt\"><img style=\"width:398px; height:352px;\" src=\"images/SURG/68967_Spigelian_hernia_imaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel is trapped in the hernia sac (arrow), which arises along the left semilunar line.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 68967 Version 2.0</div></div></div>"},"68968":{"type":"graphic_picture","displayName":"EVAR with flared limb into the common iliac artery","title":"EVAR with flared limb into the common iliac artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">EVAR with flared limb into the common iliac artery</div><div class=\"cntnt\"><img style=\"width:228px; height:355px;\" src=\"images/SURG/68968_EVAR_flared_limb.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 68968 Version 1.0</div></div></div>"},"68969":{"type":"graphic_picture","displayName":"Juvenile spring eruption 2","title":"Juvenile spring eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile spring eruption</div><div class=\"cntnt\"><img style=\"width:396px; height:409px;\" src=\"images/DERM/68969_Juvenile_spring_eruption_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and vesicles are present on the ear of this young girl with juvenile spring eruption.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 68969 Version 5.0</div></div></div>"},"68970":{"type":"graphic_figure","displayName":"Shigella in epthelial cells","title":"Diagram of Shigella spread in the epithelium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of Shigella spread in the epithelium</div><div class=\"cntnt\"><img style=\"width:339px; height:352px;\" src=\"images/ID/68970_Shigella_in_epthelial_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of intracellular movement and spread of Shigella in epithelium. Step 1: Soon after uptake by induced phagocytosis, the bacterium lyses the phagocytic vacuole, thereby releasing it into the host cell cytosol. Step 2: Short filaments of host cell actin (brown thick lines) then organize into a tight bundle that forms a tail several microns in length behind the bacterial body. Step 3: The bacterium uses this tail to motor both its movement through the cytosol and its passage into protrusions from the cell surface; the bacterium-containing protrusions can extend several bacterial lengths away from the cell surface, with the bacterium at the tip. Step 4: The bacterium-containing protrusion tips are endocytosed by adjacent cells, thereby transferring the bacterium into the adjacent cell. Step 5: Once endocytosed within the adjacent cell, the bacterium lyses the membranes that surround it, freeing itself into the cytosol of that cell.</div><div class=\"graphic_reference\">Redrawn from Goldberg MB, Sansonetti PJ. Infect Immun 1993; 61:4941.</div><div id=\"graphicVersion\">Graphic 68970 Version 2.0</div></div></div>"},"68971":{"type":"graphic_figure","displayName":"The orbital septum","title":"The orbital septum","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">The orbital septum</div><div class=\"cntnt\"><img style=\"width:490px; height:491px;\" src=\"images/ID/68971_The_orbital_septum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the proximity of the periosteum in relation to the orbital septum. Orbital cellulitis arises posterior to the orbital septum.</div><div id=\"graphicVersion\">Graphic 68971 Version 4.0</div></div></div>"},"68974":{"type":"graphic_table","displayName":"Unified Parkinson Disease Rating Scale","title":"Unified Parkinson Disease Rating Scale (UPDRS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unified Parkinson Disease Rating Scale (UPDRS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">The UPDRS is a rating tool to follow the longitudinal course of Parkinson disease. It is made up of the following sections:</td> </tr> <tr> <td class=\"sublist1\">I. Mentation, behavior, and mood</td> </tr> <tr> <td class=\"sublist1\">II. Activities of daily living</td> </tr> <tr> <td class=\"sublist1\">III. Motor</td> </tr> <tr> <td>These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. A score of 199 represents the worst (total) disability, while 0 represents no disability.</td> </tr> <tr> <td class=\"subtitle1_single\">I. Mentation, behavior, and mood</td> </tr> <tr> <td class=\"subtitle2_single\">1. Intellectual impairment</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.</td> </tr> <tr> <td class=\"indent1\">2 = Moderate memory loss, with disorientation and moderate difficulty handling complex problems. Mild but definite impairment of function at home with need of occasional prompting.</td> </tr> <tr> <td class=\"indent1\">3 = Severe memory loss with disorientation for time and often to place. Severe impairment in handling problems.</td> </tr> <tr> <td class=\"indent1\">4 = Severe memory loss with orientation preserved to person only. Unable to make judgments or solve problems. Requires much help with personal care. Cannot be left alone at all.</td> </tr> <tr> <td class=\"subtitle2_single\">2. Thought disorder (due to dementia or drug intoxication)</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Vivid dreaming.</td> </tr> <tr> <td class=\"indent1\">2 = \"Benign\" hallucinations with insight retained.</td> </tr> <tr> <td class=\"indent1\">3 = Occasional to frequent hallucinations or delusions; without insight; could interfere with daily activities.</td> </tr> <tr> <td class=\"indent1\">4 = Persistent hallucinations, delusions, or florid psychosis. Not able to care for self.</td> </tr> <tr> <td class=\"subtitle2_single\">3. Depression</td> </tr> <tr> <td class=\"indent1\">1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks.</td> </tr> <tr> <td class=\"indent1\">2 = Sustained depression (one week or more).</td> </tr> <tr> <td class=\"indent1\">3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of interest).</td> </tr> <tr> <td class=\"indent1\">4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent.</td> </tr> <tr> <td class=\"subtitle2_single\">4. Motivation/initiative</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Less assertive than usual; more passive.</td> </tr> <tr> <td class=\"indent1\">2 = Loss of initiative or disinterest in elective (nonroutine) activities.</td> </tr> <tr> <td class=\"indent1\">3 = Loss of initiative or disinterest in day to day (routine) activities.</td> </tr> <tr> <td class=\"indent1\">4 = Withdrawn, complete loss of motivation.</td> </tr> <tr> <td class=\"subtitle1_single\">II. Activities of daily living (for both \"on\" and \"off\")</td> </tr> <tr> <td class=\"subtitle2_single\">5. Speech</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mildly affected. No difficulty being understood.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately affected. Sometimes asked to repeat statements.</td> </tr> <tr> <td class=\"indent1\">3 = Severely affected. Frequently asked to repeat statements.</td> </tr> <tr> <td class=\"indent1\">4 = Unintelligible most of the time.</td> </tr> <tr> <td class=\"subtitle2_single\">6. Salivation</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Slight but definite excess of saliva in mouth; may have nighttime drooling.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately excessive saliva; may have minimal drooling.</td> </tr> <tr> <td class=\"indent1\">3 = Marked excess of saliva with some drooling.</td> </tr> <tr> <td class=\"indent1\">4 = Marked drooling, requires constant tissue or handkerchief.</td> </tr> <tr> <td class=\"subtitle2_single\">7. Swallowing</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Rare choking.</td> </tr> <tr> <td class=\"indent1\">2 = Occasional choking.</td> </tr> <tr> <td class=\"indent1\">3 = Requires soft food.</td> </tr> <tr> <td class=\"indent1\">4 = Requires NG tube or gastrotomy feeding.</td> </tr> <tr> <td class=\"subtitle2_single\">8. Handwriting</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Slightly slow or small.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately slow or small; all words are legible.</td> </tr> <tr> <td class=\"indent1\">3 = Severely affected; not all words are legible.</td> </tr> <tr> <td class=\"indent1\">4 = The majority of words are not legible.</td> </tr> <tr> <td class=\"subtitle2_single\">9. Cutting food and handling utensils</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Somewhat slow and clumsy, but no help needed.</td> </tr> <tr> <td class=\"indent1\">2 = Can cut most foods, although clumsy and slow; some help needed.</td> </tr> <tr> <td class=\"indent1\">3 = Food must be cut by someone, but can still feed slowly.</td> </tr> <tr> <td class=\"indent1\">4 = Needs to be fed.</td> </tr> <tr> <td class=\"subtitle2_single\">10. Dressing</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Somewhat slow, but no help needed.</td> </tr> <tr> <td class=\"indent1\">2 = Occasional assistance with buttoning, getting arms in sleeves.</td> </tr> <tr> <td class=\"indent1\">3 = Considerable help required, but can do some things alone.</td> </tr> <tr> <td class=\"indent1\">4 = Helpless.</td> </tr> <tr> <td class=\"subtitle2_single\">11. Hygiene</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Somewhat slow, but no help needed.</td> </tr> <tr> <td class=\"indent1\">2 = Needs help to shower or bathe; or very slow in hygienic care.</td> </tr> <tr> <td class=\"indent1\">3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom.</td> </tr> <tr> <td class=\"indent1\">4 = Foley catheter or other mechanical aids.</td> </tr> <tr> <td class=\"subtitle2_single\">12. Turning in bed and adjusting bed clothes</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Somewhat slow and clumsy, but no help needed.</td> </tr> <tr> <td class=\"indent1\">2 = Can turn alone or adjust sheets, but with great difficulty.</td> </tr> <tr> <td class=\"indent1\">3 = Can initiate, but not turn or adjust sheets alone.</td> </tr> <tr> <td class=\"indent1\">4 = Helpless.</td> </tr> <tr> <td class=\"subtitle2_single\">13. Falling (unrelated to freezing)</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Rare falling.</td> </tr> <tr> <td class=\"indent1\">2 = Occasionally falls, less than once per day.</td> </tr> <tr> <td class=\"indent1\">3 = Falls an average of once daily.</td> </tr> <tr> <td class=\"indent1\">4 = Falls more than once daily.</td> </tr> <tr> <td class=\"subtitle2_single\">14. Freezing when walking</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Rare freezing when walking; may have start hesitation.</td> </tr> <tr> <td class=\"indent1\">2 = Occasional freezing when walking.</td> </tr> <tr> <td class=\"indent1\">3 = Frequent freezing. Occasionally falls from freezing.</td> </tr> <tr> <td class=\"indent1\">4 = Frequent falls from freezing.</td> </tr> <tr> <td class=\"subtitle2_single\">15. Walking</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mild difficulty. May not swing arms or may tend to drag leg.</td> </tr> <tr> <td class=\"indent1\">2 = Moderate difficulty, but requires little or no assistance.</td> </tr> <tr> <td class=\"indent1\">3 = Severe disturbance of walking, requiring assistance.</td> </tr> <tr> <td class=\"indent1\">4 = Cannot walk at all, even with assistance.</td> </tr> <tr> <td class=\"subtitle2_single\">16. Tremor (symptomatic complaint of tremor in any part of body)</td> </tr> <tr> <td class=\"indent1\">0 = Absent.</td> </tr> <tr> <td class=\"indent1\">1 = Slight and infrequently present.</td> </tr> <tr> <td class=\"indent1\">2 = Moderate; bothersome to patient.</td> </tr> <tr> <td class=\"indent1\">3 = Severe; interferes with many activities.</td> </tr> <tr> <td class=\"indent1\">4 = Marked; interferes with most activities.</td> </tr> <tr> <td class=\"subtitle2_single\">17. Sensory complaints related to parkinsonism</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Occasionally has numbness, tingling, or mild aching.</td> </tr> <tr> <td class=\"indent1\">2 = Frequently has numbness, tingling, or aching; not distressing.</td> </tr> <tr> <td class=\"indent1\">3 = Frequent painful sensations.</td> </tr> <tr> <td class=\"indent1\">4 = Excruciating pain.</td> </tr> <tr> <td class=\"subtitle1_single\">III. Motor examination</td> </tr> <tr> <td class=\"subtitle2_single\">18. Speech</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Slight loss of expression, diction and/or volume.</td> </tr> <tr> <td class=\"indent1\">2 = Monotone, slurred but understandable; moderately impaired.</td> </tr> <tr> <td class=\"indent1\">3 = Marked impairment, difficult to understand.</td> </tr> <tr> <td class=\"indent1\">4 = Unintelligible.</td> </tr> <tr> <td class=\"subtitle2_single\">19. Facial expression</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Minimal hypomimia, could be normal \"Poker Face\".</td> </tr> <tr> <td class=\"indent1\">2 = Slight but definitely abnormal diminution of facial expression.</td> </tr> <tr> <td class=\"indent1\">3 = Moderate hypomimia; lips parted some of the time.</td> </tr> <tr> <td class=\"indent1\">4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 1/4 inch or more.</td> </tr> <tr> <td class=\"subtitle2_single\">20. Tremor at rest (head, upper and lower extremities)</td> </tr> <tr> <td class=\"indent1\">0 = Absent.</td> </tr> <tr> <td class=\"indent1\">1 = Slight and infrequently present.</td> </tr> <tr> <td class=\"indent1\">2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently present.</td> </tr> <tr> <td class=\"indent1\">3 = Moderate in amplitude and present most of the time.</td> </tr> <tr> <td class=\"indent1\">4 = Marked in amplitude and present most of the time.</td> </tr> <tr> <td class=\"subtitle2_single\">21. Action or postural tremor of hands</td> </tr> <tr> <td class=\"indent1\">0 = Absent.</td> </tr> <tr> <td class=\"indent1\">1 = Slight; present with action.</td> </tr> <tr> <td class=\"indent1\">2 = Moderate in amplitude, present with action.</td> </tr> <tr> <td class=\"indent1\">3 = Moderate in amplitude with posture holding as well as action.</td> </tr> <tr> <td class=\"indent1\">4 = Marked in amplitude; interferes with feeding.</td> </tr> <tr> <td class=\"subtitle2_single\">22. Rigidity (judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be ignored).</td> </tr> <tr> <td class=\"indent1\">0 = Absent.</td> </tr> <tr> <td class=\"indent1\">1 = Slight or detectable only when activated by mirror or other movements.</td> </tr> <tr> <td class=\"indent1\">2 = Mild to moderate.</td> </tr> <tr> <td class=\"indent1\">3 = Marked, but full range of motion easily achieved.</td> </tr> <tr> <td class=\"indent1\">4 = Severe, range of motion achieved with difficulty.</td> </tr> <tr> <td class=\"subtitle2_single\">23. Finger taps (patient taps thumb with index finger in rapid succession)</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mild slowing and/or reduction in amplitude.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.</td> </tr> <tr> <td class=\"indent1\">3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.</td> </tr> <tr> <td class=\"indent1\">4 = Can barely perform the task.</td> </tr> <tr> <td class=\"subtitle2_single\">24. Hand movements (patient opens and closes hands in rapid succession)</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mild slowing and/or reduction in amplitude.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.</td> </tr> <tr> <td class=\"indent1\">3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.</td> </tr> <tr> <td class=\"indent1\">4 = Can barely perform the task.</td> </tr> <tr> <td class=\"subtitle2_single\">25. Rapid alternating movements of hands (pronation-supination movements of hands, vertically and horizontally, with as large an amplitude as possible, both hands simultaneously)</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mild slowing and/or reduction in amplitude.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.</td> </tr> <tr> <td class=\"indent1\">3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.</td> </tr> <tr> <td class=\"indent1\">4 = Can barely perform the task.</td> </tr> <tr> <td class=\"subtitle2_single\">26. Leg agility (patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should be at least 3 inches).</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Mild slowing and/or reduction in amplitude.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement.</td> </tr> <tr> <td class=\"indent1\">3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing movement.</td> </tr> <tr> <td class=\"indent1\">4 = Can barely perform the task.</td> </tr> <tr> <td class=\"subtitle2_single\">27. Arising from chair (patient attempts to rise from a straight-backed chair, with arms folded across chest)</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Slow; or may need more than one attempt.</td> </tr> <tr> <td class=\"indent1\">2 = Pushes self up from arms of seat.</td> </tr> <tr> <td class=\"indent1\">3 = Tends to fall back and may have to try more than one time, but can get up without help.</td> </tr> <tr> <td class=\"indent1\">4 = Unable to arise without help.</td> </tr> <tr> <td class=\"subtitle2_single\">28. Posture</td> </tr> <tr> <td class=\"indent1\">0 = Normal erect.</td> </tr> <tr> <td class=\"indent1\">1 = Not quite erect, slightly stooped posture; could be normal for older person.</td> </tr> <tr> <td class=\"indent1\">2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.</td> </tr> <tr> <td class=\"indent1\">3 = Severely stooped posture with kyphosis; can be moderately leaning to one side.</td> </tr> <tr> <td class=\"indent1\">4 = Marked flexion with extreme abnormality of posture.</td> </tr> <tr> <td class=\"subtitle2_single\">29. Gait</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or propulsion.</td> </tr> <tr> <td class=\"indent1\">2 = Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion.</td> </tr> <tr> <td class=\"indent1\">3 = Severe disturbance of gait, requiring assistance.</td> </tr> <tr> <td class=\"indent1\">4 = Cannot walk at all, even with assistance.</td> </tr> <tr> <td class=\"subtitle2_single\">30. Postural stability (response to sudden, strong posterior displacement produced by pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is prepared).</td> </tr> <tr> <td class=\"indent1\">0 = Normal.</td> </tr> <tr> <td class=\"indent1\">1 = Retropulsion, but recovers unaided.</td> </tr> <tr> <td class=\"indent1\">2 = Absence of postural response; would fall if not caught by examiner.</td> </tr> <tr> <td class=\"indent1\">3 = Very unstable, tends to lose balance spontaneously.</td> </tr> <tr> <td class=\"indent1\">4 = Unable to stand without assistance.</td> </tr> <tr> <td class=\"subtitle2_single\">31. Body bradykinesia and hypokinesia (combining slowness, hesitancy, decreased arm swing, small amplitude, and poverty of movement in general)</td> </tr> <tr> <td class=\"indent1\">0 = None.</td> </tr> <tr> <td class=\"indent1\">1 = Minimal slowness, giving movement a deliberate character; could be normal for some persons. Possibly reduced amplitude.</td> </tr> <tr> <td class=\"indent1\">2 = Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some reduced amplitude.</td> </tr> <tr> <td class=\"indent1\">3 = Moderate slowness, poverty or small amplitude of movement.</td> </tr> <tr> <td class=\"indent1\">4 = Marked slowness, poverty or small amplitude of movement.</td> </tr> <tr> <td class=\"subtitle1_single\">IV. Complications of therapy (in the past week)</td> </tr> <tr> <td class=\"subtitle2_single\">1. Dyskinesias</td> </tr> <tr> <td class=\"subtitle3_single\">32. Duration: what proportion of the waking day are dyskinesias present? (Historical information.)</td> </tr> <tr> <td class=\"indent2\">0 = None.</td> </tr> <tr> <td class=\"indent2\">1 = 1-25% of day.</td> </tr> <tr> <td class=\"indent2\">2 = 26-50% of day.</td> </tr> <tr> <td class=\"indent2\">3 = 51-75% of day.</td> </tr> <tr> <td class=\"indent2\">4 = 76-100% of day.</td> </tr> <tr> <td class=\"subtitle3_single\">33. Disability: How disabling are the dyskinesias? (Historical information; may be modified by office examination.)</td> </tr> <tr> <td class=\"indent2\">0 = Not disabling.</td> </tr> <tr> <td class=\"indent2\">1 = Mildly disabling.</td> </tr> <tr> <td class=\"indent2\">2 = Moderately disabling.</td> </tr> <tr> <td class=\"indent2\">3 = Severely disabling.</td> </tr> <tr> <td class=\"indent2\">4 = Completely disabled.</td> </tr> <tr> <td class=\"subtitle3_single\">34. Painful dyskinesias: How painful are the dyskinesias?</td> </tr> <tr> <td class=\"indent2\">0 = No painful dyskinesias.</td> </tr> <tr> <td class=\"indent2\">1 = Slight.</td> </tr> <tr> <td class=\"indent2\">2 = Moderate.</td> </tr> <tr> <td class=\"indent2\">3 = Severe.</td> </tr> <tr> <td class=\"indent2\">4 = Marked.</td> </tr> <tr> <td class=\"subtitle3_single\">35. Presence of early morning dystonia. (Historical information.)</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle2_single\">2. Clinical fluctuations</td> </tr> <tr> <td class=\"subtitle3_single\">36. Are \"off\" periods predictable?</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle3_single\">37. Are \"off\" periods unpredictable?</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle3_single\">38. Do \"off\" periods come on suddenly, within a few seconds?</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle3_single\">39. What proportion of the waking day is the patient \"off\" on average?</td> </tr> <tr> <td class=\"indent2\">0 = None.</td> </tr> <tr> <td class=\"indent2\">1 = 1-25% of day.</td> </tr> <tr> <td class=\"indent2\">2 = 26-50% of day.</td> </tr> <tr> <td class=\"indent2\">3 = 51-75% of day.</td> </tr> <tr> <td class=\"indent2\">4 = 76-100% of day.</td> </tr> <tr> <td class=\"subtitle2_single\">3. Other complications</td> </tr> <tr> <td class=\"subtitle3_single\">40. Does the patient have anorexia, nausea, or vomiting?</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle3_single\">41. Any sleep disturbances, such as insomnia or hypersomnolence?</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle3_single\">42. Does the patient have symptomatic orthostasis? (Record the patient's blood pressure, height, and weight on the scoring form).</td> </tr> <tr> <td class=\"indent2\">0 = No.</td> </tr> <tr> <td class=\"indent2\">1 = Yes.</td> </tr> <tr> <td class=\"subtitle1_single\">V. Modified Hoehn and Yahr staging</td> </tr> <tr> <td>STAGE 0 = No signs of disease.</td> </tr> <tr> <td>STAGE 1 = Unilateral disease.</td> </tr> <tr> <td>STAGE 1.5 = Unilateral plus axial involvement.</td> </tr> <tr> <td>STAGE 2 = Bilateral disease, without impairment of balance.</td> </tr> <tr> <td>STAGE 2.5 = Mild bilateral disease, with recovery on pull test.</td> </tr> <tr> <td>STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically independent.</td> </tr> <tr> <td>STAGE 4 = Severe disability; still able to walk or stand unassisted.</td> </tr> <tr> <td>STAGE 5 = Wheelchair bound or bedridden unless aided.</td> </tr> <tr> <td class=\"subtitle1_single\">VI. Schwab and England Activities of Daily Living Scale</td> </tr> <tr> <td>100% = Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal. Unaware of any difficulty.</td> </tr> <tr> <td>90% = Completely independent. Able to do all chores with some degree of slowness, difficulty and impairment. Might take twice as long. Beginning to be aware of difficulty.</td> </tr> <tr> <td>80% = Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness.</td> </tr> <tr> <td>70% = Not completely independent. More difficulty with some chores. Three to four times as long in some. Must spend a large part of the day with chores.</td> </tr> <tr> <td>60% = Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; some impossible.</td> </tr> <tr> <td>50% = More dependent. Help with half, slower, etc. Difficulty with everything.</td> </tr> <tr> <td>40% = Very dependent. Can assist with all chores but few alone.</td> </tr> <tr> <td>30% = With effort, now and then does a few chores alone or begins alone. Much help needed.</td> </tr> <tr> <td>20% = Nothing alone. Can be a slight help with some chores. Severe invalid.</td> </tr> <tr> <td>10% = Totally dependent, helpless. Complete invalid.</td> </tr> <tr> <td>0% = Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Fahn S, Elton R, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale In: Recent Developments in Parkinson's Disease, Fahn S, Marsden CD, Calne DB, Goldstein M (Eds), Vol 2, Macmillan Health Care Information, Florham Park, NJ 1987. p. 153.</div><div id=\"graphicVersion\">Graphic 68974 Version 7.0</div></div></div>"},"68976":{"type":"graphic_table","displayName":"Volatile inhalant toxicities","title":"Volatile inhalant toxicities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Volatile inhalant toxicities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Toxicity</td> <td class=\"subtitle1\">Agent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute toxicity</td> </tr> <tr> <td class=\"indent1\">CNS (euphoria, hallucinations, lethargy, seizures, coma, central respiratory depression)</td> <td>All</td> </tr> <tr> <td class=\"indent1\">Cardiovascular (ventricular arrhythmias, sudden death)</td> <td>All</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypoxia</td> <td>All</td> </tr> <tr> <td class=\"indent1\">Chemical pneumonitis</td> <td>Chlorinated hydrocarbons, benzene, styrene, xylene</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> <td>Freons (Chlorofluorocarbons)</td> </tr> <tr> <td class=\"indent1\">Upper airway cold injury with edema</td> <td>Freons (Chlorofluorocarbons)</td> </tr> <tr> <td class=\"indent1\">Frostbite</td> <td>Freons (Chlorofluorocarbons)</td> </tr> <tr> <td class=\"indent1\">Methemoglobinemia</td> <td>Amyl, butyl, and isobutyl nitrites</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide poisoning</td> <td>Methylene chloride</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Chronic toxicity</td> </tr> <tr> <td class=\"indent1\">Leukoencephalopathy (dementia, ataxia, anosmia, eye movement disorder)</td> <td>Toluene</td> </tr> <tr> <td class=\"indent1\">Myeloneuropathy (distal paresthesias, posterior spinal tract abnormalities)</td> <td>Nitrous oxide</td> </tr> <tr> <td class=\"indent1\">Sensorimotor peripheral neuropathy (distal paresthesias, ascending weakness and/or paralysis)</td> <td>n-hexane</td> </tr> <tr> <td class=\"indent1\">Hepatotoxicity</td> <td>Chlorinated hydrocarbons, toluene</td> </tr> <tr> <td class=\"indent1\">Hypokalemia, hematuria, albuminuria, and pyuria</td> <td>Toluene</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 68976 Version 2.0</div></div></div>"},"68977":{"type":"graphic_figure","displayName":"Component separation technique and repaired defect","title":"Component separation technique and repaired defect","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Component separation technique and repaired defect</div><div class=\"cntnt\"><img style=\"width:527px; height:184px;\" src=\"images/SURG/68977_CST-with-repaired-defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the abdominal wall defect repaired using the component separation technique.</div><div id=\"graphicVersion\">Graphic 68977 Version 1.0</div></div></div>"},"68978":{"type":"graphic_movie","displayName":"Heel to toe walk video","title":"Balance exercise video: Heel to toe walk","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Balance exercise video: Heel to toe walk</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/68978_Heeltotoewalkvideo.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:369px; height:297px;\" src=\"images/PC/68978_HeeltotoewalkimgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Having good balance is important for many everyday activities, such as going up and down stairs.<br> <ol> <li>Position the heel of one foot just in front of the toes of the other foot. Your heel and toes should touch or almost touch. </li> <li>Choose a spot ahead of you and focus on it to keep you steady as you walk. </li> <li>Take a step. Put your heel just in front of the toe of your other foot. </li> <li>Repeat for 20 steps. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 68978 Version 1.0</div></div></div>"},"68980":{"type":"graphic_diagnosticimage","displayName":"Corpus luteum Doppler","title":"Hemorrhagic corpus luteum (Doppler color ultrasound)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic corpus luteum (Doppler color ultrasound)</div><div class=\"cntnt\"><img style=\"width:354px; height:299px;\" src=\"images/OBGYN/68980_Corpus_luteum_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler image shows a &quot;ring of fire&quot; around a hemorrhagic corpus luteum (CL).</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 68980 Version 2.0</div></div></div>"},"68983":{"type":"graphic_table","displayName":"ERS/ATS definition of severe asthma","title":"European Respiratory Society/American Thoracic Society definition of severe asthma for patients aged ≥6 years*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Respiratory Society/American Thoracic Society definition of severe asthma for patients aged &ge;6 years*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">The definition of severe asthma requires that one or both of the following levels of treatment for the previous year has been needed to prevent asthma from becoming uncontrolled or asthma that remains uncontrolled despite this level of treatment:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>Treatment with guidelines suggested medications for GINA steps 4-5 asthma (high dose inhaled glucocorticoid and long-acting beta agonist [LABA] or leukotriene modifier/theophylline) for the previous year</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <ul> <li>Treatment with systemic glucocorticoid for &#8805;50% of the year</li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Uncontrolled asthma is defined as at least one of the following:</td> </tr> <tr> <td colspan=\"3\"> <ul> <li>Poor symptom control: ACQ consistently &#62;1.5, ACT &#60;20 (or \"not well controlled\" by NAEPP/GINA guidelines)</li> </ul> </td> </tr> <tr> <td colspan=\"3\"> <ul> <li>Frequent severe exacerbations: two or more bursts of systemic glucocorticoids (more than three days each) in the previous year</li> </ul> </td> </tr> <tr> <td colspan=\"3\"> <ul> <li>History of serious exacerbation: at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <ul> <li>Airflow limitation: after appropriate bronchodilator withhold FEV<sub>1</sub> &#60;80% predicted (in the face of reduced FEV<sub>1</sub>/FVC defined as less than the lower limit of normal)</li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">The ERS/ATS definition of high doses of various inhaled glucocorticoids in relation to patient age (in mcg/day):</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Age 6 to 12 years</td> <td class=\"subtitle2\">Age &#62;12 years</td> </tr> <tr> <td><strong>Beclomethasone</strong></td> <td>&#8805;320 (HFA MDI)</td> <td>&#8805;1000 (HFA MDI)</td> </tr> <tr> <td><strong>Budesonide</strong></td> <td>&#8805;800* (MDI or DPI)</td> <td>&#8805;1600<sup>&#182;</sup> (MDI or DPI)</td> </tr> <tr> <td><strong>Ciclesonide</strong></td> <td>&#8805;160 (HFA MDI)</td> <td>&#8805;320 (HFA MDI)</td> </tr> <tr> <td><strong>Fluticasone propionate</strong></td> <td>&#8805;500<sup>&#916;</sup> (HFA MDI or DPI)</td> <td>&#8805;1000<sup>&#9674;</sup> (HFA MDI or DPI)</td> </tr> <tr> <td><strong>Mometasone</strong></td> <td>&#8805;500<sup>&#167; </sup>(DPI)</td> <td>&#8805;800<sup>&#165; </sup>(DPI)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Designation of high doses is provided from manufacturers' recommendations where possible. Equivalent high doses may be expressed differently between countries and some products (eg, beclomethasone) are available in multiple formulations with different dosing recommendations. Medication inserts should be carefully reviewed by the clinician for the equivalent high daily dosage.</div><div class=\"graphic_footnotes\">ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; DPI: dry powder inhaler; GINA: Global Initiative for Asthma; HFA: hydrofluoroalkane; LABA: long-acting beta-agonists; MDI: metered-dose inhaler; NAEPP: National Asthma Education Prevention Program.<br />* ≥720 mcg/day of US labeled budesonide DPI.<br />¶ ≥1440 mcg/day of US labeled budesonide DPI.<br />Δ ≥440 mcg/day of US labeled fluticasone HFA MDI.<br /><FONT class=lozenge>◊</FONT> ≥880 mcg/day of US labeled fluticasone HFA MDI.<br />§ ≥550 mcg/day of US labeled mometasone DPI.<br />¥ ≥880 mcg/day of US labeled mometasone DPI.</div><div class=\"graphic_reference\">Reproduced with permission of the European Respiratory Society: Eur Respir J February 2014 43:343-373; published ahead of print December 12, 2013, doi:10.1183/09031936.00202013. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 68983 Version 5.0</div></div></div>"},"68984":{"type":"graphic_table","displayName":"Oxygen delivery in anemia","title":"Physiologic mechanisms to increase oxygen delivery in anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic mechanisms to increase oxygen delivery in anemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Mechanisms that increase\narterial oxygen content</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nIncreased production of erythropoietin &#8594;\nhemoglobin synthesis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nRightward shift of oxyhemoglobin dissociation curve&nbsp;&#8594;\nincreased O2 delivery</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Mechanisms that\nincrease cardiac output</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nIncreased heart rate</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nIncreased myocardial contractility</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>\nDecreased blood viscosity and decreased peripheral vascular resistance</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 68984 Version 2.0</div></div></div>"},"68985":{"type":"graphic_table","displayName":"Diagnostic criteria in MCTD","title":"Diagnostic criteria for mixed connective tissue disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for mixed connective tissue disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n<tr>\n<td class=\"subtitle1_single\">Common symptoms</td>\n</tr>\n<tr>\n<td>Raynaud's phenomenon</td>\n</tr>\n<tr>\n<td>Swollen fingers or hands</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Anti U1-RNP antibody</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Mixed clinical features</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">SLE-like findings:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Polyarthritis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Lymphadenopathy</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Facial erythema</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Pericarditis or pleuritis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Leukopenia or thrombocytopenia</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Scleroderma-like findings:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Sclerodactyly</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Pulmonary fibrosis, restrictive changes or reduced diffusion capacity</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Hypomotility or dilation of the esophagus</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Polymyositis-like findings:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Muscle weakness</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Elevated serum muscle enzymes</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Myogenic pattern on EMG</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Diagnosis of MCTD is made when the following three conditions are fulfilled:</td>\n</tr>\n<tr>\n<td>1. Positive in either of the two common symptoms</td>\n</tr>\n<tr>\n<td>2. Positive anti-U1 RNP antibody</td>\n</tr>\n<tr>\n<td>3. Positive in one or more findings in two or three of the above diseases</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Doria, A, Ghirardello, A, de Zambiasi, P, et al, J Rheumatol 1992; 19:259.</div><div id=\"graphicVersion\">Graphic 68985 Version 1.0</div></div></div>"},"68986":{"type":"graphic_figure","displayName":"Thyroid gland blood supply","title":"Thyroid gland blood supply","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid gland blood supply</div><div class=\"cntnt\"><img style=\"width:405px; height:430px;\" src=\"images/SURG/68986_Thyroidbloodsupplyedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall anatomic relationships of the thyroid and surrounding structures. Note the course of the inferior thyroid artery, behind and perpendicular to the carotid artery. The superior thyroid artery and external branch of the superior laryngeal nerve run in close approximation.</div><div class=\"graphic_reference\">Reproduced with permission from: Surgical Anatomy of the Thyroid, Parathyroid, and Adrenal Glands. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 68986 Version 13.0</div></div></div>"},"68987":{"type":"graphic_table","displayName":"Causes eosinophilic meningitis","title":"Causes of eosinophilic meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of eosinophilic meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious, parasitic causes </td> </tr> <tr> <td class=\"subtitle2_single\">Roundworm (nematode) infections - commonly present as eosinophilic meningitis </td> </tr> <tr> <td class=\"indent1\"><em>Angiostrongylus cantonensis </em>- migrating larvae inherently neurotropic </td> </tr> <tr> <td class=\"indent1\"><em>Gnathostoma spinigerum </em>- migrating larvae in visceral and/or neural tissues </td> </tr> <tr> <td class=\"indent1\"><em>Baylisascaris procyonis </em>- migrating larvae inherently neurotropic </td> </tr> <tr> <td class=\"subtitle2_single\">Tapeworm (cestode) infections - may present as eosinophilic meningitis </td> </tr> <tr> <td class=\"indent1\"><em>Cysticercosis </em>- cysts develop in CNS and/or visceral tissues </td> </tr> <tr> <td class=\"subtitle2_single\">Fluke (trematode) infections - occasionally cause eosinophilic meningitis </td> </tr> <tr> <td class=\"indent1\"><em>Paragonimus westermani </em>- ectopic spinal or cerebral localization </td> </tr> <tr> <td class=\"indent1\">Schistosomiasis - ectopic spinal or cerebral localization </td> </tr> <tr> <td class=\"indent1\">Fascioliasis - ectopic CNS localization </td> </tr> <tr> <td class=\"subtitle2_single\">Other roundworm infections which occasionally cause eosinophilic meningitis </td> </tr> <tr> <td class=\"indent1\">Toxocariasis - migrating larvae </td> </tr> <tr> <td class=\"subtitle1_single\">Nonparasitic, infectious causes </td> </tr> <tr> <td>Coccidioidomycosis</td> </tr> <tr> <td>Cryptococcosis - CSF eosinophilia rare</td> </tr> <tr> <td>Myiasis - with CNS penetration</td> </tr> <tr> <td>Virus and bacteria - are of uncertain causality</td> </tr> <tr> <td class=\"subtitle1_single\">Noninfectious causes </td> </tr> <tr> <td>Idiopathic hypereosinophilic syndromes</td> </tr> <tr> <td>Ventriculoperitoneal shunts</td> </tr> <tr> <td>Leukemia or lymphoma with CNS involvement (Hodgkin's)</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td>Antibiotics - ciprofloxacin, trimethoprim-sulfamethoxazole, intraventricular gentamicin or vancomycin</td> </tr> <tr> <td>Myelography contrast agents</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">Adapted from Weller PF, Liu LX, Semin Neurol 1993; 13:161.</div><div id=\"graphicVersion\">Graphic 68987 Version 2.0</div></div></div>"},"68988":{"type":"graphic_table","displayName":"Description of genital ulcer II","title":"Characteristics of sexually transmitted genital ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of sexually transmitted genital ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Primary syphilis</td> <td class=\"subtitle1\">Genital herpes</td> <td class=\"subtitle1\">Chancroid</td> <td class=\"subtitle1\">Lymphogranuloma venereum</td> <td class=\"subtitle1\">Donovanosis</td> </tr> <tr> <td>Pain</td> <td>Painless; may become tender if secondarily infected.</td> <td>Common; more prominent with initial infection than with recurrences.</td> <td>Common</td> <td>Variable</td> <td>Rare</td> </tr> <tr> <td>Inguinal lymphadenopathy</td> <td>Unilateral or bilateral; firm, movable, and nontender; do not suppurate.</td> <td>Usually bilateral, firm, and tender; more common in primary episodes than in recurrences.</td> <td>Unilateral (rarely bilateral); overlying erythema; matted, fixed, and tender; may suppurate.</td> <td>Unilateral or bilateral; initially movable, firm, and tender; later indolent; fixed and matted; \"sign of Groove\" may suppurate; fistulas.</td> <td>Pseudobuboes; subcutaneous perilymphatic granulamotous lesions that produce inguinal swelling.</td> </tr> <tr> <td>Constitutional symptoms</td> <td>Rare</td> <td>Common in primary episode; less likely in recurrences.</td> <td>Rare</td> <td>Frequent</td> <td>Rare</td> </tr> <tr> <td>Course of disease if untreated</td> <td>Slowly resolves to latency (2&nbsp;to 6 weeks).</td> <td>Typically recurs.</td> <td>May progress to erosive lesions.</td> <td>Local lesions heal; systemic disease may progress; disfigurement; late complications.</td> <td>Worsens slowly.</td> </tr> <tr> <td>Diagnostic tests</td> <td>Darkfield exam, direct immunofluorescence, FTA-ABS, VDRL.</td> <td>Tzanck smear, culture, Pap smear, direct immunofluorescence, electron-microscopy, direct immunoperoxidase staining, serology.</td> <td>Culture, biopsy (rarely done); Gram stained smears have low specificity.</td> <td>LGV complement fixation test; isolation of the microorganism by culture.</td> <td>\"Donovan bodies\" in tissue smears; biopsy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FTA-ABS: fluorescent treponemal antibody absorption; VDRL: Venereal Disease Research Laboratory test; LGV: lymphogranuloma venereum. </div><div class=\"graphic_reference\">Adapted with permission from: Martin DH, Mroczkowski TF. Sexually transmitted diseases. In: The Skin and Infection: A Color Atlas and Text,&nbsp;Sanders CV,&nbsp;Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore&nbsp;1995. p.95.</div><div id=\"graphicVersion\">Graphic 68988 Version 4.0</div></div></div>"},"68989":{"type":"graphic_table","displayName":"Post-coital prophylaxis UTI","title":"Post-coital antimicrobial prophylaxis regimens for women with recurrent urinary tract infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Post-coital antimicrobial prophylaxis regimens for women with recurrent urinary tract infection</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Regimens\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Expected UTIs per year\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trimethoprim-sulfamethoxazole 40 mg/200 mg</td>\r\n  \r\n   <td>0.30</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Trimethoprim-sulfamethoxazole 80 mg/400 mg</td>\r\n  \r\n   <td>0.00</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Nitrofurantoin 50 mg or 100 mg</td>\r\n  \r\n   <td>0.10</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cephalexin 250 mg</td>\r\n  \r\n   <td>0.03</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ciprofloxacin 125 mg</td>\r\n  \r\n   <td>0.00</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Norfloxacin 200 mg</td>\r\n  \r\n   <td>0.00</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ofloxacin 100 mg</td>\r\n  \r\n   <td>0.06</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 68989 Version 1.0</div></div></div>"},"68992":{"type":"graphic_table","displayName":"Risk factors for preterm birth","title":"Risk factors for preterm birth","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for preterm birth</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>No partner</td> </tr> <tr> <td>Low socioeconomic level</td> </tr> <tr> <td>Anxiety, stress</td> </tr> <tr> <td>Depression, use of selective serotonin inhibitors</td> </tr> <tr> <td>Life events (divorce, separation, death)</td> </tr> <tr> <td>Abdominal surgery during pregnancy</td> </tr> <tr> <td>Occupational issues (upright posture, use of industrial machines, physical exertion, mental or environmental stress related to work or working conditions)</td> </tr> <tr> <td>Multiple gestation</td> </tr> <tr> <td>Polyhydramnios</td> </tr> <tr> <td>Uterine anomaly, including diethylstilbestrol-induced changes in uterus and leiomyomas</td> </tr> <tr> <td>Preterm premature rupture of membranes</td> </tr> <tr> <td>History of second-trimester abortion</td> </tr> <tr> <td>History of cervical surgery</td> </tr> <tr> <td>Premature cervical dilatation or effacement (short cervical length)</td> </tr> <tr> <td>Sexually transmitted infections</td> </tr> <tr> <td>Systemic infection, pyelonephritis, appendicitis, pneumonia</td> </tr> <tr> <td>Bacteriuria</td> </tr> <tr> <td>Periodontal disease</td> </tr> <tr> <td>Placenta previa</td> </tr> <tr> <td>Placental abruption</td> </tr> <tr> <td>Vaginal bleeding, especially in more than one trimester</td> </tr> <tr> <td>Previous preterm delivery</td> </tr> <tr> <td>Substance abuse</td> </tr> <tr> <td>Smoking</td> </tr> <tr> <td>Maternal age (&#60;18 or &#62;40)</td> </tr> <tr> <td>African-American race</td> </tr> <tr> <td>Poor nutrition and low body mass index</td> </tr> <tr> <td>Inadequate prenatal care</td> </tr> <tr> <td>Anemia (hemoglobin &#60;10 g/dL)</td> </tr> <tr> <td>Excessive uterine contractility</td> </tr> <tr> <td>Low level of educational achievement</td> </tr> <tr> <td>Maternal first-degree family history of spontaneous preterm birth, especially if the pregnant woman herself was born preterm </td> </tr> <tr> <td>Fetal anomaly</td> </tr> <tr> <td>Fetal growth restriction</td> </tr> <tr> <td>Environmental factors (eg, heat, air pollution)</td> </tr> <tr> <td>Fetal demise&nbsp;</td> </tr> <tr> <td>Positive fetal fibronectin test result in vaginal secretions&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68992 Version 11.0</div></div></div>"},"68993":{"type":"graphic_picture","displayName":"Prune belly syndrome","title":"Prune belly syndrome","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Prune belly syndrome</div><div class=\"cntnt\"><img style=\"width:497px; height:279px;\" src=\"images/PEDS/68993_Prune_belly_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two patients with the prune belly syndrome with lack of abdominal musculature.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 68993 Version 4.0</div></div></div>"},"68994":{"type":"graphic_table","displayName":"Enuresis history","title":"Important aspects of the history for a child with enuresis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history for a child with enuresis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Possible significance</td> </tr> <tr> <td>Daytime symptoms</td> <td>Dysfunctional voiding</td> </tr> <tr> <td>Lower urinary tract symptoms (voiding &#8805;8 or &#8804;3 times per day, hesitancy, straining, weak stream, intermittent stream, incomplete emptying, post-micturition dribble, genital or lower urinary tract pain)</td> <td>Dysfunctional voiding or anatomic abnormality (eg, posterior urethral valves)</td> </tr> <tr> <td>Prolonged period of dryness (&#62;6 months)</td> <td>Secondary enuresis more often associated with psychologic comorbidities</td> </tr> <tr> <td>Frequency of episodes</td> <td>Nightly enuresis is associated with persistence</td> </tr> <tr> <td>Change in frequency of episodes over time</td> <td>The natural history is of spontaneous resolution</td> </tr> <tr> <td>Approximate volume of enuretic void</td> <td>Estimate of bladder capacity</td> </tr> <tr> <td>Fluid intake diary</td> <td>May suggest etiology of nocturnal polyuria (increased afternoon/evening fluid intake; diabetes mellitus; diabetes insipidus; psychogenic polydipsia)</td> </tr> <tr> <td>Stooling history</td> <td>Constipation may contribute to decreased bladder capacity</td> </tr> <tr> <td class=\"sublist1_start\">Review of systems</td> <td class=\"sublist1_start\">May identify previously undiagnosed medical condition that contributes to enuresis</td> </tr> <tr> <td class=\"sublist1\">- Snoring</td> <td class=\"sublist1\">- Obstructive sleep apnea</td> </tr> <tr> <td class=\"sublist1\">- Weight loss, fatigue</td> <td class=\"sublist1\">- Diabetes, kidney disease</td> </tr> <tr> <td class=\"sublist1\">- Gait abnormalities</td> <td class=\"sublist1\">- Spinal dysraphism</td> </tr> <tr> <td class=\"sublist1\">- Staring spells</td> <td class=\"sublist1\">- Seizure disorder</td> </tr> <tr> <td class=\"sublist1\">- Perianal itching, vulvovaginitis</td> <td class=\"sublist1\">- Pinworms</td> </tr> <tr> <td class=\"sublist1\">- Excessive thirst, nighttime drinking</td> <td class=\"sublist1\">- Diabetes, kidney disease, psychogenic polydipsia</td> </tr> <tr> <td>Family history of enuresis</td> <td>Genetic factors may be contributing</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 68994 Version 3.0</div></div></div>"},"68995":{"type":"graphic_figure","displayName":"General microdermal jewelry design","title":"General microdermal jewelry design","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">General microdermal jewelry design</div><div class=\"cntnt\"><img style=\"width:460px; height:575px;\" src=\"images/PEDS/68995_General-microdermal-jewelry-design.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The microdermal jewelry design uses &#8220;pocketing&#8221; to insert a dermal anchor in the subcutaneous tissue. The jewelry is screwed into the anchor, appearing to be stuck to the skin.</div><div id=\"graphicVersion\">Graphic 68995 Version 1.0</div></div></div>"},"68996":{"type":"graphic_table","displayName":"Differential diagnosis of morphea","title":"Differential diagnosis of morphea*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of morphea*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Scleroderma (systemic sclerosis)</td> </tr> <tr> <td>Lipodermatosclerosis</td> </tr> <tr> <td>Eosinophilic fasciitis</td> </tr> <tr> <td>Trauma-induced</td> </tr> <tr> <td>Fat nephrogenic systemic fibrosis necrosis (intramuscular injections)</td> </tr> <tr> <td>Chronic graft-versus-host disease</td> </tr> <tr> <td>Lichen sclerosus</td> </tr> <tr> <td>Pretibial myxedema</td> </tr> <tr> <td>Connective tissue nevi</td> </tr> <tr> <td>Morpheaform basal cell carcinoma</td> </tr> <tr> <td>Chemical mediated sclerosing skin conditions (toxic oil syndrome, rapeseed oil, etc.)</td> </tr> <tr> <td>Lyme disease (acrodermatitis atrophicans)</td> </tr> <tr> <td>Phenylketonuria</td> </tr> <tr> <td>Scleromyxedema, scleroderma chronic, pretibial myxedema</td> </tr> <tr> <td>POEMS syndrome</td> </tr> <tr> <td class=\"subtitle2_left\">Exclude in pertinent setting</td> </tr> <tr> <td class=\"indent1\">Carcinoma of the breast metastatic to skin (carcinoma en cuirasse)</td> </tr> <tr> <td class=\"indent1\">Porphyria cutanea tarda</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">POEMS: <strong>P</strong>olyneuropathy, <strong>O</strong>rganomegaly, <strong>E</strong>ndocrinopathy, <strong>M</strong> protein, and <strong>S</strong>kin changes.<br> * Arranged in order of likelihood.</div><div id=\"graphicVersion\">Graphic 68996 Version 2.0</div></div></div>"},"68998":{"type":"graphic_figure","displayName":"Conventional vs impedance","title":"(A) conventional pH catheter (diameter 2.1 mm) used to monitor gastroesophageal reflux and intragastric pH, (B) multi-channel intraluminal impedance-pH catheter (diameter 2.1 mm) with impedance electrodes (4 mm in length) set in pairs at 2-cm intervals","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">(A) conventional pH catheter (diameter 2.1 mm) used to monitor gastroesophageal reflux and intragastric pH, (B) multi-channel intraluminal impedance-pH catheter (diameter 2.1 mm) with impedance electrodes (4 mm in length) set in pairs at 2-cm intervals</div><div class=\"cntnt\"><img style=\"width:500px; height:400px;\" src=\"images/GAST/68998_ConventionaL_vs_impedance.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This allows for six impedance rings and one pH electrode in the esophagus and a second pH electrode in the stomach. The pH sensor is placed 5 cm above the LES and gastric pH at 10 cm below the LES.</div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter.</div><div class=\"graphic_reference\">Courtesy of Radu Tutuian, MD and Donald O Castell, MD.</div><div id=\"graphicVersion\">Graphic 68998 Version 2.0</div></div></div>"},"68999":{"type":"graphic_diagnosticimage","displayName":"Alloprosthesis reconstruction","title":"Alloprosthesis reconstruction after resection of an extremity bone fibrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alloprosthesis reconstruction after resection of an extremity bone fibrosarcoma</div><div class=\"cntnt\"><img style=\"width:288px; height:354px;\" src=\"images/ONC/68999_Alloprosthesis_reconstructi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 68-year-old woman with a fibrosarcoma (malignant fibrous histocytoma) arising in an bone infarct underwent resection of the proximal tibia and proximal fibula, followed by reconstruction using a combined bone allograft and metal prosthesis.</div><div class=\"graphic_reference\">Courtesy of Francis J Hornicek, MD, PhD.</div><div id=\"graphicVersion\">Graphic 68999 Version 4.0</div></div></div>"}};